Treatment of Homocystinuria due to Cystathionine Beta Synthase Deficiency Including use of low-methionine natural-food diet with supplementary cysteine by Vance, David Joseph
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 1 
 
 
 
 
  
Treatment of Homocystinuria 
due to Cystathionine Beta Synthase Deficiency 
Including use of low-methionine natural-food diet 
with supplementary cysteine 
 
This 1
st
 Edition 2013 with all responses from peer/ expert invitations to comment as at 10 May 2013 
 
 
David J Vance 
 
BSc (med physiol, biochem, chem) (Hons: nutrition), James Cook U 
BA (Psychology), James Cook University 
Master of Medical Science (Epidemiology), University of Queensland 
Master of Public Health (Nutrition), University of Queensland 
Master of Medical Statistics, University of Newcastle, 
PGrad Diploma of Public Health & Tropical Medicine, James Cook U 
Grad Dipl of Health Economics & Policy, Monash University 
Naturopathic Certificate, North Coll Nat (KS Jaffery, ‘Nature Cure’) 
Dipl Clin Nutrition, Internat Acad Nutr (R Buist, ‘Orthomolecular Nutr’) 
Level 2 Sports Coach, (ACHPER) TAFE 
 
 
 
 
 
 
 
 
 
 
 
Self-published by: David Joseph Vance, Multifactor Health and Education 
Initiative (MFHEI) 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 2 
 
Self-publisher: David Joseph Vance, Multifactor Health and Education 
Initiative (MFHEI) 
 
ISBN 978-0-9871469-6-0 
 
 
 
 
 
 
 
 
 
 
 
Copyright ⓒ 2013 by David Joseph Vance:  
 
No part of this work may be reproduced for financial profit. Otherwise, it is freely available for use, as a 
humanitarian initiative of the author and the Multifactor Health and Education Initiative.  
Do not reproduce things in isolation from the appropriate context.  
Acknowledge the source and authorship of what parts you use. 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 3 
 
 
 
 
Dedication:  
 
To those sufferers unlucky enough to bear the burden of more suffering than the average. 
 
 
 
 
 
 
Acknowledgements:  
 
To my mother for her excellent early education of me.  
 
To my father for some genes, and cross-cultural experiences, and for his share of my food and lodging in 
early life, and perhaps, after all, some, poorly-manifested, affection and regard. 
 
To the University of Queensland Herston Medical Library Staff, for their competence and helpfulness. 
 
To the scientists whose work I have examined in my work here, for their shoulders to stand on. 
 
To the chaotic and causally predetermined universe for my greater share than average of good luck, the 
disparity being unfair nevertheless; a disparity that I will try to reduce nonetheless the predetermination, 
because that will make me feel like my life has ‘meaning’, because if I do not try, then certainly my life 
will have little if any ‘meaning’, and accordingly I will ultimately feel less satisfied than if I do try. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 4 
 
Contents in Brief 
 
 
 
 
Contents in Detail  p 5 
 
 
Introduction  p 8 
 
 
Chapter 1. Concise advice for treatment after infancy (from 3 years on)  p 10 
 
 
Chapter 2. Concise advice for treatment in infancy (up to 3 years)  p 16 
 
 
Chapter 3. The details of how part of this advice was derived - from an analysis of 
the data of treatment(s) outcome(s) of Yap et al (2001/2003), and consideration of 
relevant metabolism, metabolites, and nutrients  p 18 
 
 
Chapter 4. A table summarising or extracting the most important numerical data 
and word descriptions from literature on Cystathionine Beta Synthase deficiency 
Homocystinuria  p 43 
 
 
References (for works that are not dealt with only in Chapter 4)  p 158 
 
 
Peer and expert review  p 163 
 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 5 
Contents in Detail  
 
 
Introduction  p 8 
 
 
 
Chapter 1. Concise advice for treatment after infancy (from 3 years on)  p 10 
 
1.1 Eat no more than 1 gram of protein per kilogram of body weight per day, choosing low 
methionine foods  p 10 
 
1.2 Eat only balanced meals  p 12 
 
1.3 Take cysteine supplements with all meals  p 13  
 
1.4 Take daily vitamin B6 supplements if the homocystinuric is B6-responsive  p 14 
 
1.5 Take folate, Vitamin B12 and Betaine supplements as appropriate  p 14 
 
1.6 Eat a largish green salad with all meals  p 15 
 
1.7 Derive most calories from fresh fruit  p 15 
 
1.8 Don’t eat fried, roasted, sautéed, grilled, baked or toasted foods  p 15 
 
1.9 Top up total vitamin C intake to 1 gram per day  p 15 
 
1.10 Regular contact between patients/doctors  p 15 
 
 
 
Chapter 2. Concise advice for treatment in infancy (up to 3 years)  p 16 
 
2.1 Combine some amount of breast milk with low-methionine cysteine-supplemented formula 
food, the correct proportions for the individual being determined by a series of tests  p 16 
 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 6 
2.2 Later in infancy replace some amount of breast milk and low-methionine cysteine-
supplemented formula food with low-methionine whole foods and cysteine supplements, the 
correct proportions for the individual being determined by a series of tests  p 17 
 
 
3. The details of how part of this advice was derived - from an analysis of the data of 
treatment(s) outcome(s) of Yap et al (2001/2003), and consideration of relevant 
metabolism, metabolites, and nutrients  p 18 
 
 
3.1 Introduction  p 18 
 
3.2 Abstract  p 18 
 
3.3 Concise summary  p 19 
 
3.4 Background information on homocystinuria resulting from severe homozygous (or compound 
heterozygous) Cystathionine-beta-synthase (CBS) (EC 4.2.1.22) deficiency  p 20 
 
3.5 Comparison of the treatment outcomes in terms of thrombosis (formation of undesirable blood 
clots inside the body, the usual immediate cause of premature death of homocystinuric patients), 
of five major hospitals (in Dublin (Ireland), Sydney (Australia), Nijmegen (The Netherlands), 
Manchester and London (The UK)) having different mixtures of homocystinuric patient types, 
and using different combinations of treatments  p 21 
 
3.5.1 Methods  p 21 
 
3.5.2 Background information from Mudd et al (1985)  p 21 
 
3.5.3 Background information from Yap et al (2001)  p 23 
 
3.5.4 Results (of Vance, here)  p 24 
 
3.6 Discussion of results of analysis of Yap et al (2001/ 2003) data by Vance here  p 28 
 
3.7 Discussion of relevant metabolism, metabolites and nutrients: homocysteine, cysteine, 
cystathionine; sulphate; glutathionine; folate, vitamin B12, betaine; vitamin C; platelets; acid-base 
balance; and Oxidation Transamination Methionine Catabolic (OTAMC) pathway metabolites 
hydrogen sulphide, methane thiol, 3-methylthiopropionate, formate and formaldehyde  p 30 
 
3.7.1 Diagram of relevant metabolism  p 30 
 
3.7.2 Sulfate  p 31 
 
3.7.3 Cysteine  p 32 
 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 7 
3.7.4 Other Metabolites: The OTAMC pathway and hydrogen sulfide, methanethiol, 3-
methylthiopropionate, formate and formaldehyde  p 34 
 
3.7.5 Vitamin C  p 35 
 
3.7.6 Glutathione  p 37 
 
3.7.7 Acid-base balance  p 37 
 
3.7.8 Cystathionine  p 38 
 
3.7.9 Homocysteine  p 39 
 
3.7.10 Platelets  p 40 
 
  
3.8 Overall conclusion for Chapter 3  p 42 
 
 
4. A table summarising or extracting the most important numerical data and word 
descriptions from literature on Cystathionine Beta Synthase deficiency 
Homocystinuria  p 43 
 
4.1 Chronological Contents List of References for Chapter 4 Tables, in order of appearance  p 43 
 
4.2 Tables of Chapter 4  p 54 
 
 
References (for works that are not dealt with only in Chapter 4):  p 158 
 
Peer and expert review p 163 
 
 
 
 
 
 
 
 
 
 
 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 8 
 
Introduction 
 
 
 
This book(let) is about the treatment of homocystinuria due to inherited severe 
deficiency of function of the enzyme Cystathionine Beta Synthase.  
 
 
It is not about the treatment of homocystinuria due to inherited severe deficiency of function of the 
enzyme Methylene Tetrahydrofolate Reductase, nor about Cobalamin C disorder (probably currently the 
most frequently detected cause of elevated blood total homocysteine when screened for), nor about the 
related Cobalamin D, Cobalamin E, and Cobalamin G disorders. 
 
It is not about addressing mild increases in blood homocysteine due to mild deficiency of function of the 
enzyme Methylene Tetrahydrofolate Reductase, or due to low or deficient folate or low vitamin B12. 
 
It is not about addressing higher blood homocysteine levels of up to about 100 micromoles per litre due 
to lower or deficient vitamin B12. 
 
 
 
The significance, or lack of significance, of mild increases of blood homocysteine levels from the level 
usually accepted as desirable (10 micromoles per litre), up to about 20 or so micromoles per litre, such 
as are exciting the interest of various practitioners giving advice to the numerous people in this category, 
is dealt with in another book, “Homocysteine and Atherosclerosis - Causal Directions in 
Homocystinurics, the General Population, and Vegetarians” expected to be also available for purchase 
and freely from the Multifactor Health Website for those unable to afford such purchase in late 2013 or 
2014, parts of which have already been posted on the Multifactor Health website.  
 
 
 
 
 
 
 
Introduction continues next page 
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This book(let) is intended to serve a range of people, from the general public 
including cystathionine beta synthase deficient homocystinurics and their families, 
through to scientists, and health and medical personel involved in treatment(s) of 
the condition(s). 
 
This book is in six main parts and chapters: 
 
Chapter 1. The advice regarding treatment of homocystinurics after infancy (over 3 years) stated as 
concisely as possible, which is intended to be understandable by the general public, i.e. homocystinurics 
and their families. 
 
Chapter 2. The advice regarding treatment of homocystinurics during infancy (under 3 years) stated as 
concisely as possible, which is intended to be understandable by the general public, i.e. homocystinurics 
and their families. 
 
Chapter 3. The details of how part of this advice was derived from an analysis of the data of the 
treatment outcome, in terms of thrombosis (formation of undesirable blot clots inside the body, the usual 
immediate cause of premature death of sufferers from this disease), of five major hospitals (in Dublin 
(Ireland), Sydney (Australia), Nijmegen (The Netherlands), Manchester and London (The UK)). This is 
in a form resembling that required for submission to scientific journals, and includes an Abstract and a 
Concise Summary. The statistical analytic part will be difficult (though not necessarily impossible) for 
most members of the general public (and less statistically versed scientists and health and medical 
personel) to follow, but should at least provide a good portion of the general public a glimpse of the 
nature of imperfections in work done by even well qualified and otherwise generally expert scientists. 
 
Chapter 4. A table summarising or extracting the most important numerical data and word descriptions 
from literature on Cystathionine Beta Synthase deficiency Homocystinuria, arranged chronologically. 
 
References: a list of scientific journal articles and reference book chapters read by me in the course of 
writing this book. This does not include hundreds of related articles read in the course of preparing the 
larger work on homocysteine noted on the previous page. 
 
Peer and expert review comments and discussions. A list of experts in the treatment of homocystinuria 
due to cystathionine beta synthase deficiency have been provided with the pre-publication final draft of 
this book, and invited to comment critically under the conditions that they do so independently of each 
other, that their full responses will be reproduced in this section exactly as they gave them, and that 
sufficient time for responses by me, and further responses by them, to the conclusion of discussions 
through agreement or disagreement, be allowed. 
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Chapter 1. Concise advice for treatment after infancy (from 3 years on): 
 
1.1 Eat no more than 1 gram of protein per kilogram of body weight per day, choosing low 
methionine foods, in order to keep methionine (one of protein’s amino acids) intake low.  
 
Of the low amount in total to be consumed of the high-protein foods (listed immediately below) 
include a substantial proportion of Macadamia Nuts (which score 0/5 for (methionine + cysteine) 
and almonds (which score 3/5 for (methionine + cysteine) to keep methionine intake lower still. 
 
Bear in mind that the high-protein foods are also generally high-calorie foods by weight compared to 
fruit and vegetables, as fruit and vegetables have more water in them – therefore the weight of fruit 
and vegetables eaten should far exceed the weight of the high-protein foods eaten. 
 
Weighing of all/most foods need only be done until a good visual approximation of the portions is 
fixed in the memory, and thereafter need only be done occasionally as a refresher of the memory. 
 
The success of the following of these recommendations needs to be determined by serial blood tests 
of methionine levels, and of blood/ urine tests of homocysteine/ homocystine, in the same way that 
these tests are used to determine the success of other recommended treatment combinations. 
 
You need to have some knowledge of food protein levels, at least the following generalizations, of 
percent by weight as usually purchased in retail shops (the list down to and including legumes is of 
the high-protein foods, and foods listed after that are of lower protein (per energy) level):  
 
Soy Beans (as for the Other Beans, fairly well dried) 40%, wet (drained) after boiling 11 % 
 
Peanuts (a type of bean/legume) 25%,  
 
Other Beans (the seed inside the pod; includes lentils; fairly well dried) 20-25%, wet (drained) 
after boiling 5 - 6 % 
 
Sunflower Seeds, Sesame Seeds, Pumpkin Seeds 20-25%, 
 
Undried Meats (mammal, bird or fish) 20%,  
 
Almonds, Cashews, Walnuts 17%,  
 
Hazelnuts 15%, 
 
Pecans 12%, 
 
Eggs 12%,  
 
Grains (and grain products like bread) 10-12%,  
 
Pine Nuts/Seeds 7%,                                                                    (Continued below) 
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Rice (a grain) 7%, 
 
Yoghurt 4%, 
 
Milk (of any fat content) 3%,  
 
That legumes are a little low in methionine compared to other amino acids regarding human 
requirements, and that grains, seeds and nuts are a little low in lysine compared to other amino 
acids regarding human requirements (so eat more of legumes than of grains, seeds and nuts other 
than macadamia nuts and almonds), 
                                  
Root vegetables range from: 
Carrots 1% to Sweet Potatoes and Potatoes 2%,                                    
Common Green Leaf and Flower (cauliflower and broccoli) Vegetables 2%, uncommon green 
leafs sometimes being much higher,  
 
Fruits are generally 1% protein by fresh weight, and are even more useful in the diet of 
homocystinurics than they are in other people (a healthy diet should be mostly fruit by fresh 
weight) because fruits are generally at the low end of the range of protein:energy ratio of all 
food groups, and they have an unusually diverse amino acid complement, allowing the choice of 
fruits whose protein content is unusually low in methionine (ignoring cysteine, because it is 
much easier to replace this with a capsule supplement than it would be (impossible) to find 
enough foods high in cysteine but low in methionine to make up a diet acceptable to 
homocystinurics from) – such fruits include (1/5 is very low, 5/5 would be high in (methionine + 
cysteine)): 
 
Pawpaw (methionine + cysteine 1/5) 
 
Apples (methionine + cysteine 2/5), 
 
Pears (methionine + cysteine 2/5), 
 
Mangoes (methionine + cysteine 2/5), 
 
Watermelon (methionine + cysteine 3/5), 
 
Bananas (methionine + cysteine 3/5), 
 
Apricots were given as 1/5, but as peaches which are also members of the stonefruit botanical 
family, are given as 5/5, the dissimilarity seeming unlikely and therefore suspect, I hesitate to 
include them here, and the same thing applies for mandarins given as 1/5 and oranges as 4/5, 
both of the citrus botanical family. 
 
 
(Continued below) 
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(References: for food protein contents Insel, Turner Ross (2007), Shils, Shike, Ross, Caballero, Cousins 
(2006), Whitney, Rolfes (2008); for food methionine and cysteine contents the SelfNutritionData 
website) 
 
Note that previously the common practice has been more to achieve a low enough methionine in the diet 
by use of a synthetic formula diet with additional breast milk and/or normal foods added as deemed 
appropriate.  
Not enough consideration has been given to the ability to construct an acceptable, palatable diet that 
homocystinurics can and will use with little burden, based mostly on generally healthy whole fresh 
foods. 
Linder (1991) provided the following table from Acosta and Elsas (1976) of suggested methionine and 
protein intakes in homocystinuria, compared with the requirements of a normal child of 10 – 12 yrs age. 
 
  Age          Methionine               Protein                 Energy 
(years) (mg/ kg body/ day) (g/ kg body/ day) (kcal/ kg body/ day) 
0 – 0.5           42                        2.00b                        120 
0.6 – 1.0        20                        1.50                         110 
1 – 3           10 – 23                   1.25                       1300 (total/ day) 
4 – 6           10 – 18                   1.00                       1800 (total/ day) 
7 – 10         10 – 13                   1.00                       2400 (total/ day) 
 
Normal Child 
10 – 12          22                        0.81                   1500 – 3000 (total/ day) 
 
b
  More is possible if low-methionine mixtures are consumed. (
a
  referred to Vit B6 as trialworthy)      
 
It can be seen that the eating of the foods I have given above, in the amounts given, will reduce the 
dietary methionine to approximately that level suitable for homocystinurics 
 
 
 
1.2 Eat only balanced meals,  
in order to provide the best combination of amino acids, fats and carbohydrates; and the best blood 
levels of these over time. 
This is to say that each day’s intake, eaten only in 2 or 3 balanced meals, should include a total over 
the entire day no more than 100 grams (50 g for each of 2 meals, or 33 g for each of 3 meals) for 
(some mixture of, with little or no dairy) all of the beans, nuts, seeds, meats, eggs, dairy products, 
grains and grain products (e.g. bread etc) together (all the weights of all of these added together). 
– alongside this should be a good-sized pile (300-500 g at each meal) of green-leaf vegetables, 
with or without additional weights of tomatoes and carrots  
– and 1.5 – 3 kg (depending on growth and body size) of (combined total weight) starchy root 
vegetables (e.g. potatoes and sweet potatoes) (less of) and fruit (more of). 
(Reference: Vance (2011) for aspects of human diet in general) 
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1.3 Take cysteine supplements with all meals,  
up to 150 mg of L-cystine (two cysteine molecules joined) per kg of body weight per day (divided 
up into each of the day’s 2 or 3 meals), the amount for the particular patient, to normalise blood 
levels, being determined through a series of blood tests. Capsules or pills may be preferred. 
Vitamin B6-nonresponsive homocystinurics will need more cysteine than vitamin B6-responsive 
homocystinurics, as they are producing less of their own (Mudd, Levy, Kraus 2001). 
  
Because, early studies showed clear benefit from cysteine supplementation prior to the vitamin B6 
treatment era (Laster, Mudd, Finkelstein et al 1965; Carson, Dent, Field et al 1965; Brenton, 
Cusworth, Dent et al 1966; Perry, Dunn, Hansen et al 1966; Komrower, Lambert, Cusworth et al 
1966; Perry, Hansen, Love et al 1968),  
and because nitrogen (and sulphur) balance studies (Poole, Mudd, Conerly et al 1975) do not address 
some body proteins needing a higher proportion of cysteine than other body proteins, nor do they 
address the roles and levels of the sulphate (Nimni, Han, Cordoba 2007), and hydrogen sulphide and 
other potentially important biochemicals (Predmore, Lefer, Gojon 2012) that eventuate from 
cysteine metabolism (some of its breakdown products, as well as larger molecules it is made a part 
of).  
 
Also because glutathione, a smallish molecule made (in the body) from cysteine and two other 
amino acids, is protective against oxidation (is an antioxidant) and potentially enhances immune 
function (Nimni, Han, Cordoba 2007).  
 
Also because probably it is not only that excess homocysteine interferes with cysteine-cysteine 
disulfide bonding within and between proteins (i.e. fibrillin (cysteine-rich)) due to homocysteine 
bonding with the cysteines (and that more strongly than cysteines bind to each other), 
but also because a lack of cysteine probably retards the formation of those cysteine-cysteine double 
bonds thereby leaving unbonded cysteines freely available for longer periods of time so that 
homocysteine can increase its bonding with them and thus prevent the formation of those cysteine-
cysteine double bonds, cysteine deficiency thus probably being an important factor in the disruption 
of proper formation of some protein fibers that are important parts of the body structures including 
the walls of arteries and veins, the fibers that retain the lenses of the eyes in their proper positions, 
and the fibers that are part of correct bone formation (Hubmacher, Cirulis, Miao et al 2010);  
 
Also because amino acids for protein synthesis are not much stored in the body but require being 
provided fairly immediately together with each other by the body circulation at the time of protein 
synthesis;  
 
Also because the present studies of homocystinuria treatment benefit do not yet extend into older 
ages, where problems that have been only slowly developing (as yet undetected) begin to become 
((much) more) apparent.  
The fact that ascertainment bias here (generally more severe cases being the ones detected earlier in 
the history of the treatment of the disease, and therefore constituting disproportionately more of the 
natural history (untreated) reference group of patients in studies of treatment outcomes) has resulted 
in overestimation of the benefit of treatment for the real population whole group of CBS--
homocystinurics (Skovby, Gaustadnes, Mudd 2010) is not a good argument against better treatment 
– consider how most other preventable and other diseases do not become clinically highly 
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pathological or urgent until mid-life and beyond for most cases because they include a large 
proportion of milder cases that only evolve to serious disease more slowly. 
 
Although cysteine supplementation is particularly important (essential, not optional) for those 
homocystinurics whose Cystathionine Beta Synthase function is approximately nil and cannot 
therefore be improved much by vitamin B6 supplementation,  
 
it may also be particularly important for those whose cystathionine beta synthase function has 
enough residual activity to therefore be able to be significantly improved by vitamin B6 
supplementation, but who also take folate and/or vitamin B12 and/or betaine in order to further 
reduce homocysteine levels, because in this case the further reduced homocysteine levels produce 
less of a drive through the still debilitated Cystathionine Beta Synthase to produce the resultant 
cysteine, which is therefore further lowered by the folate and/or vitamin B12 and/or betaine 
treatment that allows homocysteine to escape down that other pathway (remethylation) instead of 
being forced to some (already suboptimal) extent down the transsulfuration pathway to give some 
(already suboptimal) amount of cysteine. This despite reduced binding of cysteine by the lowered 
homocysteine. 
 
Eat only at mealtimes, so that appropriate cysteine supplementation can be achieved, with good 
proportions of amino acids being absorbed together. 
 
 
1.4 Take daily vitamin B6 supplements if the homocystinuric is B6-responsive, 
the amount for the particular patient, to best as close to normalise blood levels, being determined 
through a series of blood and/or urine tests. 
Homocystinurics who do not respond to B6 with a useful decrease in homocystine should not take 
B6 supplements, because of undesirable side-effects. 
(Yap 2012; Shils, Shike, Ross et al 2006; Mudd, Levy, Kraus 2001; Mudd, Edwards, Loeb etc 1970) 
 
 
1.5 Take folate, Vitamin B12 and Betaine supplements as appropriate,  
to further reduce homocyst(e)ine levels and (the folate) to compensate for excess use of folate due to 
excess use of the alternative pathway (remethylation) for metabolizing homocysteine. The amount(s) 
of the particular nutrient(s) for the particular patient, giving the best trade-off between the beneficial 
effect of lowering homocysteine levels and the risk of any side-effects, to best on balance normalise 
blood levels, being determined through a similar sort of series of blood tests as for the vitamin B6 
supplementation (Yap 2012; Shils, Shike, Ross et al 2006; Mudd, Levy, Kraus 2001). 
It should be noted that in the case of B6-responsive homocystinurics, use of these three nutrient 
supplements (alone or together) reduces the amount of homocysteine forced by higher-than-normal 
concentrations to go down the transsulfuration pathway via the impaired but B6-partly-restored 
Cystathionine Beta Synthase enzyme, which reduces the amount of cysteine resulting from 
metabolism of homocysteine down that pathway, which may increase the need for, or potential 
benefit from, additional cysteine supplementation to the diet, despite there being less homocysteine 
to bind to cysteine. 
 
 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 15 
1.6 Eat a largish green salad with all meals, (as noted above) because this is an important part of a 
generally healthy diet for virtually all humans. (Vance 2011) 
 
1.7 Derive most calories from fresh low-methionine fruit. (as noted above)  
 
 
1.8 Don’t eat fried, roasted, sautéed, grilled, baked or toasted foods,  
 
because the oxidatively damaged fats in these will probably increase whatever damage is happening 
to artery and probably also vein walls, predisposing to atherosclerosis, and therefore possibly 
thrombosis also - there is already some artery wall damage in this disease, and it is best to minimize 
any further damage that may occur from eating these sorts of foods.  
 
Eat raw, boiled, steamed, poached or stewed foods instead.  
 
High heat in the presence of oxygen (i.e. in the air) damages fats, particularly but not only the 
otherwise generally healthy unsaturated fats. 
 
 
1.9 Top up total vitamin C intake to 1 gram per day (Pullin, Bonham, McDowell et al 2002) with a 
supplement that has other antioxidants and nutrients in conservative (lowish, mild) amounts.  
Be conservative and avoid higher doses from supplements until more is known in this field of 
science. 
 
 
1.10 Regular contact between patients/doctors can be important for helping patients adhere to 
recommendations.  
Perhaps blood sampling should be scheduled so as to maximize maintenance of doctor-patient 
contact and patient adherence to recommendations.  
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Chapter 2. Concise advice for treatment in infancy (up to 3 years): 
 
2.1 Combine some amount of breast milk with low-methionine cysteine-supplemented formula 
food, the correct proportions for the individual being determined by a series of tests 
 
For Newborns and young infants, even if the mother is known to be homocystinuric herself, it is best if 
some amount of breast milk can be used (preferably in the same meal) together with some of the 
synthetic low/nil-methionine, cysteine-supplemented feeds as commonly used (Yap 2013). 
This is because the breast milk of the first 10 or more days contains a complex mixture of protein and 
other substances the benefit of which cannot be sensibly measured as merely its amino acid content 
because much of this protein is not broken down into amino acids in the stomach and intestines of 
newborn and very young infants, but is absorbed intact into the infants bloodstream to perform various 
important functions. This probably also applies to a lesser extent after the first 10 or more days. 
 
It has been noted that ‘mature’ breastmilk as produced 10 or 14 days or so after birth and on thereafter, 
as well as being very low in protein relative to energy (because humans are by evolution a very low-
protein-requiring animal) compared to milks of other animal species (human milk is only a quarter or so 
in protein:energy ratio as other known mammals’ milks (Oftedal 1981)), and also being low in protein 
relative to energy compared to to other food groups (roughly equal to fruits) regularly eaten by humans. 
Also, this breastmilk has been said to be the highest in cystine (free cysteine, not in a protein): 
methionine (ambiguous as to whether free or in protein) ratio (2:1) of all animal products, resembling 
therein plant tissues (WHO Bulletin 1989). 
 
In any case, be the mother a homocystinuric or not; if a homocystinuric, be she vitamin B6-responsive 
or –nonresponsive; the correct mixture of breast milk and the synthetic low-methionine, cysteine-
supplemeted formula will require determination through a series of tests – tests of the blood levels of the 
important biochemicals reacting to variation in the doses or ratios of the different treatments applied 
(breast milk, special formula foods, and vitamin B6 and/or other nutrients (folate, vitamin B12, betaine) 
– tests that will roughly determine what are the best doses and ratios of the treatments to proceed with.  
The tests are necessary because there is no ready mathematical formula to calculate the doses and 
amounts for a particular homocystinuric patient – though there are in some centres some reasonable 
starting points from which to begin to test variations of treatment dose and ratios, and in the near future 
hopefully these will be better agreed by consensus and readily available as such in the literature. 
 
Presently, it seems to me that as good an authoritative opinion as any in the world on the details of these 
matters (on this page) would be that of Professor Sufin Yap of the UK, a practitioner and teacher of 
inherited metabolic disease treatment with many years of experience with a patient group that for 
decades now have been more diagnosed and treated in infancy than any other homocystinuric patient 
group in the world. 
 
Also there are known psychological benefits from breastfeeding, which are part of breastfeeding’s 
known ability to help infants thrive. 
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2.2 Later in infancy replace some amount of breast milk and low-methionine cysteine-
supplemented formula food with low-methionine whole foods and cysteine supplements, the 
correct proportions for the individual being determined by a series of tests 
 
However, I suggest that as the infant grows older, there is some scope for replacing the presently used 
synthetic low-methionine cysteine-supplemented formula by the correct combination of low-methionine 
whole foods and cysteine supplementation as detailed above but with adjustment for the increased 
protein requirements of infants in accord with the table reproduced above here in section 1.1, of 
suggested methionine and protein intakes in homocystinuria by Acosta and Elsas (1976) given by 
Linden (1991). I recommend that this be done in close consultation with the treatment team, who should 
make themselves aware of the details I have provided here, and done with the standard series of tests of 
body methionine and homocysteine levels to determine the success of both the diet specifications and 
the patient’s following of them. 
 
 
 
 
 
 
 
 
 
 
 
Aside to Chapters 1 and 2: There has been some work done on the effect of mutation topology (a 
fundamental aspect of enzyme shape, here being changed due to the replacement of one amino acid in 
the/a protein that makes up/ is part of an enzyme, with a different amino acid) on the folding of the 
protein and therefore on the enzyme’s activity (Kozich, Sokolova, Klatovska et al 2010), and on how 
this might be changed (restored towards normal) by the addition of naturally occurring or synthetic 
(bio)chemicals (interestingly betaine, taurine and glycerol, all occurring naturally in human 
biochemistry, have had potentially valuable activity) (Kopecka, Krijt, Rakova, Kozich 2011). 
This has some promise for the future, but work has only been done in in-vitro (in a test-tube or other 
such significantly artificial situation), leaving the question of whether any beneficial changes in humans 
will be worth paying the price of whatever undesirable side-effects may occur at whatever stage of the 
patient’s life.
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Chapter 3. The details of how part of this advice was derived - from an analysis of 
the data of treatment(s) outcome(s) of Yap et al (2001/2003), and consideration of 
relevant metabolism, metabolites, and nutrients  
 
 
3.1 Introduction 
 
This chapter is in a form resembling that required for submission to scientific journals, and includes a 
Title, author details, an Abstract, a Concise Summary, an Introduction, a Methods, two Backgrounds 
dealing with important work by other authors, the Results of my own analysis of data from those works, 
a Discussion including a hopefully sufficiently comprehensive complement of related nutrients, and an 
Overall Conclusion. References are given in the one Reference section for the whole book. 
 
Title: Analysis of Yap et al (2001/2003) data suggests treatment improvements for prevention of 
thrombosis in cystathionine beta synthase deficiency are available via improved cysteine 
supplementation, diet composition, antioxidant supplementation, and follow-up. 
 
Author’s name and institutional affiliations: 
David Vance, Master of Medical Science (Epidemiology), Master of Medical Statistics, etc. 
Independent researcher. 
Corresponding author:  David Vance: davidjmvance@hotmail.com,  
Word counts: Text only, 7,000 w;   Abstract, 250 w. 
Number of figures and tables: Figures, 2;   Tables, 1. 
Author contribution: The sole author is the sole planner, conductor, and reporter. 
Details of funding: Nil, self-funded. 
Ethics approval: No ethics approval was required for any research study. 
Patient consent statement: Not required for this work. 
 
 
3.2 Abstract  
 
Aim. To further analyse the data of Yap et al (2001/2003). 
 
Background. Homozygous (or compound heterozygous) Cystathionine-beta-synthase deficiency may 
result in thrombosis. Treatment has included low-methionine diets, cystine-enriched amino acid 
supplementation and formula foods, vitamin B6, folic acid, vitamin B12, and betaine. 
 
Methods. Data collated by  Yap et al (2001/2003) of the thrombosis outcomes of five major (CBS--)-
treating centers: in Dublin, Sydney, Nijmegen, Manchester and London; was statistically compared with 
outcomes predicted by Mudd et al’s (1985) untreated natural history outcomes, and then Dublin with the 
others, and treatments examined. 
Consideration was made of homocysteine, cysteine, cystathionine, sulphate, glutathione, folate, vitamin 
B12, betaine, vitamin C, platelets, acid-base balance, and the metabolites arising in the Oxidation 
Transamination Methionine Catabolic (OTAMC) pathway: hydrogen sulphide, methane thiol, 3-
methylthiopropionate, formate and formaldehyde. 
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Results. There were  less  thromboses outcomes (P<.05) in the treated and followed CBS-- patient 
groups of each of the five groups, even when considered singly, than that expected in the absence of 
treatment by reference to the natural history data of Mudd et al (1985).  
The thromboses outcome of the Dublin group is better than that of the other four groups, but this does 
not attain statistical significance at the P<.05 level (P ~ 0.16 with the other four groups combined, or P 
ranging from 0.14 to 0.23 with the other four groups each taken singly). There are differences in 
treatment regimens. 
The considerations of the other metabolites and nutrients suggested potentially important roles for these 
molecules, such that treatment that included their normalisation or optimisation would be desirable if it 
could be had at an acceptable, efficient price, which it potentially can to a substantial extent. 
 
Conclusions. Cysteine supplementation may be of more importance than generally acknowledged, and 
that maybe as a function of the use of homocysteine-lowering treatment modalities other than VitB6. 
Low-methionine, high-fruit and vegetable diets may be of more importance than generally 
acknowledged, and supplementation with vitamin C and other antioxidants should probably be 
implemented.  
Thoroughness, and psychological competence, with regard to the cultivation of treatment compliance is 
important. 
 
 
3.3 Concise summary 
 
Homozygous (or compound heterozygous) Cystathionine-beta-synthase deficiency (CBS--) may result 
in thrombosis, and its treatment has included low-methionine diets, cystine-enriched amino acid 
supplementation and formula foods, vitamin B6, folic acid, vitamin B12, and betaine. 
 
The data of Yap et al (2001/2003) was further analysed, showing that the thrombosis outcomes of five 
major (CBS--)-treating centers: in Dublin, Sydney, Nijmegen, Manchester and London, even when 
considered singly, are better (P<.05) than that expected in the absence of treatment by reference to the 
natural history data of Mudd et al (1985).  
 
The thromboses outcome of the Dublin group is better than that of the other four groups, although P ~ 
0.16 with the other four groups combined, and there are differences in treatment regimens associated 
with this, suggesting that cysteine supplementation may be of more importance than generally 
acknowledged, and that maybe as a function of the use of homocysteine-lowering treatment modalities 
other than VitB6.  
This finding, added to which the consideration of other relevant and potentially relevant metabolites and 
nutrients, suggested that low-methionine, high-fruit and vegetable diets may be of more importance than 
generally acknowledged, and supplementation with vitamin C and other antioxidants should probably be 
implemented.  
Futhermore, thoroughness and psychological competence with regard to the reinforcement/cultivation of 
treatment compliance is important. 
 
Key words: CBS, homocysteine, diet, vitamin C, FMD, cysteine  
 
References to electronic databases: Nil 
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Abbreviations list: 
ADP, adenosine diphosphate;   
CBS--, homozygous/ compound heterozygous cystathionine beta synthase deficiency (OMIM #236200); 
cbEGF, calcium binding epidermal growth factor like (protein moiety); 
ECF extracellular fluid; 
ICF intracellular fluid; 
MDA, malondialdehyde; 
MFS, Marfan Syndrome (OMIM #154700);    
OTAMC, oxidative transamination methionine catabolism (pathway);   
PAPS, 3-phosphoadenosine 5-phosphosulfate;  
VitB6, vitamin B6 (pyridoxal phosphate here);  
VitB12, vitamin B12; 
UK, United Kingdom;  
USA, United States of America; 
 
 
3.4 Background information on homocystinuria resulting from severe homozygous (or compound 
heterozygous) Cystathionine-beta-synthase (CBS) (EC 4.2.1.22) deficiency 
 
Homocystinuria resulting from severe homozygous (or compound heterozygous) Cystathionine-beta-
synthase (CBS) (EC 4.2.1.22) deficiency (CBS--) (OMIM #236200) results in a range of pathologic 
outcomes in the absence of treatment, including variably thrombosis (the focus of this (Chapter 3) 
work); premature atherosclerosis, increased Intima-Media Thickness, reduced Flow-Mediated Dilation 
of vasculature; various skeletal abnormalities including dolichostenomelia/arachnodactyly (‘Marfanoid 
habitus’), osteoporosis, genu valgum, pectus excavatum; developmental delay/ mental retardation, 
coordination and pyramidal movement disorders; ocular ectopia lentis and myopia; and fatty liver 
changes (Mudd et al 1985). 
 
Treatment is generally focused on reducing the homocysteine levels of the patient, with the focus on 
other altered metabolites having varied according to treatment locale or even individual practitioner, 
though less so lately, with more internally- homogenous treatments applied in locales (ie nations or 
major city-serviced areas), which are accordingly better differentiable.  
Treatment has included low-methionine diets, cystine-enriched amino acid supplementation and formula 
foods, vitamin B6 (responsivity to this, the major cofactor of CBS, is the criteria for dichotomising 
CBS--.), folic acid, vitamin B12, and betaine (Yap 2012; Shils, Shike, Ross et al 2006; Mudd, Levy, 
Kraus 2001; Yap et al 2001). 
 
The objective of this work is to re-examine the work of Yap et al (2001) dealing with the thrombosis 
outcomes of five major CBS-- treating centers,  in Dublin of Ireland, Sydney of Australia, Nijmegen of 
The Netherlands, and Manchester and London of the UK, and to further (i.e. statistically) compare them 
not only with Mudd et al’s (1985) untreated natural history outcomes, but with each other, and examine 
the possible relationship of any differences in thrombosis outcomes to respective treatment regimes.  
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3.5 Comparison of the treatment outcomes in terms of thrombosis (formation of undesirable blood 
clots inside the body, the usual immediate cause of premature death of homocystinuric patients), 
of five major hospitals (in Dublin (Ireland), Sydney (Australia), Nijmegen (The Netherlands), 
Manchester and London (The UK)) having different mixtures of homocystinuric patient types, 
and using different combinations of treatments.  
 
3.5.1 Methods:  
 
Outcome data collated by  Yap et al (2001) of the thrombosis outcomes of five major (CBS--)-treating 
centers, in Dublin of Ireland, Sydney of Australia, Nijmegen of The Netherlands, and Manchester and 
London of the UK, was statistically compared (with an adjustment for proportions of VitB6-respondent/-
nonrespondent CBS-- treatment years) with outcomes predicted by Mudd et al (1985)’s untreated natural 
history outcomes (using only that portion of Mudd et al’s time-to-thromboembolic event curve that is 
covered by the ageing period between the average age at commencement of treatment, and the average 
age at the Yap et al (2001) study present time).  
 
The thrombosis outcome results of Dublin of Ireland are then compared to the thrombosis outcome 
results of the other four centres combined and then individually.  
 
The basic statistical method used is the method for comparison of proportions in independent samples 
provided by Snedecor and Cochran (1989), the essential equation being: 
z = (p1hat – p2hat)/[sqrt(phat*qhat)(1/n1 + 1/n2)],  
where:  phat = (n of events1 + n of events2)/(n group1 + n group2),   
qhat = 1 – phat,     and p for statistical significance is obtained by referring z to the table for the normal 
distribution of z .  
 
The possible relationship of any differences in thrombosis outcomes to respective treatment regimes is 
then discussed.   
 
 
3.5.2 Background information from Mudd et al (1985): 
 
The following is the background information from Mudd et al (1985) necessary for thorough 
comparative considerations: 
 
Mudd et al (1985), in a seminal paper, mailed a standardized questionnaire to each clinician known from 
a previous study (cited Mudd et al 1981) to be caring for patients with CBS--. Physicians were asked to 
complete a questionnaire for each such individual about whom they had appropriate information. Further 
questions focused upon the factor(s) that led to ascertainment, whether the patient was responsive to 
VitB6, and upon the presence and age of appearance of major clinical manifestations. A detailed history 
of therapy was requested, as well as a reproductive history….Additional sources of information were 
identified by a review of the literature and by contacting centers around the world specializing in 
diagnosis and management of inborn errors of metabolism, as well as by soliciting physician 
cooperation by notices in appropriate journals. For some patients on whom recent information could not 
be obtained, published material only was used, if details were available to prove that they did not 
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overlap. Data collection occurred during 1982 and early 1983 – duplication was searched for, and 
redundant information deleted. 
For their 1985 survey, updated information was received concerning 532 homocystinuric patients with 
proven or presumed CBS--. To this group was added material from an additional 97 patients obtained 
primarily from published reports (cites 37 references), bringing the total to 629 patients.  
 
All patients admitted to the study had been demonstrated to be excreting homocystine in conjunction 
with either enzyme assay or hypermethioninemia or dislocated optic lenses: 
                   Enzyme Assay:       Yes               No 
 
Ectopia Lentis + hyperMet    147(68%)     274(66%) 
Ectopia Lentis only                 21(10%)        75(18%) 
Hypermethioninemia only       39(18%)         64(16%) 
Neither of the above                 9(4%)              0(0%) 
 
Total                                      216(100%)   413(100%)  
Where hyperMet = Hypermethioninemia 
 
58 were discovered during screening of newborns, and an additional 88 were discovered by screening all 
siblings (the balance ascertained on clinical features)….  
 
Of the 629 patients, 307 were females and 321 males…. 
 
Of the 629 patients, 231 (37%) were classified as biochemically responsive to VitB6 when not folate 
depleted; 231 (37%) were classified as nonresponsive to VitB6; 67 (11%) were judged intermediate in 
response; and 100 (16%) had not been classified. For their subsequent analyses only the 231 VitB6-
responsives and the 231 VitB6-nonresponsives were analysed. 
Of newborn screening ascertainees, 78% were VitB6-nonresponsive, whilst of untreated 
nonhypermethioninemic cases 90% were VitB6-responsive. 
The clinical features leading to investigation for homocystinuria (n = 472 not ascertained by newborn 
screening or case sibling screening, irrespective of VitB6-response) were: 
 
Clin Feature                  SoleCause   ContribCause     Total 
 
Ectopia Lentis                       21%               65%           86% 
Mental Retardation                 4.0                52              56 
Developmental Retardation    1.5                21              22.5 
Early Thromboembolism        1.1                15              16 
Marfanoid Characteristics       0.9                36              37 
Bony Abnormality                  0.2                 23              23 
Seizures                                   0.2                   3                3 
Behavioral/Psychiatric               0                   2.8             3 
Other                                        0.4                10.6           11   
 
They presented the following time-to-event graph (my projection lines) for the first thromboembolic 
event in untreated patients, both combining and differentiating the VitB6-responders from the -
nonresponders. All three curves have a substantially sigmoidal characteristic, such that under the age of 
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roughly 10 y, the slope of the curve(s) are very roughly half of the maximum slope, that is reached at 
very roughly 20 years. By 28 years of age the slope(s) has decreased again. As they note, an idea of the 
differences between the VitB6-responders and –nonresponders is given by the chances of having had the 
initial clinically detected event by age 15 y being 12% and 27% respectively: 
 
 
Figure 1. Reproduction (projections added) of Mudd et al’s (1985) Time-to-event graph for first 
thromboembolic event in untreated cystathionine beta synthase deficiency. 
 
 
3.5.3 Background information from Yap et al (2001) 
 
The following is the background information from Yap et al (2001) necessary for thorough comparative 
considerations. Selected data from that they collated, and selected results of theirs relevant to my study 
here, appear in the table in the Results below: 
 
Now, Yap et al (2001) produced a paper, the abstract for which is reproduced here: 
 
“Abstract…..We performed a multicenter (Dublin, Ireland; Manchester, UK, London, UK, Nijmegen, 
The Netherlands; Sydney, Australia. DV) observational study to assess the effectiveness of long-term 
Hcy-lowering treatment in reducing vascular risk in 158 patients.  
Vascular outcomes were analysed and effectiveness of treatment in reducing vascular risk was evaluated 
by comparison of actual to predicted number of vascular events, with the use of historical controls from 
a landmark study (Mudd et al 1985. DV) of 629 untreated patients with CBS--.  
The 158 patients had a mean (range) age of 29.4 (4.5 to 70) years; 57 (36%) were more than 30 years 
old, and 10 (6%) were older than 50 years.  
There were 2,822 patient-years of treatment, with an average of 17.9 years per patient. Plasma Hcy 
levels were markedly reduced from pre-treatment levels but usually remained moderately elevated. 
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There were 17 vascular events in 12 patients at a mean (range) age of 42.5 (18 to 67) years:  
pulmonary embolism (n = 3),  
myocardial infarction (n = 2),  
deep venous thrombosis (n = 5),  
cerebrovascular accident (n = 3),  
transient ischemic attack (n = 1),  
sagittal sinus thrombosis (n = 1), and  
abdominal aortic aneurysm (n = 2).  
 
Without treatment, 112 vascular events would have been expected, for a relative risk of .09 (95%CI .036 
to 0.228; P<.0001).” 
 
Yap (2003) provide additional comment on these findings. 
 
 
3.5.4 Results (of Vance, here): 
 
Now, firstly, it was not quite proper for Yap et al (2001) to aggregate thromboembolic events in with 
aneurysms, as they may well have differing metabolite etiologies, and also as diagnosis of aneurysms is 
not assured. 
 
Secondly, the method of calculation of the number of events expected in the treatment period had 
treatment not been applied is by no means made clear. The following is an example of what I posit is the 
most correct method without more complex computational requirements (such as individual data instead 
of the group averages available from Yap et al 2001) that would probably add little more precision to the 
outcome; it uses only that portion of Mudd et al’s curve that is covered by the ageing period between the 
average age at commencement of treatment, and the average age at the Yap et al study present time:  
 
Taking the average age of 29.4 years, minus the total treatment time divided by n (2822/158 = 17.9 
years) one derives that on average treatment commenced at age 29.4y – 17.9y = 11.5y. Extrapolating 
from the (“All types combined”, on the basis that over all five study centres there are very roughly 
similar numbers of VitB6-responsive and –nonresponsive CBS--) thromboembolic event time-curve of 
Mudd et al (1985), it can be seen that for an average individual of this group, the probability of having a 
thromboembolic event, in the absence of treatment, was: 0.52 (the probability of having a 
thromboembolic event, in the absence of treatment by age 29.4y) minus 0.10 (the probability of having 
a thromboembolic event, in the absence of treatment by age 11.5y) = 0.42. 
 
And, 0.42*158 = 66.4 thromboembolic events expected during the treatment period had treatment not 
been applied, compared to the 112 given by Yap et al. 
 
Now, take away the 2 abdominal aortic aneurysms, and the 5 repeat thromboses, to leave 10 vascular 
events instead of the 17 noted (It seems Yap et al did this).  
 
The relative risk would in fact be closer to 0.2 than the .09 claimed.  
 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 25 
The .09 relative risk reported is therefore a twofold exaggeration of treatment efficacy. And when it is 
considered that Mudd’s (1985) cases had an ascertainment bias towards more severe cases (in particular 
out of the vitaminB6-responsive cases), as the index cases (which in the early days constituted a greater 
proportion of any family case group) in any family group were nearly all discovered clinically, this 
exaggeration is even more so for the four groups other than Dublin (as they have a lower proportion of 
vitamin B6-nonrespondent patients than does Dublin), probably nearly a threefold exaggeration of 
treatment efficacy. 
(References related to the ascertainment bias in Mudd’s (1985) study being towards more severe cases: 
Skovby, Gaustadnes, Mudd 2010; Magner, Krupkova, Honzic et al 2011; Kluijtmans, Boers, Kraus et al 
1999; Cruysberg, Boers, Trijbels et al 1996; Janosik, Sokolova, Janosikova et al 2009)  
 
More to the point however, is that the treatments applied by these different groups of practitioners are 
quite different, in particular the Irish compared to the Dutch and to the Australian (See my Table 1 
below, and Yap et al 2000), and regarding the usually quite variable cysteine supplementation, which 
(Yap 2013 personal communication) is virtually universally only applied as part of the proprietary 
synthetic low-methionine, cysteine-enriched formula food, not as itself, and which has a far from perfect 
compliance with in that context by homocystinuric patients – usually the later in life treatment 
commences, the worse the compliance (Wilcken & Wilcken 1997, Walter et al 1998). It seems that with 
later average age of treatment commencement it is probable it is less attempted to prescribe, and still less 
achieved of compliance, than in the commendably thorough treatment/monitoring protocols of the Irish 
group. This lower compliance in the later-diagnosed cases is only somewhat ameliorated in its negative 
effects, due to the later-diagnosed cases being more often Vit B6-responsive cases, the Vit B6 
supplementation being substantially more complied with by homocystinuric patients. 
Analysis would more profitably have compared on this basis and sought biochemical theoretical basis 
for the differences amongst them, rather than proceeding as they have done. 
There is also an issue of non-compliant patients being excluded (maybe differentially more so from the 
Irish study group), but because ultimately further pursuance of this aspect would not change my 
recommendations, as it very probably does not distort the comparison of treatments (rather, enhances it), 
maybe only distorting comparison of centers of treatment, I only mention it here for completeness.  
 
I provide in the following table, data reproduced from tables in Yap et al (2001), as well as the results of 
my own corresponding, and further, analyses (all delineated by “According to Vance”), which includes 
the appropriate refinement of adjusting the number of thromboses for any compared group by a factor 
addressing the ratio of Total VitB6-responsive:-nonresponsive treatment years, derived in part from 
proportionate movement away from the “all types combined” graph line some commensurate distance 
towards whichever of the VitB6-responsive/-nonresponsive graph lines was appropriate, before 
projecting across to the y axis.  
 
The fact that the number of VitB6-responsive/-nonresponsive CBS-- are closely proportional to the 
number of respective treatment years meets one condition necessary for the validity of that procedure.  
 
My tests of statistical significance are by the method for comparison of proportions in independent 
samples provided by Snedecor and Cochran (1989), done by hand.  
 
The Yap et al (2001) data was drawn by them from: Yap & Naughten (1998), Kluitjmans et al (1999), 
Wilcken & Wilcken (1997), Yap et al (2000), and Walter et al (1998). 
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Table 1. Yap et al (2001) data, and comparative and further analyses on it by Vance. 
                                                Dublin    Sydney    Nijmegen    Manchester   London    
 
n CBS--                                       28           40                30             31                  41 
n CBS-- followed                        27           32                28             30                  41 
 
n VitB6-responsive followed        1           17                 19               8                 25 
Total VitB6-resp treat-years       13.7      315               250           183.1            482 
AverageVitB6-resp treat-years   13.7        18.5              13.2          22.9              19.5 
 
n VitB6-nonrespons followed     26            15                   9             22                16 
Total VitB6-nonr treat-years     444.0       288               169           385.5           291 
Average VitB6-nonr treat-years  17.1         19.2              18.8          17.5             18.2 
 
Age/y at treatment start                 0.8          12.9              22.8           6.7             11.4 
Age/y at study present (1998)     18.1          32                 38.5          26.5             30.7 
 
n thrombosis events                       0               2                   1              3              9in4pts 
 
Mudd-predicted n thrombosis      18             24                 16            23                 31 
According to Yap et al 
 
P n thrombosis events vs            <.0001    <.0001         .0026       <.0001          .0004 
Mudd-predicted n thrombosis 
According to Yap et al   
Total treat-years ratio of         1.00:31.7   1.09:1.00    1.48:1.00   1.00:2.11   1.66:1.00 
VitB6-responsive:-nonresp 
According to Vance 
 
Mudd-predicted % thrombosis   31%          37%             19%          43%             39%   
According to Vance 
 
Mudd-predicted n thrombosis       8.37        11.8               5.42         12.9             16.1      
According to Vance 
 
P n thrombo events vs                <.0001     .0004             .0414        .0004          .0002 
Mudd-predicted n thrombosis 
According to Vance 
 
P n thrombo events Dublin vs                  (                               0.139a                          )             
The other four combined                          (                               0.165b                          ) 
According to Vance 
 
P n thrombo events Dublin vs                                                            .091a        .095a 
The other four singly                                   0.230b          0.204b     0.16b        0.14b 
According to Vance 
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VitB6-responsives 
Free Hcy(ine)                   (n = 1) 9.4uM                                           13.0uM   14.6uM 
Total free Hcy                                              <20uM          7uM 
tHcy (value = derived)   (n = 1)140uM     <(40-80)uM    30uM       110uM    110uM  
 
VitB6-nonresponsives 
Free Hcy(ine)                             17uM                                               31uM     33uM 
Total free Hcy                                                33uM          34uM 
tHcy (value = derived)            108uM           80uM          88uM       130uM    130uM  
 
Diet Met/day                   200-625+aaCys  GenAdvice   600        160-900      400-1375 
Restriction (mg/day) 
 
VitB6 (mg/day)                      100-800    100-200      200-750       50-500      20-500 
 
Folate                                    5mg/day     5mg/day     5mg/day      5mg/day    5-10mg/d 
 
VitB12                                 if deficient       to all      if deficient         nil         50ugoral 
 
Betaine                                 3-6g/day      6-9g/day      6g/day     4.5-15g/day   2-6g/day 
 
Note: No further detail supplied differentiative of VitB6-responders/–nonresponders. 
 
Venupuncture                  >=8-10/year    1-4/year     1-2/year         1-4/year     2-4/year           
Where: 
a = not adj for Total treat-years ratio of VitB6-responsive:-nonresp 
b = adj for Total treat-years ratio of VitB6-responsive:-nonresp 
Free Hcy(ine) = plasma free homocystine,   
Total free Hcy (fHcy) = free Hcy(ine) + plasma Cys-Hcy, 
GenAdvice = general advice 
tHcy (value = derived) = signifies that the underlined value has been derived by me from the other 
values not underlined, presented by Yap et al (2003) but implicitly pertaining to the Yap et al (2001) 
data. The derivations use the following algorithms: 
For Manchester and London a change of the Bonham et al (1997) algorithm of  
tHcy = 60uM + 4.5 * (Hcy(ine) <20uM) + 2*(Hcy(ine)>20uM), 
to that more consistent with the Given Dublin correlates, that is,  
tHcy = 50uM + 3.5 * (Hcy(ine) <20uM) + 2*(Hcy(ine)>20uM); 
For Sydney, a rough mean of the tHcy = 40uM + fHcy rule (Wiley et al (1989) with derivations 
involving the amount of protein per blood volume) and the relationship of the Nijmegen correlates. 
 
So, there is statistically significantly (at the P<.05 level) less thromboses outcomes in the treated and 
followed CBS-- patient groups of each of the five groups, even when considered singly, to that expected 
in the absence of treatment by reference to the natural history data of Mudd et al (1985). There is a 
substantial suggestion that the thromboses outcome of the Dublin group is better than that of the other 
four groups, but this does not attain statistical significance at the P<.05 level (P ~ 0.16 with the other 
four groups combined, or P ranging from 0.14 to 0.23 with the other four groups each taken singly). 
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The possible relationship of any differences in thrombosis outcomes to respective treatment regimes is 
addressed in the Discussion section below. 
 
 
3.6 Discussion of results of analysis of Yap et al (2001/ 2003) data by Vance here: 
 
Firstly, my rough derivation, from data provided by Anderson et al’s (1991) community-wide study of 
16 short-stay hospitals in metropolitan Worcester, Massachusetts, USA, indicates that the population 
(this would include CBS-- cases) rate of incidence of deep vein thrombosis (DVT) or pulmonary 
embolism (PE) was one per 20 people over an average lifespan of 80 years. Of course the very large 
majority of these would occur at ages > 40 years, whereas most of the CBS-- subjects of this work are 
aged <40 years, and in the four groups other than Dublin had very roughly one deep vein thrombosis or 
pulmonary embolism per 10 people, at a much younger age than the age at which DVT/PE occurs in the 
general population.  
However, Anderson et al state that because of the silent nature of such events and the low rate of 
autopsy in the USA, the total incidence, prevalence, and mortality rates of venous thromboembolism 
remain elusive (and will include the CBS--).  
Even given the lack of opportunity for formal statistical comparison of the rates of thrombosis found in 
the five (four) groups studied here, taking into account the aforementioned aspects, as well as that most 
of the general population thromboses are preventable by diet and other lifestyle factors like physical 
exercise and non-smoking, it seems  safe to assume that the rates of thromboses observed in the five (the 
four other than Dublin) groups studied here are substantially in excess of the real rate in the (non-CBS--) 
general population for these age groups, and very much to the point are very likely to increase with the 
ageing of the CBS-- patients, and therefore desirable of further lowering. 
This latter aspect further validates the carrying out of the numerical and other analyses done here.    
 
Without belabouring the point of the differences in outcomes between Yap et al’s (2001) and my 
analyses (in particular their risk ratio of .09 for treatment versus non-treatment, compared to my 
calculation (using only the periods of time under treatment, not the period of time from birth, which that 
difference suggests they used) of the risk ratio being a more modest claim of treatment success of 0.2 
(that is, a claim of only half the treatment success) for the five groups combined (and substantially less 
for the four non-Dublin groups, as noted above)) I move to suggesting that the differences between the 
Irish outcomes and the other outcomes are worth noting, particularly in the light of small numbers 
overall plausibly being a factor in the statistical significances of the comparisons not quite reaching any 
(arbitrary, if generally reasonable) criteria set at P<.05. 
 
However, it is necessary to consider the fact that Dublin’s (and less so Manchester’s) patients were on 
treatment in early childhood whereas the other centers’ patients were not. It is necessary to identify 
potential biases, their types and their directions, and their potential relative magnitudes and net effect, 
such as in producing ascertainment bias of cases towards or away from a predisposition to thrombosis.  
 
Note that while on the one hand thromboses are a small part of the symptoms contributing towards 
ascertainment of the non-newborn-screening CBS-- cases that effectively do not constitute any of the 
Irish (approx all newborn-screening ascertained) and therefore insofar give an ascertainment bias 
towards the non-Irish groups having more thromboses, on the other hand the Dublin cases are on CBS 
genetic bases alone more severe, being of the vitamin B6-nonresponsive type, whereas all the other 
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centers are much closer (roughly 1:1 to 1:2)  to being evenly comprised of B6-nonresponsive and B6-
responsive, giving insofar an ascertainment bias towards the Irish group being more predisposed to 
thrombosis.  
 
It is possible that clinical detection in the non-Dublin cases would drive a higher compliance with 
treatment, particularly in the earlier-detected vitamin B6-nonresponsive cases, but also in the vitamin 
B6-responsive cases, due to non-trivial disease manifestations being already experienced by the patient 
or members of their family, compared to drive from ascertainment via family studies, and even less so 
for drive from ascertainment by population screening. 
 
Compliance is of course a function of the experienced burden of the treatment, which might be 
reasonably said to be greater insofar as it included the synthetic low-methionine high-cysteine formula 
food (though cysteine should be able to be given as a single amino acid in a capsule(s) rather than as a 
more voluminous mixture of amino acids, relying on food for the other amino acids). However 
compliance is also a function of patient-doctor contact type and frequency, including the formation of 
dietary habits very early in life – though peer-group and other societal effects at various other stages of 
life can override such established dietary habits to varying extent and duration. 
 
The ‘total’ homocysteine (tHcy) (homocysteine in Hcy-Hcy dimer + Hcy-Cysteine mixed disulfide + 
Hcy bound to plasma proteins + free homocysteine) levels of the Dublin CBS-- cases are nonetheless in 
the middle of the range of the five centers (tHcy approximately 110 micromoles per liter versus 
approximately 80-130), though it might well be the case that the B6-nonresponsive cases in the other 
centers have higher tHcy, and the B6-responsive cases lower tHcy, than the combined averages given. 
 
Furthermore, the Dublin group of CBS-- experience much more venupuncture in the course of their 
metabolic monitoring, and venupuncture is noted to promote thrombosis.  
 
Also, the repeat thromboses of the English group have not been incorporated into the analysis, which 
increases their apparent treatment success in the numerical analysis. 
 
It should be borne in mind that Dublin has absolutely no events of thrombosis (in those on treatment), as 
yet. 
 
I suggest that a fair adjustment for these differences would put the difference in thromboses outcomes 
between the Dublin (treated) and the combined other groups in the direction of being more significant, 
not less significant, and therefore close enough to being statistically significant at the p<.05 level to even 
more definitely warrant further discussion. 
 
Even if earlier treatment of the Dublin group had conferred some advantage other than better later 
adherence to homocysteine-lowering treatment (this adherence seeming, on the basis of the tHcy levels 
derived, to be not much better), it is very likely to be due to differences in the body’s more permanent 
structures, rather than to differences in less permanent things like platelets and biochemicals in solution, 
(though of course these latter might themselves cause differences in the body’s more permanent 
structures). For example the protein fiber scaffolding of tissues including the walls of arteries and veins, 
in particular the protein fibrillin with its unusually high cysteine content and cysteine-cysteine double 
bonds. 
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I take the view that when the bias-relevant factors listed above are roughly though reasonably, and also 
conservatively, adjusted for, Dublin seems to have better treatment outcomes. I do not claim that this 
proves that Dublin’s treatment practice is better, I claim only that it suggests it.  
And consideration also of other metabolites and nutrients as follows here provides a reasonable 
theoretical support for cysteine supplementation being important. 
 
 
3.7 Discussion of relevant metabolism, metabolites and nutrients: homocysteine, cysteine, 
cystathionine; sulphate; glutathione; folate, vitamin B12, betaine; vitamin C; platelets; acid-base 
balance; and Oxidation Transamination Methionine Catabolic (OTAMC) pathway metabolites 
hydrogen sulphide, methane thiol, 3-methylthiopropionate, formate and formaldehyde. 
 
 
3.7.1 Diagram of relevant metabolism: 
 
Consider the following diagram of the metabolic pathways central to considerations of the CBS-- 
situation: 
 
Figure 2. Metabolic pathways central to cystathionine beta synthase deficiency (adapted from Mudd et 
al’s (2001) use of Mudd and Poole’s (1975) work)  
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3.7.2 Sulfate. 
 
“Approximately 19 percent of total sulphate comes from ingested inorganic sulphate from foods and 
17% of total comes from inorganic sulphate in drinking water and beverages. Many other sulfur 
compounds in food can yield inorganic sulphate as a result of degradation or turnover. Among organic 
compounds, methionine and cysteine in food proteins, glutathione in both animal and vegetable products 
(Wierbicka et al., 1989), taurine in animal-source foods, lanthionine (a cross-linked sulfur amino acid 
produced when protein-bound cysteine undergoes heat treatment at an alkaline pH), and sulphated 
glycosaminoglycans in both plant- and animal-derived foods are important contributors of organic 
sulphate, providing the remaining approximately 64 percent of total sulphate available for body needs. 
… 
Table 7.2 shows a fairly similar sulphate content related to calories or good proportion of diet amongst a 
fairly wide range of foods of different types 
… 
From Table 7.3 Sulfate levels:  
Cow milk                  100 mg/ L;  
Human milk                  5 mg/ L;  
Human infant formula 66 mg/ L 
… 
Human milk is very low in sulfate (5 mg/ L), and even though an average value for infant formula 
products (both milk- and soy-based) was found to be 13 times higher than that in human milk (66 mg/ 
L), these levels of sulphate are still lower than those in many sources of drinking water (Hoppe et al., 
1998).” 
(National Academy of Sciences 2004) 
 
Now, inorganic sulfate is quite readily absorbed from the GIT (Morris and Murer 2001, Florin et al 
1991), and this and renal secretion and reabsorption (this latter predominating over secretion, as the 
molecule is freely filterable; Becker at al (1960)) are quite the main mechanism of sulfate homeostasis.  
So although, for example, the family of recessively inherited osteochondroplasias, resulting from 
mutations in the Diastrophic Dysplasia Sulfate Transporter, are due to the undersulfation of 
proteoglygans in chondrocytes (Satoh et al 1998, Hastbacka et al 1994), it seems unlikely that 
derangement of sulfation is part of the mechanism of CBS-- pathology, unless in-situ generation of 
sulfate is a requirement, but this seems unlikely, as there are a number of sulfate-transporters seemingly 
supplying sulfate from ECF to the ICF of cells (effectively all types of cells?) that require sulfate for the 
production of 3-phosphoadenosine 5-phosphosulfate (PAPS) for some use(s) or other. 
 
So, given the above information, I will not consider sulfate any further here as an etiologic agent of 
CBS--, notwithstanding its manifold and varied role in biology, as I have not encountered any 
information suggesting an important role. 
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3.7.3 Cysteine. 
 
In accord with the enzyme defect in CBS it has been shown that requirement for cysteine is increased in 
CBS-- (Laster, Mudd, Finkelstein et al 1965; Carson, Dent, Field et al 1965; Brenton, Cusworth, Dent et 
al 1966; Perry, Dunn, Hansen et al 1966; Komrower, Lambert, Cusworth et al 1966; Perry, Hansen, 
Love et al 1968), though even 2% of normal CBS activity may allow the processing of 50% of 
methionine (via homocysteine) into cysteine (Poole, Mudd, Conerly, Edwards 1975) though the 
remaining excess methionine/ homocysteine then increases up to high levels, indicating insufficiency.   
Inspection of the cysteine levels given in Chapter 4 below shows them to be consistently lower than 
normal, roughly 1/2 to 2/3 of normal, in CBS-- cases considered to be generally satisfactorily treated.  
 
Milewicz et al (2000) review that Marfan Syndrome (MFS, OMIM #154700) is an autosomal dominant 
disorder affecting multiple systems, including the cardiovascular, ocular and skeletal systems. The 
cardiovascular pathologies include aortic aneurysms and dissections, and mitral valve regurgitation/ 
prolapse. Ocular pathologies are ectopia lentis and myopia. Skeletal pathologies include 
dolichostenomelia, arachnodactyly, kyphoscoliosis, pectus deformities, pes planus, and highly arched 
palate with crowding of frontal teeth. 
They note it has been established that mutations in the gene for fibrillin-1, an elastic fiber, are 
responsible for most MFS cases.  
Sakai et al (1991) report that fibrillin contains 14% cysteine (an unusually high content among proteins), 
of which one third appeared to be in the free reactive sulfhydryl form. Disulfide bonds play a major role 
in the fibrillin protein’s structure. 
 
CBS-- has in common with MFS many of the abovementioned pathological features (hence the term 
“Marfanoid habitus of CBS--”) (Mudd, Skovby, levy et al 1985; McCully 1969; Perry et al 1968; 
Brenton et al 1966; Carson et al 1965; Gibson et al 1964), such that in times predating differentiation 
such CBS-- cases would be lumped in under the MFS diagnosis.    
 
Majors and Pyeritz (2000) report their investigations following on speculation by themselves and others 
that in CBS-- the altered plasma concentrations of homocysteine and/or cysteine may hinder the 
synthesis, deposition, or both, of fibrillin-1. They report that when arterial smooth muscle cells were 
cultured under conditions of cysteine deficiency fibrillin-1 deposition into the extracellular matrix was 
greatly diminished (and restored with addition of cysteine), but that excessive homocysteine in contrast 
had little if any effect on fibrillin-1 deposition.  
Type I collagen, the major matrix component synthesized by these smooth muscle cells, was not reduced 
by low cysteine concentrations nor high homocysteine concentrations. 
 
In VitB6-responsive CBS--, the use of VitB6, as a sole treatment, such as to lower methionine to and 
homocysteine (relatively) near to normal levels, must therefore also have increased cysteine to near 
normal levels, with regard to its coming from the CBS pathway represented at the bottom of the 
diagram. 
Now, if it is necessary to lower methionine intake to lower methionine and (focally) homocysteine to 
near normal levels, the question must arise as to whether the products of the CBS pathway, in particular 
cysteine, become deranged, and to what extent – in this particular case, it would be expected that 
cysteine would be reduced – less homocysteine to drive the CBS pathway, resulting in less cysteine. 
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The use of methionine-restriction in non-synthetic food as a sole treatment would be very likely to 
decrease the supply/ metabolic production of cysteine and to result in cysteine deficiency of some level. 
Now, if one adds folate, betaine, or VitB12 to the initially (however) successful VitB6-treatment of 
VitB6-responsive CBS--, this will reduce the drive down the CBS pathway, resulting in less cysteine. 
At this point it seems reasonable to suggest that a decrease in dietary methionine might benefit from an 
accompanying addition of cysteine to make good the resultant decrease of the latter.  
 
And likewise, an increase in folate, betaine, and/or VitB12 might benefit from an accompanying 
addition of cysteine to make good the decrease in metabolic production of cysteine due to the increased 
folate, betaine and/or VitB12 having routed more of the homocysteine down the remethylation pathway.  
Use of combinations of these would potentially benefit from further increases in the additional cysteine.  
 
In VitB6-nonresponsive CBS--, methionine-restriction as a sole therapy would be very likely to result in 
an even more deficient level of cysteine than that pre-treatment, as even careful dietary compositing 
must reduce cysteine also, as they are substantially positively correlated in foods in both being protein 
constituents – in practice this compositing constitutes a move to a lower-protein diet, with plant protein 
sources predominating over animal protein sources.  
 
The addition of folate, VitB12, and betaine to the methionine-restriction and cysteine-supplementation 
treatment of VitB6-nonresponsive CBS-- would not be expected to result in as lowered, or any at all 
less, metabolic production of cysteine, as would be the case in VitB6-responsive CBS--.  
However, in the event of folate, VitB12 and/or betaine treatments displacing, through either CBS-- 
patient non-compliance or physician non-emphasis, either the methionine-restriction of diet, or the 
cysteine supplementation (the latter two both via the same synthetic formula food, in the current 
standard treatment), then cysteine levels would be reduced accordingly.          
 
Note that the Irish treatment regime is instituted from birth, and is reinforced thereafter in the most 
thoroughgoing manner of all the CBS-- treatment centres considered here (though the Vit B6-
nonresponsivity of their patients is the highest and therefore the most needing of reinforcement), and 
that it is probable that the Irish accordingly have better compliance with cysteine supplementation than 
the other centers, particularly if it is over-connected in the minds of the patients/carers with use of the 
low-methionine (lower-protein) diet. Such over-connection is not valid, particularly in the case of 
VitB6-nonresponsive CBS--, in particularly the case of non-compliance with any low-methionine diet 
that has been structured to include higher cysteine:methionine ratio, but also in any case (cysteine-
methionine correlation in foodstuffs being sufficiently high as noted above), and it is erroneous and 
undesirable to view non-compliance with the low-methionine diet as at all a good reason for non-
compliance with cysteine supplementation, notwithstanding that cysteine supplementation seems mainly 
to have been confined to and offered as synthetic low-methionine, high-cysteine formula foods.  
In the case of VitB6-responsive CBS-- patients that have been prescribed a low-methionine diet that has 
not been structured to include higher cysteine: methionine ratio, non-compliance with cysteine 
supplementation per se (in the apparently unlikely event that it has been attempted to institute 
supplementation with cysteine as itself) is much less likely to be problematic, but is still undesirable.  
 
Hosoki, Matsuki, Kimura (1997) cite earlier work by one of their group and others (Abe and Kimura 
1996) that hydrogen sulfide can be formed from cysteine by (read via) CBS, which is highly expressed 
in the hippocampus and cerebellum, and that brain homogenates produce hydrogen sulfide, and that 
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physiological concentrations of hydrogen sulfide facilitate the induction of long-term potentiation in the 
hippocampus. Relevant to my work here they (1997) present results that they interpret as indicating that 
endogenous hydrogen sulfide may regulate smooth muscle tone in synergy with nitric oxide. 
 
  
3.7.4 Other Metabolites: The OTAMC pathway and hydrogen sulfide, methanethiol, 3-
methylthiopropionate, formate and formaldehyde. 
 
Discussion of other metabolites involved in CBS-- I am only in a position to deal with as a general 
concept, but even just the general concept is worth bearing in mind.   
 
In VitB6-responsive CBS--, if only VitB6 has been used to successfully lower both methionine and 
homocysteine to near normal levels, then it may be reasonably said that the resultant levels of all 
metabolites central to CBS-- have been perhaps close to effectively normalised – and this situation (all 
metabolites normalised) is probably/possibly the most desirable, practically. 
 
Now, if it is necessary to lower methionine intake to lower methionine and (focally) homocysteine to 
near normal levels, the question must arise as to whether (other) products of the CBS and oxidative 
transamination methionine catabolic (OTAMC) pathways become deranged, and if so to what extent.  
 
If one adds folate, betaine, or VitB12 to the initially (however) successful VitB6-treatment of VitB6-
responsive CBS--, then this will reduce the drive down the CBS pathway – but, via raised (above 
threshold >350uM, Tangerman, Wilcken, Levy 2000) methionine, will increase the drive down the 
OTAMC pathway, producing raised and potentially harmful levels of hydrogen sulfide, methanethiol, 3-
methylthiopropionate, formate, and formaldehyde  (Blom, Boers, van den Elzen et al 1989, Steele and 
Benevenga 1979). 
 
In VitB6-nonresponsive CBS--, methionine-restriction as a sole therapy would be very likely to result in 
an even more deficient level of metabolites downstream of cysteine in the CBS-- than the level pre-
treatment, unless careful dietary compositing had not reduced cysteine also (as noted above in the 
Cysteine section), but in a change towards normal of OTAMC pathway metabolites, particularly if 
assuming that normally flux through the OTAMC pathway is minimal (Tangerman, Wilcken, Levy 
2000).  
Addition of sufficient cysteine to methionine-restriction-treatment of VitB6-nonresponsive CBS-- would 
perhaps seem likely to result in little change in OTAMC pathway metabolites. 
 
The addition of folate, VitB12, and betaine to the methionine-restriction and cysteine-supplementation 
treatment of VitB6-nonresponsive CBS-- might increase OTAMC pathway metabolites via increased 
methionine. In the event of these latter treatments displacing, through either CBS-- patient non-
compliance or physician non-emphasis, either the methionine-restriction of diet or the cysteine 
supplementation, then OTAMC pathway metabolites would be expected to increase, or, metabolites 
downstream of cysteine in the CBS-- to decrease, respectively. 
 
So, there are other metabolites than the ones commonly focused on in CBS--, that are also deranged, and 
may contribute to some aspect(s) of CBS-- pathology. 
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3.7.5 Vitamin C. 
 
Pullin, Bonham, McDowell et al (2002) report that after treatment of 5 CBS-- patients (mean age 26 yrs, 
all treated with vitamin B6, and folate, four treated with betaine, two treated with a “methionine-free 
protein mix”, one treated with VitB12, such as to result in tHcy mean 100 uM vs 5 controls 9 uM) 
acutely with 2 g of vitamin C once, or chronically with 1 g of vitamin C/ day for 2 weeks or 6 months, 
endothelium-dependent Flow-Mediated Dilatation (FMD) was restored from a baseline of mean 20um 
(vs controls mean 116um) to 160um, 170um, and 170um, respectively. This was highly statistically 
significant (P<.001 for all time-points).  
Note that there was no blinding in this experiment, and that CBS-- patient behaviour in other regards, ie 
compliance to other treatment modalities ie including diet may have changed as a result. 
 
FMD has been found to be strongly negatively associated with the following prothrombotic states: 
Systemic hypertension; FMD 4.8% vs controls 8.6%, P<.001 (Felmeden, Spencer, Chung et al 2003), 
Stable coronary artery disease; FMD 2.4% vs controls 8.5%, P<.001 (Lee, Blann, Lip 2005), 
Primary antiphospholipid syndrome; FMD 8% vs controls 15%, P<.001 (Stalc, Poredos, Peternel et al 
2005).  
However, it is not clear whether differentiation of the FMD-reduction etiology has a bearing on 
tendency to thrombosis.  
Nevertheless, there is a fairly strong suggestion that reduced FMD might be a contributor to the 
thromboses found in untreated CBS-- patients, and also to a lesser extent amongst CBS-- patients under 
some treatment regimes, although of course compliance is always a factor.       
 
Now, 1g of vitamin C would be supplied by (the second digits being almost meaningless in most cases 
due to the great variability between different batches of fruit or vegetables):  
(Fruits)  
0.42 kg of Hawaiian guava,  
1.4 kg of kiwifruit,  
1.7 kg of pawpaw,  
2 kg of lychee fruit,  
2.3 kg of custard apple,  
2.9 kg of rockmelon,  
3.6 kg of mango,  
5 kg of pineapple,  
5.6 kg of honeydew melon or prickly pear,  
6.7 kg of bananas,  
7 kg of persimmon,  
17 kg of apples or grapes,  
and not at all by any even vaguely feasible quantity of pears;  
(“Vegetables”)  
0.6 kg of raw red capsicums,  
0.9 kg of raw broccoli or Brussels sprouts,  
1.2 kg of boiled broccoli or Brussels sprouts,  
1 kg of raw mustard cabbage or watercress,  
1.4 kg of raw red cabbage or raw cauliflower or raw kohlrabi,  
2.2 kg of raw common cabbage,  
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2.8 kg of boiled common cabbage,  
3.4 kg of boiled broad beans,  
5 kg of boiled potato or sweet potato,  
5.3 kg of boiled fresh kidney beans,  
5.6 kg of raw common tomato,  
6.7 kg of Lebanese cucumber,  
8 kg of raw bean sprouts,  
8.3 kg of boiled pumpkin, 
12 kg of common cucumber,  
and not at all by any even vaguely feasible quantity of lettuce and even less so of any legume dried then 
boiled  
(ANZFA 1991).  
 
Furthermore, amongst these and other foods are substantial amounts of other antioxidant nutrients such 
as vitamin E and carotenoids, which are very likely to reduce the absolute amount of vitamin C required 
for most of  its biological functions, and certainly its antioxidative functions.  
 
It can thus be seen that dietary modifications on their own could probably bring about the vitamin C 
related increase in FMD noted by Pullen et al (2002). Cultivating complete enough compliance to such 
dietary modifications might be impossible or too difficult, or inefficient, but even if so, some substantial 
compliance combined with antioxidant supplementation (vitamin C, vitamin E, carotenoids, and perhaps 
others) seems to me obviously worth doing, particularly bearing later-life outcomes in mind. 
 
The question then follows as to whether CBS-- treatment regimens that achieve compliance with low-
methionine diets, which in practice have/ should have an increased amount of fruit and vegetables, are 
achieving an improved thrombosis outcome via improved FMD via increased intake of vitamin C and 
other antioxidant nutrients. 
 
Note that the Irish treatment regime is instituted from birth, and is reinforced thereafter in the most 
thoroughgoing manner of all the CBS-- treatment centres considered here (though compliance is more 
crucial for their very predominantly VitB6-nonresponsive patient group), and that it is probable that they 
accordingly have better compliance (though they have some non-compliance) than those other centers. 
 
Also, it is potentially of importance, in regard to antioxidants, to note that cysteine in the body is joined 
to glutamate and glycine to make glutathione, which is one of the body’s most important antioxidants 
(see below). 
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3.7.6 Glutathione 
 
Glutathione is formed in the body from cysteine, joined to glutamate and glycine. 
 
Glutathione is one of the body’s most important antioxidants, reducing peroxides (Nimni, Han, Cordoba 
2007). 
 
Glutathione also functions normally to keep a substantial portion of the cysteines in protein in a reduced 
state at their thiol side-chain, rather than those thiols being linked in disulfide bonds to other cysteines in 
the same protein chain, in different protein chains, or to thiol side-chains of molecules like cysteine and 
homocysteine. 
This activity is probably a function of the extent to which the thiol (the disulphide bond, as acted on) is 
exposed, and the nature of the other molecule joined to the protein in the disulphide bond.  
Note that homocysteine is considered to bond to not only itself, but also to cysteine, more strongly than 
cysteine bonds to cysteine – this probably applies also in the context of the cysteine being part of a 
protein chain. 
 
Obviously, then, a shortage of cysteine will potentially, via a shortage of glutathione, have a negative 
effect both on antioxidation function and on protein assembly and configuration (particularly, on 
average, the greater the proportion of cysteines there are in a protein, for example fibrillin, a very high-
cysteine protein molecule the misfunction of which is very probably involved in the lenticular dysplasia 
(eye lense displacement) that is characteristic of more severe cases of CBS-- homocystinuria. 
 
 
3.7.7 Acid-base balance. 
 
Remer (2002) notes that acidification of the human body is more closely tied to higher food sulfur 
amino acid levels than to food amino acid levels per se.  
Based on this and other aspects of his review one would expect the low-methionine diet as commonly 
employed in CBS-- to lead to a reduction in acidity.  
However, the sparse literature (ie Martini, Pusateri, Uscilowicz et al 2005) suggests that acidosis is 
associated with reduced, not increased, coagulation.  
What bearing any alkalizing effect of the low-methionine diet as commonly employed in CBS-- might 
have on thrombosis (in CBS-- patients) seems unclear. 
 
In a more general sense, it seems that humans generally are evolved to best eat a predominantly 
vegetarian low-protein diet with enough fruit and vegetables to generally meet most of the water 
requirement (Vance 2011), and that this would be a more alkalizing diet than the high-protein, low-fruit 
and -vegetable diets common in most western (and increasingly, unfortunately, in many Eastern) 
societies.     
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3.7.8 Cystathionine. 
 
Brenton, Cusworth, Gaull (1965), of autopsies on two CBS-- patients dying of postoperative pulmonary 
thromboembolism aged 9 years, and 14 controls, reports:  
“….the strikingly low concentrations of free cystathionine in all parts of the brains examined in 
homocystinurics (0.0-0.4 mg/100gWetW) as compared to normal brains from patients dying from 
entirely unrelated conditions…”,  
but also  
“If (n = 11) the adult control tissues alone are considered, the various areas of brain show striking 
differences in the concentration of free cystathionine from one area to another: Occipital lobe (12-90) > 
Frontal lobe (11,13) > Pons and Medulla (8,5) > lateral lobe of Cerebellum (3.5, 2)”  
in conjunction with  
“The other sulphur containing free amino acids showed no difference either between controls and 
homocystinurics or between various areas.” (This seems suspect, fairly unlikely, to me – the assay 
techniques, and maybe therefore for cystathinine itself, used here, may have been faulty.) 
 
One meaning of this is basically that cystathionine is potentially not merely an intermediate in the 
transsulfuration pathway, with no biochemical function of its own, in all tissues. How this might relate 
to CBS-- pathology is not well defined, even regarding the possibility of involvement in CBS-- patient 
clumsiness and gait disturbance, where homocysteic acid as a neural excitotoxin must also be considered 
a possibility (Sommer, Hunzinger, Schillo et al 2004, Adalbert, Engelhardt, Siklos 2002).   
 
Further research is required to elucidate any importance of cystathionine in CBS--. 
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3.7.9 Homocysteine. 
 
It is beyond the scope of this work to consider the likely involvement of the many postulated 
mechanisms of homocysteine pathogenesis, with the thrombosis outcome that is the focus of this paper, 
and this has not been established elsewhere, so I only list the following potential mechanisms noted by 
recent reviewers:  
The high pKa (10.0) of the homocysteine sulfhydryl moiety enabling it to form stable bonds with protein 
cysteine residues, impairing the function of proteins such as albumin, fibronectin, transthyretin, annexin 
II, and factor V (Jacobsen, Catanescu, Dibello et al 2005) (Note that the bond strength of homocysteine-
homocysteine (“homocystine”) is greater than the bond strength of homocysteine-cysteine, which is 
greater than the bond strength of cysteine-ceysteine (“cysteine”)); 
angiotoxicity, neurotoxicity, and inhibition of collagen cross-linking (Kuo, Sorond, Chen et al 2005); 
impaired vascular endothelium-dependent Flow-Mediated Dilation (Moat and McDowell 2005);  
inhibition of endothelial nitric oxide synthase by its endogenous inhibitor asymmetric dimethylarginine, 
and oxidative inactivation of nitric oxide mediated by upregulation of prooxidant enzymes and 
downregulation of antioxidant enzymes (Wilson and Lentz 2005);  
attenuation of GABA-A/B receptors and increasing redox stress, which activates a disintegrin and 
metalloproteinase that suppresses tissue inhibitors of metalloproteinase (Tyagi, Lominadze, Roberts 
2005). 
 
Also note the report by Hutchinson, Aplin, Webb et al (2004) concluding that reduction of 
intramolecular calcium binding epidermal growth factor like (cbEGF) domain (i.e. of the cysteine-rich 
fibrillin-1 elastic fiber protein) disulfide bonds by homocysteine and the resulting disruption of structure 
may contribute to the change in connective tissue function seen in homocystinuria, but that other 
cbEGF-containing proteins may also be involved in CBS-- pathology. It seems plausible that both 
homocysteine excess and cysteine deficiency could play joint roles in at least this latter aspect of CBS-- 
pathology.      
 
Unfortunately, comparison of the homocysteine levels of the five centers examined in this work 
provides little information -  the algorithms I’ve used to derive those of the tHcy values that had to be 
derived, though reasonable, are fairly rough, and the tHcy values have little consistent association with 
the thromboses outcomes – while the UK centers London and Manchester had both higher tHcy levels 
and more thromboses than the other three centers, Nijmegen and Sydney had lower homocysteine levels 
but more thromboses than Dublin.  
And here of course the comparison should incorporate VitB6-responsivity, but that differentiation of 
data is not available from Yap, Boers, Wilcken et al (2001).  
Also it is not guaranteed that the different monitoring schedules (in conjunction with other aspects) of 
the different centers give rise to equal representativity of the assayed homocysteine values of the 
average homocysteine values, nor that such averages are of more relevance than i.e. maxima.  
Any attempt to relate the tHcy values to the treatment regimens should incorporate VitB6-responsivity, 
but that differentiation of data is not available from Yap, Boers, Wilcken et al (2001), and given the 
relative closeness of the five regimens, even guarded speculation has little to offer here.  
And finally, the tHcy values are not greatly different from each other.   
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3.7.10 Platelets. 
 
McDonald, Bray, Field et al (1964) used the platelet stickiness method of Wright 1941, McDonald and 
Edgill 1957, 1958, to report that 5 CBS-- patients aged 4-15y had 46%, 58%, 60%, 48%, 48%, average 
54% of platelets remaining at 20 minutes, while the 5 similarly aged controls had 50%, 85%, 77%, 85%, 
75%, average 80% of platelets remaining at 20 minutes. However a correction for platelet count (CBS-- 
average 296,000/ul, control average 216,00/ul) might have decreased the observed difference to little or 
nothing. 
 
Brenton, Cusworth, Dent et al (1966) report that during the course of nitrogen balance studies in one 
CBS-- case, SM, “The platelets appeared to be equally abnormal in the first, third and fourth periods and 
no decreased stickiness had occurred when the last measurement was made 2 days before SM’s 
discharge although the plasma methionine levels had been near normal values for 5 days.  
The only change in platelet behaviour was in the second period (supplementary cysteine replaced with 
methionine) when temporarily they were more sticky than usual and clumped together to such an extent 
that it was not possible to count them.”  
They report to the contrary that in trials of a low-methionine, low-protein diet in another CBS--, RM, 
“Platelet stickiness was measured 3 times in RM. Once before starting the diet, and on the 8th and 22nd 
day after starting it. On all three occasions the platelets were grossly abnormal in behaviour and the 
improvements induced by the diet in plasma amino acid concentration (reported: plasma methionine 
from 12mg/dl to 1-2mg/dl, free homocysteine from 130uM to 100uM) were not obviously associated 
with any decrease in platelet stickiness…. 
The dietary trial here was long enough to allow regeneration of all platelets, taking the life of a platelet 
to be 8 days, so that the failure to improve was not due to the persistence of permanently injured 
platelets in the circulation.”  
However, note that the change in homocysteine levels was not great, and not equal to that able to be 
obtained by full or even substantial compliance with the specified regimens of any of the five centers 
studied here. 
 
Komrower, Lambert, Cusworth, Westall (1966) report of a trial of a calcium cystinate-supplemented 
low-protein branched-chain ketoaciduria diet which generally achieved approximately undetectable free 
homocysteine levels (other than those attending infrequent indiscretions), that is to say tHcy levels 
approximately <40uM, in CBS-- case treated from infancy to age 2.3 years with good outcome, that 
“platelet stickiness of 72%” was “considered well within the normal range of this technique.” 
 
Harker, Schlichter, Scott et al (1974) reported on the following groups: 
Two VitB6-nonresponsive CBS-- patients, diagnosed at age 20 years and 16 years, one of whom had 
tHcy>200uM and the other probably likewise, had a platelet count of mean 297,000/ul and platelet 
survival of mean 5.0 days; 
Two VitB6-responsive treated CBS-- patients, diagnosed at age 8 years and 16 years, with tHcy of 
approximately <100uM and 50uM and a platelet count of mean 197,000/ul and platelet survival of mean 
8.6 days;  
Thirty five normal controls with a platelet count of mean 250,000/ul and a platelet survival of mean 9.5 
days. 
They carried out further platelet function tests and homocysteine infusion experiments using baboons, to 
further report that platelet destruction was not due to a direct toxic effect of homocysteine on platelets, 
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since dipyridamole therapy blocked platelet consumption, nor was it due to enhanced platelet reactivity. 
They therefore concluded that the underlying process of CBS-- thromboses probably involves formation 
of platelet thrombus on altered, nonendothelialized endarterial surfaces. 
 
Grobe, Balleisen, Stahl (1979) reported that in three VitB6-responsive CBS-- cases, collagen-, ADP-, 
and adrenalin-induced platelet aggregation was decreased (not my misprint) before treatment started, 
and returned to normal when homocystine disappeared from plasma. They concluded that the platelet 
alterations in untreated patients result from their refractory stage after a release reaction has already 
taken place, as maybe caused by homocysteine-caused endothelial damage. 
 
Hill-Zobel, Pyeritz, Scheffel et al (1982) harvested platelets from six VitB6-nonresponsive CBS-- 
patients (treated with VitB6 and folate), six VitB6-responsive CBS-- patients (treated with VitB6), and 
11 normal volunteers, labelled them with 
111
Indium and reinfused them to note no substantial differences 
(a maximum difference between any two groups of approximately 5% of the survival times found) in 
platelet survival time according to any of three different mathematical models. 
 
Newman and Mitchell (1984) report on a 20 year-old female CBS-- case diagnosed eventually (and later 
found to be VitB6-responsive) after thrombotic sequelae following one month after first parturition, 
whose platelets while on warfarin treatment (no CBS-- treatment) following on serial thrombectomies, 
had a very high count at 674,000/ul (normal <450,000/ul), and had a stirred, EDTA-added, whole-blood 
platelet disappearance of 20% in 6 minutes (normal <5%).  
However molondialdehyde-generation in clotted whole blood was normal, as was separated platelet rich 
plasma behaviour with regard to arachidonic acid-induced malondialdehyde production, and response to 
challenge with ADP, adrenaline and collagen. 
 
In conclusion, it seems reasonable to assume that platelets are more likely to generate thrombi 
when/after contacting damaged endovascular epithelium, and that reduced FMD causes pressure 
phenomena that probably increase thrombogenesis (as well as vascular endothelial damage).  
These phenomena are likely to apply not only to normal platelets, but also to deranged platelets.  
The other obvious inconsistencies in, and incompleteness of, the information discussed on platelet 
behaviour in CBS-- patients I am unable to resolve in general and in particular with regard to the 
differences in thromboses outcomes of Dublin versus the other four groups examined here.    
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3.8 Overall conclusion for Chapter 3. 
 
There seems enough evidence to warrant consideration that cysteine supplementation may be of more 
importance than generally acknowledged, in the treatment of CBS--, and that it should be seen as a 
standard part of all treatment regimes, not only as part of a synthetic formula CBS-- diet food. 
 
Perhaps in some cases the cysteine dose should be varied more systematically as a function of the use of 
homocysteine-lowering treatment modalities other than VitB6 (such as folate and/or vitamin B12 and/or 
betaine, that reduce metabolic flow of homocysteine down the CBS transsulfuration pathway in VitB6-
responsive CBS--, by allowing it to escape down the remethylation pathway), when it becomes 
potentially even more important, although reduced homocysteine levels resulting in less sequestration of 
cysteine in homocysteine-cysteine and less other interference with cysteine would (variably) ameliorate 
this.  
 
Likewise, that low-methionine, high-fruit and vegetable diets may be of more importance than generally 
acknowledged, and that where compliance with this is compromised (and perhaps in any case, to some 
extent), supplementation with (at least) vitamin C and other antioxidants should be implemented, though 
hopefully not in a manner so as to further displace the diet.  
 
Also, the apparent thoroughness of the Dublin group with regard to the reinforcement/cultivation of 
compliance with dietary treatment, though they do not have a perfect success in this regard, is 
potentially worthy of study and emulation.  
Though, perhaps those patients/ parents who do not comply with low-methionine high-cysteine synthetic 
formula diets may well potentially comply with an appealing generally healthy low-methionine 
wholefood high-fruit and vegetable diet with cysteine supplementation via a capsule. 
 
It behoves to consider that these CBS-- cohorts are not yet into older age, when pathologic outcomes in 
general are greatly increased. 
 
Further study of these matters, at least via ongoing monitoring of treatments/outcomes, and improved 
detail of data collected, is obviously desirable.  
 
Clarification of platelet behaviour and mechanisms would potentially be helpful. 
 
It is redundant for me to note that further inquiry into the role of homocysteine in disease is desirable, 
but I add that some more attention to/inclusion of related other metabolites seems warranted.     
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Chapter 4. A table summarising or extracting the most important numerical data 
and word descriptions from literature on Cystathionine Beta Synthase deficiency 
Homocystinuria reviewed by this author (David Vance) in the course of researching this topic, as 
one topic included in the monograph at present being written on the biomedical significance of 
homocysteine.  
 
 
4.1 Chronological References (with key words) for Chapter 4 
 
Notes:  
This listing with its abbreviation is most suited for experts in the special field of study; manageable for 
those with a scientific background; and will be difficult for the general public. 
However, all readers including those amongst the general public can benefit from the extraction of the 
crucial data from the original articles and its collation into Chapter 4 here for readers’ convenience – of 
course the full critical reading of the original journal articles is always the surest way of assessing the 
meaning of them if one has the background to properly do that. 
Some readers may find it satisfactory for their purposes to check if some number of randomly or 
otherwise selected extractions in the table do indeed fully cover the important information in the original 
journal article, and if so to accept for their purposes that my extraction of the information from all 
journal articles has probably been sufficient.  
 
 
McDonald L, Bray C, Field C, Love F, Davies B (1964) Homocystinuria, thrombosis, and the blood platelets. 
Lancet, April: 745-746 ; Various hospitals UK, 5CBS-- aged 4-15y, coagulation studies (cites Carson et al 1963).  
p 54 
 
Gibson JB, Carson NAJ, NeillDW (1964) Pathological findings in homocystinuria. J Clin Path, 17: 427-437 ; 
Two hospitals, Belfast, Ireland, 7 males and 3 females from 7 families, age 1.5 – 32 years at detection, pathology.  
p 55 
  
Gerritsen T, Waisman HA (1964) Homocystinuria, an error in the metabolism of methionine. Pediatrics, March: 
413-420; Provides the biochemical details for the case RS of Chou SM et al (1965) (see below); U Wisconsin, 
USA.  p 58 
 
Chou SM, Waisman HA (1965) Spongy degeneration of the nervous system: case of homocystinuria. Arch 
Path,79 (April): 357-363; U Wisconsin, USA 1 case: CBS-- or cbl-- ?, pathology.  p 58 
 
Laster L, Mudd SH, Finkelstein JD, Irreverre F, Conerly B (1965) Homocystinuria due to cystathionine synthase 
deficiency: the metabolism of L-methionine. J Clin Invest, 44(10): 1708-1719; National Institutes of Health, 
Bethesda, Maryland, USA, 2 related CBS-- and controls (case details in Mudd et al 1964 and Finkelstein et al 
1964), methionine metabolism.  p 59 
 
Carson NAJ, Dent CE, Field CMB, Gaull GE (1965) Homocystinuria Clinical and pathological review of ten 
cases. J Pediatrics, March: 565-583; 2 Irish and 1 English hospitals, UK, 10 cases of homocystinuria discovered in 
a survey of 2,920 mentally retarded individuals in Northern Ireland, clinical, pathological.  p 60 
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Brenton DP, Cusworth DC, Gaull GE (1965a) Biochemical studies of tissues including a comparison with 
cystathioninuria. Pediatrics (35, January): 50-56; University College Hospital Medical School, London, UK, 2 
Hcy-uric children dying at age 9y from pulmonary embolism after eye op, and, 14 controls dying of various other 
causes, brain regional cystathionine.  p 63 
 
Brenton DP, Cusworth DC, Gaull GE (1965b) Homocystinuria: metabolic studies of 3 patients. J Pediatrics, 67(1, 
July): 59-68; U College Hospital Medical School, London, UK, 2  CBS--, aged 2-5y, 1 CBS-+ Obligate 
heterozygote parent, 3 control normal adult males, methionine loading.  p 64 
 
Schimke RN, McKusick VA, Huang T, Pollack AD (1965) Homocystinuria: studies of 20 families with 38 
affected members. JAMA 193(9): 711-719; various eastern USA, mostly examined at Johns Hopkins Hospital, 
Baltimore, Maryland, USA, 38 CBS-- cases, age 21y (3-45y), roughly normal distributed, skewed a little to the  
young, clinical, pathological.  p 65 
 
Harris ED, Sjoerdsma A (1966) Collagen profile in various clinical conditions. Lancet, Sat 1 Oct: 707-711; 
National Heart Institute, Bethesda, Maryland USA, 2  mental retarded CBS--, 2 norm IQ CBS--, 34 controls.  P 66 
 
Brenton DP, Cusworth DC, Dent CE, Jones EE (1966) Homocystinuria Clinical and dietary studies. Quart J Med, 
139, July: 325-349; University College Hospital and Medical School, London, UK, 2 CBS-- cases, dietary 
methionine and cysteine, nitrogen balance.  p 67 
 
Note: To compare with 2 other untreated CBS-- siblings, see Perry et al (1968) below.  p 69 
 
Komrower GM, Lambert AM, Cusworth DC, Westall RG (1966) Dietary treatment of homocystinuria. Arch Dis 
Childh 41: 666-671; University College Hospital, London, UK.; 1 CBS-- case with previously diagnosed 
homocystinuric elder siblings, dietary and plasma cysteine/cysteine.  p 70 
 
Gaull GE (1967) The pathogenesis of homocystinuria. Amer J Dis Child, 113, Jan: 103-108; USA, report on a 
communication received from Perry on the follow-up of the  Perry (1966)  case (see above), nitrogen balance, 
cysteine, methionine, taurine, methionine loading.  p 70 
 
Perry TL, Hansen S, Love DL, Crawford LE, Tischler B (1968) Treatment of homocystinuria with a low-
methionine diet, supplemental cystine, and a methyl donor. Lancet, 31 Aug: 474-478; U British Columbia, 
Vancouver, Canada, 3 CBS-- cases; methionine, cysteine, pyridoxine.  p 71 
 
Carey MC, Donovan DE, Fitzgerald O, McAuley FD (1968) Homocystinuria 1. A clinical and pathological study 
of nine subjects and six families. Am J Med, July (45): 7-25; 3 Hospitals, Dublin, Ireland, 9 CBS-- cases, 
pathology reports.  p 73 
 
Parkinson MS, Harper JR (1969) Therapeutic problems of adolescent homocystinuria. Proc Roy Soc Med 62(9): 
909-910; General Hospital, Northamp-ton, UK?, 1 CBS-- case; dietary noncompliance.  p 73 
 
Hopkins I, Townsley RRW (1969) Cerebral thrombosis in a patient with homocystinuria. J Pediatr 75(6/1): 1082-
1083; Royal Children’s Hospital, Melbourne, Australia, 3 CBS-- sibling cases, thrombosis.  p 74 
 
Perry TL, Dunn HG, Hansen S, MacDougall L, Warrington PD (1966) Early diagnosis and treatment of 
homocystinuria. Pediatrics 32: 502-505 ; U British Columbia, Vancouver, Canada, 1 baby boy, CS, 3.5kg 
birthweight, product of a normal pregnancy and delivery, two elder siblings having previously diagnosed 
homocystinuria, cow’s milk, breast-feeding, low-methionine diet, cysteine.  
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McCully KS  (1969) Vascular pathology of homocysteinemia: implications for the pathogenesis of 
arteriosclerosis; Am J Pathol 56(1): 111-128; Massachusetts General Hospital, Boston, USA, 1 CBS-- case, 
pathology.  p 74 
 
McCully KS (1970) Importance of homocysteine-induced abnormalities of proteoglycan structure in 
arteriosclerosis. Am J Pathol 59(1): 181-193; Massachusetts General Hospital, Boston, USA, 2 CBS-- cases, and, 
2 control, human cell lines.  p 75 
 
McCully KS (1972) Macromolecular basis for homocysteine-induced changes in proteoglycan structure in growth 
and arteriosclerosis. Am J Pathol 66(1): 83-95 Massachusetts General Hospital, Boston, USA, 2 CBS-- cases, and 
2 control human cell lines; sulphate, homocysteine thiolactone.  p 75 
 
Cross HE, Jensen AD (1973) Ocular manifestations in the Marfan Syndrome and homocystinuria. Am J Ophth 
March: 405-420; Johns Hopkins Hospital, Baltimore, Maryland, USA, CBS-- versus Fibrillin gene Marfan 
Syndrome,  
42 CBS-- Homocystinuria, ascertained by amino acid chromatography on ectopia lentis cases referred from 
ophthalmologists. 
142 Marfan Syndrome, all without homocystinuria, ascertained by clinical evaluation, and thereafter unselected.  
p 79 
 
Harker LA, Slichter SJ, Scott CR, Ross R (1974) Vascular injury and arterial thrombosis. NEJM 291(11): 537-
543; U Washington Sch Med, USA, 4 CBS-- cases, 34 controls; Vit B6, pathology, platelet studies.  p 80 
 
Poole JR, Mudd SH, Conerly EB, Edwards WA (1975) Homocystinuria due to cystathionine beta-synthase 
deficiency. Studies of nitrogen balance and sulfur excretion. J Clin Invest 55(5, May): 1033-1048.  p 82 
 
Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG (1977) Down’s Syndrome: an atheroma-free 
model? BMJ 2(6081, July 23): 226-228; Lennox Castle Institution, Glasgow, Scotland, UK, 70 CBS +++ trisomy 
Downs Syndrome cases versus 70 age- and sex-matched non-Down’s mentally defective cases vs 135 normal 
community controls, blood pressure, atheroma, cholesterol, triglycerides.  p 82 
 
Almgren B, Erikson I, Hemmingsson A, Hillerdal G, Larsson E, Aberg H (1978) Abdominal aortic aneurysm in 
homocystinuria. Acta Chir Scand 144: 545-548; U Hospital, Uppsala, Sweden, 1 CBS-- case, aortic aneurysm.   
p 83 
 
Grobe H, Balleisen, Stahl K (1979) Platelet function and morphology in homocystinuria. Ped Res 13: 72 ; U 
Munster, Germany (is an abstract only in the journal), 3 CBS--VitB6-responsives, 5 CBS-- VitB6?non/ 
responsives already under treatment, platelet studies.  p 84 
 
Hill-Zobel RL, PyeritzRE, Scheffel U, Malpica O, Engin S, Camaroo EE et al (1982) Kinetics and distribution of 
111-Indium-labelled platelets in patients with homocystinuria. NEJM 307(13): 781-786; Johns Hopkins U, 
Baltimore, Maryland, USA, 6 CBS--VitB6-responsives, 6 CBS--VitB6-non responsives, 11 normal volunteers, 
platelet studies.  p 84 
 
Wilcken DEL, Wilcken B, DudmanNPB, Tyrrell PA (1983) Homocystinuria – the effects of betaine in the 
treatment of patients not responsive to pyridoxine. NEJM, 309(8): 448-453; Prince Henry Hospital, Sydney, 
Australia, 10 CBS--: (by enzyme, Hcy-uria, high methionine), aged 6-37y, (8 VitB6-nonresponsives, 2 VitB6-
partially responsives), 25 adult controls, methionine, cysteine.  p 85 
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Dudman NPB, Wilcken DEL (1983) Increased plasma copper in patients with homocystinuria due to 
cystathionine beta-synthase deficiency. Clinica Chimica Acta 149(2-3): 117-127; Prince Henry Hospital, Sydney, 
Australia, 14 CBS-- cases (by enzyme, Hcy-uria, high methionine), aged 4-53y,  (6 VitB6-nonresponsives,  8 
VitB6-(partially?) responsives), and, 44 controls matched for age, sex and smoking, PDO, copper, ceruloplasmin, 
SOD.  p 85 
 
Boers GHJ, Smals AGH, Drayer JIM, Trijbels FJM, Leermakers AI, Kloppenborg (1983) Pyridoxine treatment 
does not prevent homocystinuria after methionine loading in adult homocystinuria patients. Metabolism, 32(4): 
390-397; U Nijmegen, Nijmegan, Netherlands, 8 CBS-- (by enzyme, Hcy-uria, high methionine) aged 20-50y),   
(mostly non-, with some partially-at-best-, VitB6-responsiveness?..) Vit B6, methionine, cysteine.  p 86 
 
Jackson GM, Grisolia JS, Wolf PL, Jones OW, Bloor CM (1984) Postoperative thromboemboli in cystathionine 
beta-synthase deficiency. Am Heart J 108(3(1)): 627-628; U California, San Diego, USA 1 CBS-- case, Vit B6, 
coagulation studies.  p 87 
 
Newman G, Mitchell JRA (1984) Homocystinuria presenting as multiple arterial occlusions. Quart J Med New 
Series LIII(210): 251-258; U Hospital, NottinghamUK, 2 CBS—siblings, thrombosis, coagulation studies, 
cysteine.  p 88 
 
Wilcken DEL, Dudman NPB, Tyrrell PA (1985) Homocystinuria due to cystathionine beta-synthase deficiency – 
the effects of betaine treatment in pyridoxine-responsive patients. Metabolism 34(12): 1115-1121; Prince Henry 
Hospital, Sydney, Australia, 6 CBS-- (by enzyme, Hcy-uria, high methionine), aged 11-53y, 17 Controls: Normal, 
aged 21-58y. VitB6-y responsives), Vit B6, folate, betaine, methionine loading, methionine, cysteine.  p 90 
 
Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, 
Cerone R et al (1985) The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J 
Hum Genet 37(31): 1-31; Worldwide survey coordinated from USA; natural history of CBS-- in detail.  p 91 
 
Sartorio R, Carrozzo R, Corbo L, Andria G (1986) Protein-bound plasma homocyst(e)ine and identification of 
heterozygotes for cystathionine-synthase deficiency. J Inherit Metab Dis 9(1): 25-29. U Naples, Naples, Italy; 8 
CBS-- cases (by enzyme, Hcy-uria, aged ?), 7 VitB6-responsive, 1 VitB6-nonresponsive, 15 Controls, normal, 
adults, protein-bound versus free homocysteine.  p 96 
  
Abbott MH, Folstein SE, Abbey H, Pyeritz RE (1987) Psychiatric manifestations of homocystinuria due to 
cystathionine beta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and 
vitamin B6-responsiveness. Am J Med Gen 26: 959-969; Johns Hopkins U, Baltimore, Marylands, USA, 63 CBS-
- cases, pathology, psychiatry.  p 96 
 
Kempster PA, Brenton DP, Gale AN, Stern GM (1988) Dystonia in homocystinuria. J Neurol Neurosurg 
Psychiatry 51: 859-862; University College, London, UK, 3 CBS--, psychiatry, pathology.  p 97 
 
Wiley VC, Dudman NP, Wilcken DE (1988) Free and protein-bound homocysteine in cystathionine beta-synthase 
deficiency: interrelations during short- and long-term changes in plasma concentrations. Metabolism 38(8 
(August)): 734-9 Prince Henry Hospital, Sydney, New South Wales, Australia, different groups of CBS-- cases on 
different treatments of Vit B6, folate, betaine; free versus protein-bound cysteine.  p 98 
 
Wiley C, Dudman NPB, Wilcken DEL (1989) Free and protein-bound homocysteine and cysteine in cystathionine 
beta-synthase deficiency: interrelations during short- and long-term changes in plasma concentrations. 
Metabolism 38(8(August)): 734-739; Prince Henry Hospital, Sydney, New South Wales, Australia; VitB6, folate, 
betaine; methionine load; cysteine.  p 99 
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Brattstrom L, Isrealsson B, Tengborn L, Hultberg B (1989) Homocysteine, factor VII and antithrombin III in 
subjects with different gene dosage for cystathionine beta-synthase. J Inher Metab Dis 12(4): 475-482; U Lund U 
Gothenburg, Sweden, 3 CBS--, 20 CBS-+, 46 normal CBS++, 9 Downs Syndrome CBS+++, coagulation studies, 
methionine load.  p 99 
 
Cochran FB, Sweetman L, Schmidt K, Barsh G, Kraus J, Packman S (1990) Pyridoxine-unresponsive 
homocystinuria with an unusual clinical course. Am J Med Gen 35: 519-522 ; U California, San Francisco, USA, 
1 CBS-- case, pneumothorax, DVT, betaine.  p 100 
 
Rubba P, Murcurie M, Faccenda F, Iannuzzi A, Irace C, Strisciuglio P, Gnasso A, Tang R, Andria G, Bond MG, 
Mancini M (1990) Premature carotid atherosclerosis: does it occur in both familial hypercholesterolemia and 
homocystinuria? Stroke 25(5): 943-950 ; U Naples, Naples, Italy, 14 CBS-- cases, 14 Controls, 13 CBS-+, 47 
Controls ; BP, arterial lesions.  p 100 
 
Wagstaff J, Karson M, Kraus JP, Levy HL (1991) Severe folate deficiency and pancytopenia in a nutritionally 
deprived infant with homocystinuria caused by cystathionine beta-synthase deficiency. J Pediatrics 118(4(1)); 
Harvard Medical School, Boston, Massachu-setts, USA, 1 CBS-- case, megaloblastosis, pancytopenia, folate.  
 p 101 
 
Monreal M, Callejas JM, Martorell A, Silveira p, Gallego M, Lafoz E, Casals A (1991) Occlusive arterial disease 
as a form of presentation of homocystinuria. J Cardiovasc Surg 32: 137-138; U Hospital Badalona, Bercelona, 
Spain; 1 CBS-- case, DVT.  p 101 
 
Nordstrom M & Kjellstrom T (1992) Age dependency of cystathionine beta-synthase activity in human 
fibroblasts in homocyst(e)inemia and atherosclerotic disease. Atherosclerosis 94(2-3): 213-221; U Lund, Malmo, 
Sweden, 7 CBS--, 14 CBS-+, 20 CBS++ atherosclerotics, 29 CBS++ controls age>=45, 20 CBS++ Controls 
age<=44, 7 CBS+++ Down’s Syndrome, CBS activity.  p 101 
 
Mansoor MA, Ueland PM, Aarsland A, Svardal AM (1993) Redox status and protein binding of plasma 
homocysteine and other aminothiols in patients with homocystinuria. Metabolism 42(11 (Nov)): 1481-5; U 
Bergen, Bergen, Norway; 7 CBS-- cases, free and protein-bound homocysteine and cysteine.  p 102 
 
Celermajer DS, Sorensen K, Ryalis M, Robinson J, Thomas O, Leonard JV, Deanfield JE (1993) Impaired 
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Tables for Chapter 4 
 
 
Homocystinuria due to Cystathionine Beta Synthase deficiency: 
Literature numerical and word-descriptive data extraction 
 
Homocysteine is found in the urine as the homocysteine-homocysteine dimer called homocystine, and as 
the homocysteine-cysteine mixed disulphide, along with a significantly smaller amount of free 
homocysteine. In blood (i.e. plasma), there is also homocysteine bound to proteins. 
Algorithms for calculating approximate total plasma homocysteine (tHcy) include: 
Bonham et al (1997): tHcy = 60uM + 4.5 * (Hcy(ine) <20uM) + 2*(Hcy(ine)>20uM),   and 
Wiley et al (1989) tHcy = 40uM + fHcy rule  (where fHcy means ‘free’ (not bound to protein, including 
homocysteine-cysteine mixed disulphide, homocystine (homocysteine-homocysteine dimer), and 
homocysteine by itself). Note the Bonham algorithm does not include Hcy-Cys, factoring (4.5, 2) for it. 
 
 Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, Journal, 
Site 
Study Group Disease Hcy level Treatment 
and 
biochemical 
etc contexts 
McDonald L et al 
(1964); 
Lancet; 
Various Hospitals 
UK 
 
 
5CBS-- aged 
4-15y 
(cites Carson 
et al 1963) 
 
PB July 11 
PB July 12 
 
B 
C 
D 
E 
 
Av(B,C,D,E) 
 
5 Controls 
healthy, “of 
a similar 
age” 
 
? July 11 
? July 12 
 
F 
G 
H 
I 
 
Av(F,G,H,I) 
PlateletCount(per ul) PlateletStickiness(%remaining@20min 
 
 
 
 
 
 
     338,000                   45% 
     327,000                   48%  
     
      241,000                  58% 
     380,000                   60% 
     311,000                   48% 
     253,000                   48% 
      
     296,000                   54% 
 
 
 
 
     
      
     306,000                   51% 
     327,000                   50% 
      
     261,000                   85% 
     137,000                   77% 
     280,000                   85% 
     185,000                   75% 
 
     216,000                   80% 
 
Note: The possibility that correction for platelet count might 
decrease the observed difference in platelet stickiness to 
little or nothing requires consideration, which the authors do 
not address….(they cite the Platelet Stickiness method of 
Wright 1941, McDonald and Edgill 1957, 1958)                       
Hcy-uria 
present, 
Equates to 
tHcy >    
       40uM    
Not 
provided? 
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 Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, Journal, 
Site 
Study Group Disease Hcy level Treatment 
and 
biochemic
al etc 
contexts 
Gibson JB et al 
(1964); 
J Clin Path; 
Two hospitals, 
Belfast, Ireland 
 
7 males and 
3 females 
from 7 
families, age 
1.5 – 32years 
at detection 
 
 
Case 1  
All mentally retarded, IQ range up to 53 at diagnosis, 9/10 fair-
haired and –complexioned, high malar flush and ectopia lentis 
(displaced eye lenses) regularly present, high-stepping spastic 
gait, high longitudinal foot arches and knock-knees. 3/10 
kyphoscoliosis and chest deformity with arachnodactyly 
(“spider-fingers”) (Marfanoid Habitus), of which: 
 
JR, male, considered normal at birth till 13months, when, 
vomiting, convulsions, coma, permanent rhs hemiparesis, 
diffuse cerebral atrophy demonstrated by air encephalography, 
dural thrombophlebitis diagnosed, only 1 carpal centre of 
ossification vs normal 2. 
At age 5years mental age 2years, unaided walking difficult, 
fingers short and stubby, sensitive to sunlight. 
Thereafter, a few epileptiform attacks,  
died age 7years following a few grand mal and Jacksonian 
seizures, followed by pyrexia. 
 
Necropsy:  Skull asymmetrical slight rhs posterior bulge, 
pulmonary artery shows slight transverse intimal ridging, some 
small shock hemorrhages in left ventricular endocardium, 
endocardium of left atrium and mitral valve cusps slightly 
thickened by fibrous tissue, coronary arteries normal,  
liver mottled and congested (fatty),  
spleen firmer than usual under puckered regions of capsule, left 
kidney swollen, hemorrhagic, almost completely infracted,  
renal artery totally blocked by mixed thrombus, aorta slightly 
dilated in ascending part, aortic arch moderately dilated, Aortic 
wall stretched and thin as far as the left subclavian artery where 
lumen narrows and wall is thickened and encircled by 2 low 
band-like elevations of the lining each approx 2mm broad lying 
above and below the mouth of the subclavian “Just below it are 
a few wispy strands and tiny depressions of the intima; the 
vessel is unduly friable around them”, aorta again slightly 
dilated down to the level of the renal arteries, where narrow line 
of transverse striations like comb marks extend for a few 
centimetres, the lower part of which covered by laminated 
mixed thrombus several mm thick till about the level of the 
cceliac axis, another such area (0.5 * 1.5cm) of transverse 
striation  on anterior aorta just above mouth of inferior 
mesenteric artery, lowest part of aorta occluded by adherent 
thrombus which is chiefly red and extends into the common 
iliac arteries, mixed thrombus occlusion of coeliac axis into 
proximal hepatic artery, coeliac artery wall thick, splenic artery 
wall very thick and lumen minute, superior mesenteric artery at 
aortic mouth dilated and thickened following which dilation to 
thrice normal diameter in a fusiform aneurysm about 2cm long, 
mixed thrombus in lhs renal artery from kidney to aorta where 
vessel walls thick and fibrous, rhs renal artery thick walled, 
common iliac arteries have thick fibrous walls,  
dura around foramen magnum and upper spinal cord thicker 
and more fibrous than normal, superior sagittal sinus 
extensively obstructed by recanalized fibrous tissue, left 
cerebral hemisphere smaller than right particularly in occipital 
lobe, subdurally cortex brown-tinged and a little firmer than 
normal, left temporal lobe and inferior parietal lobe atrophied 
posteriorly so that the cortical pattern is small, occipital lobe 
many areas of brownish healed infarction disposed in lower 
layers of the cortex in roughly laminar distribution, orange-
brown cystic softening (1.5 * 1.0cm in posterior left thalamus, a 
few minute cysts in left putamen, leptomeninges a little 
thickened in cervical region.  
(continues)     
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Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
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(continued)
Gibson JB 
et al (1964); 
J Clin Path; 
Two 
hospitals, 
Belfast, 
Ireland 
 
Case 1 
(cont) 
(continued) (Histology) 
“The fibrous tissue of the aortic valve ring shows diffuse metachromatic 
staining. The pulmonary valve ring is similarly and less markedly affected” 
(thionine in McIlvane’s buffers, metachromasia corresponds with that in alcian 
in paraffin sections), 
early bronchopneumonia in lungs, 
interstitial fibrosis apparently the result of old partial infarction, in spleen, 
liver cells generally atrophied, some with watery vacuolation, in the pale areas 
noted grossly fatty infiltration of all except the periportal areas, 
the old softenings of the brain are healed and surrounded by a moderate degree 
of fibrillary gliosis, no specific lesions from other areas of brain and spinal 
cord, slight gliosis and swelling of oligodendroglia recognizable throughout, 
a few small nodules of bone in fibrosed areas of the dura, 
“The chief lesions are vascular. The superior sagittal sinus and some of its 
immediate tributaries are occupied by fully organised and partly recanilized 
tissue. The venae cavae are normal. In the left renal vein there is moderate 
degree of fibrous endophlebitis. Other veins are normal. Medium-sized 
muscular arteries are affected in a patchy fashion. Lesions are detected in some 
of the arteries in the spleen, pancreas, colon, thyroid, and thymus, pelvis and 
left kidney, with minor or few changes of the same type in arteries of the heart, 
liver and right kidney. The internal elastic lamina is prominent and often thick. 
The main element is intimal fibrosis without deposits of iron pigments or other 
special features. The fibrosis is either symmetrically distributed so as 
sometimes to cause severe narrowing, as in the splenic artery, or symmetrically 
distributed in the form of pads. In the intimal pads, layers of elastic fibrils have 
split of from the main elastic lamina and small degrees of metachromasia are 
present. The medial coats of these arteries do not usually stain 
metachromatically but in some sections of the left renal and splenic arteries the 
muscle fibers are separated from each other and thinned out by prominent 
deposits of interstitial material which stains as collagen and also stains 
metachromatically with moderate intensity. The external elastic lamina is often 
swollen. The adventitia is little affected except in vessels such as the proximal 
part of the hepatic artery where thrombus is being organized; in those sites the 
vasa vasorum are congested and there is little polymorphic infiltration of the 
media…..There is slight concentric intimal fibrosis which is marked in the 
common iliacs and associated there with some fatty atheromatous plaques. 
Some area of intimal fibrosis stain well with alcain. The media is a little less 
cellular than normal with increased amounts of interstitial material between 
elastic fibres….The elastica is frayed, attenuated or irregularly thickened and 
disorderly in arrangement in such areas, particularly in the superior mesenteric 
artery. A little polymorph infiltration is associated with the aneurysmal 
dilatation ofthis vessel….The microscopic structure of the aorta is most altered 
in the arch above the left subclavian artery where the wall is stretched and thin. 
The intima  of the arch is little altered. The adventitia is congested and the vasa 
vasorum are prominent; there is a little lymphocytic infiltration and no fibrosis. 
The media is deeply penetrated by by vasa vasorum and slightly fibrosed and 
the lines of the muscular and elastic fibres are disturbed and disrupted here and 
there.  In little cysts or pools around some of the vasa vasorum and in little 
clumps between cells lie small granular or hyaline areas which are brightly 
metachromatic…….mouths of the renal arteries and neighboring large 
branches. Here the findings are complicated by ridges of intimal fibrosis. These 
ridges and striations are composed of moderately cellular fibrous tissue thickly 
interspersed with elastic fibrils. Staining for fibrin and for iron pigment is 
negative in the ridges and metachromatic staining is generally slight except 
where the fibrous tissue merges with the the process of organisation of 
thrombus in the aortic lumen. The media is not extensively altered but is 
thinned under the intimal ridges and there the vasa vasorum are prominent and 
penetrate deeply into the media. The adventitia is slightly fibrosed and there is 
a little lymphocytic infiltration round the vasa. The pulmonary artery is of 
looser texture than normal and between the fibres lie many small deposits of 
material that stain metachromatically.”  
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(continued)
Gibson JB 
et al (1964); 
J Clin Path; 
Two 
hospitals, 
Belfast, 
Ireland 
 
 
(Cont) 
Case 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 4 
 
(Continued) 
GM, detected at the age of 13years, mentally retarded, Marfanoid Habitus, 
ectopia lentis, hematuria with oedema of the upper eyelids at age 6years “; 
blood pressure was 115/70mmHg, blood urea 168mm%. The subsequent 
course of his renal disease and the persistent hypertension that he 
developed have been described elsewhere (Loughridge, 1959, case 4). 
..aged 13years, he was readmitted to hospital; his blood pressure was 
170/120mmHg at the lowest reading. The left kidney, which was ectopic, 
was removed surgically.”, kidney97g, pale, capsule outer surface slightly 
granular, texture a little firmer than normal, architectural pattern of cut 
sections slightly blurred, no infarcts, main renal artery and some of the 
interlobular arteries small in calibre and walls symmetrically thickened, 
venous lesions absent, no stones. 
(Histology) glomerular lesions not seen, previous glomerulonephritus not 
indicated, “Fibrinoid change has not occurred in glomerular afferent 
arterioles; a few are slightly fibrosed…..The arteries in general have 
undergone a little symmetrical medial hyperplasia, but irregular 
asymmetrical proliferation of fibrous and other elements is commoner and 
more marked, particularly in the vessels of medium calibre. In the larger 
arteries, fibrous tissue has proliferated in the intima as a thin irregularly 
disposed layer and elastic fibres extent into it from the internal elastic 
lamina; the intima shows marked metachromasia. In the media muscle 
fibres are often enlarged and somewhat irregularly arranged with an 
increase of interstitial material which stains as collegen and is, in places, 
metachromatic; fine elastic fibrils of frayed appearance are scattered 
through the muscle singly or occasionally together in narrow wedge-
shaped segments of the vessels. The external elastic lamina is a little 
thickened and frayed; there is little or no alteration in the adventitia; 
sometimes a little metachromasia is seen. Similar changes have taken place 
in the arcuate arteries. At this level, intimal fibrosis is often marked in the 
form of pads and other asymmetrical deposits. Many elastic fibrils traverse 
these deposits and the internal elastica is often reduplicated. Sometimes the 
muscle is irregularly disposed and segmental area of fibrosis occur in the 
media. The walls of the straight arteries are thickened by fibrosis of the 
media, sometimes severely, the internal elastica is often reduplicated, and 
there is often a little ring of metachromasia beneath it and hyperplasia of 
the muscle.” 
For  other details see GM case of Carson et al (1965) below 
 
AS, male, severely mentally retarded, Marfanoid Habitus, ectopia lentis, 
several unexplained episodes of venous thrombosis in the lower limbs 
from the age of 2years 8months, at age 7years admitted to hospital with 
venous thrombosis in the lower limbs, 
liver enlarged and palpable 3or4 fingerbreadths below costal margin, 
platelets “248,000/c.mm.”, prothrombin 30%, Wassreman and Kahn 
reactions negative, generalized aminoaciduria, 
generalized osteoporosis, 
renal tubular dysfunction resemblant Fanconi Syndrome, metabolic 
acidosis, hypopotassemia, 
steatorrhea, 
laparotomically, liver markedly enlarged, soft yellowish-pink with a 
smooth surface and rounded edge, “In a surgical biopsy of liver, a marked 
degree of fatty change was seen. Fatty change extended from the centre of 
each lobule almost as far as the portal tracts and it was only round the 
portal tracts that the liver cells had their normal form. Some of the fatty 
cells were grossly enlarged.” 
Died of unknown cause aged 8years – necropsy not obtained. 
 
PB, female, age 6.5years, mentally retarded, ectopia lentis, 
liver enlarged with biopsy as per Case 3.  
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Disease Hcy level Treatmnt 
and 
biochem 
etc contexts 
Gerritsen et 
al (1964) ; 
U 
Wisconsin, 
USA 
 Provides the biochemical details for the case RS of  
Chou SM et al (1965) ; 
Arch Path; 
U Wisconsin, USA, 
See therein Immediately below.  
  
Chou SM et 
al (1965) ; 
Arch Path; 
U 
Wisconsin, 
USA 
 
And case 
detail from 
Gerritsen et 
al (1964) ; 
U 
Wisconsin, 
USA 
 
 
1 Case: 
CBS-- 
or 
cbl— 
?????.. 
 
RS, male, failure to thrive, poor developmental milestones, knock-knees, at age 2months 
extreme spasticity/rigidity and marked hyper-reflexia, 
Rossolimo, Babinski, grasping, rooting, sucking, gag, Moro reflexes ok, 
Abdominal, Magnus and De Kleijn neck reflexes absent, 
No reaction to light and little to sound, 
(Gerritsen et al 1964(  )) Homocystinuria in conjunction with higher plasma methionine 
(21,23mg/dl vs 0.5mg/dl), lower urinary cysteine (trace*4 vs 1.8mg/day), and lower 
urinary cystathionine (<1mg/day*4 vs 0.8mg/day) than a normal control, at baseline, 
despite varying non/ corroborative from various biochemical loading tests, strongly 
confirms RS to be a CBS—case rather than one of the other homocystinurias. 
Terminally, signs of severe systemic infections, death at age 1y being thought due to toxic 
sepsis, severe diarrhea, and respiratory difficulties. 
 
Autopsy: 
Body markedly underdeveloped, undernourished, dehydrated, 
Genitalia markedly hypoplastic, testes in inguinal canals,  
lungs with multiple foci of hemorrhage and abscess formation, thromboembolism within 
the right major pulmonary artery, 
iliac mucosa covered with acute inflammatory exudateand with focal hemorrhages and 
hyperemia,  
liver parenchyma contained mottled yellow areas probable representing fat, hepatocytes 
with numerous fine vacuoles,  
adrenal medulla congested and hemorrhagic in some areas, no alterations  observed in 
vascular walls in sections studied with Van Gieson stain.,  
brain weight 620g (66% normal/age), micropolygyria throughout vertex (absent from 
undersurface), very thin olfactory bulbs, normal cerebellum and brain stem, Sylvian 
fissures closed and operculum invisible, corpus collosum with marked hypoplasia, 
architecture of basal ganglia well maintained but obvious wasting of white matter, many 
microgyri present in cerebral cortex, subcortical white matter diffusely vacuolated with 
wide-spread absence of myelin, vacuoles empty, size 20-100u frequently lined by thin 
axons, a few macrophages containing sudanophylic substances seen along the small 
vessels, vacuolization most extensive at the junction of the gray and white matter 
appearing to extend diffusely into the white matter and to a lesser extent into the deep 
layer of the cortex, this change also observed in micopolygyric areas, corpus callosum 
relatively spared, loss of myelin always accompanied by vacuolation, in basal ganglia 
vacuolization present and extended thereto from the internal capsule and internal 
medullary lamina of the thalamus, milder such changes also observed in the subcortical 
white matter of cerebellum, (cerebellar?..) “Sulfhydryl and disulfide stains were used on 
sections from this patient as well as on similar sections from a 2y old child dead of other 
causes. In this control patient, the sulfhydryl and disulfide reactions were stronger in the 
white than in the grey matter. In RS, the white matter showed only very feint sulfhydryl 
reaction even in the nonvacuolated and myelinated areas; the disulfide reaction was 
absent. The reaction in the grey matter was relatively stronger than in the white, but was 
less than in the control, less marked vacuolization seen in brain stem’s central tegmental, 
coticospinal, corticobulbar, and corticopontine tracts, in the cervical spinal cord the 
vacuolization appeared most conspicuously at the junction of the grey and white matters 
“in spite of the presence of the severe spongy changes seen in the pyramids of the brain 
stem, both the ventral and lateral corticospinal tracts of the cord were less vacuolated.”,  
“No vascular lesions were observed in any of the vessels in any of the sections studied.”, 
 
From their discussion: “Indirect support for the hypothesis that this is not a primary 
demyelinating disease is provided by the absence of astrogliosis, absent gitter cell 
reaction, and remarkably well-preserved nerve cell bodies and axons. It is commonly 
supposed that the myelin loss and sponginess in this type of degeneration is secondary to 
serous imbibition, which in turn, is due to a congenital defect in the blood-brain barrier or 
osmotic dysfunction. The marked deficiency of sulfhydryl and disulfide groups at the site 
of the greatest sponginess suggests that any defect in the blood-brain barrier is due to the 
lack of sulfur proteins. However, there is no evidence for a lack of sulfur proteins in any 
of the other patients with spongy degeneration…..”  
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Authors, Journal, Site Study Group Disease Hcy level Treatment and biochemical etc 
contexts 
Laster et al (1965); 
J Clin Invest; 
National Institutes of Health, 
Bethesda, 
Maryland, 
USA 
 
Note: Most of the details for CT 
and MAG had to be retrieved from 
Mudd et al (1964); 
Science, 
and, 
Finkelstein et al (1964); 
Science 
 
Note: Milk methionine and cysteine 
details derived from data from 
Kirschmann JD, Dunne LJ 
(date!!!); 
Nutrition Almanac 2ndEd 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The estimations of CT’s and 
MAG’s daily requirement of 
methionine + cysteine are derived 
from Shils et al (1999), and a 
standard Periodic Table 
CBS—homozygotes: 
 
CT, age 9y, female, 
white, CBS activity 
nil; 
 
 
 
 
 
 
 
MAG, paternal cousin 
of CT, age 25y, 
female, white,  
CBS activity 
31“mumole/mg 
protein” 
 
 
Controls: 
5 normal volunteers, 
and, 
SM, the maternal 
grandmother of CT, 
age 56y, white 
CBS activity  
257 “mumole/mg 
protein”  
 
 
 
Mental retardation, ectopia lentis, 
knock-knees 
 
 
 
 
 
 
 
 
Asymptomatic, no mental retardation, 
minimal focal fatty change on 
histology of liver biopsy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note (continues far rhs column): 
 
The baseline diets used in the study 
provided very similar amounts of 
methionine + cysteine (they provided 
approx equal weights of each; 
MW(Methionine) =149g/mol, 
MW(Cysteine) = 121g/mol) to those 
estimated daily requirements derived 
by me (far rhs column) for CT and 
MAG, who were both excreting 
nearly the same or a little less molar 
quantities of SO4
2-  in the urine. The 
only control with this detail provided, 
JRMcC, received .07mmol of 
(Met+Cys)/ kgBW/day but was 
excreting nearly twice that molar 
quantity of SO4
2-  in the urine.  
Capsules of Met/Cys were added to 
the baseline diets to make up the 
noted amounts (0.6 or 0.8 
mmol/kgBW/day) 
 
 
 
Hcy-uria 
present, 
40-50mg 
per day, 
Equates 
to tHcy > 
(probably 
>>/>>>)    
       
40uM 
 
Hcy-uria 
present, 
Equates 
to tHcy >    
       
40uM 
 
 
 
“During infancy, CT received only 
cow’s milk, e relatively poor 
source of cystine.” 
Cow’s milk: 
.025gMethionine, 
.009gCysteine, 
per gProtein 
 
 
 
“For the first 6 weeks of life MAG 
received human milk, a richer 
source of cystine.” 
Human milk: 
.021gMethionine, 
.019gCysteine, 
per gProtein 
 
 
Study Results: 
 
On a methionine intake of 
0.6mmol/kg/day: 
 
MAG excreted SO4
2-  
0.1mmol/kg/day1 
0.2mmol/kg/day2 
 
Controls excreted SO4
2-  
0.4 mmol/kg/day1 
0.5mmol/kg/day2 
 
 
On a methionine intake of 
0.8mmol/kg/day:  
 
CT excreted SO4
2-  
0.05 mmol/kg/day1 
0.15mmol/kg/day2 
 
Controls excreted SO4
2-  
0.6 mmol/kg/day1 
0.7mmol/kg/day2 
 
Note:  
 
CT’s estimated (normal, age 9y) 
daily requirement of Methionine + 
Cysteine is 23mg/kgBW/day, 
Approx (23mg/kgBW/day) / 
(135mg/mmol, equal weighting in 
averaging the MW of Met, Cys) = 
0.17mmol/kgBW/day 
 
MAG’s estimated (normal, age 
25y) daily requirement of 
Methionine + Cysteine is 
13mg/kgBW/day, 
Approx (23mg/kgBW/day) / 
(135mg/mmol, equal weighting in 
averaging the MW of Met, Cys) = 
0.10mmol/kgBW/day 
 
(continued 2 columns to left) 
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Authors, Journal, 
Site 
Study Group Disease Hcy level Treatment and biochemical etc 
contexts 
Carson NAJ et al 
(1965); 
J Pediatrics; 
2 Irish and 1 
English hospitals, 
UK 
 
10 cases of 
homocystinuria 
discovered in a 
survey of 2,920 
mentally retarded 
individuals in 
Northern Ireland: 
 
 
 
Case1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 4 
 
 
 
 
 
 
 
 
 
 
PB, female normal gestation and birth, 
 walked alone at 15months,  
at age 4y bilateral ectopia lentis, EEG normal,  
at age 4.7y generalized major motor seizure, at age 6y 
awoke one morning with a profound weakness in left leg 
(seizure occurrence unexcludable) with gradual only 
partial return of function,  
at age 6y keratoconjunctivitis retinal detachment 
proceeding quickly to near blindness,  
at age 6.2y another similar major motor seizure,  
at age 7.7y very fine fair hair, intense malar flush, 
moderate Marfanoid continuum, moderate bilateral upper 
motor neuron paresis, shuffling gait, glaucoma, cystic 
retinal detachment with pigmentary changes, height and 
weight at 35%ile,  
EEG shows diffuse generalized dysrythmia, 
 
SR, male, normal birth,  
at age 6m first sat up, 
 at age 1.3y first walked,  
at age 2y intermittent swelling of the legs with 
enlargement of the abdomen and of the superficial 
abdominal veins,  
at age 2.5y ditto,  
at age 3y began to speak,  
at age 6y could use short sentences, history of frequent 
respiratory infections,  
at age 8y, fair-haired, intense malar flush with slight 
cyanotic tinge, ectopia lentis, enlarged abdominal and 
right inguinal varicose veins, knock knees and high foot 
arches, broad-based and clumsy gait, IQ 34. 
 
JR (brother of SR), male, normal birth, at age 6y fair hair, 
intense malar flush, IQ<30, knock-knees and high foot 
arches,  
For autopsy details see JR case of Gibson et al (1964) 
above. 
 
 
 
 
 
 
 
 
 
 
 
 
Hcy-uria 
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       40nM 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM 
 
 
 
 
 
 
 
 
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM          
 
 
 
 
 
 
 
 
 
 
 
 
At age 5.5y cystine 1g*3/day 
 
 
 
 
 
 
At age 6.2y cystine 
discontinued, 
At age 6.5y cystine 1g*3/day 
At age 6.8y cystine 
discontinued 
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(continued)
Carson NAJ 
et al (1965); 
J Pediatrics; 
2 Irish and 
1 English 
hospitals, 
UK 
 
(cont) 
Case 2 
 
 
PB (sister of PB above), female, premature birth with pre-eclamptic 
toxemia, birthweight 1023g,  
at age 10m sat alone,  
at age 1.7y first walked,  
at age 3.5y generalized motor seizure of 3-6h duration,  
at age 4.7y generalized motor seizure of 3-6h duration,  
at age 4.9y generalized motor seizure of 3-6h duration,  
at age 6y EEG within normal limits,  
at age 9y “not yet able to put two words together.” , striking physical 
resemblance to sister PB, severe fatty change of liver by biopsy,  
at 9.5y prophylactic removal of left eye lense, 2weeks later during 
apparently benign convalescence therefrom sudden cyanosis and death. 
 
Autopsy: Immediate cause of death massive pulmonary emboli in main 
pulmonary arteries, calibre and valve markings suggested a probable 
femoral/iliac venous origin but no residual thrombus detectable there, heart 
somewhat enlarged 145g, left atrium endocardium thickened and rather 
white, “Throughout the descending aorta and its main branches were 
patchy lesions which consisted of small transverse striations 1-2mm long 
and approx 0.5mm apart…apparently unrelated to vessel junctional and 
stress areas, At the beginning of the descending aorta, in an area of such 
striations, there was a bandlike elevation which narrowed the lumen and 
was apparently an advanced degree of this lesion. In the superior sagittal 
sinus, straight sinus, both transverse sinuses, and great cerebral vein and its 
tributaries there was some recent thrombus but no evidence of significant 
engorgement of the superficial cerebral veins” 
brain slightly small for age 1095g, slight malformation of right occipital 
lobe cerebral gyri,  
liver enlarged 1284g with mottled yellow appearance and fat droplets on 
section, detail for PB, JW (case Komrower et al 1963) vs Controls 1,2: 
Fat %:    Myristic Palmitic Palmitoleic Stearic Oleic Linoleic Arachidonic 
Cases:     1.2, 0.8;   22,20;         6,2;         6,9;    60,58;    5,9;       0,1               
Controls: 0.9,0.3;    29,34;         5,5;       14,13;  33,31; 14,12;     5,5    
“Corresponding to the transverse intimal striations, areas of fibrous intimal 
thickening were seen in the thoracic and abdominal aorta, the common and 
external iliac arteries, coronary artery branches, and small-sized 
pulmonary arteries. In the aorta subjacent to the intimal striations there 
were areas of disruption and fragmentation of the elastic tissue. In the 
thoracic aorta in the area of narrowing of the lumen there was a large 
pyramid of hyaline tissue.”, recent and organizing thrombus in dural 
sinuses, moderate endocardial fibrosis of left atrium,  
lung parenchyma showed some amphysematous changes,  
severe fatty liver change most marked centrilobularly (no cirrhosis),  
“Brain: Diffuse changes were mostly limited to minimal cell loss without 
reactive changes in the outer layers of the cerebral cortex. There was focal 
neuronal loss in the Ammon’s horn and the end-folium of the hippocampus 
with some fibrous gliosis. Changes in the white matter were limited to 
some beading and unevenness of myelin sheaths. Areas in the midbrain 
and around the third and fourth ventricles showed a diffuse microglial 
proliferation. The most conspicuous lesions were focal areas of incomplete 
necrosis with disappearance of nerve cells and proliferation of microglia 
found in the basal ganglia, especially the thalamus. No thrombi or 
thrombotic remnants were seen in blood vessels within the brain substance 
but some of the areas of focal necrosis and gliosis were situated around 
small blood vessels and a fresh thrombus was present in a small branch of 
the posterior central artery.”, \ 
“Eyes: The most striking pathologic change in the eyes was in the zonular 
fibres which were deficient in the region of the lens and appeared recoiled 
to the surface of the ciliary body where they lay retracted into a network 
which fused with the greatly thickened (~3*) basement membrane of the 
nonpigmented ciliary epithelium…Electron microscopic examination 
revealed zonular fibers which were disoriented and granular rather than 
fibrillar. There was peripheral cystic degeneration of the retinas”, 
 striking incidence of schizophrenia on the maternal side.   
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM    
 
 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 62 
  Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
(continued)
Carson NAJ 
et al (1965); 
J Pediatrics; 
2 Irish and 
1 English 
hospitals, 
UK 
 
(cont) 
Case 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 7 
 
 
GMcC, male, normal gestation birth neonatal,  
at age 8.5m first sat up unaided,  
at age 2.2y first stood unaided,  
never been able to bend over to pick up objects from floor nor to ascend or 
descend stairs,  
at age 5y 3%ile height & weight, fair hair, intense malar flush cyanotic on 
crying or exposure to cold,  
bilateral ectopia lentis,  
moderate Marfanoid continuum,  
speech limited to unintelligible sounds, intelligence assessed at <2y in all 
areas,  
right indirect inguinal hernia (repaired),  
bone age approx 2y “the long bones were thin with multiple Harris lines 
and wide irregular metaphyses.”,  
electrocardiographically and roentgenologically supported right ventricular 
cardiomegaly, “an angiocardiogram revealed a difference in blood supply 
to the lower lobe of the left lung in that the peripheral arteries were less 
numerous and the veins smaller than on the opposite side.”,  
“Two days following the catheterization there was a sudden onset of 
swelling of the right leg consistent with further venous obstruction,  
EEG sleep record normal,  
“slightly abnormal red fluorescence of the hair cuticle with acridine orange 
when examined under the ultraviolet microscope.”,  
“Biopsy of the rectus abdominus muscle taken at the herniorrhaphy was 
normal.” 
 
AMcC (sister of GMcC), female, birth and neonatal normal, 
 at age 6m first sat up unaided,  
at age 1.5y first walked unaided “although her gait is still a ducklike 
waddle.”, not able to bend over to pick up objects from floor nor to ascend 
or descend stairs, “The past history was remarkable for the frequency of 
respiratory infection.”,  
at 1.9y fine fair hair, intense malar flush, 10%ile height & weight,  
bilateral ectopia lentis,  
moderate Marfanoid continuum,  
“An EEG revealed a normal sleep pattern but “some of the bursts of fast 
activity were of high voltage and sharp form similar to those found in 
phenylketonuria.””,  
electrocardiographically and roentgenologically supported right atrial 
cardiomegaly. 
 
GM, male, at age 6y hematuria with eyelid edema,  
left kidney located in pelvis though no gross hydronephrotic changes,  
at age 8y attacks of nausea vomiting and weakness BP 150/100-
175/120mmHg,  
fair hair, intense malar flush, livido reticularis on extensor surfaces of legs, 
bilateral ectopia lentis,  
moderate Marfanoid continuum, peculiar wide-based gait,  
IQ 50,  
“The corneal epithelium was slightly edematous and peripheral corneal 
vascularization was present. The anterior chamber angles were obliterated 
by peripheral anterior synechiae, while the iris was atrophic.Atrophy was 
evident in the ciliary body and the zonular fibres were thickened; a hyaline 
membrane covered the ciliary epithelium and the pars plane…Both the 
choroid and retina were atrophic, the latter showing absence of ganglion 
cells and cystic degeneration of the nerve fiber layer.”,  
at 13.5y BP 200/140mmHg but no signs of congestive failure, “The renal 
artery and its branches showed changes similar to those found in arteries at 
the postmortem examination of cases 2 and 4.” 
(For further autopsy details see GM case of Gibson et al (1964) above)  
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM 
 
 
 
 
 
 
 
 
 
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM          
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Authors, 
Journal, 
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Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
(continued)
Carson NAJ 
et al (1965); 
J Pediatrics; 
2 Irish and 
1 English 
hospitals, 
UK 
 
(cont) 
Case 8 
 
 
 
 
 
 
 
 
 
 
Case 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 
10 
 
 
MMcG, female,  
at age 2y first walked,  
at age 6y first speech,  
at age 7y bilateral ectopia lentis,  
at age 29y IQ 25,  
looked much older than age, fine fair greying hair, malar flush with 
cyanotic tinge, livido reticularis on legs,  
Marfanoid habitus with arachnodactyly, unsteady shuffling gait, unable to 
ascend or descend stairs,  
at age 29y “died from what was thought to be a cerebral thrombosis 
  
AS, male, birthweight 6lb slight neonatal jaundice,  
at age 3w cyanosis,  
at age 6w cyanosis,  
at age 2y not walking,  
at age 7.2y mentally retarded,  
intense malar flush with a cyanotic tinge,  
bilateral ectopia lentis,  
moderate Marfanoid continuum,  
dilated anterior abdominal varices,  
palpable liver “An open biopsy of the liver showed fatty change with 
centrilobar accentuation without fibrosis,  
prothrombin time 17seconds (30%),  
by age 8y “had numerous hospital admissions mainly for unexplained 
venous thrombosis of the lower limbs.”, death. 
 
RK, (“provisional” case initially described as Marfan Syndrome case) 
male,  
at age 8m first sat up unaided,  
at age 1.5y first walked unaided,  
at age 7y possible meningitis,  
at age 14y IQ 50,  
incapable of unaided walking, Marfanoid habitus with arachnodactyly, 
bilateral ectopia lentis, cataracts, blindness,  
at age 28y sudden cardiac failure and death   
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM 
 
 
 
 
 
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM 
 
 
 
 
 
 
 
 
 
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM          
 
Brenton DP 
et al 
(1965a); 
Pediatrics; 
University 
College 
Hospital 
Medical 
School, 
London, 
UK  
2 Hcy-
uric 
child’n 
dying 
at age 
9y 
from 
pulm’y 
embol 
after 
eye op, 
 
and, 
  
14 
Control 
dying 
of 
various 
other 
causes 
The Case children are PB (see Carson et al 1965 above) and JW (of 
Komrower & Wilson 1963) 
“Inspection of Table III reveals the strikingly low concentrations of free 
cystathionine in all parts of the brains examined in homocystinurics (0.0-
0.4 mg/100gWetW) as compared to normal brains from patients dying 
from entirely unrelated conditions” 
“If  (n = 11) the adult control tissues alone are considered, the various 
areas of brain show striking differences in the concentration of free 
cystathionine from one area to another: Occipital lobe (12-90) > Frontal 
lobe (11, 13) > Pons and Medulla (8, 5) > lateral lobe of Cerebellum (3.5, 
2)”  
“The other sulfur-containing free amino acids showed no difference either 
between controls and homocystinurics or between various areas” (Note: 
The ranges given for most of these values so very wide as to require 
explanation of themselves, and a ss conclusion is not available, which 
latter might nearly apply to the results for cystathionine as the results are 
very patchy and sparse) 
Note: although various unexpected results for ie enzyme activities raise 
questions as to the chemical/biochemical success of these works, in some 
support of the results is their citation of Gjessing et al (1963) reporting 
large concentrations of cystathionine in the urines of four patients with 
adrenal neuroblastoma, one subsiding with regression of the metastases.    
Cases: 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM 
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Disease Hcy level Treatmnt 
and 
biochem 
etc contexts 
Brenton DP 
et al 
(1995b); 
J Pediatrics; 
U College 
Hospital 
Medical 
School, 
London, 
UK 
 
 
 
 
 
 
2  CBS--
, aged 2-
5y 
 
1  
CBS-+ 
Obligat 
het’zyg 
parent 
 
3 
Control 
normal 
adult 
males 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBS--
GMcC 
Age 5y 
 
CBS--
AMcC 
Age 2y 
 
CBS-- 
PB 
Age 7y 
 
 
 
 
 
 
 
 
 
 
 
CBS-- 
PB 
Age 7y 
 
 
Plasma Methionine and (free) Homocysteine Across Time Following Oral Methionine 
Loads of 0.1g/kgBW: 
 
 
Plasma:  Met@: 0hours  6h     24h    72h    6d    fHcy@: 0h   6h  24h   72h 
 
                         130uM   1140  810   600   340          162uM  148  148  237 
 
 
 
 
                         <70uM    740   <70                              nil         22    nil 
 
 
 
 
 
                         <70uM    540   <70 
 
 
Note: “<70” refers to a region on the the y axis not further differentiable  by my eye. 
 
Note: The results of the analogous series of experiments using intravenous 
administration of the methionine, were very much in agreement with those for the oral 
administration noted above, with the obvious exception being the more immediate 
input into the bloodstream, and the more immediate commencement of the metabolism 
therefrom. 
 
 
Further Results: 
 
“Excretion of total homocystine (homocystine + homocysteine) and the mixed 
disulfide of cysteine and homocysteine (ug/mgN) before and after loads of 
methionine” 
 
Hcy(ine): 0-2hBefore  0-24hAfter          Hcy-Cys: 0-2hBefore   0-24hAfter 
 
                 6.8                14.0                                     5.9                10.7 
 
 
 
15.2 5.7 
 
 
 
               10.5                21.6                                     6.7                14.0 
 
 
Further Results: 
 
“Excretion of homocystine, homocysteine, and the mixed disulfide of cysteine and 
homocysteine, ug/mgN, before and after intravenous methionine administration to PB; 
values were derived from iodoacetate-treated urine specimens at the times shown” 
 
@:           Basal     3-6hours      23-26hours      48hours     72hours    7days 
 
Hcy:          1.1        4.8               4.6                    2.6            2.1             1.2 
 
Hcy(ine)   8.8        8.8              20.6                  12.0            8.5           13.8  
 
Hcy-Cys   6.7      19.3              11.6                    5.8            3.6             4.4 
 
 Note: “by the automatic analyser method of Spackman, Stein and Moore (1958)” – 
difficult to explain the unexpectedly relatively high purportedly free Hcy?....Likewise 
the proportional reversal of Hcy(ine):Hcy-Cys at 3-6h?.....                                         
fHcy (add 
>40uM for 
tHcy 
 
6d       7d 
 
237    274 
 
 
 
 
 
 
unknown 
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              Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Schimke 
RN et al 
(1965); 
JAMA; 
Various 
eastern 
USA, 
mostly 
examined at 
Johns 
Hopkins 
Hospital, 
Baltimore, 
Maryland, 
USA 
38 
CBS--
age 21y 
(3-45y) 
roughly 
normal 
distrib 
skewed 
a little 
to the  
young 
“a program was initiated for screening urine from patients with ectopia lentis or presumed Marfan Syndrome, 
or both. In most cases urine was obtained by mail. The cyanide-nitroprusside test was used for screening 
purposes.” 
 
The origin of the cases seems to have been the Eastern USA in general: Wilmer Ophthalmological Institute 
and from the files of the Division of Medical Genetics 143 families screened, 9 families ascertained);  
Columbia University Institute of Ophthalmology 30, 2; University of Pennsylvania 15, 3; University of 
Michigan 53, 1; various MDs 200, 0; Washington U 2 families ascertained; MD, Buffalo 1 family ascertained; 
Children’s Hospital, Philadelphia 1 family ascertained, Indiana Medical School 1 family ascertained. 
 
“Patients with homocystinuria in each of the 20 families were examined, most of them at the Johns Hopkins 
Hospital, the others in the home or in an institution near their home.” 
 
The following excerpts omit some detail that is generally in close agreement with information provided by 
other similar though sometimes more detailed studies dealt with by me elsewhere here: 
 
“The Skeleton  - …..A feature unknown in the true Marfan Syndrome – generalised osteoporosis, usually 
leading to codfish vertebrae and some degree of vertebral collapse – is present in all cases…. 
The palate is frequently narrow and highly arched.” 
 
“Cardiovascular System – Arterial or venous thrombosis and cutaneous flushing are the main cardiovascular 
features.  
Fatal coronary occlusion accurred in a 20year old woman who had angina for a year or more before death and 
electrocardiographic evidence of a previous posterior myocardial infarction.  
Well-documented anteroseptal myocardial infarction occurred at 31y of age in a woman alive aged 45.  
Death presumably from coronary occlusion occurred in an 18y old boy.  
Another 18y old boy and a 12y old girl died of bilateral thrombosis of the internal carotid arteries. Thrombosis 
in the terminal aorta, iliacs, and subclavian arteries was manifested by arterial bruits, loss of pulses, and 
ischemic symptoms.  
Renal artery narrowing with unilateral renal atrophy was demonstrated in an 18y old with hypertension, and 
similar involvement was suspected as causing hypertension in several other patients.  
An 8y old boy was essentially pulseless because of recurrent arterial thromboses. He had also suffered 2 
cerebrovascular accidents and dilated abdominal collateral, suggesting thrombosis of the inferior vena cava, 
were apparent.  
Thrombosis of the inferior vena cava and pulmonary emboli were the causes of death in a 13y old girl. 
Recurrent thrombophlebitis in the extremities with pulmonary embolism occurred in some cases.  
A 28y old man died of portal vein thrombosis.  
Intracranial thromboses, venous and arterial, led to neurological signs, seizures, and  
in one case, the non-specific diagnosis of “cerebral palsy” from which death occurred at the age of 3… 
 
…Venipuncture and arterial puncture may initiate thrombosis. Arteriography and cardiac catheterization 
should probably be avoided and only essential surgery done. In the 2 patients dying of bilateral internal carotid 
thrombosis, acceleration of the thrombotic process by cerebral arteriograms is suspected.” 
 
“Central Nervous System – A majority of the patients show mental retardation in some degree; however, 16 of 
the 38 patients were judged to have normal intelligence….. 
Many learn well by rote but have difficulties with exercises in reasoning……. 
Marked nervousness is a striking feature of most cases…… 
Electroencephalograms, obtained in 8 patients shoed abnormality in all, including 2 with normal intelligence.  
Seizures occurred in 3 patients, related probably to intracranial arterial or venous thromboses, or both.” 
 
“Pathology – Large arteries such as the coronary, renal, subclavian, iliac, and carotid showed drastic medial 
changes with dilatation and thrombosis.  
The media was thin.  
The muscle fibers of the media were widely separated by expansion of the intercellular ground substance.  
Thrombosis and organisation without complete occlusion had occurred episodically, with formation of new 
internal elastic lamellae after each episode.  
The aorta showed an abnormal elastic weave in both longitudinal and transverse section.  
Thrombosis in the terminal aorta was present in one of the autopsied cases and was suspected clinically in 
another deceased patient.  
In at least 2 of the autopsies, extensive left atrial endocardial fibroelastosis was found.  
Fatty liver was present in all autopsied cases.”    
 
 
There were 15/38 cases noted to have had thrombotic disease  (13) or myocardial infarction (2), “presently or 
at death”, and note the age distribution as noted above column to left. 
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and 
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etc 
contexts 
Harris ED 
Sjoerdsma 
A (1966) ; 
Lancet; 
National 
Heart 
Institute, 
Bethesda, 
Maryland 
USA 
2  
mental 
retard 
CBS--, 
 
2 norm 
IQ CBS-
-, 
 
34 
control 
(age 22, 25y) 6mm skin punch biopsy from hip      
                                   3.9, 7.5% soluble collagen;        1.6, 1.5 alpha:beta 
 
 
 
(age 22, 25y) 6mm skin punch biopsy from hip      
                                   1.7, 2.5% soluble collagen;        1.2, 1.1 alpha:beta 
 
 
(all adults: 5 no dis, 10 hypertension, 9 malign, 4 cardiac, 6 misc ) “ 
biopsy  
                                    1.4-3.5% soluble collagen;        0.8-1.2 alpha:beta 
CBS--: 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM 
 
 
 
unknown 
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Authors, Journal, Site Study 
Group 
Disease Hcy level Treatment and biochemical etc contexts 
Brenton DP et al 
(1966); 
Quart J Med; 
University College 
Hospital and Medical 
School, London, UK 
 
Note: The estimations 
of SM’s daily 
requirement of 
methionine + cysteine 
(assuming normalcy 
of CBS, not the case) 
are derived from Shils 
et al (1999) 
Case 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SM, forceps delivery, early developmental 
milestones purportedly normal up to age 3years, 
from which time his mental performance 
“deteriorated and he lost the ability to count.” (no 
history of unconsciousness, epilepsy, paralysis 
suggestive of thrombotic etiology), later private 
schooling,  
myopia at age 7y progressing rapidly next 3 years, 
ectopia lentis at age 10y two separate events into 
anterior chamber spontaneously replaced with bed 
rest,  
knock-knees, Marfanoid Habitus but no 
arachnodactyly,  
“Bilateral tibial osteotomies were done and he was 
immobilized in plaster of Paris. Over the next 3 
months he developed leg oedema and engorgement 
of superficial veins of the chest, abdomen and 
thighs… .angiogram… thrombotic obstruction… 
heparin…subsided”, at age 14y IQ (WIS) – 
Vocabulary and Reasoning 60-70 Performance 
Scale 44,  
“No abnormality was found in the 
electrocardiogram or electroencephalogram.”, 
“Grossly increased” platelet stickiness 
  
 
 
  
 
(continued from far rhs column) 
 
SM’s urinary methionine sulfoxide apparently 
(graph) went from approx 0 (if measured…?) to 
300mg/day at the end of the period of substitution 
of methionine for cysteineand thereafter back down 
to 100mg/day and then to apparently (graph) 0 (if 
measured…?) during the period of substitution of 
cystine for 70% of the supplementary methionine.   
 
SM’s Hcy: “free” (I think) fHcy = 90uM, 
=>140uM tHcy did not vary much throughout 
study:  
The magnitude suggests some VitB6- 
responsivity?…. as does case history. 
 
 
 
“The platelets appeared to be equally abnormal in 
the first, third and fourth periods and no decreased 
stickiness had occurred when the last measurement 
was made 2days before SM’s discharge although 
the plasma methionine levels had been near normal 
values for 5days. The only change in platelet 
behaviour was in the second period (supplementary 
cysteine replaced with methionine) when 
temporarily they were more sticky than usual and 
clumped together to such an extent that it was not 
possible to count them” 
 
?: Heparin sulfation issue?….. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nitrogen Balance Study: 
 
“The basic diet supplied 475mg 
Methionine and only about 85mg Cysteine 
per day…SM’s diet was supplemented 
with 1g each of methionine and cystine in 
the first instance and the effect6s observed 
of replacing the 1g cystine with an 
equivalent quantity of methionine.” 
 
(Note(s):   
#SM’s estimated (normal, age 15y at BW 
= 60kg) daily requirement of Methionine 
+ Cysteine is 20mg/kgBW/day, 
Approx  1200mg/day 
 
# “Rose found, however, that cystine in 
the diet has a marked sparing effect on 
methionine, reducing by 80-90% the 
minimal methionine needs of 3 (normal) 
subjects.”(Rose & Wixom, 1955).) 
 
Nitrogen and sulfur intake were constant 
throughout the study. 
 
Study Results: 
 
When the supplementary cystine was 
replaced with methionine in SM’s intake, 
he went into marked negative nitrogen 
balance, on reversal of the adjustment the 
nitrogen balance reverted, and on 
replacement of approx 70% of the 
supplementary methionine with cystine 
the nitrogen balance became markedly 
even more positive. 
The (CBS normal) control subject’s 
responses to the same changes in intake 
were markedly nearly the exact reverse of 
SM’s, though very roughly half an order 
of magnitude less. 
 
SM’s plasma taurine approx 0.5mg/100ml 
roughly throughout but no data apparent 
for day20-26 
Analogous (CBS normal) control data 
unavailable. 
 
SM’s urinary taurine fell from 100mg/day 
(day1-14) to 10mg/day and remained 
there even through the mere reversion 
phase (day14-20-26) until the phase of 
replacement of approx 70% of the 
supplementary methionine with cystine 
(day26-37) when it was again 100mg/day 
at day 31 and 200mg/day at day 37. 
Analogous (CBS normal) control data 
unavailable. 
 
(continued 2 columns to left) 
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Authors, Journal, Site Study 
Group 
Disease Hcy level Treatment and biochemical etc contexts 
(continued) 
Brenton DP et al (1966); 
Quart J Med; 
University College 
Hospital and Medical 
School, London, UK 
 
Note: The estimations of 
SM’s daily requirement of 
methionine + cysteine 
(assuming normalcy of 
CBS, not the case) are 
derived from Shils et al 
(1999) 
Case 2 RM, between 8-18months of age 3 admittances 
with severe vomiting, abdominal distension, and 
ileus….”In retrospect these episodes might have 
been due to mesenteric vascular thromboses.”,  
recurrent respiratory infections (Respiratory 
Syncytial Virus isolated on one such),  
by age 15months behind on developmental 
milestones,  
at age 2.5y possible historic major epileptic seizure,  
liver palpable,  
mild skeletal abnormalities on Marfanoid 
continuum “The resemblance of his recent changes 
to those in acromegalic gigantism is striking….It is 
likely, therefore, that arachnodactyly will develop 
later.”,  
ectopia lentis,  
severe mental retardation, 
“Grossly increased” platelet stickiness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(continued from far rhs column) 
“…..After 5days on the diet ….Again he began to 
vomit, refused to eat or drink, and the diet was 
discontinued.” 
 
?: Was betaine used again this time?…could there 
have been a conditioned response from the pairing 
of this diet with the betaine the last time?…….. 
 
 
“Platelet stickiness was measured 3 times in RM. 
Once before starting the diet and on the 8th and 22nd 
day after starting it. On all three occasions the 
platelets were grossly abnormal in behaviour and 
the improvements induced by the diet in plasma 
amino acid concentrations were not obviously 
associated with any decrease in platelet 
stickiness….The dietary trial  here was long 
enough to allow regeneration of all platelets, taking 
the life of a platelet to be 8days, so that failure to 
improve was not due to the persistence of 
permanently injured platelets in the circulation.” 
 
?: reduced methionine causes reduced SAM which 
then has less stimulation of any residual CBS 
activity which causes reduced cysteine which 
causes reduced sulfate….reduced heparin sulfation 
or some other cysteine-related dysfunction?…… 
 
 
 
 
 
 
 
Hcy-uria 
present, 
Equates 
to tHcy >    
       
40uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diet Protein/Methionine Study: 
 
“…9.4g/day of natural protein was allowed 
in the diet in oatmeal porridge, potato, 
water-diluted double cream, Hienz tinned 
baby food, fruit, low-protein biscuits…..the 
diet was calculated to provide10-
12mg/kgBW/day of methionine….” 
 
Note: RM’s estimated (normal, age 18m at 
BW = 12.5kg) daily requirement of 
Methionine + Cysteine is 35mg/kgBW/day, 
Approx  440mg/day 
 
“….The essential amino acids (excluding 
methionine) were added to the food in the 
amounts recommended by Snyderman and 
her colleagues (Snyderman 1958) for babies 
together with histidine 35mg/kgBW/day, 
cystine 100mg/kgBW/day, and glycine 
300mg/kgBW/day.” 
 
“betaine hydrochloride tried by mouth for 
10 days” (day20-30) 
 
Study Results: 
 
Pre-diet plasma Met: 12mg/100ml 
Diet plasma Met: 1-to-2mg/100ml 
 
Pre-diet fHcy = 130uM 
= tHcy 170uM 
Diet fHcy = 100uM 
=tHcy 140uM 
 
“The diet was tolerated fairly well during 
his admission, except for an occasional 
vomit in the evening. After his discharge 
home (day27) the vomiting increased in 
frequency and one week after the discharge 
the diet was discontinued….the vomiting 
ceased within several days of stopping the 
diet..….” 
 
?:….betaine cerebroedema reaction??……. 
 
“….After 7 weeks on ordinary food at home 
the child was readmitted for another attempt 
at dietary treatment” 
 
After 5days: 
 
Pre-diet plasma Met: 18mg/100ml 
Diet plasma Met: 2.8mg/100ml 
 
Pre-diet fHcy = 180uM 
= tHcy 220uM 
Diet fHcy = 70uM 
=tHcy 110uM 
 
(continued 2 columns to left) 
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Authors, Journal, 
Site 
Study Group Disease Hcy level Treatment and biochemical etc 
contexts 
Perry TL et al 
(1966); 
Pediatrics ; 
U British 
Columbia, 
Vancouver, 
Canada. 
 
 
 
 
 
 
 
 
 
1 baby boy, CS, 3.5kg 
birthweight, product of 
a normal pregnancy 
and delivery, two elder 
siblings having 
homocystinuria such 
as to have warned in 
advance that this case 
might be subject to 
same. 
 
Note: To compare 
with 2 other untreated 
CBS-- siblings, see 
Perry et al (1968) 
below 
Gains 500gBW in days 0-16 
 
 
Gains no BW in days 17-29 
 
 
 
 
 
 
 
 
Gains 280gBW in days 30-40 
 
 
 
 
 
(Gains 600gBW….. 
 
 
 
 
….continues….. 
 
 
….. in days 41-69) “satisfactory”  
 
Note: Gaull GE (1967) provides a follow-up note on this 
case: “A recent letter from Perry indicates that at age 12m 
this patient weighed 10kg, could take a few steps alone, 
and used several recognizable words. The Griffiths 
Developmental Quotient was said to be 99. There were no 
abnormalities noted on physical examination, 
electroencephalogram, or X-ray of long bones. On a diet 
containing 27mg/kgBW/day of L-methionine he showed a 
fasting plasma methionine level of 6.2mg/dl and a total 
homocystine of 0.6mg/dl. They felt that they could not 
lower the plasma levels further without jeopardizing 
growth. This patient, in contrast to his two afflicted 
siblings, is developing normally despite elevated levels of 
methionine and homocysteine. Could this be because of 
normal cystine turnover during this critical first year of 
development? If we accept this limited data as evidence of 
a salutary effect, should we not consider whether it is due 
to the large supplement of cystine as well as to the 
limitation of methionine?” 
 
Note:  Perry et al (1968) provide a follow-up note on this 
case: “..low-methionine diet and supplemental L-cystine 
constantly since the 16th day of life” now 3y old, “he has 
shown none of the clinical manifestations of 
homocystinuria.” 
Hcy-uria 
present, 
Equates to 
tHcy >,>>    
       40uM 
Ditto 
roughly 
throughout 
,but 
various 
“nil” or 
“trace” 
readings 
for plasma 
fHcy and 
urinary 
Hcy 
seem 
dubious?.. 
Evaporated cow’s milk formula 
Plasma Cystine assay unreliable 
 
Low-methionine formula of soy 
bean protein, corn oil, 
dextrimaltose,  
Cystine 100mg/kgBW/day 
additional supplement 
Plasma Cystine rises from 0 to  
0.79mg/dl 
(normal newborn 0.7-2.0mg/dl) 
 
Breast Milk 
Cystine 100mg/kgBW/day 
additional supplement 
Plasma Cystine 0.32, 0.53mg/dl 
(normal newborn 0.7-2.0mg/dl) 
 
Low-methionine formula of soy 
bean protein, corn oil, 
dextrimaltose,  
Cystine 150mg/kgBW/day 
additional supplement 
Plasma Cystine 0.8, 0.52mg/dl 
(normal newborn 0.7-2.0mg/dl) 
 
Low-methionine formula of soy 
bean protein, corn oil, 
dextrimaltose,  
Cystine 200mg/kgBW/day 
additional supplement 
Plasma Cystine 0.92mg/dl 
(normal newborn 0.7-2.0mg/dl) 
 
 
Note: A 3-4m aged infant’s 
daily requirement of methionine 
+ cysteine is 58mg/kgBW/day  
Shils et al (1999), while that of 
a 2-5y aged child is 27, and that 
of a 10-12y aged child is 22 – 
roughly following this 
exponential trend back to the 
relevant periods of this case 
provides no quantification of 
requirements of any certainty, 
other than to say that it seems 
that the cystine supplementation 
could have been of roughly the 
right order of magnitude…and 
the plasma levels seem to 
support this…context of  
differences from normalcy  in 
cysteine input to systemic 
circulation. 
 
?: Some breast milk component 
required, at some stage?….. 
 
?: does supplementary cysteine 
spare any cystathionine 
produced by any residual CBS 
activity?…..  
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Komrower 
GM et al 
(1966); 
Arch Dis 
Childh; 
University 
College 
Hospital, 
London, 
UK. 
1 Case  
 
PW, female, the sixth offspring in a family with two previously diagnosed 
homocystinuric siblings “showing the classical signs” was able to be detected as 
homocystinuric and hypermethioninemic neonataly, and received thereafter a  
 
Diet: modified from that of the treatment for Maple syrup urine disease (Gelatin 
(deficient in branched-chain aa and methionine), milk, carrot, potato, lentils, 
cereal, fruit, Arachis oil, sucrose, mineral mix, essential amino acids, and cystine) 
“The plasma cysteine levels remained low at this time, so the intake was 
increased from 24 to 76 mg/kg. This had little effect. We wondered whether this 
might be due to poor absorption of cystine in the gut because of its low solubility, 
so, at 6months the more soluble calcium cystinate was given” 
 
Age  Diet Cystine/CaCys  Plasma Cystine   Plasma Methionine  Plas fHcy  
1d                                              1.0mg/dl                0.8mg/dl           ND         
3d                                              1.2                         1.5                      7.2uM 
9d                                              0.4                        26.8                   22 
3w          .081g/d       0g/d         0.6                         0.4                      2 
 
5w        0.329            0            trace                        0.7                     ND 
2m        0.329            0              0.3                        0.7                     ND 
3m        0.329            0              0.8                        0.4                    trace 
4m        0.329            0              0.6                        0.6                      0.02 
 
6m        0.590            0              0.2                        0.5                      2 
7m        0.590            0              0.2                        1.7                      2 
8m        0.590            0              0.1                        9.7                      2 
9m        0.590            0              0.2                        1.6                      6 
 
11m      0.850     0.500              1.0                        1.1                   trace 
13m      0.850     0.475              0.5                        4.5                     ND 
15m      0.850     0.475              ND?                     4.9                     52 
16m      0.850     0.475              ND?                   13.2                     18 
16.5m   0.850     0.475              0.8                        1.3                       9 
16.75m 0.850     0.475              1.9                        0.2                     ND 
17m      0.850     0.475              0.7                        0.7                     ND 
19m      0.850     0.475              1.5                        0.5                     ND 
20m      0.850     0.475              1.2                        0.7                      2 
22m      0.850     0.475              0.4                        1.0                      6 
24m      0.850     0.475              0.3                        1.2                     ND                          
26m      0.850     0.475              0.2                        0.8                    11 
 
Note: The anomalous rises in methionine and homocysteine around the 15-16m 
period appear to be the result of a friend of the family feeding the child extra-
dietary foodstuffs. 
 
Outcome: at age 2.3y “is in excellent health, 11.8kgBW, height 86cm, walks,  
talks, feeds herself, IQ 97, EEG normal, 
normal discs and fundi, no sign of ectopia lentis,   
slight knock-knee, no radiographic abnormal bony changes,  
platelet stickiness 72% “considered well within the normal range of this 
technique.”  
“Her mother is convinced that PW at this age is much brighter than were her 
affected but untreated sibs and is very like her normal sisters. Nevertheless, one 
must remember that several of the children reported on earlier were apparently 
normal for the first few years of life (Komrower and Wilson, 1963) and for this 
reason considerable reservations must be made in respect of the long-term 
prognosis.”  
 
Note: Unfortunately more detailed comparisons with the siblings, if only brief, 
were not made here.    
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM 
 
 
 
 
 
(roughly 
approx 
derivat’n) 
tHcy 
<40uM? 
47uM 
62  
42 
 
<40? 
<40? 
40  
40  
 
42 
42 
42 
46 
 
40 
<40? 
92 
58 
49 
<40? 
<40? 
<40? 
42 
46 
<40? 
51 
See 
middle 
column 
Gaull GE 
(1967); 
Amer J Dis 
Child; USA 
 See Perry TL et al (1966) above for his report on a communication received from 
Perry on the follow-up of that case. 
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Perry TL et 
al (1968); 
Lancet; 
U British 
Columbia, 
Vancouver, 
Canada. 
 
CBS--
Case 1 
 
 
 
 
 
 
 
 
 
 
 
 
CBS-- 
Case 2 
 
 
 
 
 
 
CBS-- 
Case 3 
 
Patient A, female,  
at age 7y severely mentally retarded,  
ectopia lentis,  
significant Marfanoid continuum,  
repeated intravascular thromboses. 
 
Note: for use in comparison with treated-from-birth sibling CS detailed in 
Perry et al (1966) above “Her younger homocystinuric brother died at the 
age of 10m from bilateral renal vein thromboses and pulmonary 
embolism” (not a subject of this study). 
 
Patient B, male, treated-from-birth sibling of Patient A, see case CS in 
Perry et al (1966) above (not a subject this study) 
 
Patient C, male,  
at age 16y,  
ectopia lentis,  
significant Marfanoid continuum, 
 “During the year before he started the dietary treatment described below, 
he had 2 life-endangering episodes of cerebral thrombosis, which left him 
with a residual hemiplegia and further impairment of intelligence.” 
 
Patient D (sister of Patient C), female,  
at age 14y mild mental defect,  
ectopia lentis,  
some marfanoid continuum,  
no recognised intravascular thromboses. 
 
Dietary treatments:  
At some point in time each of Patients A, C, and D were commenced on a 
low-methionine diet “which provided approx 1g protein and 10mg of 
methionine per kgBW/day. Half of the daily protein and methionine intake 
was supplied by soybean protein (‘Sobee’, Mead Johnson). The remainder 
of the dietary protein and methionine was derived from a wide variety of 
cereals, vegetables and fruits. All foods of animal origin were excluded 
from the diet…..Each patient was also given daily supplements of 
dicalcium phosphate, ferrous sulfate, and a multivitamin preparation.” 
Choline 10g/day was given intermittently, but a 100day period of it was 
centered about the time of the institution of the low-methionine diet in all 
cases; Patient A also received 10g/day for a 40day period 20days prior to 
the 100day period, and Patients C and D received also 10g/day for two 
periods 50days, 30days, after the 100day period. 
Pyridoxine (VitB6) 500mg/day was given for a 20day period separate from 
and partly occupying the intermission ‘twixt the latter two choline periods 
in Patients C and D, and for 20day and 40day periods bracketing the 
choline periods but well separate from them in Patient A. 
(see also continuation next table, for cystine details) 
 
Results: 
The pyridoxine (VitB6) was not associated with any change in either 
plasma methionine or homocysteine in Patients C and D, so these seem to 
be VitB6-nonresponsive cases. In Patient A there was an association with 
lower plasma homocysteine paired with barely-visibly lower plasma 
methionine in the second period but not the first. 
The choline was fairly consistently associated with lower plasma 
homocysteine paired with higher plasma methionine, of lesser magnitudes 
during the low-methionine diet periods. 
The low-methionine diet was consistently associated with decreased 
plasma methionine and decreased plasma homocysteine. 
Note: The arrangement of  these treatment periods was quite well done 
with a view to differentiating the effects, via maximising crossover in the 
context of ethical maintenance of the low-methionine diet once instituted. 
 
(continued below)    
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM 
 
 
 
 
 
 
 
 
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40uM 
 
 
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40uM          
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(continued)
Perry TL et 
al (1968); 
Lancet; 
U British 
Columbia, 
Vancouver, 
Canada. 
(cont) (continued) 
“Elimination from the diet of proteins relatively high in methionine 
content also eliminated much of the dietary cystine; and, since for the 
patient with homocystinuria, cysteine becomes and essential aminoacid, it 
was necessary to add cysteine or cystine to the diet. Thus each patient was 
given a calculated excess of L-cystine while on the low-methionine diet. 
The fact that the orally administerd L-cystine was absorbed, and was 
probably given in excess, was demonstrated by the regular presence of 
unusually large quantities of taurine, a metabolite of cysteine, on the 
patients’ urinary aminoacid paper chromatograms. Despite the 
administration of L-cystine, plasma concentrations of cystine in our 
patients were always far below the normal range (30-50uM)….Tripling the 
dose of supplemental L-cystine did not produce an increase in plasma-
cystine.” 
Patient A’s details only were provided, from which I excerpt 
(and assume that the values are for “free” ie fHcy etc and not “total” ie 
tHcy etc, and are therefore reduced disulfide forms as applicable) 
(values are mg/kgBW/day, g/day, g/day uM respectively): 
 
TreatDay  DietMet  SupCys  Chol    Plasma:  MetO   Hcy    Hcy-Cys   Cys 
  22              60               0         0                        38     119       63          trace 
 
110              60               0        10                      201       15       38             13 
124              60               0        10                      117         7       18             14 
208              60               0        10                      130       85       44               4 
 
240              15              1.5     10                         20       48       44               6 
268              10              1.5     10                       trace     34       55             15 
274              10              4.5     10                       trace     20       46             20 
286              10              4.5       0                       trace     37       42             10 
344              10              1.5       0                         17       18       35             17 
364              10              1.5       0                         20       18       48             23 
Normal                                                                 0         0         0        30-50 
 
To get tHcy equivalents double the Hcy value and add 40uM, then add the 
Hcy-Cys value to it, which gives a range of  75-340uM tHcy, mostly 100-
180uM 
 
Note that the cystine values are not “far below the normal” and that if the 
cysteine from the mixed Hcy-Cys disulfide is added to the Cys, then quite 
often the sum is within the low normal region….. 
 
Note that the above facet possibly goes some way to explaining the failure 
of the tripling of the Cys supplement of raise plasma Cys. 
 
?: Is Cys metabolized to taurine more quickly than normal?…                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(derived) 
tHcy 
340uM 
 
108 
72 
254 
 
180 
163 
126 
156 
111 
124 
10, <30 
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Carey MC 
et al 
(1968) ; 
Am J Med ; 
3 Hospitals, 
Dublin, 
Ireland 
9  
CBS-- 
The following excerpts omit much detail that is generally in close agreement with information provided 
by other similar studies dealt with by me elsewhere iabove: 
 
“ Ascertainment was by means of reviewing the records in our files of patients with presumed Marfan’s 
Syndrome and/or ectopia lentis, using the cyanide-nitroprusside test; 5 patients were thus discovered. A 
further 2 were detected by screening the sibship of each proband, and one patient received treatment for 
coeliac disease for eighteen months before a diagnosis of ectopia lentis and then homocystinuria was 
made.” 
 
Case MMcL normal platelet count, prothrombin time, activity and concentration, factor V, factor VII, 
clot retraction, clotting and bleeding times. 
 
Case PBu “seemed about half his age….a pitiful sight” (neglect?) “In 1960 he suffered a “green-stick” 
fracture of the right femur after a minor injury, in 1962 he fractured his left tibia and fibula in the 
midshaft and in 1966 fractures of 3 metacarpals were discovered after a fall. Union was slow and it was 
noted that there was undermineralisation of the long bones….crusted eczema on the chest wall” 
 
Case TK “Clinically the aortic bifurcation was occluded, and preoperative aortography confirmed this 
diagnosis. At op the internal aorta, both common iliac, common femoral and proximal profunda and 
superficial femoral systems were thrombosed with organised, friable, clot, leaving no plane of cleavage. 
….. 
Autopsy: There was no macroscopic cross-ridging, a feature regularly described by previous 
investigators in homocystinuria.  
The liver weighed 910g and was congested; the diaphragmatic and anterior surfaces were mottled with 
fatty streaks…. 
the kidneys showed, besides fresh infarcts, recent thromboses in large arteries of arcuate size. Pads of 
fibrous tissue were seen on the intima of some large vessels.  
There was extensive centrilobular fatty change in the liver.  
Moderate myocardial fibrosis was found with intimal thickening of the coronary arteries; the anterior 
descending branch of the left coronary artery showed a fresh antemortem thrombus occluding the 
lumen; the coronary arteries also showed some “pads” such as were seen in the kidney.  
The lungs were congested, with a few small thrombi in the smallest vessels.  
The aorta showed considerable intimal fibrous thickening. A few foci of bluish cystic material were 
seen in the wall resembling medionecrosis but elastic tissue seemed regular in formation and amount.” 
 
“Comments….Mandibular prognathism, which was seen in Cases 1, 2, 5 and 7, is a new addition to the 
protean manifestations of homocystinuria previously recorded….. 
The skin of the hands, elbows, knees and shins in Cases 1, 2, 3, 4 and 7 were covered with “tissue-
paper” atrophic scars like those seen in porphyria and Ehlers-Danlos Syndrome…. 
Wound repair may also be poor due to an inadequate synthesis of cystine (cysteine? DV)…… 
At variance with previous reports, the unusual gait described as “shuffling”, “ducklike” or 
“Chaplinesque” was not observed in our patients. However many were unable to climb stairs…. 
there were nonspecific EEG findings of diffuse cerebral dysfunction in all patients…… 
Only 1 patient in our series, a girl (Case 9), had thromboembolic features. The presumed “encephalitis” 
in 1961 and “meningitis” in 1963 in this patient were probably due to recurrent cerebral venous 
thrombosis.”  
 
Parkinson 
MS, Harper 
JR (1969); 
Proc Roy 
Soc Med; 
General 
Hospital, 
Northamp-
ton, UK? 
1  
CBS-- 
 
general  
comm’t 
“JD, boy aged 11.....classical features.....marked emotional lability.....plasma Hcy(ine) 185uM…. 
Unfortunately, dietary treatment in our patient was not successful. The unpalatability of the food 
regimen soon led to dietary indiscretions. The need for regular hospital attendances for plasma and 
urine monitoring became unacceptable to both patient and parents, and blood sampling was eventually 
refused. The scheme had to be abandoned after four weeks……While the value of dietary therapy in the 
affected newborn is not in dispute, the benefits for the adolescent would not seem clear. The added 
practical difficulties of dietary restriction in these mentally retarded children are considerable, while 
from the humanitarian point of view, this dietary policy seems hard to justify.” 
 
Note(s):  
Methionine restriction needs to be better differentiated from cysteine supplementation, as the former 
addresses Hcy levels, while the latter addresses amino acid (and taurine, sulfate?)  requirements, and 
the former requires actual dietary modification while the latter is supplemental (ie pill/drink form). 
Methionine restriction needs to be better differentiated from its monitoring ie via blood sampling. 
Blood sampling needs to be better differentiated from urine sampling re invasiveness and patient 
convenience. 
VitB6-responsivity requires addressing. 
Age of implementation is a factor in sustainability, particularly of diet, as well as being crucial to 
outcome. 
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Hopkins I et 
al (1969); 
J Pediatr; 
Royal 
Children’s 
Hospital, 
Melbourne, 
Australia. 
3  
CBS--, 
siblings 
“Our patient, a 17month old girl with delay in acheiving the normal 
developmental milestones and some enlargement of the head, first noted 
6months before admission, was admitted with 24hour history of fever, 
vomiting, and right-sided convulsions followed by a left hemiplegia. On 
admission signs of raised intracranial pressure were noted.  
Right carotid angiography, pneumoencephalogram, and 
electroencephalogram were not diagnostic and the cerebrospinal fluid 
contained 18 RBCs per uml and protein 10mg%.  
Repeat lumbar puncture following deterioration showed xanthochromic 
cerebrospinal fluid with a pressure of 255mmH20.  
She subsequently developed decerebrate rigidity and died 11 days after 
admission.  
At autopsy, organised thrombus of all the dural sinuses, old infarction of 
the thalamus, and calcified massive thrombus of the pulmonary artery were 
found.  
Subsequently two siblings, one of whom suffered an intracranial 
thrombosis but has survived, were found to have homocystinuria.  
We feel that angiography is contraindicated in homocystinuria; our patient 
did deteriorate following the procedure. Thus, in any child suspected of 
intracranial thrombosis, before proceeding to angiography one should test 
for homocystinuria.  
Screening of the siblings….”  
  
McCully 
KS  (1969); 
Am J 
Pathol; 
Massach’ts 
General 
Hospital, 
Boston, 
USA  
 
1 Case (presumptive CBS--) retarded mental development, congenital dislocation 
of the lenses, death from vascular thrombosis in childhood at age 8y 
both carotid artery walls thickened with severe narrowing of the lumens, 
right carotid artery further narrowed to almost complete occlusion by 
organised thrombus, right half of circle of Willis containing a recent 
thrombus, right cerebral hemisphere softened and pale “result of an 
extensive early infarction”, no gross evidence of disease within the heart, 
aorta, pulmonary artery, venae cavae, or other major vessels, except for the 
carotid arteries, right internal carotid artery intima thickened by a marked 
proliferation of loose fibrous connective tissue, disorganization of the 
media, and reduplication, fraying, thickening, and discontinuity of elastic 
fibres of the internal elastic membrane, a toluidine blue stain showed small 
amounts of metachromatic ground substance within the media and intimal 
fibrous tissue, “widespread focal alterations in the medium-sized and small 
arteries of the thymus, adrenal, kidney, heart and lymph nodes. In many 
medium-sized arteries there was focal narrowing of the lumen by intimal 
fibrosis, associated with splitting, irregularity, and focal discontinuity of 
the internal elastic membrane. As exemplified by the findings in the 
kidney and adrenal glands, many small arteries and arterioles were 
surrounded by a moderate proliferation of fibrous tissue containing 
increased numbers of fibroblasts, collagen fibres, and thin, irregular elastic 
fibres; the media of some of these vessels was moderately thickened by 
hyperplastic smooth-muscle cells. In the kidney many of the glomeruli 
were slightly to moderately hypercellular because of increased numbers of 
mesangial and endothelial cells; marked red cell congestion was present in 
many of the glomerular capillary tufts. One section of the aorta was 
normal. Moderate centrilobar fatty change was present in liver 
parenchymal cells; and extensive acute bronchopneumonia was found 
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McCully 
KS (1970); 
Am J 
Pathol; 
Massach’ts 
General 
Hospital, 
Boston, 
USA 
2  
CBS--
cases, 
And, 
2 
Control 
, 
human 
Cell 
lines 
“Fragments of dermis were obtained from a skin biopsy of a 9y-old, mentally retarded female with 
documented cystathionine synthetase deficiency and homocystinuria. A serially cultivated cell line, 
49 HC, was obtained as an outgrowth of cells from the dermal fragments…A second cell line 21HC, 
obtained from a 27y-old male with homocystinuria, and 2 normal cell lines, 26JL and 120JL, 
obtained from a 3y-old female and a 20y-old male were cultivated in the same way” 
 
(“…both methionine and cystine, found in small amounts in the cultured monolayer, are both 
present in adequate concentrations in the culture medium.”) 
 
“Results: Cells from the CBS—consistently produced moderate amounts of extra-cellular and 
intracellular material which formed aggregates and granules of varying size, frequently aligned 
along cellular processes and extracellular appearing fibrils but also scattered between the cells. The 
material was light red when stained with Giemsa but metachromatic red-violet when stained with 
toluidine blue. Reduced numbers of fibrils of normal morphology were present either in confluent 
areas or in sparsely populated areas. The abnormal material was produced throughout the growth 
cycle. When Hcy or Hcy thiolactone was added to the culture medium, larger amounts of the 
abnormal substance formed. In addition, comparison with control cultures revealed that the total 
number of cells in the monolayer was decreased after 1 week’s growth when Hcy 1000uM was 
added to the medium. The addition of Hcy 200-2000uM to the medium did not, however alter the 
cloning efficiency (26%) of the CBS—cells. In cultures with Hcy in the medium, some of the cells 
were found to contain small, uniform sized cytoplasmic granules, less than 1u in diameter, 
frequently distributed in a short linear array at the margin of the cytoplasm, and extending along 
extracellular appearing fibrils. 
 
Cells from the normal patients formed large numbers of long extracellular and intracellular fibrils of 
varying length and diameter without evidence of granular aggregated material. Addition of Hcy or 
Hcy thiolactone (He doesn’t give conc…apparently 1000uM from his Figure caption.) to the 
medium, however, resulted in the formation of moderate amounts of light red-staining granular 
flocculent substance and small amounts of fine granular material associated with fibrils.  …… 
Examination of the confluent layer of normal cells, by polarized light, revealed numerous, long, 
moderately birefringent fibrils. However, only small numbers of short, irregular, clumped 
birefringent fibrils were observed in the confluent monolayer of CBS—cells.”  
 
“Discussion  and Conclusions: The altered solubility of the glycoprotein and proteoglycan fractions 
isolated from the aorta of a patient with homocystinuria (cites Carson NAJ et al 1966) is probably 
the result of an altered state of aggregation and molecular conformation of proteoglycans 
synthesized by aortic cells. The ectopia lentis commonly observed in the syndrome was found to 
result from replacement of the normal fibrillar structure of the zonular fibers by irregular, granular 
material (cites Henkind and Ashton 1965). This morphologic change is very similar to the 
replacement of fibrils by granular fragmented material observed in the cultured cells.  The findings 
of increased amounts of soluble collagen and an increase in the amount of noncross-linked collagen 
in two individuals with homocystinuria (cites Harris and Sjoerdsma 1966(     )), as well as some 
features of the various connective tissue abnormalities in the syndrome, are presumably due to 
partial inhibition of normal collagen cross-linking by abnormal proteoglycans elaborated by the 
CBS—cells of connective tissues…..The glycousaminoglycans of human skin cultures do however, 
contain appreciable amounts of esterified sulfate. If increased homocysteine concentrations within 
the cell produced a change in the number or distribution of esterified sulfate groups on the 
carbohydrate side chains of the proteoglycan molecules synthesized by the cell, a drastic change in 
the conformationof the macromolecule at physiologic pH might be expected to result from the 
consequent alteration in the ratio of charge on polypeptide core to charge on surrounding 
carbohydrate envelope…..The finding that the addition of Hcy (1000uM from figure caption) to the 
culture medium of normal cells produced proteoglycan abnormalities similar to those found in 
CBS—cell cultures suggests that elevated concentrations of exogenous homocysteine are capable of 
producing arteriosclerotic and connective tissue changes in vivo in normal individuals without 
enzyme deficiencies.”    
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McCully 
KS (1972); 
Am J 
Pathol; 
Massach’ts 
General 
Hospital, 
Boston, 
USA 
2  
CBS—
cases, 
And, 
2 
Control 
human 
Cell 
lines 
“Fragments of dermis were obtained from a skin biopsy of a 9y-old, mentally retarded female with 
documented cystathionine synthetase deficiency and homocystinuria. A serially cultivated cell line, 49 
HC, was obtained as an outgrowth of cells from the dermal fragments…A second cell line 21HC, 
obtained from a 27y-old male with homocystinuria, and 2 normal cell lines, 26JL and 120JL, obtained 
from a 3y-old female and a 20y-old male were cultivated in the same way” 
“When pyridoxine was added to parallel cultures of the 21HC cell line the growth rate of the cells and 
production of protein was greatly increased, but there was no effect of added pyridoxine on the 49HC 
or the 120JL. The effect of pyridoxine correlates with the clinical (VitB6-responsivity: 21HC, yes; 
49HC, no) ” 
 
“To determine 35S binding, equal numbers of cells were passaged into Eagle’s minimal assential 
medium (MEM) with 10% fetal calf serum, containing 35SO4
2-  (New England Nuclear), 1uCi/ml and 
0.8mM, or 35S-Homocysteine thiolactone (Amersham), 1uCi/ml and 1.0mM, and refed twice weekly. 
The sulfate concentration of some media was doubled by adding 0.2g/l of  MgSO4 .7H20. The two 
concentrations of sulfate used, 0.8 and 1.6mM are both within the normal physiological range found in 
plasma. After the cultures reached confluence (2-8weeks), the medium was removed, and the 
monolayer was rinsed twice with cold phosphate-buffered saline (PBS), pH 7.0, and scraped from the 
dish into fresh PBS. The mixture was homogenized thoroughly in a glass homogenizer, and aliquots 
were taken for counting by liquid scintillation, using Bray’s solution, and for protein determination, 
using the Lowry method.” 
Important Note: The procedure precludes differentiation of extracellular phenomena from 
intracellular phenomena. 
 
 
Results:  
 
Initially:  
“The intercellular orientation and distribution of the CBS—cells over the surface of the culture dish 
was abnormal, since areas of sparse growth alternated with areas of growth in which cells formed 
multiple layers containing mitotic figures.”  
The VitB6-responsive CBS—cell line was purportedly more abnormal than the VitB6-nonresponsive 
CBS—cell line, unexpectedly.  
Abnormality correlated with binding of as 35S as 35SO4
2-. 
The abnormal granular substance was both within and between (see Important Note immediately 
above) the CBS-- cells. 
 
 
 
After some hours of puzzling over the inexplicably and apparently deliberately severely encrypted 
tabulation of results presented by KMcC, the following two tabulations (Series 1 and Series 2) are 
what I think is what his results presented in Table 1 were (They appear together below due to the need 
to view them concurrently): 
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                Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
(continued) 
McCully 
KS (1972); 
Am J 
Pathol; 
Massach’ts 
General 
Hospital, 
Boston, 
USA 
(cont) 
2  
CBS--
ases, 
And, 
2 
Control 
human 
Cell 
lines  
 
 
Series 
1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Series 
2: 
Cells         35SO4
2-           SO4
2-         Hcy’one              35SO4
2-nmol/mgProt   
 
Cont1       800uM             0                  0                     14, 16                                             
Cont1       800uM         800uM            0                     20, 19                
Cont1       800uM             0            1000uM               9.3, 6.3, 9.3           
 
Cont2       800uM             0                  0                    7.8, 8.1, 9.1, 9.4                            
Cont2       800uM         800uM            0                    18, 20, 30, 26        
Cont2       800uM             0            1000uM              7.0, 7.2, 8.6, 8.2          
 
CBS--1    800uM              0                  0                     29, 26, 33                                     
CBS--1    800uM          800uM             0                     58, 62, 64             
CBS--1    800uM          800uM       1000uM               88, 98, 112               
 
CBS--2    800uM              0                   0                      79, 67                                                 
CBS--2    800uM              0             1000uM                84, 62, 85  
 
Interpretation (verbalisation): 
 
#1 From Series 1, homogenates form the CBS--individuals, grown to confluence in medium containing 
35SO4
2- , had more bound sulfate per mg protein than homogenates from the normal individuals. 
 
#2  From Series 1, when the concentration of unlabelled sulfate was increased in the medium, all the cell 
lines homogenates had more protein-bound 35SO4
2-. This is unexpected on the basis of the assumption of the 
simplest molecular arrangement type, where a reduction in protein-bound 35SO4
2- would rather have been 
expected, and complicates the other interpretations. 
 
#3 From Series 1, adding unlabelled homocysteine thiolactone to the medium of the CBS--, with the total 
sulfate kept constant (at 800uM) was associated with a slight reduction of the amount of sulfate bound to 
protein for the normal controls, but with a slight increase of the amount of sulfate bound to protein for the 
CBS--, both magnitudes being small relative to the levels. 
 
#2&3 We note that the addition of Hcy to CBS-- cultures has the same association direction of an increased  
binding of sulfate, as adding extra (unlabelled) sulfate, while the addition of Hcy to the normal control 
cultures to the contrary is associated with rather a decreased binding of sulfate 
 
Cells           SO4
2-      35S-Hcy’lactone  Hcy’one    35S-Hcy’onenmol/mgProt 
 
Cont1       800uM               1000uM         0                   44, 69, 49                               
Cont1     1600uM               1000uM         0                   41, 51, 54 
 
Cont2       800uM             1000uM           0                      55,69                        
Cont2     1600uM             1000uM           0                  104, 94, 54, 85 
 
 
CBS--1      800uM             1000uM         0                    31, 51, 50                         
CBS--1    1600uM             1000uM         0                        54 
 
 
CBS--2      800uM             1000uM         0                    42, 24, 38                                
CBS--2    1600uM             1000uM         0                         40 
 
Verbalisation & cautioned Interpretation (In conjunction with Series 1): 
 
# Control protein binds Hcy in preference over sulfate, while CBS-- protein to the contrary binds sulfate in 
preference over Hcy.  
The meaning of this might be that: 
 in the CBS-- cells there is a deficit of endogenous sulfate due to the defective transulfuration pathway, 
which the cell attempts to redress by incorporating more exogenous sulfate,  
and that endogenous Hcy has already bound to a large proportion of binding sites in the CBS-- cells, leaving 
less opportunity for exogenous Hcy to bind, 
However, as we are unable to differentiate extracellular phenomena from intracellular phenomena, 
such interpretations must be viewed with caution to say the least. 
 
# No consistent effect of adding extra sulfate to medium on the binding of exogenous Hcy  
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              Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
(continued) 
McKully 
KS (1972); 
Am J 
Pathol; 
Massach’ts 
General 
Hospital, 
Boston, 
USA 
(cont) 
2  
CBS--
cases, 
And, 
2 
Control 
human 
Cell 
lines 
“Aliquots of some homogenates were mixed with cold 5% trichloroacetic acid (TCA) and filtered through 
Millipore filters; the filters and filtrates were counted in Bray’s solution.” 
 
Results: 
 
Cells        Precursor                   % 35S TCA-Insoluble          nmole35S/mgProtein 
 
Cont2        35SO4
2-                                 8                                      1.2 
Cont2       35S-Hcy’lactone                 28                                    15.1 
 
CBS--2    35SO4
2-                                17                                    12.4 
CBS--2   35S-Hcy’lactone                  33                                    11.4 
CBS--1    35SO4
2-                                12                                      3.5 
 
Interpretation:  
 
Note: All 35S-Hcy’lactone is exogenous, while some 35SO4
2- will be endogenous from the processing of  35S-
Hcy’lactone down the transulfuration pathway, mostly in the normal cells were it is available - “The 
observation that CBS—cell monolayers bind 35S in an amount aprox equal to or lower than that of normal cell 
monolayers may be explained by assuming that cellular synthesis of unlabelled homocysteine and 
homocysteic acid derived from methionine was increased due to CBS-- inability to convert the Hcy to 
cystathionine (>>>sulfate). The increased amount of unlabeled Hcy derived thusly would be expected to……”    
 
See Overall Interpretation below  
 
 
“Aliquots of some homogenates were exhaustively dialyzed for 24hours against cold calcium- and 
magnesium-free buffer containing EDTA 0.2g/l and K2SO4 0.28g/l, and the radioactivity remaining within the 
dialysis bag was determined.” 
 
Results: 
 
Cells        Precursor                  %35S Nondialyzable          nmole35S/mgProtein 
 
CBS--1     35SO4
2-                             7.5                                   2.2 
CBS--1      35S-Hcy’lactone           35                                    15.4 
 
Interpretation: 
 
See Overall Interpretation below 
 
 
“Homogenates of cells cultured in 35S-Hcy thiolactone were dialyzed against buffer containing EDTA and 
K2SO4 , hydrolysed with 6 M HCl at 110C for 22hours under N2 and chromatographed on sulfonated 
polystyrene resin.” 
 
Results:  
The CBS--1 assay recovered 88% of  35S as 35SO4
2-, while the Dunn-4 control recovered only 
73% of  35S as 35SO4
2-. 
Both lines were approx equivalent for methionine sulfoxide, methionine, Hcy, Hcy(ine), and Hcy thiolactone.  
And conversely to the former, the CBS--1 assay recovered only 2.4% of  35S as Unidentified, while the Dunn-
4 control recovered 15% of  35S as Unidentified. 
 
Interpretation: 
 
See Overall Interpretation below 
 
 
Overall Interpretation: 
 
As we are unable to differentiate extracellular phenomena from intracellular phenomena, the most that I 
am prepared to venture is that CBS-- skin cells produce an abnormal proteoglycan that is granular instead of 
fibrillar, and are sulfate deficient. KMcC ventures various surmise additional to this but due to the major 
limitation noted, which he does not sufficiently address in surmise, I will not reproduce and discuss them 
further here – the methods and data have been provided in sufficient detail to enable readers to form their own 
surmise – and they may turn to the original if they disagree with my conclusion or think it too incomplete. 
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   Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study Group Disease Hcy level 
Cross HE, 
Jensen AD; 
(1973) 
Am J 
Ophth; 
Johns 
Hopkins 
Hospital, 
Baltimore, 
Maryland, 
USA. 
 
CBS-- 
 
Vs 
 
Fibrillin gene 
Marfan Syndr 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 CBS-- 
Homocystinuria
, ascertained by 
amino acid 
chromatograph
y on ectopia 
lentis cases 
referred from 
ophthalmologist
s. 
 
142 Marfan 
Syndrome, all 
without 
homocystinuria, 
ascertained by 
clinical 
evaluation, and 
thereafter 
unselected. 
 
 
“The triad of dislocated lenses, skeletal anomalies, and cardiovascular disease 
may be present in both the Marfan Syndrome and homocystinuria…..   
 
The cardiovascular complications in homocystinuria are secondary to 
thrombosis and occlusion, mainly in medium-sized arteries and veins, in contrast 
to the defects in the valves and aorta often found in the Marfan Syndrome. 
Cerebrovascular thromboses, myocardial infarction, pulmonary emboli, 
intermittent claudication, and even death at a relatively young age often result. 
 
…Ectopia lentis, cataracts, myopia, optic atrophy, retinal detachments, and 
secondary glaucoma occur in both disorders. 
 
... McKusick suggested that the lenses are more likely to be displaced 
downwards in homocystinuria than in the Marfan Syndrome, but quantitative 
comparisons are lacking.” 
 
“It is apparent that ocular abnormalities are prominent features of both the 
Marfan Syndrome and of homocystinuria. The most frequent manifestation is, of 
course, ectopia lentis, but retinal detachment is the most serious threat to vision 
in both disorders.” 
 
“Records of the Wilmer Institute, the division of medical genetics, and the 
central records library of the Johns Hopkins Hospital were searched for all 
patients with the Marfan Syndrome and homocystinuria”: 
 
“Among 42 patients with homocystinuria, 38 (90%) had dislocated lenses (note 
ascertainment….). Dislocations were remarkably symmetrical, and no individual 
with unilateral dislocation was found. Visual acuity was normal in all eyes with 
lenses in the normal position. Ectopia lentis was discovered by the age of 5years 
in approximately 38% of homocystinuria patients and never after 25years of age. 
Only 1/3 escaped detection until age>10years. 1/3 of these lenses were 
dislocated inferiorly and 49% were displaced nasally. No lenses were dislocated 
inferotemporally or directly superiorly and only 4% had any temporal 
dislocation and only 4% had any temporal dislocation. 19% migrated nto the 
anterior chamber and 14% were found lying in the vitreous.” 
 
“A dislocated lens was detected in 79% of eyes in the Marfan Syndrome. In all 
except 3 patients the dislocation was bilateral….In patients with the Marfan 
Syndrome, the lense may dislocate in any direction, but most frequently moves 
upward. Fully 68% of lenses were displaced either superiorly, superonasally, or 
superotemporally. The direction of horizontal displacement is more nearly 
random…..Luxation into the posterior chamber is unusual, and occurred in only 
3% of eyes with ectopia lentis. Curiously, no patient with the Marfan syndrome 
was seen with the lens in the anterior chamber, although atotal fo five lenses 
subsequently migrated there, at an average age of 20years.” 
“Anomalies of the iridocorneal angle such as abnormal iris insertions with 
bridging pectinate strands, inconspicuous Schwalbe’s line, wide iris processes, 
and a broad trabecular meshwork may be unique features of the Marfan 
Syndrome, since they have not been reported in homocystinuria, but the 
statistical documentation necessary for any diagnostic application of this 
distinction is not available.” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40nM 
 
 
 
 
 
 
Approx 
normal?    
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                 Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt and 
biochem etc 
contexts 
Harker LA 
et al (1974); 
NEJM ; 
U 
Washington 
Sch Med, 
USA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Continues) 
4* 
CBS-- 
Cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4* 
CBS--, 
 
 
 
 
 
35 
normal 
control 
Case 1: Female, 
at age 20y homocystinuria detected,  
by which time at least one episode of thrombophlebitis and 
pulmonary embolism, 
at age 24y IQ 50,  
moderate Marfanoid continuum,  
calcification of aortic arch, occluded left carotid artery, flow 
reversal in left supraorbital artery, diminished popliteal flow 
bilaterally,  
Q waves V5 and V6 of ECG 
 
 
 
 
Case 2: Female, 
at age 8y homocystinuria detected, 
at age 13y IQ 70, bilateral ectopia lentis,  
decreased flow in left carotid and both superficial femoral arteries 
 
 
 
 
 
 
 
 
 
 
Case 3: Male,  
at age 16y homocystinuria detected,  
ectopia lentis,  
probable history of pulmonary embolism  
at? age 19y mentally deficient,  
malar flush, moderate Marfanoid continuum,  
non-specific ST-segment changes on ECG,  
decreased flow in right superficial femoral and left popliteal 
arteries  
 
 
 
 
 
Case 4: Male, at age 16y homocystinuria detected, mild mental 
deficiency, ectopia lentis, two pulmonary embolizations with 
occlusions of right, and left, femoral veins, acute spontaneous 
occlusion of the right superficial femoral and popliteal arteries 
eventually requiring below-the-knee amputation, 
 
 
Platelet Studies (1): 
                                                             Count        Survival 
Cases 1&4 (VitB6-nonresponsive)    297,000/ml    5.0days      
 
 
 
Cases 2&3 (VitB6-responsive)          197,000/ml    8.6days 
 
 
 
35 normal controls                              250,000/ml   9.5days 
 
 
The analogous fibrinogen and plasminogen data was less 
remarkable in magnitude but corroborative inasmuch as VitB6-
nonresponsives fibrinogen and plasminogen both had reduced  
survival vs the approx = VitB6-responsives and normal controls.    
“245uM 
Hcy(ine)” 
Probably “fHcy”, 
= 300uM tHcy, 
otherwise literally 
= 530uM tHcy 
 
“179uM Hcy(ine)” 
Probably “fHcy”, 
= 220uM tHcy, 
otherwise literally 
= 400uM tHcy 
 
 
“168uM 
Hcy(ine)” 
Probably “fHcy”, 
= 210uM tHcy, 
otherwise literally 
= 380uM tHcy 
 
“33uM Hcy(ine)” 
Probably “fHcy”, 
= 73uM tHcy, 
otherwise literally 
= 106uM tHcy 
 
 
“202uM 
Hcy(ine)” 
Probably “fHcy”, 
= 240uM tHcy, 
otherwise literally 
= 440uM tHcy 
 
“5uM Hcy(ine)” 
Probably “fHcy”, 
= 45uM tHcy, 
otherwise literally 
= 50uM tHcy 
 
 
Not given 
 
“no drop” 
 
 
 
 
 
“40uM 
Hcy(ine)” 
Probably “fHcy”, 
= 80uM tHcy,  
 
“140uM Hcy(ine)” 
Probably “fHcy”, 
= 180uM tHcy,  
 
“0uM Hcy(ine)” 
Probably “fHcy”, 
= <<40uM tHcy,  
 
 
 
(Continues) 
Nil 
 
 
 
 
 
 
After 14d of 
VitB6 
350mg/ day 
 
 
 
 
Nil 
 
 
 
 
 
 
VitB6 
50mg/d 
 
 
 
 
 
Nil 
 
 
 
 
 
 
VitB6 
300mg/d 
 
 
 
 
 
Nil 
 
VitB6 
300mg/d 
 
 
 
 
 
 
Below as 
noted 
above… 
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                    Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
(Continued)
Harker LA 
et al (1974); 
NEJM ; 
U 
Washington 
Sch Med, 
USA. 
(Cont)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4* 
CBS-- 
Cases 
 
 
 
 
35 
normal 
control 
 
 
(Continued) 
 
“Patients unresponsive to VitB6 (Cases 1 & 4) were restudied 
while receiving a combination of dipyridamole, 100mg, and 1g of 
acetylsalicylic acid once a day; platelet survivals were prolonged 
to 8.3 and 8.7days respectively. These patients have now been 
maintained continuously7 on this combination for the past 3years, 
without any clinical evidence of vascular occlusive or 
thromboembolic events, as compared with a minimum of 5 
thrombotic episodes in the year before therapy.” 
 
 
 
Platelet Studies (2): 
 
Bleeding   Collagen Fiber    GlassBead     Phospholipid      Clot 
Time           Adhesion           Retention      Availability    Retraction 
 
4.5min           48%adh           40%ret            67sec          48%of clot 
 
 
 
 
 
 
4.2min           51%adh           42%ret            65sec          47%of clot 
 
 
Their Discussion (part of):  
 
“Platelet utilization is closely related to homocysteinemia as 
evidenced by the inverse first-order relation between platelet 
survival and Hcy concentration in both patients and baboons. 
Platelet destruction, however, is not a direct toxic effect of  Hcy 
on platelets, since dipyridamole (platelet inhibitor) therapy blocks 
platelet consumption without decreasing the concentration of 
homocysteine in the plasma. Furthermore, we found no evidence 
to support the notion that the thrombotic predisposition in 
homocystine (“Hcy-uria”?…) might reflect increased platelet 
utilization secondary to enhancing platelet reactivity. Platelet-
function tests gave normal results and remained unchanged in both 
patients and animals. In view of the similarities of the thrombotic 
process of prosthetic and arterial embolic disorders, it was 
concluded that the underlying process of homocystinemic 
thrombosis probably involves formation of platelet thrombus on 
altered, nonendothelialized endarterial surfaces. This formulation 
was further supported by the known atherosclerotic vascular 
changes characteristic of homocystinuria”                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“90uM 
Hcy(ine)” 
Probably “fHcy”, 
= 130uM tHcy, 
(rough deriv’n, 
simple average)  
 
“0uM Hcy(ine)” 
Probably “fHcy”, 
= <<40uM tHcy, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Below as 
noted 
above… 
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             Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Poole et al 
(1975) 
J Clin 
Investig 
6  
Vit B6-
respons
ive 
CBS— 
And 
5 
Vit B6-
nonres
ponsive 
CBS-- 
(from abstract) 
 
 “Apparent nitrogen balances and urinary sulfur excretions were described for normal subjects, seven 
cystathionine synthase-deficient patients, and a single cystathioninuric patient on semisynthetic diets 
containing low-adequate amounts of methionine and very low amounts (12 mg daily, or less) of cysteine. 
The amounts of supplemental cysteine required to prevent abnormally high nitrogen or sulfur losses were 
determined. 
The five cystathionine synthase-deficient patients who had low residual activities of this enzyme detected in 
fibroblast and/or liver extracts did not lose more nitrogen or sulfur on diets virtually devoid of cysteine than 
did the normal subjects. 
These results suggest that the widely expressed opinion that cysteine is an essential amino acid for 
cystathionine synthase-deficient patients requires modification.” 
 
(from body of text) 
 
“All of these observations together suggest that 310-510 mg cysteine is adequate for patients with virtually no 
residual cystathionine synthase activity detected by present methods.” 
 
“The hepatic cystathionine synthase activities of the B6-responsive patients in their basal states (i.e. on B6 
intakes provided by normal diets only) were 1-2% of the mean control value (19, 49). Thus, it appears that a 
residual activity of 1-2% of this enzyme endows the patient with the capacity to convert at least 20-50% of the 
normal methionine intake to cysteine..” 
 
My comments: 
 
In table IV, subject Jo. Ho. (one of the vitamin B6-responsive CBS—patients) has nitrogen balance results in 
the opposite direction of that expected on the low versus high cysteine  intakes – with only 7 subjects in the 
study, this result, together with other variations from the average result,  throws a fair bit of doubt on the 
whole study. 
Also, the statistical significances of the difference observed were not provided, and are in doubt due to the 
variations from the average noted just above. 
 
Moreover, the result does not argue strongly against the benefit of cysteine supplementation for all CBS—
pateines, Vit B6-responsive and –nonresponsive, because some proteins have a higher content of cysteine than 
others, and the fact that in this experiment with only 7 CBS—subjects, over a a very short period of time, were 
only roughly close to being in nitrogen balance, does not argue strongly that over the whole of a lifetime, a 
CBS—patient of either B6 type without supplemental cysteine would be fairly likely to evolve by middle or 
old age significant disease due to the lack of that supplemental cysteine. 
Aside from cysteine in body proteins, there are also other metabolites of cysteine that are potentially of 
importance – cystathionine, glutationine and its anti-oxidant activity, sulphate, and hydrogen sulphide, just for 
examples.  
Many chronic diseases are known to have the contributing factors present for many years before the diseases  
finally develop to be clinically manifest in middle or old age.  
 
 
 
   Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Murdoch 
JC et al 
(1977) ; 
BMJ ; 
Lennox 
Castle 
Institution, 
Glasgow, 
Scotland, 
UK. 
CBS 
+++ 
trisomy 
 
70 
Downs 
Syndr 
# 70 Down’s Syndrome patients had ss or nearly ss lower systolic and diastolic blood pressures 
(consistent across age and sex dichotomisation subsets) than 70 age- and sex-matched non-DS mental 
defective patients living in the same institution 
 
# These DS patients and non-DS mental defective patients had remarkably similar cholesterol and 
triglycerides to each other. 
 
# Postmortem examination of 5 of these DS patients aged 40-66y showed a complete absence of 
atheroma, whereas a similar number of non-DS mental defective patients aged 42-80y were found to 
have mild or severe atheroma. 
 
# 123 normal community controls without family vascular disease history aged 20-65 had ss or nearly 
ss cholesterol and triglycerides than the abovenoted DS and non-DS institutionalized mental def’s   
 
?: Do various metabolic derangements cause atheromatous dis?… 
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    Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study Group Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
Almgren B 
et al (1978); 
Acta Chir 
Scand; 
U Hospital, 
Uppsala, 
Sweden. 
1 CBS-- 
age 35y 
“ Man, 35, admitted January 1977 for evaluation of increasing right 
calf claudication since the early 1970s. At admission he had a 
walking distance of only 100metres.  
There were no known cardiovascular cases among his relatives.  
He had been smoking 20 cigarettes/day since age 20.  
Bilateral extirpation of his eye lenses had been performed in 1971 
because of luxation.  
The patient appeared older than 35years.  
He had a course, light-coloured hair.  
He had a normal body build and  
there was no sign of mental retardation.  
Heart, lung and abdomen were normal at physical examination.  
ECG and laboratory tests including blood lipids were also normal. 
Arteriography demonstrated occlusion of the right superficial 
femoral artery.  
A femoro-popliteal vein bypass was performed. The operation was 
uncomplicated and the function of the leg was restored to normal.  
In September 1977, the patient was readmitted for further 
investigation. All routine tests were within normal limits. …. 
The cyanide-nitroprusside reaction of urine was positive…. 
Treatment with pyridoxine 320mg/day was started.  
Subsequent homocystine tests in urine were negative, indicating a 
favourable response to treatment.  
On January 8 1978, he noted the sudden onset of sever abdominal 
pain. On admission a pulsating abdominal mass was found. 
Aortography showed a large abdominal aortic aneurysm. In 
retrospect this aneurysm could be seen in the previous arteriograms. 
Emergency laparotomy was performed and a large leaking aneurysm 
was found with retroperitoneal bleeding. The aneurysm measured 
10*13cm and large organised thrombi covered the inner aneurysmal 
wall.  
The aneurysm was resected and a bifurcated dacron graft was 
inserted into the common iliac arteries.  
The postoperative course was uneventful.  
Microscopic examination of the aneurysm showed advanced 
atherosclerotic degenerative changes.”  
Hcy-uria 
present, 
Equates to 
tHcy >    
       40uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hcy-uria 
no longer 
present, 
Equates to 
tHcy <    
       40uM 
 
 
Nil 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VitB6 
320mg/d 
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                 Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study Group Disease Hcy level Treatmnt and 
biochem etc 
contexts 
Grobe H et 
al (1979); 
Ped Res ; 
U Munster, 
Germany 
(is an 
abstract 
only in the 
journal) 
3*CBS--
VitB6-
responsives 
 
 
 
 
 
 
 
 
 
 
 
 
5*CBS--
VitB6?non/ 
responsives 
already 
under 
treatment 
 
 
“Collagen-, ADP- and adrenalin-induced platelet aggregation was 
decreased (not my misprint) before treatment.” 
Platelet factor 3 availability reduced, 
Open canalicular system occupancy 7.2% of total platelets area, 
Alpha-granules 7.2% 
 
 
“Collagen-, ADP- and adrenalin-induced platelet aggregation was 
returned to normal when homocystine disappeared from plasma.” 
Platelet factor 3 availability returned to normal, 
Open canalicular system occupancy 4.5% of total platelets area, 
Alpha-granules 11.1% 
 
 
 
“Functional and morphological studies in the 5 patients already under 
treatment showed normal results.” 
 
 
 
 
 
Their Conclusion: We conclude that the platelet alterations in 
untreated patients result from their refractory stage after a release 
reaction has already taken place; the latter may be caused by the 
Hcy-induced endothelial lesions. In adequately treated patients, our 
data suggest that no additional administration of inhibitors of platelet 
aggregation is necessary.” 
Higher: 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40uM 
 
Lower: 
Hcy-uria 
not 
present, 
Equates to 
tHcy <    
       40uM 
 
Unknown, 
assume 
successful
ly??..                   
Nil 
 
 
 
 
 
 
Unknown 
but was 
some – 
VitB6? 
+ ?…… 
 
 
 
Unknown 
but was 
some – 
VitB6? 
+ ?…… 
Hill-Zobel 
RL et al 
(1982); 
NEJM; 
Johns 
Hopkins U, 
Baltimore, 
Maryland, 
USA. 
 
 
 
 
 
 
 
 
 
 
6*CBS--
VitB6-
responsives 
 
 
 
 
6*CBS--
VitB6-non 
responsives 
 
 
 
 
 
 
 
 
 
 
 
 
11*normal 
volunteers  
 
Platelets from 50ml of venous blood were harvested and labelled 
with 111Indium in an aseptic open test tube system. All patients and 
controls had platelet counts within the normal range. Then 
reinfusion, and blood samples obtained at 90min and daily thereafter 
for 10days. 
 
Platelet Survival Times according to 3 different mathematic’l 
models: 
 
Linear Model             Exponential Model      Multiple-Hit Model 
 
9.33days                            3.19days                        8.02days 
 
 
 
 
 
 
9.51days                            3.33days                        7.94days 
 
 
Inset: “The diet during the study was selected by the patients from an 
unmodified regular hospital menu. Daily calorie, protein, methionine, 
and cystine intake were determined by a dietician; the average values 
for all patients over the 12day study were 1215-3160kcal, 45-
150gprotein, 1050-4000mgMethionine, and 700-2000mgCysteine per 
day”  
Note: Here, I take it that “determined” means only “calculated”, and 
not “prescribed”, and that no supplemental cysteine was used, 
ostensibly… 
 
 
9.81days                            3.25days                        8.40days 
 
Additional Result: Spleen 111Indium accumulation  at 1day CBS--
50%dose , Controls 40%dose; at 3days all subjects 50%dose, and,  
Liver 111Indium accumulat’n from 90min-3days all subjects 15%dose 
 
 
 
 
 
 
 
 
Hcy-uria 
not 
present, 
Equates to 
tHcy <    
       40uM 
 
“48-
118uM 
Hcy(ine)” 
maybe 
“fHcy”, 
= 88-
158uM 
tHcy, 
otherwise 
literally = 
136-
276uM 
tHcy, 
suspect 
the 
latter?... 
 
Hcy-uria 
not 
present, 
Equates to 
tHcy <    
       40uM 
 
 
 
 
 
 
 
 
VitB6 
500mg/d, 
Folate 
10mg/d 
 
 
 
No VitB6, 
No folate, 
 
Methio-nine 
abnorm’y 
high, 
 
Cysteine 
abnorm’y 
low 
 
And see 
“Inset” 
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    Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study Group Disease Hcy level Treatment and 
biochem etc contexts 
Wilcken 
DEL et al 
(1983); 
NEJM ; 
Prince 
Henry 
Hospital, 
Sydney, 
Australia. 
 
 
10 CBS--: 
(by enzyme, Hcy-
uria, high 
methionine), 
aged 6-37y,  
(8 VitB6-
nonresponsives,  
2 VitB6-partially 
responsives). 
 
 
 
 
 
25 Controls: 
adults, no other 
details.  
Methionine+/-SD  Cysteine (“fCys”?)+/-SD 
 
330uM+/-347             56uM+/-15 
 
 
 
P<.01                           P<.001 
 
 
 
592uM+/-396            83uM+/-12 
 
 
 
 
 
26uM+/-7                  131uM+/-34 
 
 
 
“There were striking clinical changes after 
betaine treatment in some patients. In 2 
there was a pronounced darkening of the 
hair, which was previously fair. Parents or 
schoolteachers gave unsolicited reports of 
improvement in the behaviours of 5 
patients, although formal testing could not 
be undertaken to substantiate these 
observations. However, in a 19year old 
male patient there was a dramatic and 
unequivocal improvement. This patient had 
a long history of difficult, and at times 
violent, behaviour. During treatment with 
betaine, he stopped drinking heavily, 
acquired a part-time job, and in the words 
of his mother “became pleasant to live 
with.” This change persisted throughout the 
whole of the treatment period. 3 patients 
had a history of bronchial asthma, and 2 of 
them (age 32y, 13y) had had frequent 
attacks. Apart from I attack in the early 
post-treatment period in patient 5, there 
were no additional attacks of asthma in 
these 2 patients during treatment.”   
“fHcy”?…+/-SD. 
 
146uM+/-61 
=186uM tHcy?.. 
 
 
P<.001 
 
 
 
34uM+/-20 
= 74uM tHcy?.... 
 
 
 
 
4uM+/-1 
= <40uM tHcy?... 
 
 
VitB6>=100mg/d 
Folate 5mg/day, 
1 patient on diet 
<17mgMethionine/ 
kgBW/day, 
5 patients on diets 
low-protein 
 
(As above, but with 
Betaine2*3g/day in 
orange juice)*(5-
13months 
 
 
No details 
 
                  Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study Group Disease Hcy 
level 
Treatmnt and 
biochem etc 
contexts 
Dudman 
NPB, 
Wilcken 
DEL 
(1983); 
Clinica 
Chimica 
Acta; 
Prince 
Henry 
Hospital, 
Sydney, 
Australia. 
14 CBS--: 
(by enzyme, Hcy-
uria, high 
methionine), 
aged 4-53y,  
(6 VitB6-
nonresponsives,  
8 VitB6-
(partially?) 
responsives), 
 
And, 
 
44 Controls: 
Matched for age, 
sex and smoking  
Ratios CBS--:Normal, +/-SD 
 
Plasma                 Plasma            Plasma              Erythrocyte 
p-Phenylene-       Total          Caeruloplasmin      Superoxide 
diamine               Copper                                      Dismutase 
 oxidase 
 
1.38+/- 0.21     1.40+/-0.15        1.28+/-0.22          0.96+/-0.15 
 
P<.001               P<.001                P<.001                  nss        
No 
details 
Ambiguous 
suggestion of 
no treatment 
(refer to a cbl-- 
patient not 
presented here) 
, but 
considering 
their details 
study above, & 
dates, maybe 
treatment was 
as above?....  
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Authors, 
Journal, 
Site 
Study Group Disease Hcy level Treatmnt and 
biochem etc contexts 
Boers GHJ 
et al (1983); 
Metabolism 
U Nijmegen 
Nijmegan, 
Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Continues) 
 
8 CBS--: 
(by enzyme, Hcy-
uria, high 
methionine), 
aged 20-50y), 
  
(mostly non-, with 
some partially-at-
best-, VitB6-
responsiveness?..) 
Age at diagnosis: 20-50y 
 
Ectopia Lentis:     6/8 
Myopia:                5/8,   4 with Ect Lentis 
Glaucoma:            3/8,  all with Ect Lentis 
 
Dolichostenomelia: 3/8, all with Ect Lentis 
Arachnodactyly:    4/8,  all EL, 2 with Dol 
Osteoporosis:        7/8,   5 with Ect Lentis 
Scoliosis:              6/8   all with Ost, 5 EL 
 
Thromboembolism: 3/8,   all E L, all EEG 
Thrombophlebitis:   2/8, all with Ect Lentis 
 
Abnormal Arterial Blood Flow: all, 3 severe 
 
Convulsions: 2/8, 1 Thro’emb, all Thro’phl 
EEG abnormalities:  4/8,  
Psych’ic Illness: 2/8,  all EEG, 1 Thro’emb 
 
(Continues) 
 
(see 
continuation 
below) 
Skin fibroblast CBS 
activities: 
 
CBS-- before VitB6: 
.03-0.14 
Normal before 
VitB6:  
3.6-26 
 
CBS-- after VitB6: 
0.10-0.56 
Normal after VitB6: 
4.9-32 
 
(mostly non-, with 
some partially-at-
best-, VitB6-
responsiveness?…) 
 
 
(Continued)
Boers GHJ 
et al (1983); 
Metabolism 
U Nijmegen 
Nijmegan, 
Netherlands 
(Continued) 
8 CBS--: 
(by enzyme, Hcy-
uria, high 
methionine), 
aged 20-50y), 
  
(mostly non-, with 
some partially-at-
best-, VitB6-
responsiveness?..) 
 
 
 
 
 
20 Controls: 
Adult 
Methionine  Cysteine(“fCys”) Cystine  Hcy-Cys   Homocystine 
 
     33uM        112uM                 52uM        8uM          0.5uM 
 
 
      
 
    76uM          96uM                 29uM      38uM        29uM 
 
 
 
 
 
 
 
 
   28uM+/-2     114uM             56uM+/-2     2.2uM+/-0.4    ND 
 
 
(Continues) 
 
 
fHcy… 
= 9uM, 
tHcy 
= 49uM 
 
fHcy… 
= 96uM, 
tHcy 
= 136uM 
 
 
 
 
 
fHcy ND, 
tHcy 
approx 
10uM?… 
 
 
VitB6 
750mg/d 
for 
>1year 
 
After 
ceasing 
(VitB6 
750mg/d 
for 
>1year) 
for 
4weeks 
 
(Continued)
Boers GHJ 
et al (1983); 
Metabolism 
U Nijmegen 
Nijmegan, 
Netherlands 
Further Results: 
 
Following an oral methionine-loading at 0.1mg/kgBW (more than 6* the daily requirement in one lot, making the 
absolute values of the results somewhat irrelevant),whilst on VitB6 treatment the distribution of the cysteine 
between cystine and Hcy-Cys was changed from 52uM:8uM to 19uM:41uM pretty much linearly over 8hours.  
The total (“free”) cysteine “fCys” is therefore much the same, but it’s distribution moves to Hcy-Cys as the Hcy 
level rises in response to the methionine load’s (plasma methionine up from 33uM to roughly 1000-600uM 
decrease across the 8hours) increase of the fHcy from approx 9uM to approx 130uM increase across the 8hours .        
 
Following an oral methionine-loading at 0.2mg/kgBW (more than 12* the daily requirement in one lot, making 
the absolute values of the results fairly irrelevant),whilst not on VitB6 treatment the distribution of the cysteine 
between cystine and Hcy-Cys was changed from 29uM:38uM to 9.5uM:43 pretty much linearly over 8hours.  
The net (“free”) cysteine “fCys” is therefore much the same, but it’s distribution moves to Hcy-Cys as the Hcy 
level rises in response to the methionine load’s (plasma methionine up from 76uM to roughly 1000-750uM 
decrease across the 8hours) increase of the fHcy from approx 96uM to approx 180uM increase across the 8hours. 
 
So the qualitative effect of adding methionine, or removing the VitB6 therapy are similar, as expected, as the 
increased Hcy takes up more cysteine. The absolute methionine values will need to be compared with those 
attending ie methionine- unrestricted diets in order to make propose inferences regarding cysteine…. 
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    Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
Jackson 
GM et al 
(1984); 
Am Heart J; 
U 
California, 
San Diego, 
USA 
1 
 CBS-- 
case 
Previously recurrent thromboembolic events. 
At age 45y, Hcy-uria diagnosed, skin fibroblast enzyme assay 
No thromboembolic events in 5years prior to admission for following op 
“A 56y-old man was admitted for resection of an asymptomatic squamous 
cell carcinoma lung tumour ….All preoperative laboratory tests were 
normal including coagulation studies (prothrombin time 11.3sec/ control 
11.3sec; partial thromboplastin time 32.5sec/ control 29.6sec; platelet 
count 310,000/mm3…… Right upper lobectomy was performed under 
halothane anesthesia. Pyridoxine supplement was withheld. Postoperative 
complications included new onset atrial fibrillation, adult respiratory 
distress syndrome, and unexplained fever…..By the third postoperative 
day he was unresponsive to verbal command…..Three days later bleeding 
was noted with concomitant platelet count of 11,000/mm3, prothrombin 
time 15.7sec/ control 11sec; partial thromboplastin time 34.6sec/ control 
29sec …..On the seventh postoperative day homocystinuria and 
methioninuria. Pyridoxine Supplementation was resumed and folic acid 
and dipyridamole were provided. Neurologic examination on the tenth 
postoperative day was consistent with pontine, right frontal cortical, and 
left frontoparietal cortical ischemia. The following day he had the second 
episode of atrial fibrillation. By the thirteenth postoperative day platelet 
count rose to 158,000/mm3, and the patient was again awake, alert, and 
responding to verbal command. The next day he was unresponsive to pain, 
quadriplegic, with central neurogenic hyperventilation, bilateral 
papilledema, and asymmetric unreactive pupils. Apneusis was followed by 
ataxic respirations and death.  
Postmortem….Several verrucous, fibrin vegetations were present on the 
tricuspid, pulmonic, and aortic valves. These were consistent with 
noninfective thrombotic endocarditis. An old myocardial infarct and one 
about two weeks old were present in the lateral wall of the left ventricle. 
Several pale cortical infarcts were seen within each kidney. A focal infarct 
was seen in the spleen. The brain weighed 1670g. The cerebral cortical 
surfaces were edematous, soft and showed scattered subpial hemorrhages. 
The sectioned cerebral hemispheres showed confluent petechial 
hemorrhages limited to the cortical grey matter. Microscopic examination 
showed many hemorrhagic and nonhemorrhagic cortical infarcts varying 
in age from hours to days. Rarely, thrombi were present within the lumen 
of small parenchymal vessels. No lesions were seen in the brainstem or 
cerebellum….This report is the first to demonstrate disseminated 
postoperative thromboembolism with thrombocytopenia and 
microangiopathic features in a patient with VitB6-responsive CBS-- in 
whom VitB6 supplement was withheld….measures to prevent 
intraoperative hemostasis, and perioperative provision of antiplatelet 
therapy, dietary and/or vitamin therapy, and adequate hydration seem 
prudent.”   
 
“Plasma 
Hcy(ine) 
normal’d” 
? 
? 
? 
? 
? 
? 
? 
? 
? 
? 
Hcy-uria 
present, 
Equates to 
tHcy >    
       40uM 
? 
? 
? 
? 
? 
? 
 
 
VitB6 
“pharma-
cologic 
doses” 
 
VitB6 
witheld 
 
 
 
 
 
 
VitB6 
“pharma-
cologic 
doses” 
resumed 
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Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc contexts 
Newman G 
Mitchell 
JRA 
(1984); 
Quart J 
Med; 
U Hospital, 
Nottingham
UK 
2  
CBS-- 
siblings 
A 20y old woman presented 2months after the delivery of her first child. 
Labour had been induced after a small ante-partum Hemorrhage but the 
pregnancy was otherwise normal.  
The vaginal delivery was complicated by a retained placenta which was 
removed manually under general anaesthesia.  
She remained well until 1month post-partum when she noticed that both her 
feet felt cold and numb.  
When walking she developed aching pain in both calves which abated after 
rest; during the next month her right leg gradually improved but she continued 
to have pain in the left.  
2months post-partum she suddenly developed pain, numbness and paraesthesia 
in her left arm…. 
For 10minutes she also had intense vertigo and a disturbance of vision which 
she described as  “like staring at a bright light”.  
There was no relevant past medical history and she had never taken the 
contraceptive pill.  
During pregnancy she had taken ferrous sulphate and  
during labour she received oxytocin (Syntocinon), pethidine, promethazine and 
ergotamine with oxytocin (Syntometrine).  
After manual removal of the retained placenta a single dose of ergometrine was 
given intravenously.  
No drugs were given to suppress lactation and on admission she was taking 
inositol nicotinate (Hexopal)…. 
Initial investigations to identify a source of emboli, a vasculitis or a thrombotic 
tendency were negative. These included a chest radiograph, echocardiogram, 
blood cultures, full blood count and film, ESR, anti-thrombinIII level, 
fibrinolytic screen, VDRL, TPHA, and a search for immune complexes and 
cryoglobulins.  
An arch aortogram via the femoral route showed complete obstruction at the 
origins of the left subclavian and vertebral arteries and injection of contrast into 
the lower aorta showed marked narrowing of both external iliac arteries and 
occlusion of the right internal iliac artery. The left subclavian artery was 
explored; it was found to have a normal external appearance but to be occluded 
by a large thrombus which was removed. Histology showed this to be 
laminated platelet-leucocyte-fibrin material which was sterile on culture.  
The brachial pulse was restored but was lost again several hours after the 
operation. In spite of re-exploration, the removal of further thrombus and 
anticoagulation with heparin, the artery occluded yet again.  
She was subsequently anticoagulated with warfarin and made good progress 
apart from developing a left ulnar nerve palsy and a tender swollen left calf 
which had the clinical appearance of a typical deep vein thrombosis….. 
positive cyanide-nitroprusside reaction…confirmed aa analysis,  
but detailed clinical examination after the acute episode showed no stigmata of 
homocystinuria save for quivering of the iris of both eyes (iridodonesis) on slit-
lamp examination.  
Her first-degree relatives were screened….1 of her brothers (CBS--). He was 
6ft 2inches tall, with long thin fingers and face…apart from mild pectus 
excavatum and the Marfanoid features, physical examination was normal and 
there was no ocular abnormality….. 
Platelet behaviour was measured by our standard techniques. The tests were 
done on the patient 14days after her last operation, when she was on warfarin, 
but before pyridoxine treatment had been started.  
Her whole- blood platelet count was found to be very high 674,000/ul (normal 
range up to 450,000/ul).  
Her whole-blood platelet aggregation, as judged by the disappearance of single 
platelets from stirred whole blood to which EDTA had been added as 
anticoagulant was 20% in 6minutes (upper limit of normal 5%)  
but her ability to generate malondialdehyde (MDA) in clotted whole blood was 
normal at 12.5uM. Tests of platelet activity in separated platelet rich plasma 
were within our normal range (arachidonic acid-induced MDA production – 
9,7nmol/109platelets; platelet release reaction, as judged by the 5HT liberated 
in response to challenge with ADP, adrenaline and collagen was normal).  
 
(Continues)  
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(Continued)
Newman G 
Mitchell 
JRA 
(1984); 
Quart J 
Med; 
U Hospital, 
Nottingham
UK 
2  
CBS-- 
Sibl’s 
 
 
 
 
 
 
 
 
 
 
 
Sister 
 
 
 
 
 
 
 
 
 
Brother 
 
 
 
 
 
 
 
 
(Continued) 
Vessel biopsies were obtained from the patient while she was on warfarin and 
from her brother before he was on any medication. Segments of forearm vein 
were excised under local anesthesia and were immediately fixed both intact and 
after opening up. The blocks also included some small arteries. Scrutiny of the 
vessels by light, transmission, and where appropriate, scanning electron 
microscopy, showed them to be normal. In particular, normal endothelial cells 
were seen to be covering the intima with no breaks or defects….. 
Pyridoxine 250mg/day was added to her warfarin 1month after the episode of 
subclavian/vertebral occlusion. 
 
Plasma:                                                         Methionine            “Cystine” 
 
                                                                         80uM                       Nil                                                                           
 
 
 
                                                                         40uM                       40uM 
 
 
 
 
 
                                                                          10-100uM              10uM 
 
 
 
                                                                           40uM                      60uM 
 
 
 
 
Her ulnar nerve palsy progressively improved, but when she became more active 
after leaving hospital, she experienced left calf claudication at 50yards.  
2months later she could walk for 2miles on the flat without pain, although she 
still had some discomfort on hurrying up steep hills.  
This was matched by a return of the left dorsalis pedis pulse and a stronger left 
femoral pulse but there has been no return of the pulses in the left arm. She 
continues on pyridoxine 250mg daily and on warfarin to produce Thrombotest 
levels of 5-10%. We can document the contribution which the former has made to 
render the amino acid metabolism normal (overgeneralisation. DV) so we can 
confidently advise her to continue it indefinitely.  
What is less clear, however, is whether the correction of the homocystinemia with 
pyridoxine has now controlled her “thrombotic tendency” so that we could stop 
the anticoagulants. 
 
(Note: Consider the possibility that rebound hyposulfatism resulted from the 
cessation of the ferrous sulfate in the context of apparently no cysteine 
supplementation and the only minor activity of the other (methionine- 
metabolising) pathway generating endogenous sulfate – could this lead to heparin 
hyposulfation and a resultant increase in platelet stickiness?....DV) 
  
We are similarly uncertain as to the part played by pregnancy in her thrombotic 
episodes and do not know how to advise her about the risks of a second 
pregnancy, with or without anticoagulant cover.  
The brother has remained symptom free but has elected to start pyridoxine 
treatment. 
 
We are reporting these cases because we believe that the true prevalence of 
homcytinuria may have been underestimated by a tendency to seek it only in 
patients with typical features.”  
 
Note: Their Summary and Discussion comments (“normal platelet behaviour”, 
“no abnormalities of platelet function”) seem most peculiar given the reported 
whole-blood platelet aggretation…..   
 
 
 
 
 
 
 
 
 
 
 
Hcy(ine) 
 
20-100uM
= >80-240 
uM tHcy 
 
Nil 
= <40uM 
tHcy 
 
 
 
40uM 
= >120uM 
tHcy 
 
Nil 
= <40uM 
tHcy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nil
 
 
 
VitB6 
250mg/d 
 
 
 
 
Nil 
 
 
 
VitB6 
250mg/d 
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Wilcken 
DEL et al 
(1985); 
Metabolism
 ; 
Prince 
Henry 
Hospital, 
Sydney, 
Australia. 
 
6 CBS--: 
(by enzyme, Hcy-
uria, high 
methionine), 
aged 11-53y,  
VitB6-y 
responsives). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 Controls: 
Normal, aged 21-
58y.  
Methionine+/-SD  Cysteine (“fCys”?)+/-SD 
 
 
 
 
 
34uM+/-10                     94uM+/-12 
 
 
660uM+/-96                   86uM+/-22 
 
 
560uM+/-104                 92M+/-20 
 
 
500uM+/-105                 88uM+/-19 
 
 
350uM+/-165                 90uM+/-21 
 
 
 
 
 
 
 
 
 
 
107uM+/-156?15.6?      96uM+/-17 
 
 
760uM+/-130               101uM+/-19 
 
 
670uM+/-110              105uM+/-15 
 
 
580uM+/-120              103uM+/-23 
 
 
410uM+/-170              104uM+/-23 
 
 
 
 
 
26uM+/-4                   123uM+/-21 
 
 
560uM+/-70               134uM+/-22 
 
 
380uM+/-110             126uM+/-18 
 
 
230uM+/-120            125uM+/-16 
 
 
46uM+/-17                 119uM+/-23 
 
Additional Results:      Plasma Serine: 
CBS-- Pre-betaine:         94uM+/-19 
CBS-- During-betaine: 117uM+/-14 p<.03 
CBS-- During-betaine+MetLoad: average 
34% increase over Pre-betaine+MetLoad 
“fHcy”?…+/-SD. 
 
 
 
 
 
8.7uM+/-5.2 
=49uM tHcy?.. 
 
47uM+/-20 
= 87uM tHcy?.... 
 
51uM+/-22 
= 91uM tHcy?... 
 
48uM+/-23 
= 88uM tHcy?.... 
 
61uM+/-30 
= 101uM tHcy?. 
 
 
 
 
 
 
 
 
 
6.4uM+/-3.4 
= 46uM tHcy?.... 
 
17uM+/-7 
= 57uM tHcy?... 
 
23uM+/-13 
= 63uM tHcy?.... 
 
23uM+/-17 
= 63uM tHcy?... 
 
21uM+/-15 
= 61uM tHcy?.... 
 
 
 
 
3.4uM+/-0.8 
= <40uM tHcy?... 
 
14uM+/-6 
= 54uM tHcy?.... 
 
14uM+/-6 
= 54uM tHcy?... 
 
11uM+/-4 
= 51uM tHcy?.... 
 
5.2uM+/-1 
= 45uM tHcy?... 
 
VitB6 200mg/d 
Folate 5mg/day, 
following oral 
methionine load of 
4g/m2BodyArea, at: 
 
0hours 
 
 
4hours 
 
 
8hours 
 
 
12hours 
 
 
24hours 
 
 
(As above, but with 
Betaine2*3g/day in 
orange juice) *? 2-
3weeks later: 
following oral 
methionine load of 
4g/m2BodyArea, at: 
 
0hours 
 
 
4hours 
 
 
8hours 
 
 
12hours 
 
 
24hours 
 
Following oral 
methionine load of 
4g/m2BodyArea, at: 
 
0hours 
 
 
4hours 
 
 
8hours 
 
 
12hours 
 
 
24hours 
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Study Group Disease 
Mudd SH et 
al (1985); 
Am J Hum 
Genet; 
Worldwide 
survey 
coordinated 
from USA 
“Data Base 
A standardized questionnaire was designed and mailed to 
each clinician known from a previous study (cites Mudd 
et al 1981) to be caring for patients with CBS--. 
Physicians were asked to complete a questionnaire for 
each such individual about whom they had appropriate 
information. To encourage participation, the questionnaire 
was kept relatively simple (cites availability through 
National Auxiliary Publications Service). …Further 
questions focused upon the factor(s) that led to 
ascertainment, whether the patient was responsive to 
VitB6, and upon the presence and age of appearance of 
major clinical manifestations. A detailed history of 
therapy was requested, as well as a reproductive 
history….Additional sources of information were 
identified by a review of the literature and by contacting 
centers around the world specializing in diagnosis and 
management of inborn errors of metabolism. Further, 
physician cooperation was solicited by notices in 
appropriate journals…some patients upon whom recent 
information could not be obtained….published 
material….only…details available to prove that they did 
not overlap. Data collection occurred during 1982 and 
early 1983…search for duplication…redundant 
information was deleted… 
For the present survey, updated information was received 
concerning 532 homocystinuric patients with proven or 
presumed CBS--. To this group was added material from 
an additional 97 patients obtained primarily from 
published reports (cites 37 references), bringing the total 
to 629 patients. All patients admitted to the study had 
been demonstrated to be excreting 
homocystine…either…enzyme assay or 
….hypermethioninemia or dislocated optic lenses: 
 
                   Enzyme Assay:       Yes               No 
 
Ectopia Lentis + hyperMet    147(68%)     274(66%) 
Ectopia Lentis only                 21(10%)        75(18%) 
Hyermethioninemia only        39(18%)         64(16%) 
Neither of the above                 9(4%)              0(0%) 
 
Total                                      216(100%)   413(100%)  
 
58 were discovered during screening of newborns, and an 
additional 88 were discovered by screening all siblings 
(the balance ascertained on clinical features)….  
 
Of the 629 patients, 307 were females and 321 males…. 
 
Of the 629 patients, 231 (37%) were classified as 
biochemically responsive to VitB6 when not folate 
depleted; 231 (37%) were classified as  nonresponsive to 
VitB6; 67 (11%) were judged intermediate in response; 
and 100 (16%) had not been classified. For subsequent 
analyses in this presentation (only the 231 VitB6-
responsives and the 231 VitB6-nonresponsives were 
analysed)” 
 
Note:  
Newborn screening ascertainees 78% VitB6-
nonresponsive;  
Untreated nonhypermethioninemic cases 90% VitB6-
responsive 
 
“Clinical Features Leading to Investigation for 
Homocystinuria (n = 472 not ascertained by 
newborn screening or proband sib screening, 
irrespective of VitB6-responsiveness): 
 
Clin Feature       SoleCause   ContribCause     Total 
 
Ectopia Lentis          21%               65%            86% 
Mental Retard            4.0                52              56 
Devel Retard              1.5                21              22.5 
Early Thromboemb    1.1               15               16 
Marfanoid Charact     0.9               36               37 
Bony Abnormality     0.2               23               23 
Seizures                      0.2                3                 3 
Behav/Psychiatr         0                 2.8                3 
Other                          0.4             10.6              11  ” 
 
“Mental Capabilities 
 
…To eliminate the effect of very early therapy, data 
on patients discovered by newborn screening were 
not used in constructing these plots of IQ or in the 
alternative analyses of mental capabilities… 
(Note: The VitB6-responsives were still probably 
less-treated, and the VitB6-nonresponsives more-
treated. dv) 
 
IQ Percentiles:             20%ile    40      60      80 
VitB6-Responsive           60       72       82      94 
VitB6-Nonrespons           42       51      60      68 
 
Doc’s Estim: GrossRetard  MildRet  LearnDis  Av’g   
VitB6-Respon       5%           33%         11%       51%        
VitB6-Nonresp    38%          47%           4%       11% 
 
….The effect of early treatment is illustrated in 
figure 2. IQs for VitB6-nonresponsive patients 
identified as neonates and treated from very early 
ages with methionine restriction, usually 
accompanied by L-cystine supplementation (early-
treated), are compared to IQs of VItB6-
nonresponsive patients not detected by newborn 
screening (late detected). If treated at all, very few 
of the latter patients had commenced therapy at ages 
of less than 1-2years” 
 
In that figure, whether having age at ascertainment 
or age at last follow-up on the x-axis, the IQs of the 
low-Met-CysSuppl-early-treated VitB6-
nonresponsives lay about my visually estimated line 
of best fit from IQ 100 to IQ 80 left to right, while 
the non-early-treated VitB6-nonresponsives lay 
about their line of best fit from IQ 60 to IQ 57 left to 
right. There was minimal overlap, p<.001. 
 
 
 
 
 
 
(Continues) 
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“Dislocation of Optic Lenses 
 
Data on ages of lens dislocation were analysed according to the Kaplan and Meier method, with the 
important stipulation that for each patient the only interval considered was that prior to initiation of 
treatment specific to CBS--. Hence, a patient was removed from the group at risk for lens dislocation 
(censored) at the time that he or she started such treatment…These plots demonstrate that for all 
groups of patients, there was a lag period of approximately 2years before appreciable lens dislocation 
occurred. After age 2, lens dislocation began to be detected but at different rates in VitB6-
nonresponders and VitB6-responders, so that 50% of untreated VitB6-nonresponsive had dislocated 
lenses by age 6y, whereas for untreated BitB6-responsive patients, 50% dislocation was attained at 
approximately age 10y.”  
 
                                                                                         n     Lens Dislocation: Expected  Observed  P 
 
VitB6-responsive Late-Detected                                     
treated only and continuously by VitB6+/-Folate          24                                     8.4             5         nss       
 
VitB6-nonresp’v Late-Detected  
treated only and continuously by  
Methionine restriction +/- Cysteine supplementation    10                                      3.6            4          nss                
 
VitB6-nonresp’v Early- Detected 
treated only and continuously by  
Methionine restriction +/- Cysteine supplementation    30                                      11.7          3     <.001   
 
 
VitB6-nonresp’v Late-Detected  
treated only and continuously by  
Methionine restriction +/- Cysteine supplementation  
+/- (VitB6 and/or Folate)                                                 13                                     4.6            7        nss     
 
VitB6-nonresp’v Early- Detected 
treated only and continuously by  
Methionine restriction +/- Cysteine supplementation 
+/- (VitB6 and/or Folate)                                                  31                                   12.5           4      <.001 
 
 
VitB6-responsive Late-Detected  
treated varyingly in all regards by VitB6+/-Folate          26                                    10.8            5     <.05        
 
VitB6-nonresp’v Late-Detected  
treated varyingly in all regards by  
Methionine restriction +/- Cysteine supplementation 
+/- (VitB6 and/or Folate)                                                 23                                       6.9           9       nss      
 
VitB6-nonresp’v Early- Detected 
treated varyingly in all regards by  
Methionine restriction +/- Cysteine supplementation 
+/- (VitB6 and/or Folate)                                                 30                                      16.2          6    <.001 
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(Continued 2)   “Thromboembolic Events 
From the thromboembolic events originally reported, 9 described as “possible” or “partial” and 2 that were only 
questionably related to the underlying condition were deleted. There remained a total of 253 events, occurring in 
158 patients. No reported events occurred in 471 patients. Of these 253 events, 81 (32%) were cerebrovascular 
events, 130 (51%) affected peripheral veins (with 32 resulting in pulmonary embolism), 10 (4%) produced 
myocardial infarctions, 28(11%) affected peripheral arteries, and 4 fell into none of these categories. The 
distributions of these types of thromboembolic events were only marginally related to the VitB6-responsivity of 
the patients….. 
(versus Ectopia Lentis. dv) The lag for thromboembolism is longer: 8-12years before maximal rates are attained. 
The rates of occurrence of thromboembolic events are far less. For example, for the total group, the chances of 
suffering such an event were only about 25% by age 16y and 50% by age 29y. While the overall curves for VitB6-
responders and for VitB6-nonresponders remain significantly different from each other (P = .02) the extent of the 
difference is not as striking as the case of lens dislocation….. 
Sufficient data were not available to permit construction of time-to-event curves for untreated patients after first 
episodes. To see if vitamin or dietary therapy had any major effect on the rate of occurrence of thromboembolic 
events subsequent to the first, it was therefore necessary to use a simplified analysis that included the assumption 
that the rates of such events is constant regardless of the age of the patient…..VitB6-responders off relevant 
treatment had 24 events during 3,744months of exposure and 7 events during 2028months of exposure on 
pyridoxine treatment (with or without folate), yielding rates of .08 and .04 events per year, respectively.  VitB6-
nonresponders off relevant treatment had 11 events during 1,264months of exposure and 4 events during 
836months on methionine restriction (more often with cysteine than without. dv). The corresponding rates were 
0.10 and .06 events per year. 
                                                                                         n    Thromboembolism: Expected  Observed  P 
 
VitB6-responsive Late-Detected                                     
treated only and continuously by VitB6+/-Folate         120                                       14.9           3    <.001          
 
VitB6-nonresp’v Late-Detected  
treated only and continuously by  
Methionine restriction +/- Cysteine supplementation     26                                         2.1           1      nss                    
 
VitB6-nonresp’v Early- Detected 
treated only and continuously by  
Methionine restriction +/- Cysteine supplementation     30                                         1.7           0      nss  
 
 
 
VitB6-nonresp’v Late-Detected  
treated only and continuously by  
Methionine restriction +/- Cysteine supplementation  
+/- (VitB6 and/or Folate)                                                 41                                         4.1          2      nss          
 
VitB6-nonresp’v Early- Detected 
treated only and continuously by  
Methionine restriction +/- Cysteine supplementation 
+/- (VitB6 and/or Folate)                                                 32                                         2.1          0      nss       
 
 
 
VitB6-responsive Late-Detected  
treated varyingly in all regards by VitB6+/-Folate        135                                       19.9          4   <.001               
 
VitB6-nonresp’v Late-Detected  
treated varyingly in all regards by  
Methionine restriction +/- Cysteine supplementation 
+/- (VitB6 and/or Folate)                                                 68                                          6.2         8      nss        
 
VitB6-nonresp’v Early- Detected 
treated varyingly in all regards by  
Methionine restriction +/- Cysteine supplementation 
+/- (VitB6 and/or Folate)                                                 41                                          2.9         1      nss” 
 
“Because many of the early-treated VitB6-nonresponders have not yet attained the ages when thromboembolic 
events are most likely to occur, few events were expected among this group. Therefore, the fact that almost none 
have occurred, although encouraging, is not yet proof of the efficacy of treatment.”                                            
(Continues) 
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“Osteoporosis 
 
Osteoporosis on the basis of a lateral radiograph of the spine was the definition of this finding. Time-to-event 
graphs for such spinal osteoporosis again demonstrate a progressive appearance that is significantly less rapid in 
VitB6-responsive patients than in VitBb-nonresponsive patients (P<.002).” 
 
Seizures 
 
Among all patients in the late-detected group, 114 were reported to have had seizures, and 422 were said not to 
have had seizures (incidence 21.3%). Among late-detected VitB6-responsive patients the incidence was 36/214 
(16.8%), and among late-detected VitB6-nonresponsive patients the incidence was 43/184 (23.4%). Although 
this difference is not statistically significant, time-to-event curves indicated that seizure onset tended to occur 
somewhat earlier in untreated VitB6-nonresponsive (20% seizures by age 12y) than in untreated VitB6-
responsive patients (20% by age 21y) (P = .04). 
 
Mortality 
 
Of the 629 patients covered in this study, 64 were deceased. The cause of death was unknown for three patients, 
and two died for reasons apparently unrelated to CBS—(accidental drowning at age 8; metastatic abdominal 
cancer at age 61). Of the remaining 59 deaths, thromboembolism was known to be the chief causative factor in 
42 (71%) and was a probable, but less clearly established, major contributing factor in at least 5 others (8%). 
Pneumonia, other pulmonary infections, or sepsis were reported as the cause of death in 7 patients (12%). The 
latter were all grossly mentally retarded with IQs less than 50. For 5 patients, the causes were of uncertain 
relationship to the underlying disorder (heart failure at 15y in a severely retarded patient; subarachnoid 
hemorrhage at age 10 from two aneurysms of the basilar artery; spongy degeneration of the central nervous 
system with toxic sepsis; pulmonary hemorrhage in a 36d old infant; suicide at age 18)…..Mortality among 
patients classified with regard to VitB6-response was 5.5% (29 of 529 patients). Survival for VitB6-responders 
was significantly higher than that for VitB6-nonresponders (P<.0001). For example, the expected mortality at 
age 20 was less than 5% among those responsive to VitB6 and approximately 20% in those not responsive” 
 
 
Ascertainment Bias 
 
….“(1) Mental Capabilities. The “complete-sibship-screened” group of VitB6-responsive patients had a mean 
IQ 21 pints higher than the VitB6-responsive probands, a difference which was statistically significant. When IQ 
scores were not available, however, the proportions of each of these groups judged to be mentally retarded were 
not significantly different.  Among VitB6-nonresponsive patients, no significant difference was present in the 
mean IQ scores for the “complete-sibship-screened” group compared with the probands, but only 65% of the 
former were judged to be retarded, as compared to 91% of the probands (P<.05) 
(2) Seizures. In the “complete-sibship-screened” group, seizures were reported in 16 of 85 patients (19%), an 
incidence not significantly different from that in the proband group: 98 of 449 (22%). 
(3) Lens dislocation. There were no statistically significant differences in the time-to-event curves for any of the 
“complete-sibship-screened” groups when compared with the proband groups. 
(4) First thromboembolic events. The results were the same as those for lenses. 
(5) Osteoporosis. The results were the same as for lenses and first thromboembolic events, except that for 
VitB6-responders the time of detection of osteoporosis in the “complete-sibship-screened” group was slightly 
delayed compared with that in the proband group (60% undetected vs 45% undetected respectively) (P = .04)….. 
…. 
 “Data from screening programs of newborns furnish one means to arrive at a crude estimate of the possible 
magnitude of usch underascertainment. This was done for the USA, the country with the greatest number of 
patients reported (37% of all those classified as either VitB6-non/responsive). Combination of the results from 
screening programs of newborns in the Rocky Mountain states, New England, and Maryland and Delaware 
(various citations) leads to a rate of detection of CBS-- of  1/209,000 newborns (total 3+ million screened). 
Extrapolating this combined ratio to the country as a whole, assuming from the results reported here that 78% of 
those detected are VitB6-nonresponsive and taking into account the age structure of the population of the USA 
and the less than normal survival of VitB6-nonresponsive, one may estimate that in the USA the number of 
living VitB6-nonresponsive CBS-- persons <=25y of age should be 299, and incidence of 1/738,000 persons in 
the total population. Reports were obtained for the survey concerning 63 patients of this sort, or 1/3,500,000. 
Although the above estimate is no better than a very rough approximation, it appears that a substantial 
proportion of potential VitB6-nonresponsive subjects in the USA have been both diagnosed and reported on in 
the present survey. However, probably an even greater proportion remain to be diagnosed or (in our opinion less 
likely) are known to physicians but were not reported upon. …..(Continues).” 
(Continued) 
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(Continued) Ascertainment Bias  
 
…..“The analogous calculations for VitB6-responders indicates that in the USA there should be only 
55 such patients alive at <=25y of age (1/4,700,00). The low estimate is due to the fact that only 13% 
of patients detected in screening of newborns have been VitB6-responsive. In actuality, reports were 
obtained upon 47 such patients… (a little faulty reasoning. DV)…., these combined results support the 
likelihood that VitB6-responders are being missed in current screening programs of newborns, so that 
the above estimate of the potential number of these patients is probably too low (conclusion 
nonetheless correct. DV).” 
 
“Among the patients in this survey who had been detected by screening of newborns, and classified as 
to VitB6-responsiveness, only 13% were VitB6-responsive. Among late-detected patients, the 
corresponding value was 47%.” 
 
“The USA provides a useful example for this sort of calculation, not anly because far more patients 
were reported from this country than from any other, but also because, in terms of patients reported per 
unit population, the USA fell at neither the upper nor the lower extreme of the range.” 
 
 
 
Note: Mudd et al here have been fairly painstaking to address the issue of ascertainment bias, and 
readers interested in viewing a prologue to their work here may like to read their earlier work (cites 
Mudd et al 1981) and some of the discussion that followed on it in this regard (Swift and Morrell 1983 
(), and Mudd et al response). It may be safely assumed that this work here effectively supercedes their 
earlier work in every aspect, and so I do not deal with that work.   
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Sartorio R 
et al (1986); 
J Inherit 
Metab Dis; 
U Naples, 
Naples, 
Italy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 CBS--: 
(by enzyme, Hcy-
uria, aged ?), 
 
7 VitB6-
responsive  
1 VitB6-
nonresponsive 
 
 
 
 
 
 
15 Controls, 
normal, adults 
  
 
VitB6-responsives  Protein-bound Hcy    “fHcy” 
 
DAM                            4.0uM                    ND 
BF                               10.3uM                    ND 
DA                              13.4uM                    ND 
SG                               23.8uM                  traces 
MA                              32.0uM                    ND 
SS                                40.0uM                  traces 
SR                                43.4uM                 traces 
 
VitB6-nonresponsive 
 
TG                                60.0uM                61.9uM 
 
Normal Controls            4.3+/-1.5uM 
 
 
Where  
ND = None Detected, 
“fHcy” apparently also includes Hcy-Cys 
 
“For determination of protein-bound homocyst(e)ine in plasma, 
the method proposed by Kang and colleagues (1979) was 
modified as follows. Fasting plasma samples, obtained from 
heparinized venous blood by immediate centrifugation were 
mixed with sulphosalicylic acid to a final concentration of 
4.54%. After centrifugation (3000g for 10min) protein 
precipitates from plasma were washed seven times in water by 
successive centrifugations. Washed precipitates were 
suspended in water to the original plasma volume and then 
mixed with hydroxide to a final concentration of 0.4%, to 
solubilize proteins. The solution was brought to pH 7 by adding 
7ul of concentrated HCl, mixed with 2-ME (1/10 v/v) and 
incubated at 37C for 120min. Proteins were reprecipitated with 
sulphosalicylic acid as indicated above and the clear 
supernatants were used for amino acid analysis. Amino acid 
analysis was carried out on a Becknman Model 119 CL Amino 
Acid Analyzer, according to the following conditions: 1st 
buffer: 0.2M lithium citrate, pH 2.83; 2nd buffer: 0.2M lithium 
citrate, pH 3.70; buffer change: 50min; column temperature: 40 
and 65C; temperature change: 43min.” 
(derived) 
 
4-10uM? 
11-20uM? 
14-20uM? 
24-40uM? 
32-40uM? 
45-55uM? 
50-60uM? 
 
 
 
<180uM 
 
4-10uM? 
 
 
VitB6 
“ 
“ 
“ 
“ 
“ 
“ 
 
 
 
Betaine 
 
 
Abbott et al 
(1987); 
Am J Med 
Gen; 
Johns 
Hopkins U, 
Baltimore, 
Marylands, 
USA. 
63 CBS-- “Our sample consisted of 63 patients with homocystinuria. All 
had typical clinical manifestations in at least three of four 
systems (ocular, skeletal, vascular, and central nervous system) 
and either a positive cyanide-nitroprusside test of urine, 
elevated plasma homocysteine, and methionine, or deficient 
CBS activity in cultured skin fibroblasts. In no patient was 
psychiatric aberration a criterion for diagnosis….36 males 27 
females 45 sibships, mean age at diagnosis 19y…..mean age at 
psychiatric assessment 20y range 10-31y.” 
 
PsychDis  IQ<80  IQ>=80  VitB6-resp  VitB6-nonresp B6?resp 
 
MajDepr      3%       15%         7%                    7%             14% 
BehDisord  33%        3%         7%                   33%            19% 
ObsComp   10%        0%         4%                   13%              0% 
Personality  20%     18%        22%                  20%             14% 
 
TotalPsy      66%     36%        40%                  73%             47% 
 
Total %      100%   100%      100%                100%           100% 
 
Cases n        30         33           27                      15               21   
Not Given Not 
given, 
VitB6 for 
the 
VitB6-
resp, 
LowMet 
+/- Cys 
for the 
VitB6-
nonresp? 
Folate? 
VitB12? 
 
From 
unknown 
age…. 
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CBS-- 
“Case 1: An 11y old boy with intellectual impairment (IQ = 60),  
Marfanoid skeletal deformity,  
osteoporosis and  
bilateral lens dislocation  
was found to have homocystinuria.  
The biochemical changes were not improved by treatment with pyridoxine.  
At the age of 18y he developed spasmodic torticollis followed by truncal and upper limb dystonia. He 
had prominent retrocollis and truncal hyperextension which were exacerbated by walking. 
Tetrabenzine and anticholinergic agents had no effect on the dydtonia although bromocriptine 
produced a modest improvement.  
He died at the age of 22 from bronchopneumonia secondary to severe neurological disability. 
Neuropathological examination.  
The brain weighed 1520g and 
 showed no macroscopic abnormalities on external and cut surfaces. The vessels of the circle of Willis 
were of normal configuration and serial sections of the main cerebral vessels revealed no sign of 
organised thrombus. Histological examination with haematoxylin and eosin staining showed no 
evidence of thrombosis affecting small intraparenchymal vessels. Sections through areas of frontal 
lobe convexity and orbital cerebral cortex and temporal lobe cerebral cortex were normal with respect 
to the thickness of the cortical ribbon, and cell numbers, type and layering; there was no sign of gliosis. 
Sections of caudate nucleus, putamen, globus pallidus, subthalamic nucleus, red nucleus and substantia 
nigra were normally pigmented. Cell populations in all of these areas were assessed semi-
quantitatively in luxol fast blue/cresyl violet sections; standard areas were examined using eyepiece 
graticule and stage micrometer to check magnification and compared to an age and sex matched 
control. This did not indicate any significant loss of neurons. 
 
Case 2:  This girl presented at age 7years with mental retardation (IQ = 60) and 
 bilateral lens dislocation.  
At that time a diagnosis of pyridoxine-resistant homocystinuria was made.  
At age 9, upper right limb tremor and hypertonia associated with abnormal posture of the right 
shoulder were observed and over the subsequent years she developed progressive dystonia affecting 
limbs, neck, trunk and tongue associated with dysarthria, generalised hypertonia, hyperreflexia and a 
shuffling gait.  
A cranial computed tomographic scan at the age of 20 was normal apart from a small cortical area of 
low density in the right temporal region.  
Now aged 26, she has persistent generalised dystonia which has proved resistant to treatment with 
haloperidol, Lioresal, bromocriptine and clonazepam. 
 
Case 3: This boy presented at the age of 4years with marked developmental delay and  
bilateral lens dislocation.  
Pyridoxine resistant homocystinuria was diagnosed.  
At age 9years he began to have tonic-clonic and akinetic seizures, which were treated with phenytoin 
and sodium valproate.  
He developed a Marfanoid body habitus and  
was severely intellectually impaired (IQ<50).  
At age 5years he first showed a tendency to walk on his toes and  
by the age of 10 his gait was unsteady, he was dysarthric and there was generalised hyperreflexia. 
Thereafter gradual evolution of involuntary movements affecting neck, trunk and lower limbs 
occurred.  
At the present time, aged 19, he has dystonic posturing of the neck and feet with superimposed rapid 
torsional neck movements and choreiform lower limb movements.  
A cranial CT scan at the age of 13 was normal: electroencephalography showed bilaterally 
synchronous paroxysms of polyspike and wave activity.  
Haloperidol and clonazepam were ineffective in controlling the disorder.” 
 
“Discussion 
 
…..our findings suggest that dystonia in homocystinuria may relate to functional disturbance in 
neurotransmission rather than to detectable neuronal damage…….homocysteic acid, an oxidation 
product of Hcy is known to have excitotoxic activity in vitro (cites Olney 1974)…shows a similar 
glutamate displacing pattern to N-methyl-D-aspartate in neural tissue……Taurine has an inhibitory 
action in the central nervous system (cites Kuriyama et al 1978) and may modulate neurotransmitter 
release, including that of dopamine (cites Okuyama S et al 1985). Reduction in basal ganglia taurine is 
therefore a possible cause for dystonia in homocystinuria.” 
 
      
 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 98 
                 Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt and 
biochem etc 
contexts 
Wiley C et 
al (1988); 
Metabolism
; 
Prince 
Henry 
Hospital, 
Sydney, 
New South 
Wales, 
Australia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Continues) 
 
 
6 VitB6-
responsiv 
CBS-- 
 
6 VitB6-
responsiv 
CBS-- 
 
 
3 VitB6-
partlyresp 
CBS-- 
 
1 VitB6-
partlyresp 
CBS-- 
 
 
7 VitB6-
nonresp 
CBS-- 
 
6 VitB6-
nonresp 
CBS-- 
 
 
21 
Controls: 
fCys and 
fHcy data 
only 
available 
for 7 of 
these, but 
boundCys 
and 
boundHcy 
were 
respective
ly very 
similar  
for the 7, 
14, so 
given here 
as one 
value(s). 
 
 
 fCys   boundCys   boundCys   tCys           fHcy   boundHcy   boundHcy 
 
96uM  1.7umol/g   126uM   >222uM         6.4uM   0.24umol/g  18uM 
 
 
 
94uM  1.4umol/g  104uM   >200uM       11.1uM   0.31umol/g   23uM 
 
 
 
 
77uM  0.76umol/g  56uM   >133uM        41uM    0.52umol/g    38uM 
 
 
 
46uM  0.24umol/g  18uM   >64uM       240uM    1.85umol/g    140uM 
 
 
 
 
82uM  1.1umol/g   81uM   >163uM        52uM   0.68umol/g     50uM 
 
 
 
56uM  0.23umol/g  17uM   >73uM       175uM   1.1umol/g       81uM 
 
 
 
 
114uM  2.3umol/g  170uM  >284uM      3.0uM  0.15umol/g     11uM 
 
Note: The second  “boundCys/Hcy” (uM) in each of the sections above 
was derived by me from multiplication of their first “boundCys/Hcy”  
(umol/g, where g is grams of protein) by the factor of 74 g protein per 
litre of Serum (midrange of Mosby’s Manual of Diagnostic Laboratory 
Tests (Pagana and Pagana 2002 () 64-83g/L for normal adult). 
The tCys/Hcy was then derived by me by adding the uM units for bound 
and free Cys/Hcy – the derivations are therefore not quite correct from 
the volumetric aspect, but are close enough to give the useful 
comparisons visible between the groups. 
 
Note: Due to the degree of any methionine restriction/ lowness of 
protein in diets, and particularly the use of supplementary cystine, being 
probably as poorly documented here as generally elsewhere, and note 
any cystine supplementation being more facile of compliance than food 
modification/restriction, it may’nt be assumed that these are as given, 
nor that they are equivalent between any two of the six patient groups. 
 
“Samples of venous blood were drawn after an overnight fast or during 
the period of an oral methionine load. The plasma was immediately 
separated (700g, 10min, 4C) and deproteinized by addition of 20% 
sulfosalicylic acid to give a final concentration of 4%. The 
deproteinized plasma preparation was centrifuged (13,000g, 10min) and 
the supernatant stored at -16C for aa analysis…..The protein pellet was 
washed twice twice with distilled water, covered with distilled water 
and stored at -16C….Levels of bound Cys and bound Hcy were 
estimated using 15-20mg of dried protein by the method of Smolin et al 
(cites Smolin and Benevenga 1982)…The following changes were 
made to the published method: reduction occurred for 60min; 50uL of 
octanol was used; the reaction was run under humidified nitrogen and 
consequently no adjustment ot volume of solution was made; and 
particulate matter was removed from samples by centrifugation 
(13.000g, 10min) and filtration (Amicon Seraclear filters….standards… 
the recovery for cysteine was mean 82%, and for Hcy mean 87%.....All 
results have been adjusted for these recoveries”        (Continues)    
tHcy 
 
>24uM 
 
 
 
>34uM 
 
 
 
 
>79uM 
 
 
 
>380uM 
 
 
 
 
>102uM 
 
 
 
>256uM 
 
 
 
 
>14uM 
 
 
VitB6 + 
folate + 
betaine 
 
VitB6 + 
folate e 
 
 
 
VitB6 + 
folate  
 
 
Nil 
 
 
 
 
VitB6 + 
folate + 
betaine 
 
VitB6 + 
folate e 
 
 
 
Nil 
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New South 
Wales, 
Australia. 
 
See 
Above 
The Authors provide 2 scatterplots, one with plasma free Cys (fCys) on the x axis, the other with 
plasma free Hcy (fHcy) on the x axis, the y axes being “Ratio:  Bound Cys/Free Cys (Hcy) ((umol/g 
protein x 1000)/umol/l)” – note that the factor 1000 should have been 74 as noted above, so for the 
following discussion I have corrected their y axes’ s scales by dividing them by 1000/74 = 13.5. 
 
For the cysteine there is a slight curve ascending to the right, such that  
at plasma fCys 50uM the ratio = 0.3,  
at plasma fCys 75uM the ratio = 1.0,  
at plasma fCys 100uM the ratio is 1.4,  
at plasma fCys 125uM the ratio is 1.7,  
at plasma fCys 150uM the ratio is 1.9. 
 
For the homocysteine there is a quite sharp reverse-J-curve descending to the right, such that  
at plasma fHcy <10uM the ratio = >2.0 (max 6 at far left),  
at plasma fHcy 20uM the ratio = 1.3,  
at plasma fHcy 30uM the ratio is 1.1,  
at plasma fHcy 50uM the ratio is 1.0,  
at plasma fHcy 100uM the ratio is 0.9,  
at plasma fHcy 200uM the ratio is 0.6  
 
It may be concluded that Hcy has a greater affinity than Cys for plasma proteins 
 
It may be concluded that my operating assumption that Hcy<40uM is bound to protein and 
thereafter free as Hcy(ine) or Hcy-Cys is simplistic (and that not surprisingly), as tHcy goes up to 
say 200uM, then boundHcy goes up to say 75uM, so that where I have added only 40uM to higher 
values of fHcy in the literature to derive a rough tHcy, it may be taken that the tHcy value is lower 
than it ought be, by as much as 100uM at say 400uM fHcy. At low ie trace or nil values of fHcy the 
assumption of tHcy<40uM is roughly correct enough for most useful purposes. Also the 
ramifications regarding the higher values ie in CBS-- are trivial for most useful purposes, and for 
mine in this work.     
Wiley C et 
al (1989); 
Metabolism
; 
Prince 
Henry 
Hospital, 
Sydney, 
New South 
Wales, 
Australia. 
See next 
column 
6 CBS--VitB6-responsive patients on VitB6 + folate +/- betaine & 
7 CBS--VitB6-non-responsive patients on VitB6 + folate +/- betaine 
from the study immediately above  
(which groups of patients thereof ???…unknown) 
 
The findings of this study add little to those of their study detailed immediately above, for my 
purposes here, other than that the same general trends notable in their study above with respect to 
the distribution of Hcy and Cys between free and protein-bound plasma pools, applies also 4hours 
after an oral methionine load of 4g/M2 body surface area.  
Brattstrom 
L et al 
(1989); 
J Inher 
Metab Dis; 
U Lund U 
Gothenburg
, Sweden 
 
 
CBS--1 
CBS--2 
CBS--3 
 
20 CBS-+ 
 
46 normal 
CBS++ 
 
9 Downs 
Syndrome 
CBS+++ 
Age   FactorVIIAntigen     AntithrombinIIIActivity    Post-methionine-load tHcy        Fasting tHcy 
 
30y               80%                                  81%                                                                        244uM 
18y               82%                                105%                                                                          54uM 
38y            110%                                125%                                                                        178uM 
 
56+/-12y   111+/-20%                        119+/-9%                    51+/-27uM***                      13+/-5uM* 
 
52+/-7y     113+/-22%                        120+/-10%                  21+/-8uM                               11+/-3uM 
 
 
41+/-4y     122+/-12%                        102+/-2.3% ***          22+/-8uM                               10+/-2uM 
 
* = P<.05;   *** = P<.001 compared to normal CBS++ contrrols 
 
 
Methionine load was 3.84g/M2 body surface area. 
 
CBS-- all had ectopia lentis, hypermethioninemia and Hcy-uria,  
Treated with methionine restriction, VitB6 and folate. 
 
Downs Syndrome by chromosome analysis . 
 
CBS-+ obligate heterozygote parents of a CBS--.  
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             Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy 
level 
Treatmnt and 
biochem etc 
contexts 
Cochran FB 
et al (1990); 
Am J Med 
Gen ; 
U 
California, 
San 
Francisco, 
USA. 
 “The Propositus is the only child of non-cansanguinious parents.  
The diagnosis of asthma was made in infancy with a history of frequent 
exacerbations and hospitalizations since age 8y.  
He maintained an “A” average in school and participated in the school 
band, despite frequent absences for asthma treatment.  
At age 14y he was hospitalized because of recurrent left pneumothoraces 
requiring chest tubes. Soon thereafter he developed a right pneumothorax 
and staphylococcal pneumonia, and presented with headache, nausea, 
vomiting, syncope, diplopia, and dizziness.  
CT scan (head) showed diffuse white matter edema consistent with 
psuedotumour cerebri. He was transferred to the U of California SF 
because of increasing intracranial pressure and bradycardia. At the time of 
transfer he was being treated with theophylline, prednisone, Micronase, 
phenobarbiatal, erythromycin, vancomycin, Bronkosol, meperidine, 
hydroxyzine, and metaproterenol nebulizer…..Neurological examination 
was normal except for 2-3 beats of clonus bilaterally and right extensor 
plantar response (which later became flexor).  
There was a mild papilledema without hemorrhage or vessel abnormality.  
Visual acuity was 20/20 uncorrected, O.U. and visual fields were full with 
normal color vision.  
On lumbar puncture the opening pressure was 225mm H2O, and on 
closing pressure was 85mmH2O.  
Results of CSF studies were normal, and all CSF and blood cultures were 
sterile.  
Hypercoagulability workup showed no abnormality.  
Subsequently he developed empyemia, necrotizing pneumonia, deep 
venous thromboses, and hypertension treated with antibiotics, heparin, and 
anti-hypertensive medications, respectively. His symptoms of increased 
intracranial pressure responded to acetazolamide…. 
The diagnosis of homocystinuria was made on the basis of a urine cyanide 
nitroprusside reaction and elevated plasma homocystine and methionine 
…..CBS activity in cultured skin fibroblasts = 0.3% of control, and was 
not altered by the addition of pyridoxine.  
CT scan of the head showed decreased density of the white matter 
diffusely, with normal-appearing grey matter….small focus of low 
density…superior sagittal sinus….MRI confirms sagittal sinus 
thrombosis…. 
The delta sign, indicative of superior sagittal sinus thrombosis, was absent 
on repeat head CT scan 24days later.  
 
A methionine-restricted diet 10mg/kgBW/day was instituted, and the 
patient was begun on supplemental pyridoxine up to 500mg/day, and 
folate 0.5mg/day without change in plasma Hcy(ine).  
 
 
 
The addition of betaine 3g BID to the regimen resulted in a substantial 
reduction in plasma Hcy(ine) levels during the initial 4months of 
treatment   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fHcy 
(assume) 
42uM = 
tHcy 
>82uM  
 
fHcy 
(assume) 
7uM = 
tHcy 
>47uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methioni 608uM 
 
 
 
 
Methioni 745uM 
 
See column 2 to 
left for therapies 
details 
Rubba P et 
al (1990) ; 
Metabolism
 ; 
U Naples, 
Naples, 
Italy. 
 
 
14 CBS-- 
14 Contrls 
 
13 CBS-+ 
47 Contrls 
Age  AnkleSBP/ArmSBP<0.97   IliacArteryLesions  CarotidArtLesions 
 
20y       6legs (21%)*                     5arteries (18%)*       0arteries (0%) 
20y       0legs (0%)                         0arteries (0%)           0arteries (0%) 
 
46y      2legs(8%)                           8arteries (31%)**     6arteries (23%)* 
43y      3legs(3%)                           2arteries (2%)           3arteries (3%) 
 
SBP = Systolic Blood Pressure 
* = P<.05;   ** = P<.01 compared to normal CBS++ controls 
 
Controls clinically healthy U Naples admin staff volunteers, and some of 
their younger relatives, age-matched; CBS-+ obligate heterozygotes.  
Not 
Given 
All  
CBS-- on VitB6 
600-900 mg/day, 
1 VitB6-nonresp 
CBS--also on 
betaine 8g/day 
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 Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Wagstaff J 
et al (1991); 
J Pediatrics; 
Harvard 
Medical 
School, 
Boston, 
Massachu-
setts, USA  
1 CBS-- 
case 
“The patient was born to a 28y old gravida 4, para 4 woman after a pregnancy complicated by emesis that was treated with 
pyridoxine.  
Both parents were of Portuguese-Azorean ancestry, and there was no known consanguinity.  
Results of neonatal screening for hypermethioninemia at age 14days were normal.  
The diet for the first 10weeks of life was commercial formula with iron. After an episode of gastroenteritis, the family changed 
the patient’s diet to diluted cow’s milk mixed with cornstarch and then boiled. After 1month of this diet, the patient became 
irritable with epistaxis and hematochezia developed. When seen at Children’s Hospital at 4months of age, he was irritable and 
pale and had scattered petechiae……platelet count 12,000/mm3….bone marrow aspirates showed marked megaloblastosis….. 
The serum folate was 5.7nM (normal 7-36nM), the RBC folate was 20nM (normal 340-1360nM); serum VitB12 270pM 
(normal 150-660pM);  
Hcy(ine) 39uM (normally undetectable)…… 
The patients pancytopenia resolved with folic acid therapy.  
The subsequent addition of oral pyridoxine hydrochloride in doses as high as 500mg/day did not produce any substantial 
decrease in his plasma methionine or Hcy levels.  
He was subsequently fed a low-methionine diet supplemented with L-cystine. His methionine levels dropped to the normal 
range and homocyst(e)ine became undetectable.  
He has no evidence of lens dislocation, and his motor development at age 8months is within the normal range for age.”  
Monreal M 
et al (1991); 
J 
Cardiovasc 
Surg ; 
U Hospital 
Badalona, 
Bercelona, 
Spain. 
1 CBS-- 
case 
“A 28y old woman presented at the Hospital with severe left limb ischemia.  
She had a 3year history of smoking 10 cigarettes a day and  
she did not take contraceptive pills.  
She was born from nonconsanguineous parents and  
when he was 8year old both lenses were removed because of ectopia lentis.  
Since 1985, she had experienced symptoms of intermittent claudication in her left leg, and two months before admission in 
April 1988, she was operated upon in another hospital, where a left femoroperoneal bypass was performed, but a few hours 
later this thrombosed. One month later the patient was referred to us. On admission, severe signs of ischemia were apparent in 
the left leg. Blood pressure was normal but the heart rate was persistently elevated (124bpm).  
No abnormalities were found on respiratory, abdominal and neurological examination.  
All the blood coagulation tests, blood cell counts and routine biochemical tests were also normal. Five days after admission we 
amputated three toes n the left foot. Nine days later, she developed sudden dyspnoea and chest pain. A ventilation-perfusion 
lung scan showed perfusion defects consistent with pulmonary embolism, and heparin therapy was started. Twelve days later, 
the heparin was switched to oral anticoagulants and at this time the patient developed pallor, cyanosis and rest pain in the left 
leg. Arteriography showed complete obstruction of the right popliteal artery…… 
Thus, tests for antinuclear, antitissue and antiphospholipid antibodies (including VDRL and anticardiolipin antibodies), as well 
as antithrombin III, protein-C and protein-S measurements were performed; all were either negative or within normal reference 
values.  
However….ectopia lentis….homocystinuria….. 
Subsequently, in September 1988, she underwent a supracondylar amputation of her left leg after many unsuccessful 
revascularization attempts.  
Sixteen month later, while being on VitB6 therapy, the patient remains well, and she has not, so far, presented any additional 
ischemic events.”  
Nordstrom 
M & 
Kjellstrom 
T (1992) ; 
Athero-
sclerosis; 
U Lund, 
Malmo, 
Sweden. 
 
 
 
 
7 CBS-- 
 
14 CBS-+ 
 
20 CBS++ 
Athero-
sclerotics 
 
29 CBS++ 
Contr 
Age>=45 
 
20 CBS++ 
Contr 
Age<=44 
 
7 
CBS+++ 
Downs 
Syndrome 
CBS activities (nmol/hour/mgProtein) (+/-SD) in skin punch biopsies 
 
Age          No added pyridoxal phosphate      With added pyridoxal phosphate 
 
28+/-12y                                   0.00                     .04               Note: Unexamined for VitB6-response 
 
52+/-9y                                    0.88+/-0.7           2.31+/-2.0       Note: Obligate heterozygote parents 
 
52+/-9y                                    1.5+/-1.2             2.90+/-2.4       Note: Varied, no hepat, renal, diabet 
 
 
 
>=45y                                      2.19+/-2.0            4.37+/-3.7     Note: Clinically healthy screen volun 
 
 
 
 <=44y                                     7.79+/-3.7         17.8+/-10         Note: Clinically healthy screen volun 
 
 
 
 42+/-17y                                 3.35+/-1.7           7.34+/-4.1 
 
Additional:   Embryonic cells 14-16weeks gestation –   14.4+/-5.1,   25.4+/-9.6,   respectively  
 
  
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 102
  Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal,  
Study 
Group 
Disease Hcy level Treatment and biochem etc 
contexts 
Mansoor 
MA et al 
(1993); 
Metabolism 
U Bergen, 
Bergen, 
Norway. 
7 CBS-- 
 
Case 1 
 
Case 2 
 
Case 3 
 
Case 4 
 
Case 5 
 
Case 6 
 
Case 7 
 
Age/Sex  CardiovascDis           PlasmaMethionine 
 
18y F        Cerebrovascular                           83uM 
 
20y F        VenousThromboembol              158uM 
 
20y M      VenousThromboembol               574uM 
 
3y  F         None                                             94uM 
 
19y M       Cerobrovascular                         830uM 
 
14y F         None                                          320uM 
 
17y F         None                                          490uM 
 
 
Additional: The authors provide a graphing on log 
scale y axis, some salient overall features of which I 
deign to graciously here present: 
# Protein-bound Hcy is very roughly twice as much 
as each of reduced and oxidised Hcy such that if the 
latter two were combined to give fHcy, it would be 
very roughly equal to protein-bound Hcy.    
 
# Protein-bound Cys is very roughly equal to each 
of reduced and oxidised Hcy such that if the latter 
two were combined to give fCys, it would be very 
roughly twice protein-bound Cys. 
 
# Protein-bound “Cyst(e)inylglycine” is very 
roughly equal to each of reduced and oxidised 
“Cyst(e)inylglycine” such that if the latter two were 
combined to give f“Cyst(e)inylglycine”, it would be 
very roughly twice protein-bound 
“Cyst(e)inylglycine”. 
 
# tHcy very roughly thrice tCys, which is very 
roughly thrice # tHcy very roughly thrice tCys. 
tHcy 
 
360uM 
 
360uM 
 
290uM 
 
200uM 
 
320uM 
 
240uM 
 
130uM  
 
 
VitB6 160mg*3/day 
 
VitB6 200mg*3/day 
 
VitB6 450mg*3/day 
 
Folate 40mg*3/day 
 
None 
 
None 
 
Folate 5mg*3/day + 
Betaine 12g/day 
Celermajer 
DS et al 
(1993) ; 
JACC ; 
Hospital for 
Sick 
Children, 
London, 
UK 
 
 
9 CBS--
children 
Age  
11+/-1.3y 
33%Male 
 
18Control 
Children 
Age  
12+/-0.7y 
33%Male 
 
P 
 
 
 
Chol  VesselSize FMD NTG RestFlow ReactHypem 
 
4.1mM  4.0mm    2.8%  13%  219ml/min  349% 
 
 
 
 
 
4.2mM  4.2mm   9.0%  16%  204ml/min   391% 
 
 
 
 
 
0.74      0.45    <.0001  0.27     0.78             0.55 
 
FMD = Flow Mediated Dilation 
NTG = Nitroglycerin-induced dilation 
Chol = Cholesterol 
Restflow = blood flow at rest 
ReactHypem = Reactive Hyperemia 
  
CBS—Detail: “In these children, the age at 
diagnosis was 4months to 7.5years (mean 4y) and 
the age at time of study was 4-17years (mean 11y). 
Of the 9 children, 7 (78%) had lens dislocation and 
4 (44%) were at a special school because of mental 
retardation.”  
tHcy 
 
63uM 
(38-104) 
 
 
 
 
(7-19uM) 
?.... 
 
 
“8 were taking a low-protein 
diet, 6 were taking VitB6, 7 
were prescribed betaine, and 
all were taking folic acid 
supplements.” 
 
“normal diet” 
 
 
 
 
 
 
 
 
 
 
 
 
Note: “No child had 
symptoms or signs of 
vascular disease or 
ultrasound evidence of 
arterial narrowing or plaque 
formation in the vessel 
studied.” 
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            Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt and 
biochem etc 
contexts 
Allen RH et 
al (1993); 
Metabolism 
U Colorado, 
Denver, 
Colorado, 
USA. 
5 CBS-- 
 
Case 1 
 
Case2 
 
Case 3 
 
Case 4 
 
Case 5 
 
 
Normal 
Range 
 
 
 
 
 
 
 
 
Betaine    NNDMGly    NMGly      Methionine      Cystathionine    tCys 
 
 24uM          2.9uM          2.3uM        22uM                 74nM        300uM     
 
660uM       34uM           19uM           76uM                114nM       186uM       
 
 20uM         4.8uM           7.7uM        43uM                  38nM       136uM 
 
560uM     158uM           25uM         530uM                  39nM       185uM 
 
170uM     250uM           49uM         660uM                  30uM       123uM 
 
 
17-73         2-6.6            0.6-2.7        13-43                   65-300     200-360 
NNDMGly = NNDimethylglycine,  NMGly = NMethylglycine 
 
“Serum samples from 60 subjects, 30 male, aged 18-65y, were obtained from 
healthy blood donors at the Belle Bonfils Blood Bank, Denver… .The 
diagnosis of CBS—was based on criteria that included increased serum levels 
of Hcy(ine), tHcy, and methionine, direct enzyme assays on cultured 
fibroblasts, and the presence of ectopic lenses.” 
 
“Finally, in the course of our studies we have noted that many physicians are 
surprised to find that their patients’ total homocysteine levels are still 
markedly increased even after their markedly increased serum homocystine 
levels (as measured with the amino acid analyser) have decreased to very low 
or undetectable levels following treatment with pyridoxine in the case of CBS-
- …..The disparity between measurements of total homocysteine and those of 
homocystine is due to the fact that Hcy and Cys are monosulfides that compete 
with each other to form disulfides of Hcy-Hcy (homocystine), Cys-Cys 
(Cystine and cysteine bound to cysteine residues in protein), and Hcy-Cys 
(Hcy-Cys mixed disulfide and Hcy bound to cysteine residues in protein). 
Since the levels of Cys are relatively constant in CBS-- (Concentrations of 
total cysteine are actually often decreased in these patients and increase toward 
or to normal with standard therapy; this has the effect of magnifying the 
differences in fold-response of tHcy versus Hcy(ine)) levels of Hcy(ine) 
increase exponentially as tHcy increases and decrease exponentially as tHcy 
decreases with therapy. This relationship is illustrated in Table 4, where it can 
be seen that a decrease in tHcy of only 6fold or 20fold results in respective 
decreases of 21fold and 210fold in Hcy(ine) level…. 
 
Table 4 Calculated Values for Serum tHcy, Hcy(ine), Cystine,  and Hcy-Cys in 
a Hypothetical Patient with a Constant tCys level of 300uM and tHcy levels of 
300, 150, 50, 30, and 15uM 
 
tCys           tHcy        TotalDimer    Hcy(ine)      Cystine       Hcy-Cys 
 
         Ammt Decrease                Ammt Decr   Ammt Incr   Ammt Decr 
 
300        300 nil             300             75 nil             75 nil         150 nil 
300        150 2fold         225             25 3fold       100 1.3fold 100 1.5fold 
300          50 6fold         175               3.6 21fold  129 1.7fold   43 3.5fold 
300          30 10fold       165               1.4 55fold  136 1.8fold   27 5.5fold 
300          15 20fold       157.5            0.4 210fold 143 1.9fold  14 10fold 
 
Note. Results are based on the assumption that Cys and Hcy can only form 
disulfides with themselves and each other in a random manner. This example 
is an oversimplification since significant amounts of tCys and tHcy also form 
disulfides with Cys residues in albumin and other proteins and peptides. 
Nevertheless, it illustrates fully how Hcy(ine) changes exponentially as tHcy 
changes in a linear manner.” 
 
Note: The great variation in not only the use of supplemental Cys in CBS-- 
treatment, but also the reporting/documentation thereof ought be kept in mind. 
A decrease in tCys to say 100uM would decrease the exponentiality of the 
Hcy(ine) changes but not abolish it. 
tHcy 
 
 19uM 
 
 50uM 
 
 91uM 
 
 99uM 
 
156uM 
 
 
5-16uM 
Betaine 
 
No 
 
Yes 
 
No 
 
Yes 
 
Yes 
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Authors, 
Journal,  
Study 
Group 
Disease Hcy level Treatmnt and 
biochem etc contexts 
Rubba P et 
al (1994) ; 
Stroke ; 
U Frederico 
II, Naples, 
Italy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cite the 
following 
authors 
whose data 
they collate 
here: 
 
 
Gibson et al 
(1964) 
Carson et al 
(1965) 
Shimke et 
al (1965) 
Carey et al 
(1968) 
McCully 
(1969) 
Hopkins et 
al (1969) 
Almgren et 
al (1969) 
 
 
 
 
11 normal 
Controls 
Age 21-35 
 
12 CBS-- 
Age 8-42y 
 
10 
Familial 
Hyper-
cholest’ia 
Age 4-49y 
 
P (Anova) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBS-- 
cases 
 
 
 
1 case 
 
1 case 
 
6 cases 
 
1 case 
 
1 case 
 
1 case 
 
1 case 
Wall  Thicknesses of Carotid Arteries and Flow Velocities in Middle 
Cerebral Arteries and Heart Rate and Pulsatility Index 
 
AvMaxThick MaxThick    AvSystolVel AvDiastolVel    HR  AvPulsatil 
 
     0.564mm   0.807mm          95cm/sec  46cm/sec           70bpm   0.80 
 
 
     
     0.620mm   0.908mm        100cm/sec  48cm/sec            73bpm   0.82 
 
      
     1.42mm     2.60mm            94cm/sec  37cm/sec            75bpm   1.02 
 
 
 
 
           <.01      <.01                        nss       .01                      nss      <.01 
 
“Quantitative B-mode ultrasound imaging and flow velocity evaluation 
with transcranial Doppler ultrasound”  
 
“The diagnosis of CBS-- was based on the following criteria: (1) 
presence of Hcy in the urine and (2) abnormally low CBS activity in 
cultured skin fibroblasts and/or hypermethioninemia and 
hyperhomocystinemia with low or undetectable levels of cystinemia. 
Index cases were referred by local ophthalmologists after diagnosis of 
lens dislocation; the other affected patients were identified by screening 
the families of the index cases.” 
(In all CBS--) “Ankle pressure estimated by the continuous-wave 
Doppler method was abnormally low and indicative of obliterating 
arterial disease of the lower limbs in 3 of 12. 4 of 12 had wall 
irregularities in the iliac arteries based on Duplex evaluation. None 
reported previous MInfarct, stroke, angina pectoris, intermitt claud.” 
 
“The mechanism underlying the thrombotic events that occur even in 
early-treated, pyridoxine-responsive patients is unknown. On the basis 
of our observations it is unlikely that typical atherosclerotic lesions 
precede thrombus formation in Hcy-uric patients within this age range. 
It is possible that the vascular lesions in more severe cases of Hcy-uria, 
in which patients have not been treated for several years, are to some 
extent different from those seen in our early-detected well-treated cases. 
However pathology studies in untreated patients who prematurely died 
of severe thromboembolic disease rarely show typical atherosclerotic 
lesions (Table 2). A more consistent finding in these patients is arterial 
dilatation, which has been suggested to precede the thrombotic event… 
   
Table 2. Gross pathology and histological findings in 12 Hcy-uric 
patients who prematurely died of cardiofvascular diseases 
             Gross Pathology           Histology 
   Thrombi               
Arteries Veins   Aneurysm   IntimThick  AbnElasFibr  AbnMed  Athero 
  
Yes      Yes        Yes              Yes                Yes             Yes          Yes 
 
Yes      Yes        No                Yes                Yes             Yes          No 
 
Yes      Yes        Yes               Yes                Yes              Yes         No 
 
Yes      No          No                Yes                No               Yes         No 
 
Yes      No          No                Yes                Yes              Yes         No 
 
Yes     Yes     
 
Yes      No          Yes              No                   Yes             Yes         Yes     
 
 
 
 
 
 
 
 
 
tHcy 
<100uM? 
 
 
 
 
 
 
 
 
 
CBS—received VitB6 
since diagnosis for 3-
5y – all but one were 
responsiv 
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    Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
Schienle 
HW et al 
(1995); 
Thromb 
Res; 
Philipps U 
Baldingerstr 
Marburg, 
Germany 
2 CBS—
cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case 1 
 
Case 2 
Case 1, male, for many years prior to age 23y ectopia lentis known,  
no Marfanoid signs,  
good intelligence occupation computer programmer,  
at age 23y knee op no complications, low prothrombin time (64%), low 
level of F VIIc (28%), aPTT normal, liver function tests normal,  
at age knee op + 5months stupor and seizures (12/89), superior sagittalis 
vein thrombosis diagnosed by MRI,  
AT III activity low, Heparin….aPTT prolonged to approx 90sec… 
discharged after 5weeks…dicoumarol not instituted because 
prothrombin time was prolonged (median quick value 53%). 
Antiepileptic therapy was given for 1year because of  
focal necrotic-ischemic changes in the occipital lobes… 
although heparin therapy was continued,  
thrombosis of calf and thigh veins with subsequent lung embolism 
occurred 2months later,  
CBS-- diagnosed  
VitB6 600mg/day, Folate 15mg/day started (response as tabulated 
below) heparin continued for another 1.5years  
patient does normal sports and studies computer science. 
 
Case 2, female, sister of case 1. ectopia lentis known for many years,  
no Marfanoid signs,  
following on the brothers experience , CBS-- diagnosed VitB6 
600mg/day, Folate 15mg/day started. 
 
 
Plasma:      fHcyPre   fHcyPost                        MetPre  MetPost 
 
                  >280uM   0-40uM                            75uM    30uM 
 
                    >56uM   0uM                                520uM   20-50uM 
 
“In patient 1 RiCoF (Von Willebrand Factor) was measured on 3 
occasions during the clinical phase without thromboembolic disease and 
without vitamin treatment and found to be elevated to 224% of the 
normal value. During thromboembolic disease RiCoF was 336% of 
normal. During specific vitamin therapy the median value of RiCoF (n 
= 15) decreased to 144% of normal (66-168%). The time course of 
RiCoF shows that RiCoF dropped slowly to normal values. 
In patient 2, RiCoF was 168% on 2 occasions, whereas under vitamin 
therapy the median of 13 measurements was 108% of normal (66-
168%)                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcyPost 
 
54uM 
 
16uM 
 
Applegarth 
DA et al 
(1995); 
Eur J 
Pediatr; 
U British 
Columbia, 
Vancouver, 
Canada. 
N = ? 
CBS-- 
“In many cases, the tHcy level rose to about 50uM befote any increase 
in plasma fHcy(ine) or Hcy-Cys could reliably be detected on the amino 
acid analyser system. In some patients, tHcy levels of about 20uM did 
demonstrate fHcy or Hcy-Cys, but in most patients the tHcy levels 
needed to be at least 50uM (about 4 times the upper limit of the control 
range) before any fHcy was detected.”  
fHcy = nil 
until  
tHcy 
>50uM 
Low-
methio-
nine diet 
and/or 
VitB6 
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   Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Sebastio G 
et al (1995); 
Am J Hum 
Genet; 
Federico II 
U, Naples, 
Italy. 
18 CBS— 
 
1         LG 
2        ON 
3a       SS 
3b       SR 
3c       SG 
4a       ML 
4b      MA   
5        PV 
6a      DM 
6b      DA 
7        PA 
8       QE 
9        TG 
10      SA 
11      TL 
12      CG 
13     MN 
14     TR 
 
DiagnAge   EctopiaLent   Osteopor   VascDis   MentalRetard     VitB6-responsiv      Allele1 Allele2 
 
4y                      +                    +                +                 +                     partial                G374A  G374A 
1y                      +                    +                -                  +(&epilepsy)     -                      C770T  C770T 
6y                      +                    +                -                  -                         +                     C262T  T833C 
2y                      -                     -                 +                 -                         +                     C262T  T833C 
0.5y                   -                     -                 -                  -                         +                     C262T  T833C 
9y                      +                    +                +                 +                        +                      T833C    ? 
3y                      +                    +                -                  -                         +                      T833C    ? 
29y                    +                    +                -                  -                         +                           ?         ? 
12y                    +                    +                -                  -                         +                      C341T    ? 
10y                    +                    +                +                 +                        +                      C341T     ? 
12y                    +                    +                +                 +                        +                              ?       ? 
25y                    +                    -                 -                  +                        +                      C341T     ? 
4y                      +                    +                +                 +                         -                      C341T     ? 
7y                      +                    -                 -                  +(&epilepsy)     +                      C341T     ? 
6y                      +                    +                -                  +                        -                                ?       ? 
33y                    +                    -                 -                  -                         +       T833C+ins68bp  T833C 
15y                    +                    +                -                  -                         +                      T833C  T833C 
35y                    +                    +                -                  -                         +                              ?        ? 
 
« Clinical findings of 18 patients belonging to 14 unrelated families, all originating from southern 
Italy, are listed. Minimal criteria for CBS—were: Hcy(ine)-uria and hypermethioninemia, 
associated with dislocation of optic lenses. All patients met these criteria except 3b and 3c, who 
have not developed the ocular finding due to early VitB6 treatment. CBS activity in skin fibroblasts 
was tested and found to be <1% of normal values in patients 1, 2, 4a, 4b, 7, and 8.   
 
 
    Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
Kluijtmans 
LAJ et al 
(1996); 
J Clin 
Invest 
 
 
1 CBS--
case 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contr 
“The patient is a woman, now 20y of age, who had been       Methionine 
 admitted to the hospital at the age of 9y because of  
psychomotoric retardation and                                                       83uM 
Marfanoid features such 
 as excessive height, dolichostenomelia, and arachnodactyly 
……At present time ie 11years after diagnosis and start of  
therapy, she is in a very good physical condition and                    79uM 
her intellectual development has reached an average level.  
Her length is 182cm and weight 75kg.  
She has not any physical complaint.  
Ectopia lentis, osteoporosis, and vascular complications did         80uM 
not occur till now. (Ambiguity as to disease outcome status,  
due to the inconsistency of the latter two sentences, may be  
due to language translational difficulties. DV)….. 
Direct sequencing of the entire CBS cDNA revealed the               69uM  
presence of a homozygous G1330A transition. This mutation  
causes an amino acid change from aspartic acid to asparagine  
(D444N) in the regulatory domain of the protein…. 
Despite the homozygous mutation, CBS activities in extracts  
of cultured fibroblasts of this patient were not in the                 16-38uM  
homozygous but in the heterozygous range.  
Furthermore, we observed no stimulation of CBS activity by S-
adenosylmethionine, contrary to the 3fold stimulation in control 
fibroblast extract” 
fHcy 
 
178uM = 
>218uM 
tHcy 
 
121uM = 
>161uM 
tHcy 
 
62uM = 
>102uM 
tHcy 
 
18uM = 
>58uM 
tHcy 
 
 
0.2-2.6uM 
= 10uM 
tHcy 
 
 
None 
 
 
 
VitB6 
500mg/d 
 
 
+ Folate 
5mg/day 
 
 
+(cumul) 
Betaine 
6g/day 
 
 
normal 
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    Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
Cordoba-
Porras A et 
al (1996); 
J Mol Med; 
U 
Antioquia, 
Medellin, 
Columbia. 
 
 
6 CBS--
mean age 
13y 
 
6 Controls 
mean age 
13y 
 
P 
LDLTBARS HDLTBARS  LDL%eNeg  LDLOx HDLOx    Met   tCys 
 
0.39nmoleq   .04nmoleq           10.6%    59.6min 40.0min  440uM 55uM 
 
 
 
0.37nmoleq   .13nmoleq             8.5%    57.3min 33.5min  25uM 233uM 
 
 
 
nss                  nss                      nss          nss         <.05      <.05     <.05 
 
Where:  
LDLTBARS = native LDL ThiobarbituricAcidReactiveSubstance, in 
units of nmol equivalents of MDA/mg lipoprotein protein  
HDLTBARS = native HDL ditto   
LDL%eNeg = proportion of electronegative LDL in native LDL in units 
of %   
LDLOx = susceptibility to oxidative modification of LDL and HDL 
measured by the kinetics of diene formation (Lag phase in units of 
minutes given here, they also provided maximal curve slopes in units of 
change in absorbance/min (not tabulated here but see next note))  
HDLOx = ditto for HDL    
Met = methionine 
tCys = total Cysteine 
 
Note: the maximal curve slope of the LDL oxidative modification (not 
tabled here) was in agreement with the difference in lag times noted 
here, while that of the HDL oxidative modification was very slightly 
(though vnss) in disagreement with the difference in lag times noted 
here. 
 
Note: It is quite obvious that the ss given above have not noted any 
point of reference other than P<.05, and some of the ss is obviously 
much greater than that ie P<.001…  
 
“The patients studied were diagnosed with severe 
hyperhomocysteinemia on the basis of their homocysteine 
concentrations. The clinical information available at the time of 
withdrawal supported the diagnosis of classical hyperhomocysteinemia 
in all six patients” 
 
Note: The generally poor and easy/offhand treatment given here in the 
context of clinical practive initiated in that locality in the era of less 
stress on low-methionine diet (it may well have been somewhat in any 
case, there…) and cystine supplementation provides a good opportunity 
to view the low cysteine levels, and that in a group possibly milder in 
CBS deficiency than others on average.  
 
tHcy 
 
146uM 
 
 
 
8uM 
 
 
 
<.05 
Two 
CBS--
treated 
with 
VitB6 + 
Folate, 
One with 
only 
VitB6 
 
Controls 
approx 
nil 
treat’nt 
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               Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt and 
biochem etc 
contexts 
Mandel H 
et al 
(1996)a; 
NEJM; 
Rambam 
Medical 
Center, 
Haifa, 
Israel. 
 
Note: high 
degree of 
consanguin.  
in this 
population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See also 
Quere & 
Lamarti 
(1996) imm 
below, and 
Mandel et 
al (1996)b 
imm below 
that  
 
 
CBS--
Family1a 
 
CBS--
Family1b 
 
CBS--
Family1c 
 
CBS--
Family2a 
 
CBS--
Family2b 
 
CBS--
Family3 
 
 
MTHFR-- 
Family1a 
 
MTHFR-- 
Family1b 
 
MTHFR-- 
Family2 
 
MTHFR-- 
Family3 
 
 
cbl(C/D)-- 
 
 
APCResRatio    FVLeiden    ThrombOnset  ThrombSite  ThrombTrig?? 
 
 ?                      homz/hetz         7years        deepvein, lung     diarrhea  
 
 
                        homz/hetz         8years        deepvein, lung        ? 
 ?                                                                   brain 
 
1.3                       homz             8years        deepvein, lung     surgery 
 
 
2.0                       hetz               7years         deepvein, brain    surgery 
 
 
3.4                       none              none             none  
 
 
2.2                       none              none             none 
 
 
 
?                        homz/hetz         0.2years       brain                      ? 
 
 
1.6                         hetz              none              none 
 
 
1.6                          ?                  0.2years         brain                  diarrhea 
 
 
2.1                       none               none              none 
 
 
 
2.4                      none                none              none 
 
Where:  
APCResRatio = Activated Protein C Ratio    
FVLeiden = Factor V Leiden mutation     
ThrombOnset = Age of thrombosis onset   
ThrombSite = Body site of thrombosis   
ThrombTrig?? = Possible thrombosis trigger 
+MRetar = severe mental retardation 
MRetard = moderate/mental retardation 
-MRetard = mild mental retardation 
homz = homozygote     hetz = heterozygote             
tHcy 
 
>40uM 
(Hcy-uria) 
 
>40uM 
(Hcy-uria) 
 
290uM 
 
 
274uM 
 
 
322uM 
 
 
350uM 
 
 
 
47uM 
 
 
62uM 
 
 
50uM 
 
 
79uM 
 
 
 
43uM 
Outcome 
 
Death at age  
8y 
 
Death at age  
13y 
 
MRetard age  
8y 
 
+MRetar age  
15y 
 
MRetard age  
17y 
 
-MRetard age  
15y 
 
 
Death at age 2y 
 
 
Healthy at 1.5y 
(warfarin 
 
Death at age 
1.5y 
 
MRetard age 
1y 
 
 
+MRetar age  
3y 
 
Quere I 
Lamarti H 
(1996); 
NEJM; 
St Eloi 
Hospital & 
Necker 
Hospital, 
France 
 
 
 
 
See also 
Mandel et 
al (1996) 
imm above 
15 CBS-- “We have tested for FVLeiden in 15 patients who were CBS-- (by all 
tests) and who were members of 13 unrelated white French Families. 
Among them 5 patients had deep-vein thrombosis, 2 had arterial 
thrombotic disease (myocardial infarction and thrombotic aortic 
aneurysm), and 8 were free of any vascular or thrombotic disease (age 
4-28). Of the 15 patients only 3 were heterozygotes for the R506Q 
(FVLeiden) mutation. 2 of these 3 patients presented with venous 
thrombosis; the other 1 had not had thrombosis before the age of 11. 
Thus, 3 patients without the R506Q mutation had venous thrombosis. 
The activity of protein C, protein S, and Antithrombin III was normal in 
2 of these 3 patients; the third could not be tested. The 2 patients 
presenting with arterial disease did not carry the R506Q mutation. 
Although the frequency of the mutation seems to be high (20%) in our 
population, it is very different from that reported by Mandel et al (64%), 
…….Since 3 of our patients without the R506Q mutation had venous 
thrombosis, this mutation does not appear to be a necessary requirement 
for thrombosis in our 13 families”  
                                                               Thromb-    Thromb+ 
                (no mut allele) FVLeiden++        9                3 
          (one mutant allele) FVLeiden-+         1               2  
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    Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
Mandel H 
et al 
(1996)b; 
NEJM; 
Rambam 
Medical 
Center, 
Haifa, 
Israel. 
 
See also 
Mandel H 
et al 
(1996)b 
two imm 
above, and 
Quere & 
Lamarti 
(1996) imm 
above 
Those of  
Mandel et 
al (1996)b 
two imm 
above, 
and  
Quere & 
Lamarti 
(1996) 
imm 
above 
“The comments of Quere et al are of great interest, since they also 
report the occurrence of thrombosis in patients CBS-- in the absence of 
a coexisting FVLeiden mutation. Yet the frequency of R506Q 
heterozygotes in their series (20%) is 3-5 times higher than that reported 
among Western Europeans. They correctly point out the influence of the 
different consanguinity rates and genetic makeups in our two study 
populations, since the frequency of heterozygosity for the R506Q 
mutation in Arab Israeli communities is as high as 17% (unpublished 
data). ” 
 
  
  
Dawson PA 
et al (1996); 
Aust NZ J 
Med; 
U 
Queensland 
Brisbane, 
Queensland 
Australia. 
1 CBS-- Age          Plasma:   Methionine      fCys    tCys(derived)           fHcy 
 
3years                         790uM         27uM     35uM                     172uM 
 
3years                         650uM         38uM     50uM                     183uM 
 
 
 
 
6years                       1000uM        70uM     140uM                      50uM 
 
 
Note: Patient homozygous for G307S mutation, known to be VitB6-
nonresponsive. 
 
Note: Patient 17y old in 1996, so delay in implementing betaine is 
possibly excusable at the date time of delay (approx 1982-85), though 
why methionine-restriction and cysteine-supplementation were not 
implemented remains cause for question…... 
 
Note: Patient had “ectopia lentis, mild mental retardation, and a number 
of bony abnormalities”, apparently from the text sequence already at the 
age of 3years.  
 
Note: If the change in cysteine levels came about without any change in 
cysteine intake (cysteine supplementation in CBS-- becoming very 
poorly considered and recorded at an early stage of vitamin/betaine 
treatment) then this is cause for major query as to the metabolic cause of 
this, as excess stimulation of CBS by SAM would be expected to be 
pretty near maximal already given the methionine levels……      
tHcy 
 
>212uM 
 
>223uM 
 
 
 
 
>90uM 
 
 
Nil 
 
VitB6 
100mg/d 
for 
2weeks 
 
VitB6 
100mg/d 
+ Folate 
5mg/day 
+ Betaine 
3g*2/day 
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   Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Van Der 
Molen EF 
et al (1997); 
Thromb 
Haemost; 
U Hospital 
St Radboud, 
Nijmegen, 
Netherlands 
1 CBS—
Endothe-
lial Cell 
Line,  
&, 
>=3 
Normal 
Cell Lines 
“Endothelial cells from the human umbilical vein (HUVECs) were obtained from umbilical cords of 
healthy fetuses from uncomplicated pregnancies and deliveries of healthy mothers (non-smoking 
and without medication). Within 24h after cord collection endothelial cells were isolated by 
collagenase treatment according to the procedure of Jaffe at al. HUVECs were cultured under 
standard conditions ….our previous article. All HUVEC experiments were performed in 12-well 
plates with cells of 3 days in confluence in the third or fourth passage….All experiments with 
normal HUVECs were performed in duplo with at least 3 different cell lines. All experiments with 
CBS-- HUVECs were performed in triplo.” 
 
The following statement by the authors (“The Hcy export and the markers of endothelial function 
did not differ between the control and the CBS--HUVECs under various test conditions.”) is correct 
only with regard to the export of Hcy under only one test condition – the rest of it is very incorrect – 
the reason being that a simplistic, inappropriate and insufficient statistical analysis was slavishly 
adhered to in the face of obvious trends visible in the tabulated data (comparing only each pair of 
(small groups of) data within itself, and not the much larger amount of comparable data within each 
table).  The results quite visible to me are as follows: 
 
# As they assert, across 0, 3, 30, 100nM Folinic Acid, over 24, 48, 72hours, the Hcy export did not 
differ between the CBS-- and Control cells, and both types of cell lines had similar increase of Hcy 
export over increasing time, and similar decrease (reduced to roughly only 30% at the highest dose) 
over increasing folinic acid. 
 
This is suggestive, in accordance with the authors, that human vascular endothelial cells do not have 
CBS activity, at least at that age, but this needs be considered in the light of other observations that 
CBS activity is low in neonates, increasing thereafter…..  
 
 
#  Across 0, 0.3, 1, 10, 100, 1000uM Pyridoxine HCl, over 24, 48, 72hours, 13.5 times/18 the CBS--
cells exported more Hcy than the Control cells, and 4.5 times/18 the converse – this difference 
might have been ss…..  
 
#  Across 0, 5, 10, 50, 100, 200uM Methionine, over 24, 48, 72hours, 17 times/18 the CBS-- cells 
exported more Hcy than the Control cells, and 1 time/18 the converse – this difference would have 
been ss….. 
 
 
# Across 0, 3, 30, 100nM Folinic Acid, over 24, 48, 72hours, the von Willebrand Factor was always 
(12/12) higher for the CBS-- cells than for the Control cells by an average proportion of roughly 5 
or 6% – this difference would have been ss….. 
 
 
# Across 0, 3, 30, 100nM Folinic Acid, over 24, 48, 72hours, the Tissue Plasminogen Activator 
(tPA) was always (4/4) higher (rough average proportion by 20%) for the Control cells than for the 
CBS-- cells at 24hours,  while thereafter at 48, 72hours, the Tissue Plasminogen Activator (tPA) 
was always (4/4 & 4/4) higher (rough average proportion by 20%, 50%) for the CBS-- cells than for 
the Control cells – even with multiplication of the P value by *2, *3 for the post hoc split of the 
group into 2 or 3 different timepoints, this difference(s) would still have been ss….  
 
# Across 0, 3, 30, 100nM Folinic Acid, over 24, 48, 72hours, the Plasminogen Activator Inhibitor 
(PAI-1) had a fairly similar overall trend (4/4, 3/3, 3.5/0.5) as that of the tPA, but of less magnitude.  
 
Note: As the latter two are antagonists, it might be taken as signifying not much other than personal 
idiosyncrasies, but there were always at least 3 (out of an unknown total n Controls) Controls in a 
comparison, so….? 
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                 Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt and 
biochem etc 
contexts 
Watanabe T 
et al (1997); 
J Med 
Invest; 
U 
Tokushima 
School of 
medicine, 
Tokushima, 
Japan.  
2 CBS--
siblings: 
Case 1, 
boy age 
9y 
 
Case 2, 
girl age 
7y  
 
Normal 
Plasma:                                         Methionine                  Hcy-uria 
 
Age 5days                                        536uM                    not examined 
Age 19days                                   1,421uM                          negative 
Age 1-3months                             1,500-1800uM     negative-positive              
 
Age 5days                                       <67uM                    not examined 
2.5years                                           556uM                strongly positive 
 
 
                                                          20-50uM                  negative 
 
“Case 1…..Although hypermethioninemia was detected on routine 
screening at 5days old, diagnosis of Hcy-uria was not made until he 
was 3months old because of undetectable urinary levels of non-
protein bound Hcy. Hcy(ine) was detected in urine at 3months old 
and a marked reduction in (“markedly reduced” meant? DV) CBS 
activity was observed in cultured skin fibroblasts……(see table. 
DV)…  
Since this patient did not respond to high dosages of VitB6 
(500mg/d*10days),  
a low methionine diet and betaine were initiated.  
His subsequent physical and psychomotor development were normal. 
 
Case 2 …..However, her blood concentration of methionine was 
below the normal cutt-off value in mass screening at 5d old 
(tHcy<67uM).  
While her physical development was normal,  
she exhibited retardation, especially of speech development. At the 
age of 2.5y she visited Tokushima U Hospital. At that time her 
development quotient was 57.  
A test for cyanide-nitroprusside in urine was positive….(see table. 
DV) ….. 
No activity of CBS was detected in cultured skin fibroblasts.  
Since the patient failed to to high doses of VitB6 (500mg/d*8days), 
she was administered a low methionine diet and betaine.  
Her IQ rose from 57 at age 2.5y to 99 at age 6.5y…… 
 
The specific activities of methionine adenosyltransferase and 
betaine-homocysteine methyltransferase are lower in the fetal liver 
than in the adult liver, whereas the activity of 5-
methyltetrahydrofolate-homocysteine methyltransferase is higher in 
fetal tissue than in adult tissue (cites Gaull et al 1972, 1973). This 
fetal enzyme pattern should direct a large portion of the available 
homocysteine to the 5-methyltetrahydrofolate-dependent methylation 
cycle rather than towards the synthesis of cystathionine, then change 
to an adult pattern during development.  
(Seems these two former abovementioned lower enzyme activities 
would lead to an increase in Hcy, while the latter abovementioned 
higher enzyme activity would lead to a decrease in Hcy?..... relative 
proportions of metabolic activity, as well as developmental evolution 
of other enzymes in these pathways need be considered also. DV). 
The failure to detect homocystinuria or hypermethioninemia in some 
newborn infants with CBS-- may therefore be explained by a 
quantitative difference in the activities of enzymes involved in the 
metabolism of methionine and Hcy for the first few weeks after 
birth……Most VitB6-responsive CBS-- are missed on newborn 
screening, because the blood level of methionine is not sufficiently 
elevated in the plasma during the first few days of life. However our 
patients did not have a VitB6-responsive form of CBS--. ….. Poor 
protein intake can be excluded as a cause in our patient. Therefore 
we suggest that the activities of enzymes other than CBS in 
methionine metabolism probably differed in the neonatal period in 
these patients.  
Thus genotype may not always be consistent with phenotype in 
patients with inherited diseases.  
tHcy 
 
not exam 
72uM        
67uM 
 
not exam 
96uM 
 
 
6-10uM 
 
 
Normal milk 
formula, protein 
intake 2.5g/ 
kgBW/d at age 
5days and 
normal diet 
thereafter  
for both 
 
 
 
 
 
 
 
 
 
 
 
 
Low-methionin 
diet + betaine 
 
 
 
 
 
 
 
 
 
 
 
 
Low-methionin 
diet + betaine 
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                 Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt and 
biochem etc 
contexts 
Surtees R et 
al (1997); 
Pediatr Res; 
Institute of 
Child 
Health, 
London, 
UK 
   
 
5 CBS--
age 6-14y, 
VitB6-
non-
responsiv 
 
 
Normals, 
age-
matched 
(0.4-
12.5y) but 
to who?... 
 
 
10 CBS-- 
Including 
the above 
5,  
age 
otherwise 
unknown,
VitB6-
responsiv 
otherwise 
unknown 
 
Normals, 
age-
matched 
(0.4-
12.5y) but 
to who?... 
 
                                    Gly  Ser    5-MTHF    Methionine  S-Ado-Met   
 
CSF beforeBet:       4.8uM  23uM  .050uM        35uM          0.25uM  
Stat Signif:             ss vsRR                                ss vsRR         
 
CSF afterBet:         3.3uM  34uM  .031uM        78uM          0.38uM 
Stat Signif:            ss vsRR                                 ss vsRR       ss vsRR 
 
 
Ref Range:              7.8uM  61uM   .061uM         4uM          0.21uM  
 
P(ANOVA):            <.001    .001      .08               <.001         .006 
 
 
 
 
 
Plasma beforeBet: 272uM  110uM                     275uM   
Stat Signif:                                                          ss vsRR 
 
 
Plasma after Bet:   178uM  161uM                     275uM 
Stat Signif:            ss vsbB  ss vsbB                    ss vsRR 
 
 
 
 
 
 
Ref Range:            221uM  130uM                       21uM  
 
P(ANOVA):            .006     .009                          <.001 
 
 
Where:  
CFS = CerebroSpinal Fluid,           Gly = Glycine,     Ser = Serine,  
5-MTHF = 5-methyl-tetrahydrofolate, 
S-Ado-Met = S-Adenosyl-Methionine, 
Stat Signif = Statistical Significance,  
ss = statistically significant (and see note below), 
vsRR = versus Reference Range,       vsbB = versus before Betaine 
vsBoth = versus both the other two values, 
 
Note: “Post hoc significance testing used Tukey’s HSD test; P values 
<.05 were regarded as significant. Because of the relatively small 
number of CFS samples, these results were also analysed using 
nonparametric statistical methods (….analogous. DV).” 
 
“The primate brain normally contains CBS (cites Rassin et al 1981), 
and its deficiency would be expected to lead to an accumulation of 
Hcy within the cells of the CNS. In other tissues, intracellular 
accumulation of Hcy causes export of Hcy into the extracellular 
space. In the CNS, CSF is in continuity with the extracellular space, 
and accumulation of Hcy in this fluid is likely to reflect accumulation 
within the brain. The mammalian brain does not contain the enzyme 
betaine-homocysteine methyltransferase (cites McKeever et al 1991). 
So the effect of betaine is most probably mediated through changes 
in the plasma Hcy concentration. Because we found that CSF Hcy 
concentrations decreased with betaine treatment, it suggests that the 
reduction in plasma tHcy caused by betaine is responsible for the 
decrease in CSF tHcy. It is possible that a reduction in plasma 
concentration of Hcy facilitates the active removal of Hcy fthe brain, 
thereby reducing its accumulation in the CFS…..Another potential 
mechanism might involve oxidation of Hcy to homocysteid acid, 
which is an excitotoxin that activates the glutamate N-methyl-D-
aspartate receptor (cites Cuenod et al 1990).”  
tHcy 
 
1.2uM 
ss vsBoth 
 
0.32uM 
ss vsBoth 
 
 
<0.10uM 
 
<.001 
 
 
 
 
 
99uM 
ss vsBoth 
 
 
43uM 
ss vsBoth 
 
 
 
 
 
 
6uM 
 
<.001 
 
 
2 on low-Met 
diet + Folate 
 
Ditto + 
+ Betaine 
250mg/ 
kgBW/d * 3-
6month 
 
 
 
 
 
 
 
3 on low-Met 
diet + Folate 
 
 
Ditto + 
+ Betaine 
250mg/ 
kgBW/d * 3-
6month 
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(Continues) 
40 CBS--, 
17 VitB6-
responsiv 
15 VitB6-
nonrespon 
Age 30, 
(9-66) 
years 
8 VitB6?? 
Age?? 
“Patients and Methods 
The study population comprises 40 patients from 25 sibships for whom there is 
long-term follow-up with known outcomes. 3 recently diagnosed patients are not 
included. The patients were diagnosed on the basis of characteristic and clinical 
features plus elevated levels of plasma methionine and free homocyst(e)ine with 
low free cyst(e)ine. All patients had elevated urinary homocystine. …… 
 
Treatment Regimens 
All treated patients received pyridoxine 100-200mg/day, folic acid 5mg/day, and 
most had intermittent hydroxocobalamin by injection according to the serum 
VitB12 levelmeasured usually twice-yearly.  
Pyridoxine nonresponsive patients all received in addition 6-9g/day oral 
trimethylglycine (betaine) given in two divided doses.  
One pyridoxine-responsive patient also received betaine and this was maintained 
throughout her subsequent pregnancy.  
Diet was not closely monitored, but general advice was given to reduce the intake 
of foods with high methionine content.  
During the last 4years VitB12 therapy 1mg by intramuscular injection every 1-
3months has been given to pyridoxine-nonresponsive patients irrespective of their 
serum VitB12 levels.  
(Note: The high detail of this description suggests that cysteine supplementation 
was in fact not implemented, rather than merely not mentioned. DV) 
 
Vascular Events 
Vascular events were documented in surviving and nonsurviving patients in 
relation to whether or not they were receiving treatment at the time of the event, 
and to what the treatment was.  
We assessed the effect of treatment on the occurrence of vascular events by 
comparing the findings in our treated patients with those in the untreated patients 
reviewed by Mudd and Colleagues (1985). They found that at the time of 
maximum risk (beyond the age of 10y) there was 1 event per 25y. We compared 
our risk data with that statistic.  
This is a conservative estimate since, before treatment started, 2 patients had 
already had vascular events, which enhances the risk in untreated patients to about 
1 event in 10y (Mudd et al 1985). 
(Note: this “enhancement” might only apply if a patient doesn’t know why the 
event occurred, or what to do about it – otherwise it might not, and might even 
decrease risk by fright value and a resulting increase in treatment 
compliance…DV) 
 
Results 
In the 40 patients there were 10 deaths at ages 2-30y. …only 2 were receiving 
effective treatment at the time of death, and only 1 of the 2 was CBS---related, 
…massive pulmonary embolus. (Note: There were 2 deaths whilst on “No effective 
treatment” for which no further details are provided. DV). 
Of the 32 patients receiving effective treatment, 17 were pyridoxine-responsive. 
During 281 patient years of treatment which maintained plasma total free 
homocyst(e)ine consistently <20uM, there were 2 vascular events in this group. 1 
patient, referred to above, succumbed from a pulmonary embolus and a second 
patient, who had had 4 vascular events prior to starting treatment at age 41y, 
subsequently had a myocardial infarction at the age of 55y.  
From the data of Mudd et al (1985), untreated, 11 events would have been 
expected, relative risk =0.17 (CI .04-0.80) P = .026.  
During 258 patient-years of treatment I the 15 pyridoxine-non-responsive patients, 
no vascular event occurred. These 15 nonresponsive patients have current mean+/-
SD total free homocyst(e)ine of 33+/-17uM.  
From the data of Mudd et al (1985), in untreated nonresponsive patients at least 10 
events would have been expected, P = .005.  
19 patients of the series had a total of 19 major and 15 minor operatios requiring an 
anaesthetic and there were 3 successful pregnancies, one in a patient receiving 
betaine. There were no thromboembolic complications.  
Thus, during 539 patient-years of treatment in all 32 patients there were 2 vascular 
events, whereas, if untreated, 21 events would have been expected. These findings 
indicate that treatment markedly reduced the relative risk to .09 (95%CI .02-0.38) P 
= .0001.” 
(Continues) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcy very 
roughly 
<40uM 
 
 
 
 
 
tHcy very 
roughly 
66uM 
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(Continued)
Wilcken 
DEL 
Wilcken B 
(1997); 
J Inher 
Metab Dis; 
Prince 
Henry, 
Prince of 
Wales, and 
New 
Children’s 
Hospitals, 
Sydney, 
NSW, 
Australia 
(Contin) (Continued) 
Now, as Mudd et al (1985)’s risk of thrombosis is not constant over time, but rather 
sigmoidal, with the risk at <10y of age and >32y of age being approximately half 
the risk at (max) age 21, and as the average ages of the subgroups of pyridoxine-
responsive(-nonresponsive) have not been provided here by W & W, the only 
comparison that may be properly attempted is that between W & W’s combined 
(VitB6-responsive(-nonresponsive)) group and Mudd et al’s combined group. That 
of the sentence immediately preceeding this paragraph.  
Now, as Mudd et al’s statistic of 1 event per 25y refers to (both of, approximately 
equal) the respective periods of maximum risk of thrombosis of the VitB6-
responsive(-nonresponsive) subgroups (ages 22y and 15y respectively, mean 
18.5y), and as the average age of W & W’s combined group is 32y, then their 
group here is expected to be a nontrivialy lower risk group, and therefore their 
estimation of relative risk is not conservative, but a rather a nontrivial 
overestimation/inference of treatment efficacy.  
Furthermore, here, as in Mudd et al the oldest cases are milder cases by survival, 
but their oldest cases here will be milder cases than Mudd et al’s due to 
(hopefully…) improved diagnosis.  
Also, their youngest cases here will too be milder cases than Mudd et al’s due to 
(hopefully…) improved diagnosis.  
Therefore the real relative risk is likely to be nontrivialy higher (less treatment 
efficacy) than they report here, possibly so as to include unity in the CI, though 
note that given the lowish n, the suggestion of efficacy is certainly strong enough to 
warrant continuing with the treatment, while considering possible improvements 
(ie earlier detection, cysteine supplements, VitC, VitE, and better dietary 
achievements?....)           
 
Bonham JR 
et al (1997); 
J Inher 
Metab Dis; 
U Wales 
College of 
Medicine, 
Cardiff, UK 
12 CBS--, 
13 CBS-+ 
Obligate 
Heterozyg 
22 
Normal 
“We have compared the relationship between total homocysteine and free 
homocystine in plasma in 12 patients with CBS—over a 2year period, 13 obligate 
heterozygotes and 22 normal individuals.  
The correlation of free and total homocystine shows a tri-phasic distribution:  
(i) an increase in free homocystine could not be detected reliably when the total 
homocysteine was less than 60uM  
(ii) an increase in free homocystine between <1 and 20uM correlated with a linear 
but more pronounced increase in total homocysteine ranging from 60-150uM, 
indicating some binding of free homocystine to components in plasma  
(iii) when free homocystine exceeded 20uM there was an equal increase in total 
homocysteine in the range of 150-250uM, suggesting that the plasma binding 
capacity for homocystine had been exceeded.” 
 
“A patient assessed at a time of poor control (tHcy 160uM, free homocystine 
20uM) showed a marked impairment in endothelium dependent brachial artery 
dilation compared to age/sex matched healthy subjects (n = 7, -.08mm vs 
+0.20mm).  
Following a short period of better control (tHcy 35uM, free homocystine <1uM) 
the response remained impaired (+.01mm), which suggests that even modest 
hyperhomocystinemia in these patients may be clinically important.  
It seems likely that increased tHcy in the range 30-60uM may be important and that 
measurement of free homocystine may be an inadequate means of monitoring 
patients in this range” 
Triphasic 
Hcy 
pooling: 
 
tHcy 
<60uM & 
fHcy(ine) 
<1 
 
tHcy 
60-150uM 
& 
fHcy(ine) 
1-20uM 
 
tHcy 
150+xuM 
& 
fHcy(ine) 
20+xuM 
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Lobo CA, 
Millward 
SF (1997); 
J Vasc 
Interv 
Radiol; 
Ottowa 
Civic 
Hospital, 
Ottowa, 
Canada 
1 CBS--?? Female aged 34 in 1990, hypercholesterolemia, 12-pack-year smoking history, 
hypertension for 17years, no diabetes,  
Oct 1989 left hemispheric stroke, 
May 1990 admitted with 2week history of painful and discoloured left big toe, 
angiographic 2cm 50% stenosis of left popliteal artery…..percutaneous 
transluminal angioplasty, anticoagulation not continued post-op, antiplatelet 
therapy not initiated, 
1day post-op thrombosis of popliteal artery and of tibioperoneal trunk, 
“….intraarterial streptokinase infusion. This resulted in successful recanalization of 
the popliteal artery with no residual stenosis or thrombosis but only the anterior 
tibial artery was still patent, the tibioperoneal trunk was still occluded. The 
streptokinase was discontinued and the intravenous heparin was initially continued; 
then anticoagulation was continued with oral warfarin (5mg/d), although no 
antiplatelet treatment was initiated.” 
2Weeks later deterioration, rest pain, open surgical thrombectomy of the popliteal 
artery and tibioperoneal trunk, 
4weeks later recurrent rest pain, angiographic complete occlusion of superficial 
femoral and popliteal arteries with reconstitution of anterior tibial artery, pre-op 
Ancrod andti-fibrinogen,  common femoral to anterior tibial artery reverse 
saphenous vein graft placed, post-op warfarin 5mg/d…. 
3weeks later recurrent rest pain, leg critically ischemic, black eschar along calf 
incision, no distal pulses left leg, amputation, pathology: arterial and venous 
thrombosis with no underlying pathology and only minimal atherosclerosis, oral 
warfarin discontinued, 
1992 “3 pulmonary emboli and a myocardial infarction. Great difficulty was 
experienced in controlling the degree of anticoagulation with warfarin; therefore 
treatment with a continuous subcutaneous heparin infusion was initiated. 
April 1995, it was noted that she had developed osteoporosis, which was thought to 
be secondary to her long history of heparin use. A hickman catheter was inserted 
for Ancrod infusion. After insertion of this catheter, she developed thrombosis of 
the superior vena cava. A subcutaneous catheter was inserted for injections of low-
molecular-weight heparin 15,000 U twice daily.” 
November 1996, she suffered a small right hemispheric stroke, all normal lab: 
antithrombinIII, anticardiolipin antibody, lupus anticoagulant, antinuclear antibody, 
rheumatoid factor, antigenic protein C, functional protein C, free protein S, C3, C4, 
…….tHcy 58uM and >80uM, would not consent to further testing, so etiology? 
“Nevertheless, she was subsequently treated with VitB6 (pyridoxine) 100mg/day, 
VitB12 500ug/day, and folate 1mg/day and she continued to receive subcutaneous 
low-molecular-weight heparin 5000U*2/day.  
No further thrombotic events have occurred after 1year of follow-up”  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcy 
58uM & 
>80uM 
Naughten 
ER et al 
(1998); 
Eur J 
Pediatr; 
World 
reviewed 
CBS--
screening 
programs 
& 
epidemiol 
inferences 
world-
wide 
“Abstract Newborn screening for CBS-- (homocystinuria; HCU) was started in the 
late 1960s using a bacterial inhibition assay (BIA).  
At least 7 countries have either national or regional screening programmes;  
12 programmes are known to have discontinued.  
The wrldwide incidence of HCU is approximately 1 in 335,000 but varies from 
1:65,000 (Ireland) to 1:900,000 (Japan).  
Methodologies include the BIA, one-dimensional or thin-layer amino acid 
chromatography and, more recently, tandem mass spectrometry. The BIA 
diagnostic cut off concentration of blood methionine varies from 67 to 270uM (10-
40mg/l) with a median of 135uM (20mg/l). 
In Ireland, 25 cases of HCU from 19 families have been identified from 1.58 
million newborn infants since 1971; 21 cases were detected through the screening 
programme. Of the 4 missed cases, 3 were breast-fed (= lower-methionine diet. 
DV) at the time of blood collection and 1 was pyridoxine responsive.  
These findings are in broad agreement with the results from 5 other programmes, in 
which approximately 1 in every 5 cases was missed by the screening programme. 
Early hospital discharge, low protein intake, high blood methionine cut-off 
concentration and pyridoxine responsiveness were all identified as contributing to 
missed cases.” 
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Yap S, 
Naughten E 
(1998); 
J Inher 
Metab Dis; 
The 
Children’s 
Hospital, 
Dublin 
Ireland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Continues) 
All 25 
CBS--
detected 
in Ireland 
1971-96. 
12 
females, 
19 
families. 
24/25 
VitB6-
non-
responsiv 
“Subjects:  
This is a retrospective study of all 25 cases of HCU detected in Ireland between 1971 
and 1996 either by the national newborn screening programme or by clinical 
presentation. The data were extracted from the clinical notes.  
21 cases were identified by the national screening programme.  
Of the remaining 4 cases missed on screening, 3 were breast-fed and 1 is pyridoxine 
responsive.  
All but one were started on treatment at diagnosis…. 
Of the 4 cases missed on screening, 3 presented with ectopia lentis after the age of 
2years…. 
All 21 cases of HCU detected by newborn screening had high blood methionine 
concentration of more than 100uM, assayed by the bacterial inhibition assay (BIA) on 
the heel prick blood sample taken on day3 to day5 of life. A liquid blood sample, 
separated and deproteinized within 10min of collection, was requested from these 
infants and assayed using an amino acid analyser for methionine, free homocystine and 
cystine. A high blood methionine and free homocystine with a low cystine confirmed 
the diagnosis for those detected on newborn screening and those that presented 
clinically…. 
 
Clinical management and follow-up:  
All patients diagnosed as having HCU had their pyridoxine status (pyridoxine-
responsivity status meant. DV) determined clinically by commencement on oral 
pyridoxine 50mg*3/day as inpatients….Pyridoxine responsiveness was indicated by a 
rapidly falling methionine level and clearing of free homocystine from the plasma, 
while pyridoxine nonresponsiveness was indicated by persistently high or rising plasma 
methionine and free homocystine.  
In pyridoxine-nonresponsive patients, dietary management was commenced by 
restricting dietary methionine and using a methionine-free, cystine-supplemented 
synthetic mixture.  
Methionine was added as a proprietary food preparation or as breast milk and the 
amount was titrated against the plasma methionine and free homocystine concentration.  
Two-thirds of the total protein intake was derived from the synthetic methionine-free, 
cystine-supplemted mixture and the remaining third from the natural methionine-
containing foods (P. Howard, personal communication).  
Plasma VitB12 and folate were assayed and, if they were found deficient, the patient 
was given supplements.  
Once stabilized, blood was drawn, deproteinized, and analysed for methionine, free 
homocystine and cystine at least once a month, or more frequently if clinically 
indicated, to monitor biochemical control.  
During all episodes of acute illness, prompt treatment of the illness with additional 
supportive care, including adequate hydration and aspirin or dipyridamole, was given to 
prevent blood stasis….. 
Upon discharge from hospital, patients initially attended the outpatient department 
fortnightly and thereafter at 4- to 6-weekly intervals. They were reviewed minimally at 
least 4 times per year. At every clinic visit, growth parameters were measured, a 
general physical examination was carried out by a doctor, and blood was drawn, 
deproteinized and analysed for methionine, free homocystine and cystine to monitor 
biochemical control.  
Experienced dieticians… 
Annual detailed ophthalmological examination….. 
Initially, skeletal radiology was performed yearly….. 
Up to 1990, annual clinical cardiovascular assessments…… 
IQ assessments were performed at 2- to 6-yearly intervals.  
Psychological support was provided whenever necessary by the clinical psychologist. 
 
Results: 
“3 patients who were detected by screening developed complications due to non-
compliance with the prescribed diet, as indicated by dietary history and poor 
biochemical control are in Group 2.  
The 4 cases missed on screening presented with complications after 2years and are in 
Group 3.  
1 of the 4 cases missed on screening and never treated was recently referred to our 
clinic aged 21years with recognized complications of untreated HCU. She had bilateral 
ectopia lentis and optic atrophy, mental retardation, osteoporosis, dolichostenomelia 
(arm span 164cm, height 163cm) but no documented evidence of thromboembolic 
events.” (And see also the second of the following tables)                     (Continues) 
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(Continues) 
(Contin)  
 
 
 
Group 1 
n = 18 
 
Group 2 
n = 3 
 
Group 3 
n = 4 or 3 
 
All 25 
CBS--
detected 
in Ireland 
1971-96. 
12 
females, 
19 
families. 
24/25 
VitB6-
non-
responsiv 
(Continued) 
 
Age AgeTx  nPunct   meanMetM meanMetL meanMetH   meantHcyL meantHcyH 
 
14y       19d    58punct    73uM           16uM          348uM         <60uM          178uM 
(2.5-23) (7-42) (19-98)  (47-134)        (1-35)        (76-762)           (?)         (136-302) 
 
17y       21d    82punct    78uM            17uM         452uM           91uM          225uM 
(12-23) (9-42) (63-101)  (70-85)         (4-43)        (161-789)     (<60-154) (211-238) 
 
18y       4y      60punct    60uM            21uM          353uM         <60uM         172uM 
(17-21) (2.4-7) (30-94)  (50-67)          (3-36)         (116-791)         (?)        (157-192) 
 
Where:  
 
Group 1 were detected on screening; on diet; no complications, 
Group 2 were detected on screening; noncompliant (whole life, whole life, last 6.5 
of 23years) to diet; with corresponding complications (osteoporosis + lowIQ, 
ectopia lentis + lowIQ, iridodonesis, respectively) 
Group 3 were missed on screening and presenting subsequently with complications 
(3* ectopia lentis) 
 
Age = age at survey,    AgeTx = age at commencement of treatment,    
 
nPunct = the minimum number of venupunctures experienced consistent with data 
reported over treatment period surveyed (ie the maximum of the number of 
methionine, or Hcy, (which were close to each other though not always equal) 
measures in each individual’s data),      
 
meanMetM = the mean of each Group (1,2,3) of individual patients lifetime 
median plasma methionine, 
meanMetL =  the mean of each Group (1,2,3) of individual patients lifetime range 
Lowest value of plasma methionine  
meanMetH = the mean of each Group (1,2,3) of individual patients lifetime range 
Highest value of plasma methionine    
 
meantHcyL = the mean of each Group (1,2,3) of individual patients lifetime 
median plasma tHcy  
meantHcyH = the mean of each Group (1,2,3) of individual patients lifetime range 
Lowest value of plasma tHcy 
meanHcM = the mean of each Group (1,2,3) of individual patients lifetime range 
Highest value of plasma tHcy 
(Where tHcy was derived using the relationship of fHcy(ine) (data values provided 
by Yap and Naughten here) to tHcy reported by Bonham et al (1997), such that:  
tHcy = 60 + 4.5(fHcy(ine)) for values of  fHcy(ine) < 20uM, and  
tHcy = 60 + 90 + (fHcy(ine) – 20) for values of tHcy(ine) >=21uM 
 
                                                      Detected by Screening        Missed by Screening 
                                Total             Group 1        Group2                   Group 3 
Tot n Detected           25                      18                  3                           4 
 
Ectopia Lentis             6                         0                  2                           4 
Osteoporosis               2                         0                  1                            1 
Mental Handicap        4                         0                  2                            2 
Thromboembolism     0                         0                  0                            0  
 
“Increasing myopia may be the first sign of persistent poor compliance, prior to 
ectopia lentis (Burke et al 1989), as seen in 3 cases in Group 1 with high lifetime 
medians of free homocysteine levels of 18, 18, and 48uM, despite their insistence 
on good dietary compliance.” 
 
“Mudd et al (1985), in a large HCU group, reported that the chance of suffering a 
clinically detected thromboembolic event event for the untreated pyridoxine-
nonresponsive patient is 25% by the age of 16years and 50% by 29years, with the 
maximal likelihood of the event occurring between 12.5 and 17.5y of age 
(Confirmed. DV). None of the patients reported in this study developed detectable 
thromboembolic events.”                  (Continues)            
tHcy 
 
meanHcM 
 
104uM, 
(78-178) 
 
169uM 
(141-188) 
 
 87uM 
(80-98) 
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Yap S, 
Naughten E 
(1998); 
J Inher 
Metab Dis; 
The 
Children’s 
Hospital, 
Dublin 
Ireland 
 
All 25 
CBS--
detected 
in Ireland 
1971-96. 
12 
females, 
19 
families. 
24/25 
VitB6-
non-
responsiv 
Now, given that the CBS-- cases here are very nearly all (24/25) VitB6-
nonresponsive, the comparison with Mudd et al (1985)’s data for untreated 
outcomes is relatively straightforward compared to the analogous comparison of 
Wilcken and Wilcken (1997)’s outcome data with Mudd et al’s data – as the 
average age of Group 1 and Group 3 combined (n = 18 + 4 = 22) is 15years (this 
includes the untreated years of group 3) , at least 5 thromboembolic events would 
have been expected in the absence of treatment, and the difference between 0 and 5 
events is roughly ss at the 95% confidence level.  
 
Now, although it may certainly not be said that the treatment here could have been  
statistically significantly more efficacious than that of the Australian CBS-- cases 
repoted on by Wilcken and Wilcken, there is a substantial suggestion that it may 
have been in regard to thromboembolism,  
on taking into account that there has been far more venupuncture (which has been 
documented as a precipitant of thromboembolism, which theoretical considerations 
strongly support) in the Irish cases of Yap and Naughten (an average of a minimum 
of 58 punctures each) than in the Australian cases of W & W,  
and that the increased sulfate provided by the cystine supplementation plausibly 
increases the sulfation of ie heparin to an extent that increases its ability to prevent 
thrombosis (CITATION). The obvious implication being that increased Hcy is not 
the only metabolite level change that is pathogenic in CBS--. 
Noteworthy also is the apparently scrupulous attention to establishing the low-
methionine, cystine-supplemented dietary treatment at a very early stage of 
infancy, and following through with comprehensive reinforcement, for which the 
practitioners ought be highly commended.  
However, note that even so, some ammount of non-compliance is likely to creep in 
as time passes, and that in this regard, it is likely that the cystine supplementation 
would suffer less non-compliance than the low-methionine diet.  
Overall, there is a fairly strong suggestion, that all CBS--treatment regimes should 
include cystine supplementation – which many apparently do not.  
Note that CBS-- cohorts have not yet been followed into old age, where factor 
suboptimality is manifest in increasingly worse outcomes, in general. 
 
Ps (the absence of the plasma cystine/cysteine values from the data of Y & N???)      
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Walter JH 
et al (1998); 
Eur J 
Pediatr; 
Royal 
Manchester 
Children’s 
Hospital, 
Manchester, 
UK. 
All 31 
CBS--
diagnosed
/managed 
since 
1962  
Since 1962 we have been responsible for the diagnosis and/or the management of 31 
patients with CBS--, 23 of whom have been non responsive to pyridoxine.  
12 patients, all of whom are non responsive, were diagnosed after an initial finding of 
raised methionine on our newborn screening programme (started in 1969). The eldest 
patient from this group is now 25y of age.  
All other patients (10 non responsive, 8 responsive presented with typical clinical 
features of homocystinuria.  
 
Patients non responsive to pyridoxine have been assessed 3-monthly and those with 
pyridoxine responsive disease yearly. On each occasion blood has been collected, 
deproteinised and assayed with an amino acid analyser. The concentration of 
homocystine measured in this way represented plasma free homocyst(e)ine…. 
 
In our patients only 8 of 31 were pyridoxine responsive, presumably due to a different 
genetic population and also to to ascertainment bias as a consequence of our newborn 
screening.  
Following a diagnosis of CBS--, patients should be treated with VitB6 at a dose of at 
least 500mg/day for a period of several weeks to determine their response.  
Folic acid requirements are probably higher in CBS-- as a consequence of increased 
flux through the remethylation pathway, and lack of folate may lead to a suboptimal 
response to treatment with pyridoxine (cites Wilcken and Turner 1973). Patients should 
therefore be treated with folic acid (5mg/day) in addition to pyridoxine.  
Although large doses of pyridoxine may be associated with the development of 
peripheral neuropathy this has not been a complication in our patients (cites Mpofu et al 
1991)……. 
 
Because raised methionine is not prominent in newborn infants with pyridoxine 
responsive disease this type of homocystinuria is rarely diagnosed by newborn 
screening. The diagnosis is consequently made only after the development of 
complications which are largely irreversible.  
In our experience, however, the skeletal, neurological and vascular problems associated 
with homocystinuria have not progressed following treatment with pyridoxine.  
The median IQ for our patients with pyridoxine responsive disease was 82 with a range 
of 57-101. There was no fall in IQ after treatment had been started.  
Eye disease, however, if advanced, may lead to glaucoma and further damage…….. 
 
Dietary restriction of methionine, by limiting natural protein intake, necessitates the use 
of an amino acid supplement, to provide other essential amino acids, vitamins minerals 
and trace elements and special low protein foods to provide sufficient caloric intake 
(This might not be correct – limitation of protein to the physiological minimum on the 
bases of the essential amino acids other than methionine, in the context of choosing 
those food protein sources that are relatively lower in methionine, might not require the 
use of any supplemental amino acids other than cysteine (However the use 
supplemental cysteine can be applied to reduce the amount of methionine, which is 
largely thereby substitutable, required in the diet, ie reduction of the methione intake to 
a level so low that other essential amino acids then require supplementation…CHECK 
THIS against the earlier good works examining this, and food tables). Furthermore, 
there is nothing “special” about fruit, or vegetable oils, which in general can meet 
caloric requirements with little addition to the protein (and somewhat particularly 
methionine) intake. DV).  
 
Cysteine becomes an essential amino acid in CBS-- and needs to be provided in an 
amino acid supplement.  
The practicalities of the diet are similar to phenylketonuria. We use a protein exchange 
system in both conditions but in CBS-- one exchange contains approximately 20mg 
methionine, rather than 50mg of phenylalanine.  
The daily amount of methionine tolerated in order to achieve good control (plasma free 
homocyst(e)ine < 10uM) varies somewhat between patients but is relatively constant 
throughout life. In the 23 patients treated in our clinic methionine has been restricted to 
a median value of 230mg/day with a range of 160-900mg.  
Many children, particularly adolescents and those diagnosed after infancy, find the low 
methionine diet difficult. Problems with compliance are common, and an increase in 
natural protein intake is rapidly followed by a rise in plasma homocyst(e)ine levels.  
Reduced intake of the amino acid supplement may also be associated with raised 
homocyst(e)ine levels and poor growth due to protein catabolism…… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equates to 
tHcy 
<50uM 
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(Continues) 
(contin) 
All 31 
CBS--
diagnosed
/managed 
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1962 
(Continued) 
We have used betaine in 13 of our patients with non pyridoxine responsive CBS--
(250mg/day two to three divided doses). In the majority of patients methionine 
levels increased significantly (before treatment: mean plasma methionine 83 uM, 
after treatment: mean 295uM, P = .004) although, as a group, biochemical control, 
as assessed by a fall in plasma free homocyst(e)ine, was not improved (before 
treatment: mean plasma free homocyst(e)ine 35uM, after treatment: mean 33uM, P 
= 0.89).  
Compliance with betaine in many cases was poor, and this probably explains the 
lack of efficacy (Their reasoning here seems dubious – it might be at least as likely 
that compliance with the low-methionine diet decreased, in response to a 
perception that with the additional treatment, less stringent adherence to the diet 
would be necessary….assuming the amino acid supplement was easy enough to 
comply with?......DV)….. 
 
None of our 11 patients diagnosed on newborn screening developed physical 
stigmata of homocustinuria during childhood.  
The median IQ for this group of patients was 100 with a range of 84-117.  
This is significantly better than that found in patients diagnosed after infancy 
(pyridoxine non responsive patients diagnosed after infancy: median IQ 58, range 
20-86, P<.0001;  
pyridoxine responsive patients diagnosed after infancy: median IQ 82, range 57-
101, P = .02).  
During adolescence control in some individuals deteriorated. One patient suffered 
from fainting episodes, numbness and weakness of the left arm and leg from the 
age of 17, although a brain scan and angiography were reported as normal. Despite 
these symptoms she failed to comply with diet or take regular pyridoxine. At 21y 
of age she was found on ophthalmological review to have developed iridodonesis 
and phacodonesis, with backward displacement of both crystalline lenses leading to 
a progressive myopia. Another patient whose control had deteriorated had a 
respiratory arrest and died at the age of 19y following a short history of headache 
and increasing confusion. At post mortem he was found to have an extensive 
thrombosis of the superior sagittal sinus and transverse and lateral sinus. There 
was, however, no evidence of atheroma in the cerebral arteries. 
 
The outcome for patients with pyridoxine non responsive disease diagnosed after 
infancy was poor with a median IQ of 58, range 20-86.  
Two siblings diagnosed shortly after the original description of homocystinuria at 
the ages of 7 and 13y were unable to comply with treatment and died in childhood 
from pulmonary embolism and thrombosis…. 
 
The clinical manifestations of the disease can be avoided with appropriate therapy 
but only in those children treated from soon after birth. Unfortunately patients with 
pyridoxine responsive disease rarely have a sufficiently raised methionine in the 
first weeks of life to be detected on current screening programmes. As a 
consequence treatment is most often started in patients with pyridoxine responsive 
disease only after the development of irreversible damage.  
Although pyridoxine, with the addition of folic acid, prevents further deterioration 
in patients with pyridoxine responsive CBS--, a better outcome for such patients 
will only be achieved if they are identified earlier in life.  
More sensitive newborn screening methods will need to be developed that are able 
to detect pyridoxine responsive disease.  
In non responsive patients a low methionine diet with amino acid, mineral and 
vitamin supplements can be highly successful treatment.  
However, homocyst(e)ine levels must be kept throughout life, as a loss of good 
biochemical control at any age is associated with the development of serious 
complications which may be life-threatening.” 
 
Note: It may well be that if response to VitB6 alone is not sufficient to decrease 
Hcy levels to very near normal, and if VitB6 is not used alone in any case, that it 
may be desirable to incorporate cystiene supplementation in treatment (in order to 
ensure more optimal amounts of each of  cysteine and sulfate to be available for 
their respective biological roles), due to decreased production through the CBS 
pathway. This desirability of cysteine supplementation may also apply in the case 
of suboptimal compliance even when VitB6 alone is sufficient to decrease Hcy 
levels to very near normal, and VitB6 is used alone.                  (Continues)   
 
 
 
 
 
 
Equates to 
tHcy 
>75uM, 
>73uM 
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(contin) 
All 31 
CBS--
diagnosed
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1962 
 
 
Group 1 
n = 11 
 
Group 2 
n = 2 
 
Group 3 
n = 10 
 
Group 4 
n = 8 
 
 
All 31 
CBS--
diagnosed
/managed 
since 
1962 
(Continued) 
 
Note: The Groups in the table above have been ordered and numbered so as to 
correspond (1, 2, 3) with those of Yap and Naughten (1998) of the study 
immediately above, and so facilitate comparison.  
 
 
Age    AgeTx    nPunct    Myop  EctLent  Irid     DevD Ep  Marf/Arach/Scol   CVA  
 
15y      <1m         60            0           0         0            0     0              0                     0 
(2-25) 
 
20y      <1m     <?80            1           1         1            0     0              0                 1or2? 
(19-22)                                                                                                    (>=1 thromb) 
 
25y      10y           60           4            7      >7             8     3             4                     2 
(12-39) (3-32)                                                                                             (2 thromb) 
 
37y      16y            21           4            6        7            2     1             3                     1 
(27-48) (9-29)                                                                                             (? thromb) 
 
Where:  
 
Group 1 VitB6-nonresponsives detected on newborn screening; on diet with 
cysteine etc suppl; no complications, 
Group 2 VitB6-nonresponsives detected on newborn screening; noncompliant 
(beginning from adolescence in both) to diet with cysteine etc suppl; with 
corresponding complications (as tabled) 
Group 3 VitB6-nonresponsives missed on newborn screening and presenting 
subsequently (treatment as noted) with complications (as tabled) 
Group 4 VitB6-responsives missed on newborn screening and presenting 
subsequently (treatment VitB6 + Folate) with complications (as tabled)  
 
Age = age at survey,    AgeTx = age at commencement of treatment, 
nPunct = the approximate number of venupunctures derived from the description of 
the monitoring schedule  
Myop = Myopia,     EctLent = Ectopia Lentis,       Irid = Iridodonesis      
DevD = Developmental Delay,    Ep = Epilepsy or Salaam (infantile) spasms      
Marf/Arach/Scol = Marfan Syndrome/ Arachnodactyly/ Scoliosis      
CVA = CardioVascularAccident    
 
Now, Mudd et al (1985), reported that the chance of suffering a clinically detected 
thromboembolic event event for the untreated pyridoxine-nonresponsive patient is 
25% by the age of 16years and 50% by 29years, with the maximal likelihood of the 
event occurring between 12.5 and 17.5y of age. (See Mudd et al (1985) ( ) above, 
and in print, for greater detail.) 
So, on that basis, Group 1 if untreated would have been expected to have suffered 
approx 2 thromboembolic events, but suffered 0 events, which would be a nss 
(potentially due to insufficient n) difference. 
Likewise, Group 2 would have been expected to have suffered <1 thromboembolic 
event during the treated period (assume up to adolescence at 13years), and suffered 
0 events. And, during the untreated period would have been expected to suffer <1 
thromboembolic event but suffered >=1 event. Differences would be nss on the 
basis of insufficient n alone. 
Likewise, Group 3 would have been expected to have suffered approx 2  
thromboembolic events during the untreated (assuming perfect compliance for the 
8 non-fatal cases) period of their lives, and experienced 2 (fatal) events. And,  
during the treated period (n =8) (following diagnosis), if untreated would have 
been expected to have had approx 2 thromboembolic events, but had 0 events. 
Differences would be nss on the basis of insufficient n alone. 
Likewise, Group 4 would have been expected to have suffered approx 1  
thromboembolic event during the untreated  period of their lives, and experienced 
?(<=1) event. And,  during the treated period (following diagnosis), if untreated 
would have been expected to have had approx 3 thromboembolic events, but had 
?(<=1) events. There was only 1 CVA noted and the report did not allow this to be 
allocated to either pre- or post-diagnosis/treatment periods, hence the “?”. 
Differences would be nss on the basis of insufficient n alone.  
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(contin) 
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(Continued) 
Now, here, as in Mudd et al (1985) the oldest cases are milder cases by survival, but 
their oldest cases here will be milder cases than Mudd et al’s due to (hopefully…) 
improved diagnosis.  
Therefore the real relative risk is likely to be (trivialy?) slightly(?) higher (less 
treatment efficacy) than implied here, increasing the noted probability that unity would 
be included in any CI for any comparisons of Groups 1, 3 or 4 with Mudd et al’s 
outcomes report, though as noted given the lowish n, the suggestion of efficacy is 
certainly strong enough to warrant continuing with the treatment, while considering 
possible improvements (ie earlier detection, , VitC, VitE, and better dietary and 
cysteine supplementation achievements?....)           
 
Now, although it may certainly not be said that the treatment here could have been  
statistically significantly more efficacious than that of the Australian CBS-- cases 
repoted on by Wilcken and Wilcken, there is a substantial suggestion that it may have 
been in regard to thromboembolism, particularly in the case of the VitB6-
nonresponsive cases.  
On taking into account that there has been far more venupuncture (which has been 
documented as a precipitant of thromboembolism, which theoretical considerations 
strongly support) in the English cases of  Walter et al (an average of a >60 punctures 
each) than in the Australian cases of Wilcken & Wilcken (1997) ( ) above,   
and that the increased sulfate provided by the cystine supplementation plausibly 
increases the sulfation of ie heparin to an extent that increases its ability to prevent 
thrombosis (CITATION). The obvious implication being that increased Hcy is not the 
only metabolite level change that is pathogenic in CBS--. 
Noteworthy here, similarly to as in Yap and Naughten (1998) ( ) above, is the (though 
somewhat less scrupulous?) attention to establishing the low-methionine, cystine-
supplemented dietary treatment at a very early stage of infancy, and following through 
with reinforcement. 
However, some ammount of non-compliance is likely to creep in as time passes, and 
that in this regard, it is likely that the cystine supplementation would suffer less non-
compliance than the low-methionine diet.  
Overall, there is a fairly strong suggestion, that all CBS--treatment regimes should 
include cystine supplementation – which many apparently do not.  
Note that CBS-- cohorts have not yet been followed into old age, where factor 
suboptimality is manifest in increasingly worse outcomes, in general. 
 
Kluijtmans 
LAJ et al 
(1998); 
Blood; 
U Hospital 
Nijmegen, 
Nijmegen, 
The 
Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Continues) 
24 CBS--
Dutch 
cases, 
23/24 
VitB6-
responsiv, 
Possibly 
not all of 
Dutch 
CBS--
cases 
known at 
the time. 
“Patients.  
24 patients, 14 men and 10 women from 18 unrelated kindereds, with homocystinuria 
caused by CBS-- were studied for FVL and the MTHFR 677C>T polymorphism.  
23 patients were pyridoxine-responsive.  
The diagnosis of homocystinuria caused by CBS-- in patients was made at a mean age 
of 24.7years (4-54),  
by establishing sever hyperhomocysteinemia and homocystinuria, hypermethioninemia, 
and decreased level of cysteine in plasma.  
Furthermore, CBS activities measured in extracts of cultured fibroblasts were less than 
2% of the mean in controls, except in 1 patients, in whom we observed CBS activites in 
the heterozogous range. However in this patient we were able to show a defective CBS 
regulation by S-adenosylmethionine (AdoMet) leading to severe 
hyperhomocysteinemia.  
Up to now, in 18 of 24 patients homozygous CBS deficiency was confirmed by 
molecular genetic analysis of the CBS cDNA…. 
Deep venous thrombosis was diagnosed by means of flebography and pulmonary 
embolism by perfusion-ventilation scintigraphy….. 
 
Results. 
Of 24 CBS-- patients, 3 individuals, all belonging to the same kindred, were carriers of 
FVL; no homozygotes for FVL were observed.  
In the study group, 6 individuals, mean age 23years (9-40y) suffered from a thrombotic 
complication; 4 patients had deep venous thrombosis and 2 patients had pulmonary 
embolism…. 
Venous thrombosis occurred in these 6 patients before the start of homocysteine 
lowering treatment,  
which had been prescribed immediately after the diagnosis of homocystinuria had been 
established.  
All 6 patients with thrombosis proved to be VitB6-reponders.”  
(Continues) 
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Nijmegen, 
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(Contin) 
24 CBS--
Dutch 
cases, 
23/24 
VitB6-
responsiv, 
Possibly 
not all of 
Dutch 
CBS--
cases 
known at 
the time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n = 5 
 
n = 16 
 
 
(Continued) 
Note: Using the data from Mudd et al (1985), there would have been 
expected to have been approx 10 thromboembolic events in the 
period preceeding diagnosis, and in fact there were only 6 such, 
which raises the question of whether these Dutch VitB6-responsive 
mutations might be less severe than those of Mudd et al, or 
alternatively whether some other Dutch factor (environment/genetic) 
is more protective than that of Mudd et al, but the difference would 
probably not be ss on the basis of low n alone, but might go 
close……  
Unfortunately the (then) present age of the group was not provided, 
so the analogous comparison for the treated period is not possible. 
(See Kluijtmans et al (1999) regarding this)  
 
Results. 
 
There was 1 venous thrombotic event amongst the 3 FVL 
heterozygotes. 
There were 5 venous thrombotic events amongst the 21 FVL wild-
type homozygotes. 
So, some difference (33% vs 24%) but certainly not ss on the basis of 
low n alone. 
 
There was 3 venous thrombotic events amongst the 5 C677T TT 
homozygotes. 
There was 1 venous thrombotic event amongst the 11 C677T CT 
heterozygotes. 
There were 2 venous thrombotic events amongst the 8 C677T CC 
wild-types. 
So, some difference (60% vs 9% vs 25%) (or 60% vs CT + CC 16%) 
but would certainly not be ss for the trichotomous comparison 
trendwise, while possibly would be ss for the dichotomous 
comparison (oddly enough, neither of these were tested for ss, while 
tests for the difference in genotypes of CBS—vs the Dutch general 
population were….?.....) 
 
“The total amount of nonprotein-bound homocysteine was calculated 
as twice the concentration of homocystine plus the concentration of 
the Hcy-Cys mixed disulfide” 
 
C677T                                                      Methionine              fHcy 
 
TT                                                                75uM                   155uM 
 
CT + CC                                                     117uM                   128uM 
 
                                                                    P = 0.4                   P = 0.6 
 
In lieu of treatment details not provided by the authors here, I 
provide the following from their (1999) ( ) work summarised further 
below: 
“Pyridoxine responsiveness was examined after 6 weeks of treatment 
with VitB6 750mg/day in adults or 200-500mg/day in children. 
Patients in whom non-protein-bound serum Hcy had decreased to 
<20uM, or tHcy to <50uM, were classified as pyridoxine responsive. 
All other patients were categorized as pyridoxine-nonresponsive 
homocystinurics……Long-term Hcy-lowering therapy (mean term, 
13years (1-29y) consisted of maximally 75mg pyridoxine. 15 (56%) 
patients were concomitantly treated with 5mg/day folic acid, and 8 
(30%) patients also with betaine 6mg/day. Only 1 patient had a 
methionine-restricted diet, with a methionine content of 600 mg/day. 
Intramuscular injections with 1mg hydroxycobalamin every 1-
2months were given to 4 patients, because of development of a 
VitB12 deficiency.”  (Note: This info for a group of 29 CBS--, which 
very likely included the very large majority of the 24 comprising 
their study summarised here)                                       . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcy 
 
>195uM 
 
>168uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VitB6 
<=75mg/d 
+/- Folate 
5mg/day 
+/- Betaine 
6mg/day 
+/- VitB12 
1mg/1-
2months, 
And, 1 
patient on 
low-Met diet. 
(see column 2 
to left for 
further n 
details. 
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(Continues) 
14 (10 
CBS--, + 
4 ???- -) 
 
15 Their 
controls 
 
 
15 CBS-+ 
obligate 
heterozyg 
parents 
 
15 Their 
controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 (10 
CBS--, + 
4 ???- -) 
 
15 Their 
controls 
 
 
15 CBS-+ 
obligate 
heterozyg 
parents 
 
15 Their 
controls 
“14 subjects with homozygous homocystinuria (10 CBS-- and 4 
defects of remethylation), including 2 pairs of siblings (I think a 
comma should be here. DV) aged 3-34years (mean 13years) and 15 
of their heterozygous parents coming from 8 families and aged 32-
47y (mean 41y) underwent ultrasonographic investigation of the 
carotid artery between 1996 and 1997. They were compared with 2 
control groups of healthy subjects of similar ages studied with the 
same technique of carotid investigation during the same 
period…..The age at diagnosis of homozygous subjects ranged from 
0-22years (mean 5years).” 
 
“At the time of investigation, 12 homozygous subjects were 
consuming a low methionine diet, 3 were taking pyridoxine (of 
whom 2 were pyridoxine sensitive), 6 were taking folic acid 
supplements, 3 were taking cobalamin, and 11 were prescribed 
betaine. 3 homozygous subjects had a previous (Assume pre-
diagnosis?..DV) history of cardiovascular disease, including 1 
cerebral trunk thrombosis, 1 stroke with iliac artery stenosis, and 1 
cerebral arterial spasm with iliac artery thrombosis.  
(Note: Assuming the 8 CBS-- had a mean age of diagnosis of 5y, 
then according to the data of Mudd et al (1985) 0.3 thromboembolic 
events would have been expected to have occurred prior to 
diagnosis/treatment – the shortcomings of attempting any such 
comparisons given the data incompleteness is fairly obvious. DV). 
No homozygous subject had any ultrasonic evidence of arterial 
narrowing  or plaque in the carotid arteries. Heterozygous subjects 
had no present or past history or sign of cardiovascular disease and 
did not take any cardiovascular drug treatment, but 1 subject had 
ultrasonic evidence of plaque in the left carotid artery bifurcation.” 
 
“Arterial Investigations. 
A high-resolution ATL Ultramark 9 B-mode ultrasound system was 
used to measure IMT in the far wall of the right common carotid 
artery….Simultaneously, the lumen diameter was imaged between 
the far-wall and near-wall lumen-intima interfaces (leading edges), 
frozen in telediastole, and transferred to the computer for automated 
measurement with the edge-detection program. The cross-sectional 
area of the intima-media complex (CSA-IMC) was calculated from 
IMT and lumen diameter as pye*IMT*(IMT+D).” 
 
Age    Smoking  HT  Diab  HypChol         IMT     Diam     CSA-IMC 
 
13y     1.4py       0       0         2               0.50mm  5.00mm   8.69mm2 
 
 
 
                                                                0.44mm  5.31mm   7.81mm2 
                                                                P<.001    P<.05       P<.05 
 
 
41y    7.5py       3       0          4               0.50mm  5.57mm   9.57mm2 
P<.001 P<.05   nss   nss      nss 
 
 
 
                                                                 0.48mm  5.93mm  9.65mm2  
                                                                 nss         nss           nss 
 
Where: py = pack years, HT = HyperTension, Diab = Diabetes, 
IMT = Intima-Media Thickness, Diam = diameter,   
CSA-IMC = the Cross-Sectional Area of the Intima-Media Complex, 
The latter three measures being those adjusted for body surface area, 
chosen as the most meaningful, and not in much disagreements with 
the other versions provided.                         (Continues)          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcy 
 
91uM 
(9-179) 
 
 
 
 
 
 
15uM  
(4-56) 
P<.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Varied, 
see 
column 
two to 
right 
above - 
note at 
least 2 of 
the 
remethyla
tion 
defects 
must have 
been on a 
low-Met 
diet….. 
inappropr 
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14 (10 
CBS--, + 
4 ???- -) 
 
15 Their 
controls 
 
 
15 CBS-+ 
obligate 
heterozyg 
parents 
 
15 Their 
controls 
(Continues) 
Unfortunately, it is not possible from the data/figures provided to 
determine whether the Diam and CSA-IMC measures of the four 
remethylation defects are likely to differ from those of their controls, 
while it is possible to say that the average of their IMT must have 
been higher than all but 1 of their controls, and this might  have been 
ss. 
In two multiple regression models with Age being the only other ss 
(P = .04, .02 respectively) IV in the model(s), body surface area and 
height (respectively) being nss, tHcy was ss (P = .008, .008 
respectively), and R2 was 0.25, 0.27 (respectively), in predicting 
IMT. Something similar applied for predicting CSA-IMC, though the 
lower ss do not seem to be in accord with the higher R2 values?.... 
tHcy was not similarly a ss (was vnss) predictor of Diam. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De Stefano 
V et al 
(1998) ; 
Ann Hum 
Genet; 
11 
European 
Countries 
785 
individ’s 
particip’g 
in the 
European 
Athero-
sclerosis 
Research 
Study II 
(EARSII), 
from 11 
countries 
across 
Europe 
“Summary. 
We have examined 4 apparently non-functiional polymorphisms in 
the CBS gene and have determined their frequency, degree of linkage 
disequilibrium and association with plasma Hcy levels. 
The polymorphisms are a 68bp insertion in exon 8, C699T in exon 8, 
C1080T in exon 11 and C1985T in the 3’ untranslated region. 
785 individuals participating in the European Atherosclerosis 
Research Study II (EARSII), from 11 countries across Europe were 
genotyped for these polymorphisms. 
The 68bp insertion ahd the highest frequency in the UK and in the 
middle region, with a lower frequency in the Baltic and the South (P 
= .01), and the exon 11 polymorphism had the highest frequencies of 
the rare allele in the Baltic (P<.05). 
There was a high degree of linkage disequilibrium between the 
polymorphisms (P<.001 overall), except between C699T and the 
C1985T, with 3 common haplotypes accounting for nearly 80% of 
the chromosomes. 
Examination of the association between these polymorphisms and 
plasma Hcy levels revealed that the carriers of the rare alleles of the 
C699T, C1080T and C1985T polymorphisms had lower plasma Hcy 
concentrations than those homozygous for the common alleles, 
although these differences were not ss. 
The thermolabile valine variant caused by a substitution of a C for a 
T at nucleotide 677 in the methylenetetrahydrofolate reductase 
(MTHFR) has previously been shown to have profound effects on 
plasma levels of Hcy in this sample, but the Hcy-raising effect 
associated with this thermolabile variant was not seen incarriers of 
the 68bp insertion, with this interaction being ss (P<.001). 
These data demonstrate that variation in the CBS gene as detected 
with these 4 polymorphisms, had no ss effect on plasma Hcy levels 
in these healthy young men. 
However, the presence of the 68bp insertion, 
which is found in approximately 7.5% of individuals in the 
population of Europe sampled, 
abolishes the raising effect of thermolabile MTHFR Val/Val 
genotype….” 
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(Continued 
29(27) 
CBS--, 
Dutch, 
Very 
roughly 
an even 
mixture of 
VitB6-
responsiv 
and non-
responsiv, 
no 
newborn 
screening 
done 
“Patients. 
We studied 29 patients with homocystinuria due to CBS--, from 21 
unrelated pedigrees. Patients were initially diagnosed on the basis of 
clinical manifestations of CBS--, in combination with a quantitative 
determination of severe hypermethioninemia. In 2 patients (19, 29), the 
diagnosis was made only on the basis of severe homocystinuria, which 
was demonstrated by qualitative urine analyses. Homozygous CBS-- in 
these 2 patients has been confirmed by detection of a homozygous 
mutation (patient 19) and by the clinical manifestation  of ectopia lentis 
(patient 29), never observed in CBS-+…. 
 
Pyridoxine Responsiveness. 
Pyridoxine responsiveness was examined after 6 weeks of treatment with 
VitB6 750mg/day in adults or 200-500mg/day in children. Patients in 
whom non-protein-bound serum Hcy had decreased to <20uM, or tHcy to 
<50uM, were classified as pyridoxine responsive. All other patients were 
categorized as pyridoxine-nonresponsive homocystinurics…… 
14 (48%) of 29 patients were classified as pyridoxine responsive and 9 
(31%) patients as pyridoxine nonresponsive….. 
In 6 patients (12, 13, 16, 21, 28, and 29), responsiveness to pyridoxine 
alone could not be assessed. In view of their extremely high homocysteine 
levels at diagnosis, these patients were treated directly with a combination 
of therapeutic regimens (pyridoxine and folic acid, with or without 
betaine). 
Pyridoxine responders were diagnosed at a mean age of  29years (median 
26y, range 7-45y), and nonresponders at a mean age of 19years (median 
16y, range 4-30y); P = .08. 
7 (58%) of 12 homozygotes for the I278T mutation showed in vivo 
pyridoxine responsiveness, 3 (25%) were nonresponders, and, in 2 (17%) 
patients, this specific responsiveness could not be assessed. In 17 
individuals with other genotype combinations, including compound 
heterozygotes for I278T, these numbers were 7 (41%), 6 (35%), and 4 
(24%), respectively. 
Conversely, in 14 pyridoxine-responsive patients 18 (64%) of 28 alleles 
carried the I278T mutation (7 homozygotes, 4 heterozygotes), versus 6 
(33%) I278T alleles in 9 nonresponsive patients (3 homozygotes). 
There was an absolute concordance of pyridoxine responsiveness between 
siblings. 
 
Response to Homocysteine-Lowering Treatment. 
Long-term Hcy-lowering therapy (mean term, 13years (1-29y) consisted 
of maximally 75mg pyridoxine. 
15 (56%) patients were concomitantly treated with 5mg/day folic acid, 
and 
8 (30%) patients also with betaine 6mg/day. 
Only 1 patient had a methionine-restricted diet, with a methionine content 
of 600 mg/day. 
Intramuscular injections with 1mg hydroxycobalamin every 1-2months 
were given to 4 patients, because of development of a VitB12 deficiency. 
2 patients could not be followed after diagnosis had been made: patient 6 
refused treatment and patient 13 moved to another country. Hence follow-
up was recorded in 27 (93%) of the patients with homocystinuria. 
The mean length of follow-up was 11y (range 1-20y, n = 11) in 
homozygotes for the I278T mutation and 16years (range 3-27y, n = 16) in 
patients with other genotypes. 
Biochemically, pyridoxine treatment resulted in a marked decrease in Hcy 
concentrations of 90% in homozygotes for the I278T mutation and of 67% 
in patients with other genotypes (P<.02). 
Extended intervention with folic acid, with or without betaine, further 
decreased Hcy concentrations in both genotype groups by 84% and 47% 
respectively (P<.05). 
Hcy concentrations normalized (ie fHcy<20uM or tHcy<50uM) in 21 
(78%) of 27 patients. …….” 
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Disease Hcy level Treatmnt and 
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(Continues)
Kluitjmans 
LAJ et al 
(1999); 
Am J Hum 
Genet; 
U Hospital 
Nijmegen, 
Nijmegen, 
The 
Netherlands 
 
(Contin) 
29(27) 
CBS--, 
Dutch, 
Very 
roughly 
an even 
mixture of 
VitB6-
responsiv 
and non-
responsiv, 
no 
newborn 
screening 
done 
(Continues) 
fHcy 
 
11 I278T homozygotes                                                         13uM 
 
16 other genotypes                                                                23uM 
 
P = 0.3 
 
“On the basis of genotype classification, 121 patient-years of treatment were 
recorded in 11 homozygotes for the I278T mutation, during which, in 1 
patient (7)(VitB6-responsive. DV), peripheral arteriosclerosis, already 
present at diagnosis, proceeded to development of an abdominal aortic 
aneurysm that required vascular surgery. 
During 257 patient years of treatment in patients with another genotype, 1 
patient (25)(VitB6-responsive) who suffered from a cerebrovascular event 
before diagnosis died, at age 42y, of a myocardial infarction. 
In summary, in 378 patient-years of Hcy-lowering treatment, only 2 vascular 
events were recorded. 
From the data of Mudd et al (1985), an expected number of primary vascular 
events of 2 per 25years can be calculated for untreated patients. 
Without treatment in our group fo 27 homocystimurics, at least 30 vascualr 
events would have been expected (P<.01). 
During long-term follow-up, no first involvement of any involved organ 
system was noticed. 
Furthermore, no deterioration fo clinical symptoms was recorded, except for 
recurrent depressive episodes in 2 patients (2, 15).” 
 
Now, as the data provided does not enable the outcomes in terms of 
thromboembolic events to be related to patient-years of treatment with 
regard to VitB6-responsiveness, the only appropriate comparison with 
regard to Mudd et al’s (1985) data would be that of the combined whole-
group here with that of Mudd et al. 
So Roughly averaging the age at diagnosis for the whole group is by 
[14*29years + 9*19years]/(14 + 9 = 23) = 25years, 
this being for the 14 known VitB6-responsives with the 9 known VitB6-
nonresponsives, and assuming representativity for the other 6 with 
undetermined VitB6-responsiveness. 
And, 378 patient-years of treatment for the whole group of 27 cases, so the 
average age ‘now’ is by 25years + 378py/27p = 39years. 
Now, referring these ages to Mudd et al’s (1985) Time-to-event graph for 
first thromboembolic event, the proper method is to subtract the probability 
of having had a thromboembolic event by age 39y (P = 0.59) from that by 
age 25y (P = 0.43), that is P = 0.19, then to multiply this by the number of 
patients, 27, such that 
0.19*27 = 4.3 (4 and 3tenths) thromboembolic events would have been 
expected had the group been untreated, during the period of treatment. 
This is obviously in great disagreement with their claim here of 30 
thromboembolic events being expected given no treatment, and far from ss 
being P<.01 as claimed, in fact the difference would be nss. 
Furthermore, as analogously noted in my analysis of their earlier (1998) 
work, using the data from Mudd et al (1985), there would have been 
expected to have been approx 0.43*27 = 11.6 first thromboembolic events in 
the period preceeding diagnosis, and in fact there were only 8 such, which 
raises the question of whether these Dutch CBS-- might be less severe than 
those of Mudd et al, or alternatively whether some other Dutch factor 
(environment/genetic) is more protective than that of Mudd et al, but the 
difference would probably not be ss, on the basis of low n alone – in any 
case the ramification for adjustment of their  thromboembolic ss to less ss. 
 
Of the 8 cases presenting with a thromboembolic event, only 2 (25%) also 
had arteriosclerosis on presentation, and there were 7 (24%) presentations 
with arteriosclerosis out of the 29 in the whole group. 
 
tHcy 
 
30uM 
 
67uM 
 
P<.01 
 
See column 2 to 
left, above 
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Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
Peter-
schmitt MJ 
et al (1999); 
NEJM; 
New 
England 
Newborn 
Screening 
Program, 
Boston, 
USA 
USA 
newborn 
screening 
“For the first 23.5years of the review period, the blood methionine 
cutoff value was 2mg/dl (134uM). Among the 2.2million infants 
screened during that period, 8 with homocystinuria were identified 
(1:275,000). 
In 1990, the cutoff value was reduced to 1mg/dl (67uM). Among the 
1.1million infants screened in the subsequent 8.5years, 7 with the 
disorder were identified (1:157,000). 
During the latter period, the specimens were collected from 6 of the 7 
infants when they were 2days of age or less; 5 of the 6 had blood 
methionine concentrations below 2mg/dl. 
Use of the reduced cutoff level increased the false positive rate from 
.006%  (16.5: 275,000) (1:16,700) to .03%. (47.1:157,000) 
(1:3,330).” 
  
Yap S et al 
(1999); 
Thromb 
Haemost; 
The 
Children’s 
Hospital, 
Dublin, 
Ireland 
(Assume 
from their 
1998 
work see 
above) All 
26 CBS--
detected 
in Ireland 
1971-
97/98?. 
12 
females, 
19 
families. 
25/26 
VitB6-
non-
responsiv 
“Activated Protein C resistance is currently the most common 
hereditary cause of thrombophilia, accounting for 21% of deep vein 
thrombosis in individuals under 70years of age and for up to 50% of 
familial venous thrombosis (cites Rees et al 1995). 
A missense mutation in coagulation factor V (Factor V Leiden, FVL) 
accounts for 95% of cases with activated Protein C resistance (cites 
Bertina et al 1994 and Dahlback 1995). This single point mutation in 
the gene coding for  Factor V (G1691A) predicts the synthesis of the 
FVL molecule, where glutamine has been substituted for arginine at 
position 506 (Arg506Gln). This renders the molecule resistant to 
inactivation by activated Protein C which results in a 
hypercoagulable state conferring a lifelong increased risk of 
thrombosis. 
The allelic frequency of FVL in Europe is about 4.4% with the 
highest frequency found in Greeks at 7%. 
The estimated risk of thrombosis in conjunction with FVL is 5-10 
fold in heterozygotes and 50-100 fold in homozygotes.” 
 
“…26 individuals with homocystinuria (median age 17.6years, range 
3.5-32.8years) and 36 obligate heterozygotes (median age 51.5years, 
range 34-74years) were screened for FVL. All the homocystinuric 
individuals received treatment, except one, within 6weeks of birth for 
those who were diagnosed at birth through the national newborn 
screening programme (n = 20) and at the time of diagnosis in those 
late detected (n = 5, mean age of atarting treatment 4.9years, range 
1.4-11years). 
All had been free from venous thrombosis, except one CBS-- and one 
CBS-+. Neither of the 2 individuals with venous thrombosis carried 
FVL. 
2 independent CBS-- (ages 15, 18y) were heterozygous for FVL 
(allelic frequency 3.8%) and 3 independent CBS-+ (ages 40, 46, 46y) 
were also heterozygous for for FVL (allelic frequency 4.2%).” 
 
(Where tHcy was derived using the relationship of fHcy(ine) (data 
values provided by Yap and Naughten here) to tHcy reported by 
Bonham et al (1997), such that:  tHcy = 60 + 4.5(fHcy(ine)) for 
values of  fHcy(ine) < 20uM, and 
tHcy = 60 + 90 + (fHcy(ine) – 20) for values of tHcy(ine) >=21uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcy = 
107uM, 
range 80 – 
180uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See Yap 
et al 1998 
above 
 
 
 
 
 
 
 
 
 
 
 
 
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 129 
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Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt and 
biochem etc 
contexts 
Yap S et al 
(2000); 
Sem 
Thromb 
Hemost; 
Meta-
analysis 
Irish, 
Australian 
& Dutch 
84 CBS--, 
 
“Abstract……The study on the natural history of untreated CBS--
disclosed that, at the time of maximal risk, in other words beyond 10years 
old, there was one vascular event (VE) per 25years. Recent studies from 
Australia (n = 32), The Netherlands (n = 28), and Ireland (n = 24) have 
documented the effects of long-term treatment on the vascular outcome of 
a total of 84 patients with 1314 patient-years of treatment for CBS--. The 
mean (range) age was 27.8 (2.5 to 70) years. 5 VE were recorded during 
treatment; 1 pulmonary embolism, 2 myocardial infarctions, and 2 
abdominal aneurysms. All 5 VE occurred in VitB6-responsive patients at 
a mean (range) age of 48.8 (30-60) years. In 1314patient-years of 
treatment, 53 VE would have been expected if they remained untreated; 
instead only 5 were documented, relative risk = .091 (95%CI .043 – 
0.190).”   P <.001 
 
Now, firstly, it was not proper to aggregate thromboembolic events in 
with aneurysms, as they may well have differing etiologies, and also as 
diagnosis is not assured. 
Secondly, the method of calculation of the number of events expected in 
the treatment period had treatment not been applied is by no means made 
clear. Taking the average age of 27.8years, minus the total treatment time 
divided by n (1314/84 = 15.6years) one derives that on average treatment 
commenced at age 27.8y – 15.6y = 12.2y. Going to the thromboembolic 
event time-curve of Mudd et al (1985) it can be seen that for an average 
individual of this group, the probability of having a thromboembolic event 
was 0.47 (by age 27.8y) – 0.12 (by age 12.2y) = 0.35. 
And, 0.35*84 = 29.4 thromboembolic events expected during the 
treatment period had treatment not been applied. 
By coincidence the risk ratio would be somewhat similar to the one given. 
More to the point however, is that the treatments applied by these three 
different groups of practitioners are quite different, in particular the Irish 
compared to the other two, and analysis would more profitably had 
compared on this basis, and sought biochemical theorietical basis for the 
differences amongst them, rather than proceeding as they have done. See 
also Yap & Naughten (1998),  Kluitjmans et al (1999), Wilcken & 
Wilcken (1997) all above, as well as for comparison Walter et al (1998) 
above. See also my analysis of these noted aspects below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See 
respective 
studies as 
noted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See respective 
studies as noted 
Tangerman 
A et al 
(2000); 
Metabolism 
Various 
sources of 
patients, 
possibly 
The 
Netherlands
, Australia, 
USA, & 
elsewhere 
22 CBS--, 
selected to 
have 
higher 
meth-
ionine 
levels 
“To assess the ability of patients with CBS-- to perform the reactions of 
the methionine transamination pathway, the concentrations of the products 
of this pathway (“Transamination metabolite values are expressed as the 
sum of methanethiol released sequentially into the gas phase at pH 7 
(protein-S-S-CH3), pH 10 (X-S-S-CH3), and pH 12.5 to 13 (chiefly 4-
methylthio-2-oxo-butyrate)”.) were measured in plasma and urine. The 
results clearly demonstrate that CBS-- patients develop elevations of these 
metabolites once a threshold of 350uM for the concurrent plasma 
methionine concentration is exceeded. The absence of elevated 
methionine transamination products previously reported amongst 16 
CBS—VitB6-responsive patients may now be attributed to the fact that in 
those patients the plasma methionine concentrations were below this 
threshold. The observed elevations of transamination products were 
similar to those observed among patients with isolated 
hypermethioninemia. Plasma Hcy did not exert a consistent effect on 
thransamination metabolites, and betaine appeared to effect 
transamination chiefly by its tendency to elevate methionine.” 
To describe the scatterplots, firstly the results for those on betaine 
treatment not have been differentiable from those not. For plasma the 
upper level of the reference range is given as 0.5uM – once the plasma 
methionine levels come above approx 350uM the transamination products 
are fairly widely scattered but increasing with the methionine – up to 
methionine 600uM, mostly 1 to 2uM – from methionine 600 – 15000uM, 
plenty of values all the way from 2 to 20uM. For urine the scatterplot is 
entirely in agreement with that for the plasma, in its proportions with 
regard to the reference range. 
It seems unlikely that sulfate production dimished in CBS-- is fully 
restored by methionine metabolism through transamination. 
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Lentz SR et 
al (2000); 
Am J 
Physiol 
Heart Circ 
Physiol; 
U Iowa, 
Iowa, USA 
CBS++ & 
CBS-+ 
littermate 
mice. 
“We have used genetic and dietary approaches to produce hyperhomocystinemia in mice. CBS-+ mice, 
which have a selective defect in Hcy transsulfuration, and wild-type CBS++ littermates were fed either a 
control diet or a diet that is relatively deficient in folic acid for 6weeks. 
Plasma tHcy was 5.3+/-0.7uM in CBS++ mice and 6.4+/-0.6uM in CBS-+ mice (P = 0.3) given the 
control diet. 
Plasma tHcy was 11.6+/-4.5uM in CBS++ mice and 25.1+/-3.2uM in CBS-+ mice (P = .004) given a 
low-folate diet. 
In mice fed the control diet, relaxation of aortic rings in response to the endothelium-dependent 
vasodilator acetylcholine did not differ significantly between CBS++ and CBS-+ mice. 
In contrast, in mice fed a low-folate diet, maximal relaxation to acetylcholine was markedly impaired in 
CBS-+ mice (58+/-9%) comparted with CBS++ mice (84+/-4%) (P = .01). 
No differences in relaxation to the endothelium-independent vasodilator sodium nitroprusside were 
observed among the four groups of mice.” 
Weiss N et 
al (2001); 
Arterioscler 
Thromb 
Vasc Biol; 
Boston U 
School of 
Medicine, 
Boston, 
USA. 
CBS++ & 
CBS-+ 
littermate 
mice. 
“Previous in vitro experiments have shown that hyperhomocystinemia leads to oxidative inactivation of 
nitric oxide, in part by inhibiting the expression of cellular glutathione peroxidase (GPx-1). 
To elucidate the role of intracellular redox status on Hcy-induced endothelial dysfunction and oxidant 
stress, CBS-+ and wildtype CBS++ mice (fed standard chow (LabDiet 5001, PMI Nutrition International) 
ad libitum. DV) were treated with the cysteine donor L-2-oxothiazolidine-4-carboxylic acid (OTC). 
CBS-+ mice had significantly lower GPx-1 activity compared with their CBS++ littermates, and OTC 
treatment led to a modest increase in tissue tissue GPx-1 activity and significant increases in total thiols 
and in reduced glutathione levels in both CBS++ and CBS-+ mice (OK, see below. DV). 
Superfusion of the mesentery with Beta-methacholine or bradykinin produced dose-related vasodilation 
of mesenteric arterioles in CBS++ mice and and in CBS++ mice treated with OTC. In contrast, 
mesenteric arterioles from the CBS-+ mice manifested dose-dependent vasoconstriction in response to 
both agonists. OTC treatment of CBS-+ mice restored normal microvascular vasodilator reactivity to 
Beta-methacholine and bradykinin. (OK. DV) 
These findings demonstrate that mild hyperhomocysteinemia leads to endothelial dysfunction in 
association with decreased bioavailable nitric oxide. Increasing the cellular thiol and reduced glutathione 
pools and increasing GPx-1 activity restores endothelial function.” 
 
“The levels of total thiols and of glutathione were 15- to 20-fold higher in hepatic tissue compared with 
cardiac tissue. 
In cardiac tissue, the levels of total thiols and of total, reduced, and oxidised glutathione, as well as the 
ratio of reduced to oxidized glutathione increased to a more reduced state (with OTC treatment, ss for 
CBS-+, but (& some ss) also very much in agreement for CBS++. DV) (& note total thiols 3.79 vs 3.16 
respectively with OTC, but otherwise no difference anywhere. DV). 
The total thiols and glutathione levels were more variable in hepatic tissue and did not differ significantly 
between CBS++ and CBS-+ mice nor between untreated and OTC-treated mice. (overall CBS-+ > 
CBS++, unexpected; 
CBS-+(-OTC) > CBS-+(+OTC), unexpected, except for total thiols which were exactly equal, 
unexpected (one wonders therefore if the data columns hadn’t been switched by mistake.); 
CBS++(-OTC) < CBS++(+OTC), as expected. DV” 
Note: taken overall, it is fair to say that the physiological changes documented bear no relationship to the 
levels of thiols and glutathione documented, unless the cardiac tissue is more representative of the 
vascular tissue tested, than is the liver. In this and in any case the liver thiol situation here is completely 
enigmatic…. 
 
“As shown previously in 20week old CBS-+ mice (cites Weiss et al 2000), 10-12week old CBS-+ mice 
had significantly lower hepatic cellular GPx-1 activity compared with their CBS++ littermates (620 vs 
540, ss). 
1week of treatment with OTC led to a 20% and 30% increase in cellular GPx-1 activity in both CBS++ 
and CBS-+ mice, respectively. After OTC treatment, the enzyme activity was not different between 
CBS++ and CBS-+ mice (740 vs 700, nss)” 
 
“Plasma levels of soluble P-selectin were 40% higher in CBS-+ mice compared with CBS++ mice. 
1week of treatment with OTC normailized plasma P-selectin concentrations to values not different from 
those in CBS++ mice. OTC treatment had no effect on plasma P-selectin values in CBS++ mice (ELISA 
method DV). 
Immunostaining of aortic sections of mice with anti-P-selectin antibody showed more intense staining of 
the luminal surface of the endothelialcell layer in CBS-+ mice compared with CBS++ mice, consistent 
with increased endothelial P-selectin expression. In some sections, platelet-rich thrombi were seen 
adherent to the endothelial surface in CBS-+ mice but not in CBS++ mice. OTC treatment suppressed the 
increase in P-selectin expression in aortic sections of CBS-+ mice to levels observed in untreated CBS++ 
mice. (Purportedly representative section photographs support this. DV)” 
Note: No formal tests of statistical significance of these latter were reported. 
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Davi G et al 
(2001); 
Circulation; 
U Chieti,  
U Naples 
Federico II, 
Italy. 
13 CBS--, 
12 VitB6-
responsiv, 
1 
nonrespon 
“…Hcy may exert its effects by promoting oxidative damage. In the present 
study, we investigated whether in vivo formation of 8-iso-
ProstaglandinF2alpha (8-iso-PGF2alpha), a platelet-active product of 
arachidonic acid peroxidation, is enhanced in CBS-- and whether it 
correlates with in vivo platelet activation, as reflected by thromboxane (TX) 
metabolite excretion…. 
 
Urine and blood samples were obtained from patients with CBS-- (n = 13, 7 
male, age 14-51y, belonging to 8 unrelated families) and age-matched 
healthy subjects.  
Urinary 8-iso-PGF2alpha excretion was significantly higher in CBS—than 
in control subjects (640+/-384 vs 213+/-43pg/mg creatinine; P = .0015) and 
correlated with plasma Hcy (rho = 0.398, P = .0076).  
Similarly, urinary 11-dehydro-TXB2 excretion was enhanced in CBS—
(1166+/-415 vs 324+/-72pg/mg creatinine; P = .0015) and correlated with 
urinary 8-iso-PGF2alpha (rho = 0.362, P = .0153). VitE supplementation 
(600mg/day for 2weeks) was associated with a ss increase in its plasma 
levels (from 16.6+/-4.6 to 40.4+/-8.7uM, P = .0002) and with reductions in 
8-iso-PGF2alpha (from 790+/-159 to 559+/-111pg/mg creatinine, P = .018) 
and 11-dehydro-TXB2 (from 1273+/-383 to 913+/-336pg/mg creatinine, P = 
.028).  
A ss inverse correlation was found between urinary 8-iso-PGF2alpha and 
plasma VitE levels (rho = -0.745, P = .0135), although 2weeks of VitE 
supplementation at 600mg/day failed to normalize enhanced lipid 
peroxidation ” 
 
“….ectopia lentis, osteoporosis, and different degrees of mental retardation.  
All but 1 were responsive to pyridoxine and had been on pyridoxine 
treatment (600-900mg/day) from the time of diagnosis.  
The pyridoxine-unresponsive patient was on betaine 8g/day.” 
 
Average age at diagnosis was 15.3years,  
and average duration of treatment was 16.9years,  
therefore average age now (then) is 32.2years.  
Using the time-to-event curve for first thromboembolic event curve from 
Mudd et al (1985) the number of thromboembolic events expected during 
the treatment period had treatment not been used was (0.5 – 0.13 = 0.37) * 
13 = 4.8.  
 
“None of the CBS-- patients showed ST depression or Q waves on the ECG, 
and their clinical records were negative for angina pectoris, myocardial 
infarction, and venous thromboembolism. All had normal peripheral pulses 
and were negative for bruits over the caratid vessels. Duplex scanner 
analysis confirmed the negativity with respect to carotid arteries, whereas it 
revealed early signs of iliac stenosis (n = 1), ankle/arm ratio <0.85 (n = 3), 
and 1 of these also exhibited a chronic vein insufficiency.” 
 
The difference between the observed 0 thromboembolic events during 
treatment and the 4.8 expected during that treatment period if treatment had 
not been applied is almost ss at the .05 level.   
 
 
 
 
 
 
 
CBS-- 
tHcy = 
113uM, 
range 17-
287uM 
 
 
 
 
 
 
 
VitB6 600-
900mg/d 
only(?) for 
responsiv, 
betaine 8g/day 
for the 1 VitB6-
nonrespon  
Trondle U 
et al 
(2001) ; 
Acta Med 
Austriaca ; 
U Vienna, 
Vienna, 
Austria. 
2 CBS-- 
VitB6-
semi/non-
responsiv 
“…We identified the CBS 833T>C/1058C>T and CBS 
828ins104/1358del134 comp hetz genotype in our index patients.  
Both patients showed mental retardation and ectopia lentis.  
CBS 833T>C/1058C>T was associated with severe vascular complications 
(1week post-surgery for ectopia lentis at age 25years, approx time of CBS-- 
diagnosis with tHcy approx 190uM, Cysteine 1.7uM (ref 30-80uM)), which 
was not the case for CBS 828ins104/1358del134 (neonatal diagn, no 
treatment  till age 29y?..).  
The patient with CBS 828ins104/1358del134 was negative for FVLeiden, 
F2G20210A, MTHFR C677T, and MTHFR A1298C, while the patient with 
CBS 833T>C/1058C>T was heterozygous for MTHFR A1298C.  
A combination therapy including pyridoxine, folic acid, hydroxycobalamin, 
and betaine failed to lower tHcy plasma levels below 50uM in both 
patients.” 
tHcy 145, 
420uM 
on VitB6 
alone, 
respect’ly 
No treatment till 
ages 25, 
29years?... 
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Yap S et al 
(2001a); 
Arterioscl 
Thromb 
Vasc Biol; 
Meta-
analysis 
Irish, 
Australian  
Dutch and 
UK. 
158  
CBS-- 
“Abstract…..We performed a multicenter (Dublin, Ireland; Manchester, UK, London, UK, Nijmegen, The 
Netherlands; Sydney, Australia. DV) observational study to assess the effectiveness of long-term Hcy-lowering 
treatment in reducing vascular risk in 158 patients.  
Vascular outcomes were analysed and effectiveness of treatment in reducing vascular risk was evaluated by 
comparison of actual to predicted number of vascular events, with the use of historical controls from a landmark 
study (Mudd et al 1985. DV) of 629 untreated patients with CBS--.  
The 158 patients had a mean (range) age of 29.4 (4.5 to 70) years; 57 (36%) were more than 30years old, and 10 
(6%) were older than 50years.  
There were 2822 patient-years of treatment, with an average of 17.9years per patient.  
Plasma Hcy levels were markedly reduced from pre-treatment levels but usually remained moderately elevated. 
There were 17 vascular events in 12 patients at a mean (range) age of 42.5 (18 to 67) years: pulmonary embolism (n 
= 3), myocardial infarction (n = 2), deep venous thrombosis (n = 5), cerebrovascular accident (n = 3), transient 
ischemic attack (n = 1), sagittal sinus thrombosis (n = 1), and abdominal aortic aneurysm (n = 2).  
Without treatment, 112 vascular events would have been expected, for a relative risk of .09 (95%CI .036 to 0.228; 
P<.0001).” 
 
Now, firstly, it was not proper to aggregate thromboembolic events in with aneurysms, as they may well have 
differing etiologies, and also as diagnosis is not assured. 
Secondly, the method of calculation of the number of events expected in the treatment period had treatment not been 
applied is by no means made clear. Taking the average age of 29.4years, minus the total treatment time divided by n 
(2822/158 = 17.9years) one derives that on average treatment commenced at age 29.4y – 17.9y = 11.5y. Going to 
the thromboembolic event time-curve of Mudd et al (1985) it can be seen that for an average individual of this 
group, the probability of having a thromboembolic event was 0.52 (by age 29.4y) – 0.10 (by age 11.5y) = 0.42. 
And, 0.42*158 = 66.4 thromboembolic events expected during the treatment period had treatment not been applied. 
Taking away the 2 abdominal aortic aneurysms to leave 15 vascular events instead of the 17 noted, the relative risk 
would in fact be closer to 0.2 than the .09 claimed. 
More to the point however, is that the treatments applied by these different groups of practitioners are quite 
different, in particular the Irish compared to the Dutch and the Australian (see Yap et al 2000 above) other two, and, 
one needs to know the amino acid supplementation used by the two UK groups – given their average age of 
treatment commencement it is probable that they do not achieve (if they even attempt it…) compliance in this 
respect the equal of the Irish group. Analysis would more profitably had compared on this basis and sought 
biochemical theorietical basis for the differences amongst them, rather than proceeding as they have done. See also 
Yap & Naughten (1998),  Kluitjmans et al (1999), Wilcken & Wilcken (1997), Yap et al (2000) all above, as well as 
for comparison Walter et al (1998) above. See also my analysis of these noted aspects below. 
 
                                                Dublin        Sydney       Nijmegen            Manchester      London    
 
n CBS--                                       28                40                30                       31                  41 
n CBS-- followed                        27               32                 28                       30                  41 
 
n VitB6-responsive followed        1               17                 19                         8                 25 
Total VitB6-resp treat-years       13.7          315               250                      183.1           482 
AverageVitB6-resp treat-years   13.7            18.5              13.2                     22.9             19.5 
 
n VitB6-nonrespons followed     26               15                   9                      22                 16 
Total VitB6-nonr treat-years     444.0          288               169                    385.5            291 
Average VitB6-nonr treat-years  17.1            19.2              18.8                   17.5              18.2 
 
n thrombo events                           0                 2                   1                        3                   9in4pts 
 
 
Diet Met/day restriction  200-625+aaCys  GenAdvice     600                  160-900       400-1375 
 
VitB6                               100-800mg/d   100-200mg/d    200-750mg/d   50-500mg/d  20-500mg/d 
 
Folate                                    5mg/day               5mg/day   5mg/day             5mg/day      5-10mg/d 
 
VitB12                                 if deficient            to all          if deficient            nil            50ugoral 
 
Betaine                                 3-6g/day            6-9g/day      6g/day           4.5-15g/day       2-6g/day 
 
Note: No further detail supplied differentiative of VitB6-responders from –nonresponders…. 
 
Venupuncture                     >=8-10/year       1-4/year        1-2/year            1-4/year        2-4/year           
 
Amino Acid Suppl’n ???   
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         Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Yap S et al 
(2001b); 
J Inher 
Metab Dis; 
The 
Children’s 
Hospital, 
Dublin, 
Ireland 
23 CBS—
VitB6-
nonrespon
sives, (13 
early-
detected 
good-
complianc
, 6 early-
detected 
poor-
complianc
, 2 
detected 
at 2years 
good-
complianc
, 2 
untreated 
at 22, 
12years, 
& 
10 sibling 
controls 
“Summary:….The mental capabilities of 23 pyridoxine-nonresponsive individuals with 339 patient-years of 
treatment were assessed (by 1 blinded psychologist. DV) using age-appropriate psychometric tests and were 
compared to those of 10 unaffected siblings (controls).  
Of the 23 individuals, 19 were diagnosed through newborn screening with early treatment, 2 were late-detected 
and 2 were untreated at the time of assessment.  
13 of the newborn, screened group who were compliant with treatment had no complications, while the 
remaining 6, who had poor compliance, developed complications.  
Good compliance was defined by a lifetime plasma free homocystine median <11uM (equivalent to tHcy < 
110uM. DV).  
The newborn screened, good compliance group (n = 13) with a mean age of 14.4years (range 4.4-24.9) had a 
mean full-scale IQ (FIQ) of 105.8 (range 84-120),  
while the poorly-compliant group (n = 6) with a mean age of 19.9years (range 13.8-25.5) had a mean FIQ of 
80.8 (range 40-103).  
The control group (n = 10) with mean age of 19.4years (range 9.7-32.9) had a mean FIQ of 102 (range 76-116).  
The 2 late-detected (at ages 2.4, 2.9years) patients aged 22.4 and 11.7years had FIQ of 80 and 102,  
while the 2 untreated patients aged 22.4 and 11.7years had FIQ of 52 and 53, respectively.  
There was no statistical evidence of significant differences between the compliant, early-treated individuals and 
their unaffected siblings (controls) except for the FIQ, which was significantly higher than that of the unaffected 
siblings (P = .040).” 
 
“Statistical analysis: …..In 1 family of 3 children, 2 of whom were compliant patients, the same unaffected 
sibling was used as the control. There were 8 newborn-screened compliant patient-unaffected sibling control 
pairs used in the analysis. The remaining 2 were poorly compliant newborn-screened-unaffected sibling pairs.” 
 
Note: The comparison should also have compared only between the 8 newborn-screened compliant patient-
unaffected sibling control pairs, excluding those 2 poorly-compliant sibling pairs. The first sentence above is 
incorrectly worded in any case.  
In any case there is the possibility of confounding through parents and teachers being not blinded to the child’s 
CBS condition and reacting to this with different volume/quality of teaching/other social factors.  
Also, tests of ss should have been done on various other pairs of groups, ie the 13 good-compliance with the 6 
poorly-compliant, and reported.  
 
“Treatment regimens: All patients diagnosed with CBS-- were commenced on oral pyridoxine while on a 
normal diet, to ascertain their clinical responsiveness to pyridoxine. Once pyridoxinje-nonresponsiveness was 
confirmed, as indicated by a persistently high or rising plasma methionine and free homocystine, the patient 
was commenced on dietary management of methionine restriction and a methionine-free cystine-supplemented 
synthetic amino acid mixture. Plasma VitB12 and folate were assayed and if these were found deficient the 
patient was given supplements.  
Betaine, a remethylating agent, was used in the last 5years as an adjunct to treatment only in those patients (late 
adolescent/young adults) who became poorly compliant to dietary management (Yap and Naughten 1998).  
In the late-detected pyridoxine-nonresponsive patients, betaine was started with cofactor (pyridoxine, VitB12 
and folate) supplementation.  
This regimen of betaine and cofactors did not seem to lower the free homocystine and methionine 
concentrations (this would be very unexpected regards the homocystine – perhaps they meant “sufficiently” 
DV) in our patients and the addition of dietary methionine restriction with supplementary methionine-free 
amino acid mix was necessary to obtain biochemical control.” 
Kalkanoglu 
HS et al 
(2001); 
J Inherit 
Metab Dis; 
Hacettepe 
U, Ankara, 
Turkey. 
6 CBS-- “Summary:... We analysed 6 CBS-- for FVLeiden and prothrombin G20210A mutations. Only 1 patient was 
found to have the FVLeiden mutation in homozygous form and this patient had suffered from severe 
thrombosis. 1 patient was found to be heterozygous with no documented thrombosis. None of the patients had 
prothrombin G20210A mutation.” 
 
Note: There was in fact another of the 6 patients, who had experienced deep vein thrombosis, who was 
homozygous wild-type for FVLeiden. 
No treatment details whatsoever provided.  
Sokolova J 
et al (2001); 
Hum Mutat; 
Charles U, 
Prague, 
Czech 
Republic. 
Pop Prev's 
of CBS-- 
(abstract) “….First, the incidence of CBS-- estimated by selective biochemical screening in the Czech and 
Slovak Republics was 1:349,000…two most common pathogenic mutant alleles…..IVS11-2A>C calculated 
prevalence 1:2,381; c.833T.C 1:5,556.  
Second…1284 unselected newborns…. ….c.833T.C observed prevalence 1:513; IVS11-2A>C not detected 
amongst 2,568 newborns. 
The estimated incidence of CBS-- of 1:83,000, calculated in a combined model, suggests that selective 
biochemical screening may ascertain only approx 25% of all CBS--. 
In conclusion, CBS-- in Central Europe may be sufficiently common to consider sensitive newborn screening 
programs for this disease.” 
Note: Differential fetus viability purportedly seems not causing/contributing to this difference. 
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     Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal,  
Study 
Group 
Disease 
Gaustadnes 
M et al 
(2002); 
Hum Mutat; 
Prince of 
Wales 
Hospital, 
Randwick, 
The 
Children’s 
Hospital, 
Sydney, 
Royal 
Brisbane 
Hospital, 
Brisbane, 
Women’s 
and 
Children’s 
Hospital, 
Adelaide, 
all 
Australia. 
36 CBS--, 
13 VitB6-
responsiv 
2 VitB6-
partially-
responsiv 
21 VitB6-
nonrespon 
“We determined the molecular basis of CBS-- in 36 Australian patients from 28 unrelated 
families, using direct sequencing of the entire coding region of the CBS gene.” 
 
Sib Pat EthnicOrigin  Allele1        Allele2         VitB6resp AgeD Diagnosis Lent Retard Other 
 
1     1    Anglo-Celtic  I278T           I278T         responsive    20   Osteopor    no    no    PectCarin 
1     2    Anglo-Celtic  I278T           I278T          responsive   17   FamilScr   yes    no 
2     3    Anglo-Celtic  I278T           L101P         responsive   13   EctLentis   yes    no  
2     4    Anglo-Celtic  I278T           L101P         responsive   11   FamilScr    no     no 
3     5    Anglo-Celtic  I278T           C109R        responsive    14   EctLentis  yes    no 
4     6    Anglo-Celtic  I278T           IVS8+1G>A responsiv   14   Retard,Tall no   mild   
5     7    Anglo-Celtic  I278T           IVS1+insC  responsive   12   EctLentis   yes    no    Marfanoid 
5     8    Anglo-Celtic  I278T           IVS1+insC  responsive   14   FamilScr     no    no   
6     9    Anglo-Celtic  I278T           1221delC     responsive   11   FamilScr     no   no 
7   10    Anglo-Celtic  I278T           G347S,T191T  respons     9    EctLentis   yes   no 
8   11    Anglo-Celtic  I278T           undetermined   respons     8    EctLentis   yes  mild  Osteopen 
 
9   12   Anglo-Celtic  E144K           P49L            responsive    4    FamilScr    no    no 
 
10 13   Anglo-Celtic  E144K           V371M        partially        8    EctLentis   yes  border PectExc 
11 14   Anglo-Celtic   I278T            T353M        partially      29    EctLent,Skel y   no   Kyphoscol 
 
12 15   Anglo-Celtic  G307S            G307S         nonrespons   3    EctL,Retard y   mild 
13 16   Anglo-Celtic  G307S            G307S         nonrespons   3    EctL,Marfan y  mild Marfanoid 
14 17   Anglo-Celtic  G307S            G307S         nonrespons   4    EctLentis    yes  no 
15 18   Anglo-Celtic  G307S            G307S         nonrespons   7    EctL,Retard y   moder Scoliosis 
15 19   Anglo-Celtic  G307S            G307S         nonrespons  23   FamilScr    no    no   TIA(?DV) 
16 20   Anglo-Celtic  G307S            C165Y         nonrespons   7    EctLentis   yes   no     Scoliosis 
17 21   Anglo-Celtic  G307S            R336C,A335A nonresp  <1    NewbornScr no  no 
18 22   Anglo-Celtic  G307S             533del18     nonrespons  7     EctL,DevDel  y  mild Marfan 
 
19 23   Anglo-Celtic  E144K             IVS1+1G>A nonresp      5     EctLentis  yes mild Kyphoscol 
20 24   Anglo-Celtic  E144K,R439Q E320K        nonrespons  6     EctLentis  yes  no  Marfanoid     
21 25   Anglo-Celtic  E144K,R439Q 829insC      nonrespons  9     EctL,DevDel y mod sevOstPor 
 
22 26   Anglo-Celtic  A331E              442insG     nonrespons  2    DevDel,OstImp y sev sevOstPo 
23 27   Anglo-Celtic  N228K             IVS11+1G>A nonresp   6    Marfanoid    yes  mild  Marfan 
24 28   Anglo-Celtic  C109R              undetermined nonresp  12    EctLentis    yes border 
25 29   Anglo-Celtic  C109R             533del18     nonrespons  1     DevDel      no   mild 
 
25 30   Anglo-Celtic  R369C             533del18      responsive  24   FamScr,DVT no  no PulmEmb 
 
26 31   Portugese       R125Q             R125Q        nonrespons  <1  NewbornScr yes  no 
26 32   Portugese       R125Q             R125Q        nonrespons    2   FamilScr   yes  mild  SternDef 
 
27 33   Sth African     C165Y            1622insTGAA nonresp   41   EctL,Skel  yes  no 
 
28 34   Lebanese        19insC             19insC         nonrespons   5    AbnMethotrex y border 
28 35   Lebanese        19insC             19insC         nonrespons   9    FamilScr  no     no 
28 36   Lebanese        19insC             19insC         nonrespons   1    FamilScr  no     no 
 
Where: Sib = Sibship #,      Pat = patient #,     EthnicOrigin = ethnic origin, 
Allele1 = one allele, Allele2 = the other allele, 
VitB6resp = VitB6-responsivity,        AgeD = age at diagnosis,        
Diagnosis = phenomena at diagnosis  
Lent = Ectopia Lentis,          Retard = mental retardation,      Other = other features, 
&,  EctLentis, EctL = Ectopia Lentis, 
Y = yes, 
DevDel = developmental delay,      mod, moder = moderate, sev = severe,  
Marfan = Marfanoid, 
responsiv, respon = responsive,    nonrespons, nonresp = nonresponsive, 
NewbornScr = newborn screened,      FamilScr, FamScr = family screened, 
Kyphoscol = kyphoscoliosis,    sevOstPor = severe osteoporosis,    SternDef = sternal defect, 
OstImp = Osteogenesis Imperfecta,                 PectCarin = Pectus Carinatum,  
PectExc = Pectus Excavatum,        Skel = skeletal 
PulmEmb = pulmonary embolism,     TIA = ?,  AbnMethotrex = abnormal Methotrexate response 
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Authors, 
Journal,  
Study 
Group 
Disease Hcy level Treatmnt and biochem 
etc contexts 
Levy HL et 
al (2002); 
J Inherit 
Metab Dis; 
Various 
USA & 
Canada. 
11 CBS--
Mothers, 
& offspr. 
Family# 
 
1 
 
 
 
 
2 
 
 
 
 
 
 
3 
 
 
4 
 
 
 
 
 
 
5 
 
 
 
 
6 Preg1 
    
Preg2 
 
 
 
Preg3 
 
7 
 
 
 
8 Preg1 
 
   Preg2 
 
9 Preg1 
 
   Preg2 
 
10 
 
 
 
11   
 
 
 
 
 
 
 
 
 
NormVal 
Note: No offspring homocystinuric 
 
 
VitB6Resp  AgeDiagn  PregComplic     CongenAnom   OAge  OIQ 
 
Nonrespon   7years   ToxemiaDelivery   ColobIrisChor,   14y    IQ60 
                                                                 UndescTestis,NTD 
 
 
 
Nonrespon  newborn  BleedTrim1&2          none                 4y  IQ103 
 
 
 
 
 
 
Nonrespon   6years   UTI,borderHT             none                5y   IQ90 
 
 
Nonrespon   4.5years       none                      none                7y  IQ109 
 
 
 
 
 
 
Nonrespon   6years    SpontAbort 
 
 
 
 
Responsive  32years  SpontAb                      none                7y  IQ121 
 
                                     none            Beckwith-Wiedemann:  5y   IQ90 
                                                        Macroglossia,PulmValveStenosis, 
                                                          Hemihypertrophy. AutDom?                                      
                             
                        ElevAFP,ThromPhl 
 
Responsive  25years     none                         none                8y  IQ104 
 
 
 
Responsive  23years    UTI                           none                7y  IQ113 
 
                                      HT                           none                5y  IQ101 
 
Responsive  17years     ElectAb                   none             2.5y  DQ108 
 
                                         none 
 
Responsive  11years        none                     none            1.3y  DQ111 
 
 
 
Responsive   5years         none                     none            0.7y  DQ98 
 
Where: VitB6Resp = VitB6-responsivity,  AgeDiagn = age of CBS-- 
diagnosis,  PregComplic = complications of pregnancy,      
CongenAnom = congenital anomalies,   OAge = offspring’s age, at 
which OIQ = offspring’s IQ/DQ, ColobIrisChor = coloboma of iris 
and choroid, UndescTestis = undescended testes, NTD = neural tube 
defect, HT = hypertension, UTI = urinary tract infection, SpontAb = 
spontaneous abortion, ElectAb = elective abortion, ThromPhl = 
thrombophlebitis, LMetD = low-methionine diet 
Maternal 
tHcy 
during 
gestation 
 
>170uM 
 
 
 
 
111uM, 
5uM  
 
 
 
 
 
279uM 
 
 
208uM 
 
 
 
 
 
 
222uM 
 
 
 
 
 
 
 
 
 
 
 
120uM  
 
 
 
6uM  
 
 
 
9-36uM 
 
 
 
9-17uM 
 
 
 
15-30uM 
 
 
 
 
 
 
 
 
 
7.9(2)uM 
& treatment start t 
 
 
 
 
12weeksG  VitB6 + 
folate + betaine 
 
 
 
10weeksGLMetD;  
12weeksGVitB6 + 
folate + betaine 
 
 
 
 
VitB6 + folate 
 
 
VitB6 + folate + 
betaine; aspirin, 
heparin, coumadin 
 
 
 
 
VitB6 + folate + 
betaine; aspirin 
 
 
 
Nil 
 
 
 
 
 
 
 
VitB6 + from 
25weeksGVitB12 
 
 
VitB6 
 
 
 
VitB6 + folate; aspirin 
 
 
 
VitB6 + folate; aspirin 
 
 
 
16weeksG LMetD; 
VitB6 + folate + from 
32weeksG  betaine 
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Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt and 
biochem etc 
contexts 
Pullin CH 
et al (2002); 
J Inherit 
Metab Dis; 
Various, 
UK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Continues) 
5 CBS--, 
& controls 
 
  
5 CBS--: 
 
CM 
 
 
 
DF 
 
 
 
 
AC 
 
 
 
 
 
 
 
 
CA 
 
 
 
LW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                   AgeD/T             Age    VitB6Resp   
 
                                                     5y                     23y     Responsive 
 
 
 
                                                     15y                   25y     Responsive 
 
 
 
 
                                                      21y                   46y     Responsive                   
 
 
 
 
 
 
 
 
                                                      NewbornScr    16y      Nonrespons 
 
 
 
                                                      2y                     21y     Nonrespons 
 
 
Where: AgeD/T = age at diagnosis/treatment,    Age = age at time of 
study,    VitB6Resp = VitB6-responsivity, 
LMetD = low-methionine diet       
 
“Methods. 
Subject Recruitment: The patient group comprised 5 individuals (1 
male, 4 female) aged 16-46years (mean age 26y) with CBS--,  
all of whome were receiving Hcy-lowering treatment…. 
None of the patients recruited to the study smoked.  
Age and gender-matched controls were recruited from workplace 
staff, and were specially selected to be free from cardiovascular risk 
factors including hypertension (diastolic BP<80mmHg), diabetes, 
smoking and hypercholesterolemia (total chol<6.2mM). Plasma tHcy 
was within the normal range (5-15uM) and subjects were not taking 
vitamin supplements….. 
 
Study design: The study was divided into 2 phases designed to 
investigate the vascular effects of both acute and chronic 
administration of high-dose VitC (500mg tablets, Boots plc). 
Subjects were required to attend on 3 study days. 
 
Baseline investigation: (Study day 1) Following an overnight fast, 
blood was sampled and brachial artery responses to increased blood 
flow, ie endothelium-dependent FMD, and sublingual nitroglycerin 
(NTG, 400ug) administration (endothelium-independent dilatation) 
were assessed. 
 
Acute effects of vitC: (Study day 1) Following baseline assessment, 
subjects were administered 2g oral VitC in a single dose. Blood was 
sampled and brachial artery FMD was reassessed 1, 2, 3 and 4h 
following VitC ingestion. Endothelium-independent responses were 
not assessed so as to avoid nitrate carry-over effects. Subjects were 
given a standardized low-fat, low-protein sandwich and caffeine-free 
drink between the baseline and 1h assessments. 
(Continues) 
tHcy at 
study 
entry 
 
 
 
47uM 
 
 
 
36uM 
 
 
 
 
141uM 
 
 
 
 
 
 
 
 
96uM 
 
 
 
181uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VitB6 + folate 
+ betaine 
 
 
VitB6 + folate 
+ betaine + 
LMetD 
 
 
VitB6 
(increased 
600+% from 
40mg/d fr 
week7) + folate 
+ VitB12 
 
 
 
VitB6 + folate 
+ betaine 
 
 
VitB6 + folate 
+ betaine + 
LMetD 
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Authors, 
Journal,  
Study 
Group 
Disease Hcy level 
(Continued) 
Pullin CH 
et al (2002); 
J Inherit 
Metab Dis; 
Various, 
UK 
(Contin) 
5 CBS--, 
& controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBS-- : 
Baseline; 
 
 
 
2weeks; 
 
 
 
6months 
 
 
 
 
Controls: 
Baseline; 
 
 
 
2weeks; 
 
 
 
6months 
 
(Continued) 
Chronic effects of VitC: Subjects provided a fasting blood sample and underwent 
reassessment of brachial artery responses following 2weeks’ administration of VitC in a 
single dose (2g/day) (study day 2), and after 6months’ administration of VitC in a single 
dose (1g/day) (study day 3) (numeration of study days seems peculiar/poor/incorrect. 
DV).  
 
Noninvasive measurements of vascular endothelial function: …..Brachial artery end-
diastolic diameter (EDD) was measured by high-resolution (+/-3um) ultrasonic vessel 
‘wall-tracking’  (Vadirec), blood flow by continuous wave Doppler, and blood pressure 
by photoplethysmography (Finapres).  
Following baseline measurements, a wrist cuff was inflated to suprasystolic BP. Inflation 
of this cuff for 5min induced ischemia in the hand. Release of the cuff stimulated reactive 
hyperemia in the hand, resulting in a secondary increase in blood flow along the brachial 
artery. EDD, blood flow, and pressure were recorded at 1, 2, 3, and 5min after cuff 
release, and again at 10min to demonstrate vessel recovery. FMD was taken as the 
maximum absolute change in EDD (um) observed during the first 3min after cuff release.  
Then, as appropriate (baseline only on study day 1, and study days 2 and 3), EDD, blood 
flow and pressure were measured 3min after 400ug sublingual NTG administration.” 
 
Diam     FMD    NTG    SystBP DiastBP   HR    VitC  5-MeTHF       Met    tCys 
 
 
3.2mm     20        388   114mmHg  72    63bpm    55uM  72nM       440uM 139uM 
             ***vC              *vC                                   *vC      ***vC     ***vC   ***vC 
 
 
              170        450   118mmHg  72    65bpm  120uM   75nM       436uM 165uM 
             ***vB                                                     1***vB   1***vC   1***vC  *vC 
 
 
              170        390   125mmHg  71    67bpm    95uM   78nM       241uM 173uM 
             ***vB              1*vB                                 1**vB  1***vC    1***vC  *vC 
                                                                                                             1***vB 
 
 
 
3.2mm   116        470    127mmHg  72   63bpm  89uM     23nM         25uM  248uM 
 
 
 
              140        450    116mmHg  65   63bpm  120uM   27nM        22uM   232uM 
 
 
 
              130        450    125mmHg  68   63bpm  105uM   25nM        23uM   264uM 
 
Where: Diam = as detailed above,       
FMD = Flow Mediated Dilatation,       NTG = arterial response to nitroglycerin,     
SystBP = systolic blood pressure,        DiastBP = diastolic blood pressure, 
HR = Heart Rate,            VitC = vitamin C,   5-MeTHF = 5-methyl-tetrahydrofolate       
Met = methionine,       tCys = total plasma cysteine 
 
 
Note: some of the comparisons ’twixt CBS—and controls only considered ss to the level 
of P<.05, and not to any level of ss greater than this, so some of those comparisons may 
in fact be more ss ie P<.01, <.001, but are unable to be noted here as such….while others 
(ie methionine) were obviously more ss than noted, and I have taken the liberty of 
adjusting my reporting of the ss accordingly, denoting these by placing a “1” before any 
such asterisk(s). 
 
Note: In properly multivariate considerations, the change in methionine and cysteine, 
conjuntively indicating better compliance with dietary recommendations, assuming some 
other improvement in that metabolism has not taken place, and the increase in systolic 
blood pressure, all these in the CBS--, ought be adjusted for, which would reduce the 
apparent effect associated with the VitC treatment, though very probably not so much as 
to make it nss. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcy 
 
 
101uM 
 
 
   
  85uM 
   
 
 
  95uM 
 
 
 
 
 
9uM 
 
 
 
9uM 
 
 
 
9uM 
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Authors, 
Journal,  
Study 
Group 
Disease Hcy level 
Atalay S et 
al (2002); 
Acta 
Paediatr; 
Ankara U, 
Turkey. 
13 consec 
intracard 
thrombos 
(Abstract) “The objective of this study was to determine the association between intracardiac 
thrombosis and heridatary causes of thrombophilia, including factor V 1691 G-A (factor V 
Leiden, FVL) and prothrombin 20210 G-A mutations.  
Over a period of 3years, genetic risk factors were evaluatedin 13 consecutive children (mean age 
6.27+/-5.44y) with intracardiac thrombosis, diagnosed by cross-sectional echocardiography. 
Thrombi were localized in the left heart in 4 patients and the right heart in 9 patients.  
All children had predisposing conditions for thrombus formation:  
ventriculoatrial shunt for hydrocephalus (n = 3),  
indwelling catheter for chemotherapy (n = 5),  
cardiomyopathy (n = 2),  
sepsis (n = 1),  
homocystinuria (n = 1), and  
tetralogy of Fallot (n = 1).  
6 of the 13 children with intracardiac thrombosis were heterozygotes for FVL mutation. 3 of 
these 6 children had ventriculoatrial shunt for hydrocephalus, 2 had cardiomyopathy, and 1 had 
sepsis.  
None of the children carried the prothrombin 20210 G-A mutation.”  
(Note: as inferred, the homocystinuria (CBS-- ?) case did not carry the FVLeiden mutation) 
 
Kruger WD 
et al (2003); 
Hum Mutat; 
Fox Chase 
Cancer 
Center, 
Philadelph., 
Pennsylvan. 
USA. 
12 CBS—
from 11 
different 
families, 
from 
Georgia, 
USA, 
including 
4 African-
American 
(abstract) “….By DNA sequencing of all the coding exons we identified mutations in in the CBS 
genes in 21 of the 22 possible mutant alleles. 10 different missense mutations were identified 
and 1 novel splice-site mutation was found.  
5 of the missense mutations were previously described (G307S, I278T, V320A, T353M, and 
L101P),  
while 5 were novel (A226T, N228S, A231L, D376N, Q526K)…. 
The I278T and T353M mutations accounted for 45% of the mutant alleles in this patient cohort.  
The T353M mutation, found exclusively in 4 African American patients, was associated with a 
VitB6-nonresponsive phenotype and detection by newbornm screening for hypermethioninemia.  
The I278T mutation was found exclusively in Caucasian patients and was associated with a 
VitB6-responsive phenotype.” 
 
AgeD     VascEv   tHcy   EctLent                        AgeD      VascEv   Met   EctLentis 
 
12y            yes      210uM    yes                           Birth          no     2000uM     no 
13y             no      196uM     no                            Birth          no     1181uM     no 
21y             no      187uM    yes                            Birth         yes      835uM     no 
12y             no      186uM    yes                            Birth          no      831uM     no 
 
6y            yes      174uM    yes                               6y           no      603uM    yes 
20y             no       171uM    yes                             13y           no      578uM     no 
22y            yes       169uM    yes                             12y           no      504uM    yes 
 
Birth           no       155uM     no                             20y           no       418uM    yes 
Birth           no       152uM     no                             22y          yes      256uM    yes 
Birth          yes       150uM     no                               6y          yes      111uM    yes 
Birth           no       118uM     no                             12y          yes      105uM    yes 
 
Note: The LHS and RHS contain the same cases, but that the one is ordered according to the 
tHcy level, the other is ordered according to the mehtionine level. 
 
Where: AgeD = age at diagnosis,       VascEv = had a vascular (thrombotic) event, 
tHcy = pre-treatment plasma tHcy, derived from Hcy(ine) given using algorithm of Bonham et 
al (1997), such that:   
tHcy = 60 + 4.5(fHcy(ine)) for values of  fHcy(ine) < 20uM, and  
tHcy = 60 + 90 + (fHcy(ine) – 20) for values of tHcy(ine) >=21uM, 
Met = pre-treatment plasma methionine,      
EctLent = Ectopia Lentis,                  Birth = newborn screening 
 
First note the ascertainment bias resulting from diagnosis by raised methionine in the case of the 
newborn screening. In any case, they may be safely excluded from the following considerations, 
which in any case do not approach ss.  
Vascular events are associated with Ectopia Lentis; the ss of course is negligible, and the 
ascertainment bias of Ectopia Lentis probably being the presentation trigger to test for CBS-- 
precludes much/any meaning being derivable from this. 
Vascular events are not associated with tHcy level, here. 
Vascular events are associated with lower methionine levels, here. 
The latter two observations are not in accord with generally accepted extancies.    
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Kelly PJ et 
al (2003); 
Neurology; 
Massachu-
setts 
General 
Hospital, 
Boston,  
Massachu-
setts, USA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Continues) 
3CBS--
without 
usual 
stigmata 
“Patient A was a 47y-old white woman of northern European descent 
who presented with acute left-sided weakness.  
She was of normal intelligence,  
with a history of hypertension  
and tobacco use.  
Family history was unremarkable for premature atherosclerosis, 
thrombosis, or intellectual impairment…. 
left hemiparesis (MRC grade 4/5), hemisensory impairment, and 
extinction to tactile stimuli, without skeletal abnormalities or lens 
displacement…. 
(imaging DV) consistent with acute infarction…. 
hypoechoic mass in the proximal right internal carotid artery 
consistent with thrombus… 
.but no evidence of extra- or intracranial atherosclerosis…. 
Serum and red cell folate, VitB6, VitB12, lipids, hypercoagulability 
screen (protein C, protein S, antithrombin 3, anticardiolipin 
antibodies, prothrombin gene 20210 polymorphism), transthoracic 
echocardiography, and 24hour Holter monitoring results were 
normal.  
…Repeat B-mode carotid ultrasound at 5weeks showed complete 
resolution of the of the intraluminal signal abnormality, consistent 
with dissolution of thrombus… 
Marked improvement occurred, with resolution of the sensory 
deficits and minimal residual weakness at 6months…. 
heterozygous for T833C (I278T aa substitution). Severe 
hyperhomocystinemia is rare (ever? DV) in T833C heterozygotes, 
suggesting compound heterozygosity for another unidentified CBS 
mutation on the other allele….. 
MTHFR C677T was homozygous wildtype. 
 
The asymptomatic 46y-old sister…..heterozygous CBS T833C, 
MTHFR C677T was homozygous wildtype. 
 
 
 
 
Patient B was a 39y-old Venezuelan man  
presented with a right frontal headache and acute visual loss in the 
right eye.  
Medical history was unremarkable for neck trauma or vascular risk 
factors.  
Examination revealed an afferent pupillary defect, reduced visual 
acuity, and superior altitudinal field defect in the right eye. 
Fundoscopic examination revealed edema in the territory supplied by 
the inferior temporal branch of the right central retinal artery. 
Neurologic and general examination findings were otherwise normal, 
although  
he was noticeably tall and thin.  
CT scan of the brain was normal.  
Cerebral  angiography was unremarkable except for a tapering 
“flamelike” occlusion of the right ICA at the origin, with “double 
density” of contrast at the site of occlusion, suggesting pooling of 
dye in the space created by an intimal flap. Together with the clinical 
presentation , these findings were strongly suggestive of ICA 
dissection.  
Mild scoliosis was present on chest radiography…. 
cultured skin fibroblasts…(heterozygous G1330A (D444N aa 
substitution)… partial response to pyridoxine….FVLeiden not 
detected….. 
The patient was followed clinically for 17years, without recurrent 
ischemic events.  
 
 
(Continues) 
tHcy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
279uM 
 
8uM (? 
Seems too 
low) 
 
 
 
 
 
 
 
 
128uM 
 
16.5uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
212uM 
 
 
 
43-102uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Met = 
125uM 
 
Warfarin; 
VitB6 
300mg/d, 
Folate 
1mg/d 
 
 
 
 
 
Met = 
60uM 
 
VitB6 
300mg/d, 
VitB12 
80ug/d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Met = 
58uM 
 
 
 
Aspirin; 
VitB6 
200mg/d, 
Betaine 
4.5g/d 
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(Continued)
Kelly PJ et 
al (2003); 
Neurology; 
Massachu-
setts 
General 
Hospital, 
Boston,  
Massachu-
setts, USA 
3CBS--
without 
usual 
stigmata 
(Continued) 
An asymptomatic sister…. 
5’8“ tall with mild scoliosis of the thoracic and lumbar spine.  
There was no clinical evidence of ocular, intellectual, or vascular 
manifestations…… 
(heterozygous G1330A (D444N aa substitution). 
 
 
Patient C was an 18y-old man of Irish ethnicity with known CBS--, 
referred for evaluation of abrupt deterioration of school mathematical 
ability, which was nonprogressive and had begun acutely 4months 
previously.  
Medical history was remarkable for mitral valve prolapse (MVP) and 
severe hyperhomocysteinuria detected 1year earlier, unresponsive to 
supplemental vitamins and dietary methionine restriction.  
There was a strong paternal family history of premature coronary 
artery disease and a maternal family history of aortic dissection, but 
no family history of stroke or intellectual impairment…. 
tall thin man with mild pectus excavatum.  
Neurologic examination was normal. 
An abnormal focus of FLAIR MRI hyperintensity was present in the 
right parietal subcortical white matter, consistent with ischemic 
stroke.  
MRI and MRA of head and neck showed no signal abnormality 
suggestive of dissection, atherosclerosis, or venous thrombosis 
(normal venous flow voids on T1 MRI). …. 
Holter cardiac monitoring, lipid and hypercoagulability profiles 
(anticardiolipin antibodies, proteins S and C, antithrombin 3, lupus 
anticoagulant assay, FVLeiden) were normal.  
Neuropsychological evaluation revealed impaired retention of new 
information and impaired ability to perform geometric constructions 
and other visual-spatial tasks, consistent with right parietal lobe 
lesion…. 
G919A (G307S aa substitution)… 
Despite therapy (as noted column right DV) tHcy remained elevated 
2years later.” 
 
 
“First, they support the rationale for screening for subclinical 
hyperHcy in young adults with premature stroke, despite the apparent 
absence of classic phenotype features of CBS--, such as ectopia 
lentis, intellectual impairment, seizures, and skeletal abnormalities… 
Secondly…….may also promote embolic stroke of cardiac and 
arterial origin, possibly in individuals otherwise predisposed to 
thrombophilia by conditions such as cardiac structural abnormailities, 
atrial fibrillation, and FVLeiden.” 
 
 
 
91uM 
 
62-85uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
175uM 
 
 
 
 
 
281uM 
 
 
 
 
 
 
 
 
 
 
Met = 
98uM 
 
VitB6 
300mg/d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Met = 
821uM, 
Normal 
folate, 
VitB12 
 
 
Low-Met 
diet; 
VitB6, 
folate, 
VitB12 
(com-
pliance?) 
Yap S 
(2003); 
J Inherit 
Metab Dis; 
Children’s 
University 
Hospital, 
Dublin, 
Ireland. 
158  
CBS-- 
Irish, 
Australian  
Dutch and 
UK. 
This paper does not seem to add anything to the contents of Yap et al 
(2001a), see above. 
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Orendac M 
et al (2003); 
J Inherit 
Metab Dis; 
Charles U, 
Prague, 
Czech 
Republic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(continued) 
9 or 5 
CBS--, 
Czech 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#2 
 
 
 
#3 
 
 
 
 
 
#7 
 
 
 
#8 
 
 
#9 
“Summary : To explore the pathogenesis of CBS-- and to test the 
efficacy of pharmacological therapy we examined a panel of 
metabolites in 9 CBS-- patients under treated and/or untreated 
conditions.  
Off pharmacological treatment, the biochemical phenotype was 
characterized by accumulation of tHcy (median 135uM) and blood S-
adenosylHcy (median 246nM), and by normal levels of 
guanidinoacetate and creatine. In addition, enhanced remethylation 
was demonstrated by low serine level (median 81uM), and by 
increased concentration of methionine (median 76uM) and N-
methylglycine (median 6.8uM).  
Despite the substantially blocked transulfuration, which was 
evidenced by undetectable cystathionine and severely decreased 
cysteine levels (median 102uM), blood glutathione was surprisingly 
not depleted (median 1155uM).  
In 5 patients in whom pharmacological treatment was 
withdrawn….(see table below DV)… 
In summary, our study shows that conventional treatment of CBS-- 
by diet and pyridoxine/betaine normalizes many but not all metabolic 
abnormalities associated with CBS--.  
We propose that the finding of low plasma serine concentration in 
untreated CBS-- patients merits further exploration since 
supplementation with serine might be a novel and safe component of 
treatment of CBS--.” 
 
The subset of 5 patients whose data comprise the tabulation further 
below: 
 
Age  VitB6resp  Mutations                                            StudyWashout   
 
10y  nonrespons  AIVS11-2C + (c.G430A + c.G463A)      Completed 
 
 
 
14y  nonrespons  AIVS11-2C + (GIVS7+1A + IVS11+39del99)     “ 
 
 
 
 
 
20y  responsive  c.C341T + c.G1226A                                Completed 
 
 
 
25y  responsive  c.T833C + AIVS11-2C             (partially)Completed 
 
 
32y  responsive  c.T833C + c.T833C                                  Completed 
 
 
Note: Completion of the study washout period was the criteria for 
data contribution to the table below – the other 4 patients did not 
complete, and therefore no data is included from them.  
The partial completion of washout noted lasted 14days until 
abandoned due to increase of tHcy, on decision by unknown 
patient/practitioner/scientist/protocol. 
 
 
(continued)  
tHcy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre-
washout 
 
VitB6, 
folate, 
betaine 
 
VitB6, 
folate, 
betaine 
 
 
 
VitB6, 
folate, 
betaine 
 
VitB6, 
folate, 
 
Untreated, 
non-
compliant 
 
Note: All 
compliant 
were on 
low-Met 
diet 
through-
out whole 
study  
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(Continued)
Orendac M 
et al (2003); 
J Inherit 
Metab Dis; 
Charles U, 
Prague, 
Czech 
Republic. 
 
(Cont) 
9 or 5 
CBS--, 
Czech 
 
(Continued) 
 
Metabolite               RefRange           CBS--Treatment         CBS--OffTreatment            P 
 
tHcy                         5.4-13.9uM        32.7 (6.6-65.3)uM       125 (19-135)uM                .009 
 
SAH                         12-99nM            59 (21-162)nM             132 (47-350)nM               .06 
 
Met                          13-43uM             26.3 (17-156)uM          76 (16-78)uM                 0.75 
 
SAM                        1.2-2.3uM          1.8 (1.4-2.0)uM             1.9 (1.5-2.4)uM              0.16 
 
SAM/SAH               20-118               29 (12-86)                      14 (5-43)                          .06 
 
 
Cystathionine           50-342nM         subdetection                   subdetection                    n.a.          
 
tCys                          200-360uM       211 (137-258)uM          139 (102-192)                  .05 
 
 
Guanidinoacetate     1.67-4.0uM       2.7 (1.9-3.6)uM              2.8 (1.7-4.0)                   0.92 
 
Creatine                   16.4-58uM        20.1 (16.4-36.1)              20.7 (16.7-33.3)             0.32 
 
 
N-methylglycine      0.6-2.7uM         12.7 (3.8-38)uM              6.8 (3.2-8.9)uM            0.15 
 
N,N-dimethylglycine 2-6.6uM          38.0 (3.5-275.5)uM        2.9 (2.1-5.2)uM             0.16 ???? 
 
 
Serine                       97-267uM         103 (69-111)uM             53 (50-81)uM                  .036 
 
Glycine                    152-413uM        234 (165-295)uM           226 (188-361)uM          0.25 
 
Glutathione             790-1,350uM      1290 (980-1,580)uM      1160 (940-1,230)uM     0.15 
 
 
Where: SAH = S-adenosylHcy,   Met = methionine,        SAM = S-adenosyl-methionine, 
tCys = plasma total cysteine 
 
Note: although ideally there should be adifferentiation on the basis of VitB6-responsivity, their 
figure with all individual measurements plotted does not indicate much difference between these. 
 
“On day 1, the pharmacological therapy was discontinued, and patients were instructed to 
continue the low-methionine cystine-supplemted diet (M-AM, SHS International).” Apparently 
the diet was continued throughout.  
This makes it difficult to assess the meaning of the data, in particular to relate it to reality where 
it is more likely that compliance will be achieved with the pharmacological than the dietary 
treatments. 
 
“Oral glucose tolerance test:…..In conclusion we did not find any gross signs of impaired 
endocrine pancreatic function in CBS--.” 
 
“Markers of endothelial dysfunction: We examined whether patients with CBS-- exhibited 
abnormalities in factors of the thrombolytic system (tPA and PAI-1) and signalling molecule 
ICAM-1, all of which are considered markers of endothelial dysfunction.  
There was no correlation between tHcy and plasma ICAM-1 concentrations.  
In contrast, there was a strong correlation between tHcy and tPA concentrations (r2 = 0.51, P = 
.0018), and between tHcy and PAI-1 concentrations (r2 = 0.48, P = .0029).  
These data suggest that severe hyperHcy impairs endothelial function.” 
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Linnebank 
M et al 
(2003); 
J Inherit 
Metab Dis; 
U Munster, 
U Bonn, 
Germany. 
Stroke 
and sinus 
thromb-
osis 
patients, 
apparently 
unselected 
?.... 
“…DNA samples of patients with stroke (n = 225) and sinus thrombosis (n = 46) were screened 
for the most common homocystinuria mutation, CBS I278T…. 
The frequency of I278T heterozygosity (0 of 46 patients with sinus thrombosis and 2 of 225 
patients with stroke) was not elevated in comparison to the healthy German population 
(Linnebank et al 2001). Therefore, this study does not provide any hint of CBS-+ as a risk factor 
for thrombophilia.  
However, 2 individuals were found to be of homozygous allele state for I278T…. 
In the stroke group, there was a homozygous 34y-old male with bilateral occlusion of the carotid 
arteries and of one vertebral artery, and with 3 previously documented stroke episodes.  
In the sinus thrombosis group, a 24y-old woman, who developed symptoms after delivery of a 
healthy daughter via Caesarian section, was of a homozygous allelic state.  
Several further risk factors relevant for thrombosis such as MTHFR C677T and A1298C, 
prothrombin G20210A, plasminogen inhibitor polymorphisms, APC resistance, proteins C and S, 
lipoprotein(a), and antiphospholipid antibodies were investigated.  
The stroke patient was heterozygous for APC resistance, which leads to an additional 4- to 5-fold 
increased risk of recurrent thrombosis (McKusick 227400);  
the patient with the sinus thrombosis was without respective risk factors…….. 
(I278T is VitB6-responsive DV)……. 
the 2 CBS--in this report did not present with any other nonvascular symptoms of 
homocystinuria.” 
Sueyoshi E 
et al (2004); 
AJR; 
Nagasaki  
U, 
Nagasaki, 
Japan. 
 “A 21y-old man was admitted to our hospital with a 3year history of intermittent claudication. 
Arteriography of the lower extremities showed stenosis of both external iliac arteries. 
Venography of the lower extremities showed thrombus in the left poplitiael vein and 
development of collateral vessels.  
Initially the patient was treated with urokinase and antiplatelet agents.  
13days after admission, he complained of chest pain and dyspnea. A pulmonary perfusion 
scintigram revealed multiple perfusion defects in both lungs, and the diagnosis of pulmonary 
embolism was made.  
After treatment with urokinase and antiplatelet agents, the symptoms of pulmonary embolism 
gradually subsided.  
(Is this implying that the thrombus was released from the popliteal vein to relocate to the 
lung?...seems quite possible….DV)…. 
(hyperHcy and VItB6-responsive CBS-- established DV)…. 
After the patient underwent treatment with VitB6, his coagulability and Hcy returned to normal. 
(Note: In 1980 when this was assayed, often fHcy, not tHcy, was assayed, and the former may be 
undetectable at tHcy of up to 40uM DV). 
The patient was discharged and treated with a supplement of VitB6 as an outpatient.  
He had remained symptom-free after discharge,  
and follow-up arteriography and venography of the lower extremities showed no abnormality.  
However imaging studies of the lung showed a gradual increase in the size of segmental branches 
of the pulmonary arteries. Pulmonary ventilation-perfusion scintigrams showed multiple newly 
developed mismatched defects in both lungs.  
Fortunately there have been no symptoms related to chronic pulmonary embolism.  
His pulmonary arterial systolic pressure has slightly increased, but remained below 90mmHg 
during the follow-up period.  
The patient is still doning well after 25years of follow-up.” 
 
Note: None of the other common stigmata of CBS-- extant?.... 
treatment with VitB6 alone (assume?....) means the Hcy is Going down the CBS pathway, 
providing both cysteine (ie for fibrillin) and sulfate (ie for heparin sulfation) – so, is some other 
connective tissue disorder overlayed on the CBS--?..... 
What was compliance?.... 
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Singh RH et 
al (2004); 
Genet Med; 
Emory U, 
Atlanta, 
Georgia, 
USA. 
5 CBS-- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#, Age 
 
#1, 1y 
 
#2, 10y 
 
#3, 11y 
 
#4, 18y 
 
#5, 19y 
 
 
All 
“5 patients with biochemically confirmed CBS-- cared for by the Division of 
Medical Genetics at Emory U were recruited for this study…….3 of the 5 
patients were identified by positive newborn screening for 
hypermethioninemia, and 2 were identified later in life after the discovery of 
ectopia lentis.  
All patients required methionine restriction to <30mg/kg/day, to decrease their 
free Hcy and total Hcy.  
Met-restricted diets were implemented concurrently with VitB6 
supplemetation at doses up to 20mg/kg/day.  
We selected for this study 5 patients classified VitB6-nonresponsive.  
All were treated with methionine restriction and pharmacological 
supplementation of VitB6, but could not maintain plasma methionine below 
50uM or fHcy below 5uM (tHcy<45uM DV).  
The treatment of VitB6-nonresponsive CBS-- patients with “methionine 
restriction” was accomplished in part by the simultaneous dietary restriction of 
natural protein, and supplementation withy medical foods free of methionine.  
These Met-free medical foods were supplemented with conditionally-essential 
l-cysteine, in the form of l-cystine. 
 
Study Design. 
Patients were first treated with natural protein restriction, supplementation 
with Met-depleted, l-cystine-fortified medical foods, and 5 to 20mg/kg/day of 
pyridoxine.  
Upon attaining the lowest plasma methionine and tHcy, we began betaine at 
prescribed doses of 20-50mg/kg/day. Dosages were increased to 120-
150mg/kg/day and provided as 3 divided doses until stabilization of tHcy to 
the lowest concentrations for the individual. Biochemical measurements were 
obtained every 1-3months, until the tHcy reached a nadir.  
Three-day diet histories were analysed and compared for methionine content, 
and other essential nutrients throughout the studies….. 
All patients were classified VitB6-nonresponsive by clinical criteria.” 
 
Ethnic        Mut1 Mut2    MetPre MetBet  tCysPre tCysBet  tHcyPre 
 
Afr-Am  T353M Q526K   24uM 116uM    109uM 118uM         28uM      
 
Caucas   V320A V320A   21uM 38uM       203uM 150uM        38uM 
 
Caucas    I278T D376N    12uM 21uM       194uM 217uM        31uM 
 
Caucas    I278T L101P    123uM 103uM    138uM 284uM      135uM 
 
Afr-Am  T355M T355M  69uM 140uM       97uM 144uM      119uM 
 
 
Average Change (P):     +34uM(P=0.18)     +34uM(P=0.35)     -47uM 
 
Where: Ethnic = ethnicity       Mut1,Mut2 = the two CBS- mutations,   MetPre, 
MetBet = methionine before, and with, betaine, 
tCysPre, tCysBet = plasma total cysteine before, and with, betaine, 
tHcyPre, tHcyBet = tHcy before, and with, betaine. 
 
However, note: “Although we observed 4/5 patients with a near doubling of 
their plasma methionine during maximal betaine therapy, the mean plasma 
methionine in our betaine treatment group did not change. This was because of 
the decrease in the plasma methionine of patient 4, ….. this patient reported 
improved compliance with both methionine restriction and consumption of the 
methionine-depleted, cystine-enriched medical food…..evidence supporting 
improved compliance by patient 4 was the doubling of his total plasma 
cysteine and the decrease in plasma methionine during betaine treatment, 
which was only observed in this subject. This patient reported being partially 
compliant with his betaine dosing regimen, only taking one fourth of the 
prescribed dose (approx 20-30mg/kg/day)…..Of interest was that his ratio of 
Met/tHcy increased as in other patients indicating that remethylation of Hcy 
was enhanced by betaine. 
tHcy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcyBet 
 
7uM 
 
6uM 
 
11uM 
 
31uM 
 
60uM 
 
 
(P=.02) 
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Devlin AM 
et al (2004); 
J Pediatr; 
Newcastle 
General 
Hospital, 
Newcastle-
upon-Tyne 
& Willink 
Bio-
chemical 
Genetics 
Unit, Royal 
Manchester 
Children’s 
Hospital, 
Manchester, 
Both UK  
1 CBS-- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This Case 
 
Normal 
Range 
 
CBS--s on 
betaine 
(abstract) “….Betaine is formed naturall in choline metabolism.  
It is involved in the maintenance of cell volume against osmotic stress and  
acts as a chemical chaperone, protecting proteins against denaturation.  
It is also a substrate for the hepatic enzyme betaine-homocysteine methyltransferase. For 
>20years, pharmacological doses of betaine have been used to lower homocysteine 
concentrations in homocystinuria. The usual dose in children has been 250mg/kg/day, but 
recent studies suggest that there is little benefit from increasing >150mg/kg/day (cites 
Matthews et al 2002). The response to betaine is variable. Plasma homocysteine 
concentrations often fall by >=50%. Plasma methionine concentrations usually rise, 
sometimes only slightly but sometimes as high as 1000-1200uM.  
There have been few clinical problems, but cerebral edema was reported in a patient treated 
with betaine (cites Yaghmai et al 2002).  
We report a second patient with CBS-- who had this complication while receiving betaine.” 
 
“Case History. 
A 4.5year-old boy was diagnosed with homocystinuria after presenting with dislocated 
lenses. He had poor speech articulation, clumsiness, and frequent falls, but development 
was otherwise normal.  
Baseline plasma tHcy concentrations ranged from 334-430uM (normal 5-17uM). The 
plasma methionine concentration was 203uM (normal 10-54uM)  
with a normal VitB12 level and  
a normal urinary organic acid profile.  
CBS activity in fibroblasts was undetectable, with no change after the addition of pyridoxal-
phosphate or SAM. Clinically, there was only a partial response to pyridoxine (500mg/day) 
and folic acid (5mg/day) with tHcy of 253-340uM.  
At age 5years, betaine was started and increased gradually to 3g/day (150mg/kg/day), and 
dietary protein was restricted (methionine intake 500mg/day) (VitB6 and folate 
continued?....DV).  
4weeks after starting betaine, the patient began having morning headaches and vomiting, 
which increased in frequency and severity. 2weeks later, he presented to the hospital with 
papilledema but with no other neurological signs.  
Cranial MRI with magnetic resonance angiography and venography showed no evidence of 
sinovenous thrombosis.  
There was however a widespread abnormal signal from the white matter in both cerebral 
hemispheres.  
Lumbar puncture revealed an opening pressure of 48cm of CSF (normal <20cmH2O. DV) 
but was otherwise normal and resulted in a marked reduction of symptoms.  
4days later, symptoms returned and were relieved by a second lumbar puncture (opening 
pressure 47cmCSF).  
Aspirin, dexamethasone, and acetazolamide were started.  
The betaine dose was doubled to to 3g twice daily.  
After another 4days, symptoms worsened, and lumbar puncture showed an opening pressure 
>80cmCSF.  
Relevant plasma and CSF results are shown in the Table. 
 
CSF:    Betaine     Met             Plasma:  Betaine       Met    N,N-DMG  
 
             6.6uM     235uM                         98uM    1,190uM    64uM 
         
           Mosby’s-   1-5uM                  18-73uM   10-54uM   1.4-5.3uM  
 
 
             ?                ?                      170-660uM  <1,200uM  33-250Um 
 
4hours after the third lumbar puncture, the patient became hypertensive and bradycardic 
with a falling level of consciousness and unilateral pupillary dilatation. Computed 
tomography showed diffuse brain swelling with loss of the basal cisterns. The patient was 
intubated, ventilated, and given mannitol, after which bilateral frontotemporal 
decompressive craniotomies were performed. Invasive angiography revealed no evidence of 
sinovenous or corticovenous thrombosis. Betaine was discontinued. Ventilation and fluid 
restriction were continued for 48hours, after which the patient recovered consciousness. 
Neurological examination was normal at discharge 8days later and at 9months. 
Psychomotor development has progressed normally. Cranial MRI after 6months showed 
resolution of edema and white matter signal abnormalities. Satisfactory levels of tHcy 
(<50uM) and Met (43-111uM) achieved with low methionine diet (200mg/day) and Met-
free amino acid supplements (assume Cys-supplemented?..)” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
334-430uM pre-
treatment 
 
 
 
253-340uM on 
VitB6 500mg/d, 
Folate 5mg/day 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcy 
 
239uM 
 
5-17uM 
 
 
? 
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biochem etc 
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Vilaseca 
MA et al 
(2004); 
J Inherit 
Metab Dis; 
U Hospital 
St Joan de 
Deu, 
Barcelona, 
Spain. 
2 CBS-- 
siblings, 
VitB6-
non-
responsiv, 
pregnancy 
experienc 
of one 
“The patient was the second daughter of healthy parents.  
One older brother died undiagnosed at the age of 4months and a younger 
one, diagnosed with homocystinuria (tHcy = 250uM on treatment with 
300mg/day pyridoxine) has ectopia lentis with blindness, mental retardation, 
and skeletal abnormalities.  
The woman was diagnosed at the age of 1year owing to ectopia lentis and 
was treated with pyridoxine (300mg/day).  
At the age of 30, clinical reevaluation showed severe myopia, ectopia lentis, 
disc herniation (L5), venous insufficiency, Marfanoid habitus, thin skin, dry 
and thin hair, and emotional lability.  
Biochemical data on 300mg/day pyridoxine treatment showed tHcy 
180uM….Met 80uM and cystine (not cysteine DV) undetectable. Treatment 
was modified by increasing pyridoxine to 600mg/day, and by adding folate 
10mg/day, cystine 0.5mg/day and betaine 6g/day. tHcy decreased to 56uM 
and Met to 55uM, while cystine increased to 38uM. (Only 28years too late, 
in 2004….DV). 
Genetic analysis showed R125W/T191M mutations in the CBS gene and 
homozygosity for the MTHFR C677T mutation. 
The first pregnancy occurred at 33years of age. At the 10th week of 
gestation, ultrasound showed a minimal detachment area, and rest was 
prescribed, without further events.  
Pyridoxine treatment was reduced to 300mg/day and acetylsalicylic acid 
(100mg/day) was added, while cystine and betaine treatments were 
maintained at the same doses.  
Increased ingestion of milk derivatives to prevent osteopenia resulted in 
raised tHcy (100uM) and Met (75uM) levels,  
which suggested the need to start a Met-restricted diet (XMET Maxamaid, 
75mg/day) at the 29th week of gestation. This resulted in a marked decrease 
in tHcy (10uM) and Met (27uM) levels. 
Spontaneous eutocic delivery (3.6weeks of gestation) resulted in a normal 
girl (birth weight 2840g, size 46cm, cephalic circumference 34cm, Apgar 
9/10) with transitory jaundice.  
The postpartum period was uneventful in the mother; acetylsalicylic acid 
was withdrawn before delivery and heparin (20mg s.c./day) was added for 
40days. The Met-restricted diet (tHcy 14uM, Met 27uM) and specific 
treatment for homocystinuria were continued. 
Following an early miscarriage (normal fetus),  
the patient became pregnant again at the age of 38. After an uncomplicated 
pregnancy, following the same treatment (pyridoxine, acetylsalicylic acid, 
folate, cystine, betaine, Met-restricted diet), with good metabolic control 
(tHcy 13uM, Met 35uM), a normal boy (Birth weight 3055g, Apgar 9/10) 
was born at 36.4weeks of gestation.  
Both children had normal development and attend regular school at present. 
tHcy 
 
250uM 
 
 
 
 
 
 
 
180uM 
(cystine 
undetect-
able) 
56uM 
(cystine 
38uM) 
 
 
 
 
 
 
 
 
100uM 
 
 
10uM 
 
 
 
 
 
14uM 
 
 
 
 
 
13uM 
 
 
VitB6 
300mg/d 
 
 
 
 
 
 
VitB6 300mg/d 
 
VitB6 300mg/d, 
Folate 
10mg/day, 
Betaine 6g/day, 
Cystine 
0.5mg/day 
 
 
 
 
 
 
Changes as per 
text + milk 
derivativs 
 
Then + Low-
Met diet 
 
 
 
 
ditto 
 
 
 
 
 
ditto 
Orendac M 
et al (2004); 
Hum Mutat; 
Various 
Polish & 
Czech 
institutions 
 
 
 
 
 
Stroke 
 
 
 
Stroke 
6 CBS--, 
VitB6-
non-
responsiv, 
Polish 
ancestry 
 
#1 
 
#2 
 
 
#3 
 
#4 
 
#5 
 
#6  
From 5 unrelated families of Polish ancestry. All strongly VitB-
nonresponsive  
 
 
 
AgeD  EctLent  Marfan  Osteopor  Kyphoscol  IQ  Spast Pyram  BA 
 
8y         yes         no?           no              yes         54    yes    yes     yes 
 
12y       yes        yes             no               no         72    yes    yes     yes 
 
 
5y         yes        yes             yes             yes         54   yes     no      yes 
 
5y         yes         yes            yes             yes         75   no      no      yes 
 
3y         yes         yes            yes             yes          54   no      no      no 
 
9y         yes         yes            yes             yes          54   no       no     yes 
Where:     AgeD = age at diagnosis,      EctLent = Ectopia Lentis,  
Marfan = Marfanoid habitus,         Osteopor = osteoporosis, 
Kyphoscol = kyphoscoliosis,      IQ = IQ,        Spast  = spastic paresis Pyram 
= pyramidal signs,        BA = brain atrophy 
 
 
(pre-
treatment
) 
tHcy 
 
283uM 
 
385uM 
 
 
419uM 
 
385uM 
 
348uM 
 
340uM 
 
 
 
CBS-- 
Mutations 
 
 
C429G 
A1224-2C 
C429G 
A1224-2C 
 
C684A 
C684A 
T833C 
A1224-2C 
G442A 
G442A 
G1039+1T 
G1039+1T 
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Miles EW 
& Kraus JP 
(2004); 
J Biol 
Chem; 
NIH, 
Bethesda, 
Maryland, 
U Colorado, 
Denver, 
Colorado, 
both USA. 
CBS--: 
Biochem: 
function, 
regulation  
“Alternate Substrates and Reactions. 
CBS catalyses pyridoxal-phosphate(PLP)-dependent beta-replacement reactions (Eq2) in which 
the electronegative substituent (X) in the beta-position of the amino acid substrate is replaced by 
a nucleophile YH (cites reviews by Miles (1986) and Braunstein & Goryachenkova (1984)). 
Beta-replacement reactions (Eq2) are also catalysed by tryptophan synthase, O-acetylserine 
sulfhydrylase, and several other PLP enzymes. 
 
XCH2CH(NH2)COOH + YH <-> XH + YCH2CH(NH2)COOH       (Eq2) 
 
Where X is OH or SH and Y is S or S-alkyl. 
 
Amino acid substrates for CBS include L-serine (X is OH), L-cysteine (X is SH), 3-chloroalanine 
(X is Cl), and serine-O-sulfate (X is SO4);  
Nucleophile substrates (YH) include L-Hcy, 2-mercaptoethanol, and H2S….. 
Recent studies provide evidence that H2S is a gaseous neuromodulator and smooth muscle 
relaxant and that H2S is produced by CBS (cites Kimura 2002). Although the author suggests that 
H2S is produced by a beta-elimination reaction with L-cysteine, H2S may be a product of the 
beta-replacement reaction of L-cysteine with another thiol (cites Maclean and Kraus 2004).  
CBS will also very efficiently catalyze the formation of L-cysteine from L-serine and H2S. This 
serine sulfhydrylase reaction may be an alternative method of cysteine synthesis and H2S 
detoxification…... 
 
Regulation of Cystathionine Beta-Synthase. 
The human CBS gene is transcriptionally regulated by two promoter regions designated -1a and -
1b. The major promoter (-1b) is serum and fibroblast growth factor-responsive and is down-
regulated by insulin, growth arrest due to contact inhibition, nutrient depletion, or the induction 
of differentiation (cites Maclean et al 2002). The CBS -1b promoter is regulated in a redox-
sensitive fashion by synergistic interactions between Sp1 and NF-Y and Sp1 and Sp3. Sp1 and 
Sp3 are the specificity factors 1 and 3, respectively, whereas NF-Y is the nuclear factor Y, a 
histone-like CCAAT-binding trimer. The dominant and indispensable role of Sp1 in regulating 
both GC-rich CBS promotors may allow tissue-specific repression by Kruppel-like factors. S1-
like proteins and Kruppel-like factors are highly related redox-sensitive zinc-finger proteins that 
are important components of the eukaryotic cellular transcriptional machinery. 
In contrast to the relatively slow transcriptional response, AdoMet can instantaneously activate 
human CBS.  
Proteolytic removal of the C-terminal region also activates human CBS; the extent of the 
activation is similar to that observed with AdoMet….. 
AdoMet does not activate the yeast enzyme….. 
The role of heme in human CBS is still not clear. Heme is not essential for catalysis because it is 
absent in yeast CBS and T.cruzi CBS and because heme-free human CBS has activity. Human 
CBS may be regulated by the redox state of the heme. Whereas one group observed an ~2-fold 
decrease in CBS upon reduction of heme, another group did not observe this change.” 
 
Note: No mention of metal enzyme cofactors….. 
Schwahn 
BC et al 
(2004); 
Metabolism
; Montreal 
Children’s 
Hospital, & 
associated 
institutions 
CBS-+ 
mice 
(Abstract) “We studied Hcy metabolism in mice with mild hyperhomocysteinemia due to CBS-+. 
Mice were fed diets  
(text: “This control diet….but contained choline at 5 instead of 10mmol/kg diet…diet thus 
contained only 20% less labile methyl groups than the AIN-93M reference diet, and similar diets 
have been considered to be methyl-sufficient in other dietary studies in rodents. The lower 
choline concentration was chosen to avoid saturating conditions for the choline-dependant 
remethylation pathway”)  
supplemented with betaine or dimethylsulfonioacetate (DMSA);  
betaine and DMSA provide methyl groups for an alternate pathway of Hcy metabolism, 
remethylation by betaine-Hcy methyltransferase (BHMT).  
On control diets, CBS-+ mice had 50% higher tHcy than did CBS++ mice.  
Betaine and DMSA had similar effects in both genotype groups: liver betaine increased 
dramatically, while plasma Hcy decreased 40-50%.  
With increasing betaine supplementation, Hcy decreased by 75%.  
Plasma Hcy and BHMT activity both showed a strong negative correlation with liver betaine.” 
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Ekinci B et 
al (2004); 
Movement 
Disorders; 
Cerrahpasa 
Medical 
School, 
Istanbul U, 
Turkey. 
2 CBS-- 
siblings 
Patient 1. 
A 38year-old woman with generalized dystonia was followed-for 4years by our movement disorders clinic.  
She was born at full term after an unremarkable pregnancy,  
and when she was 7months old she experienced 3 febrile convulsions.  
She reached developmental milestones with delay such as walking at 1.5years and talking at the age of 
3years; as a esult of mental retardation she could not attend primary school.  
Her family noticed a forward-bent spine when she was 2years old.  
She was diagnosed with homocystinuria at trhe age of  9years following the development of a cataract in the 
right eye.  
When she was 14, she developed involuntary tremor-like movementsand twisting contractions appearing first 
on the right foot and later on the left, which in time spread to the upper extremities.  
Since that time, axial dystonia has been gradually developing leading by age 20 to scoliosis with deviation of 
the body and neck to the right side.  
Later her hair became light-clored and  
she had a major depressive illness that responded well to treatment.  
In the late of her 20s she finally became wheelchair-bound and mostly dependent on others in her activities of 
daily living as a result of generalized dystonia…. 
Neurological examination of the patient at age 34 showed moderate mental retardation. 
Generalized dystonia was prominent on the right side leading to the right latero- and retrocollis, extensor 
posture in the rigtht leg and plantar flexion posture of the feet associated with a high amplitude dystonic 
tremor at the limbs as well as the head and trunk, causing twisting movement to the right and back of her 
body, worse with action.  
The physical examination revealed grey hair,  
bilateral pes cavus and equinovarus deformities and kyphoscoliosis.  
Ophthalmologic examination disclosed amaurosis in the right eye with corneal calcification and shrinkage of 
the iris and -10 dioptri myopia on the left eye.  
At the age of 38, the clinical picture became worse with gait and stance problems due to extensor right leg, 
inversion posturing of the right foot and plantar flexion of the feet and toes.  
Her speech became incomprehensible because of dystonic contractions of the maseter and laryngeal  muscles.  
Achilles clonus in the right foot was present,  
but neurological examination was otherwise normal.  
Lab investigations of blood and urine, including the serum levels of copper and ceruloplasmin, VitB12, folate 
as well as 24hour urinary copper, the panel of liver and renal function tests were all normal except to an 
increased level of Hcy (I think they meant Hcy(ine), considering their normal value, and everything 
else….DV) in the urine at 85uM (Normal 0uM).  
MRI of the brain in T1-weighted images showed bilateral hyperintense gliotic lesions in the centrum 
semiovale, corona radiata and periventricular deep white matter.  
Axial T2-weighted images of MRI of the brain showed no abnormaility in the basal ganglia. The defined 
lesions were considered to be consistent with homocystinuria.  
L-dopa given for treatment of the dystonia (500mg/day) was ineffective.  
Repeated injections of botulinum toxin-A into the cervical and masseter muscles gave clinical benefit.  
Since the diagnosis of homocystinuria was established, the patient has taken pyridoxine 750mg/day, 
dipyridamole 225mg/day, folic acid 5mg/day and betaine 30mg/day. 
 
Patient 2. 
The first patient’s 34year-old brother, an office worker, was diagnosed with homocystinuria at the age of 
5years upon the development of a cataract.  
He was able to graduate from primary school but then developed stenotic valvular disorder of the aorta, 
varicose veins on the legs, hypertension and osteoporosis when he was age 10.  
2years later, he had stiffness without pain in the back musculature and could not bend forward, but did not 
ferer to a physician.  
He was diagnosed as Karteneger’s syndrome at the age of 27. In 1997,  
when he was 29, his score on the Short Test of Mental Status was 14 (normal = 38).  
In January 2002 his neurological examination revealed mild bradymimia,  
decreased eye blinking,  
bilateral bradykinesia, and  
rigidity which was prominent on the left side in the axial musculature in addition to  
dementia.  
He did not display dystonia.  
He was independent in his activities of daily living. We were recently informed that he had died of 
pneumonia in July 2002.” 
 
Note: Some combination of VitB6-nonresponsivity, parental neglect, treatment non-compliance, late-ish 
diagnosis, and failure to include cystine supplementation in the treatment prescription, nor low-Met diet, must 
be considered in the etiology of very unsatisfactory and substandard outcomes for these two cases. Note also 
the lack(?) of Ectopia Lentis in either case.  
 MFHEI Multifactor Health and Education Initiative 
 http://sites.google.com/site/multifactorhealth 149 
                Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Lebowitz 
EA (2004); 
J Vasc 
Interv 
Radiol; 
Santa Clara 
Valley 
Medical 
Center, San 
Jose, 
California, 
USA. 
1 CBS-- 
case 
“A 19year-old man presented with gangrene of the right great toe that progressed to cyanosis of the distal 
half of the right foot within 2weeks.  
Risk factors noted initially included minimal smoking history, no diabetes mellitus, no hypertension, and 
no trauma, although the patient was an avid soccer player.  
Subsequent questioning during the following year revealed a history of trauma to the right knee with a 
baseball bat 6months before presentation and use of cocaine.  
Physical examination revealed a well-developed, well-nourished, athletic-appearing man with dry 
gangrene at the tip of the right great toe and wet gangrene at the base of the right great, second, and third 
toes. He was entirely nondysmorphic.  
All pulses were 4+, with the exception of the right popliteal, dorsalis pedis, and posterior tibial pulses, 
which were absent. An ankle-brachial index of 0.47 was measured in the right lower extremity and a non-
invasive diagnosis of right superficial femoral artery occlusion was made. Treatment was started 
immediately with 325mg/day aspirin and 75 mg/day clopidogrel bisulfate and the patient was advised to 
quit smoking……. 
 
Initial Management. 
The patient was treated with tissue plasminogen activator at 1mg/hour through a Gragg-Macnamara 
valved infusion catheter positioned in the right popliteal thrombus and heparin at 200U/hour. No 
improvement was present the next day…..stopped, and the patient was brought to the operating room, 
where a right popliteal thrombectomy, saphenous vein patch angioplasty, and proximal popliteal vein-to-
peroneal saphenous vein interposition grafting were performed.  
At operation, the patient had no atherosclerotic arterial disease, which suggested an etiology of 
thromboembolism from an unknown source…. 
The following laboratory data were obtained:….platelet count of 277,000/uL, prothrombin time of 
11.7s,….antithrombin III activity of 82%, Protein C activity of 99%, Protein S activity of 101%, 
FVLeiden negative, lipoprotein(a) level <7mg/dL, VitB12 level 271pg/mL, echocardiograpy results 
demonstrating no embolic source……..MTHFR homozygous wildtype, tHcy 194uM, and cystathionine-
beta-synthase (CBS) activity in fibroblast tissue of 0.0nmole/hour/mg (normal 5.4-18.5). 
 
Later Management. 
The patient was prescribed a regimen of anticoagulant therapy but presented again 1month later with 
exacerbated right lower-extremity ischemic symptoms. An arteriogram demonstrated occlusion of the 
right popliteal artery and graft. The patient underwent an operative thrombectomy and a saphenous vein 
bypass from his right superficial femoral artery to his peroneal artery.  
However, occlusion of the graft and occlusion of the distal right superficial femoral artery occurred in the 
ensuing 4months and required repeat thrombolysis attempts, operative thrombectomy, and a new 
operative bypass from the proximal superficial femoral artery to the posterior tibial artery with the use of 
a CryoVein because his native saphenous vein had already been used.  
At the time of the CryoVein bypass the diagnosis of homocystinuria was made  
(Note: It seems peculiarly obscure exactly when the diagnostic lab tests noted above in Initial 
Management were made, and why this diagnosis occurred so late in the course of events…DV)  
and medical therapy with VitB6, VitB9, and VitB12 was added to the warfarin, aspirin, and clopidogrel 
he was already taking.  
The tHcy decreased from 194uM to 11.1uM within 1month of treatment  
(Note: This is an unexpectedly great decrease in tHcy, given the CBS enzyme activity of nil, 
notwithstanding no report of any trialing of VitB6 addition to the enzyme, and this suggests VitB6-
responsive CBS--, which is also consistent with the lack of any of the other stigmata of CBS--, which are 
more severe in untreated VitB6-nonresponsive cases – given that until this response was established he 
was suspect for non- or low-responsiveness, it would have been better to have also included cystine 
supplementation in the treatment, particularly as the other vitamin treatments re-route Hcy metabolism 
away from the CBS pathway that provides the sulfate potentially important in heparin sulfation which is 
potentially important in reducing thrombogenesis.... DV).  
When the CryoVein bypass graft thrombosed 2weeks after insertion, the patient was offered a below-the-
knee amputation, which he refused. Consequently, repeat thrombectomy was performed and 2weeks later 
transmetatarsal amputation was performed. The wound healed well.  
Anticoagulation and vitamin treatment continue to the present, and in the 1.5years since the last 
thrombectomy, the graft has remained open and no new thromboembolic events have occurred… 
 
Discussion. 
The differential diagnosis for distal lower-extremity ischemia in a young patient 
includes……Homocystinuria was diagnosed and treated several months after presentation….. 
The principal lesson.is that interventional radiologists and surgeons may be called on to treat young 
patients with ischemic disease secondary to homocystinuria before the diagnosis has been made. The 
diagnosis may not even be considered because typical phenotypic features are absent. Such patients will 
fail to respond to standard therapies for peripheral vascular occlusive disease until their plasma Hcy 
levels are reduced, and the consequences may be severe. 
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De Luca M 
Casique L 
(2004); 
Mol Genet 
Metab; 
Center for 
biosciences 
and 
molecular 
medicine, 
Caracas, 
Venezuela  
7 CBS--, 
Venezuel-
an 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBS--# 
 
#930 
 
#1110, sib 
 
#2255 
 
#MB, sib 
 
#2954 
 
#3800 
 
#5169 
“This center has detected (no timespan provided. DV) 53 suspected 
cases out of 24,755 sick or healthy children, using the cyanide-
nitroprusside technique in urine (no basis for the application thereof 
provided. DV).  
In order to confirm the homocystinuria diagnosis by quantifying 
tHcy, 26 out of 53 families have been contacted until the present, and 
9 cases were confirmed including 2 couples of siblings, though no 
DNA samples of 2 of them were available. These 9 patients were 
diagnosed on the basis of a severe hyperhomocysteinemia in 
combination with clinical manifestations of CBS--. 10patients out of 
the total of the confirmed 26 have already died  
(no mention of the other 26 – 9 – 10 = 7. DV)……  
Blood samples were obtained from 7 Venezuelan HCU patients, 
including 2 sib pairs and 5 unrelated genotypes….. 
Patients were not compliant with dietary therapy….. 
They presented the total number of cases studied (thusly. DV) so far 
in Venuezuela.” 
 
AgeD AgeO  Ethnic  Mut1 Mut2 MTHFR  Skel Eye CNS  VitB6resp 
  
4y        10m  Venez  C699T C699T hetz       yes  yes   yes      partial  
 
10y      2y     Venez  C699T C699T norm      yes  yes  yes      partial 
 
19y     17y    Portug C1080T C1080T norm   no   yes   ?     
 
21y     7y      Portug C1080T C1080T norm   no   yes  yes 
 
4y       2y      Indigen  T191M T191M hetz     no   yes  yes      partial 
                     +Venez 
11y     2y      Venez  D234N D234N  hetz      yes  yes  no   
 
7y       2y      Venez  Q243X C699T  norm     yes  yes  yes 
 
Where:  AgeD = age at diagnosis,   AgeO = age at onset,   
Ethnic = ethnic origins, where indigen = indigenous,  
Venez  = indigenous + Spanish/Italian, and Portug = Portuguese,   
Mut1,Mut2 = mutations on alleles 1 & 2,   
MTHFR = MTHFR C677T mutation where norm = homozygous 
normal, hetz = heterozygous, 
Skel = Marfanoid habitus/ scoliosis/ skeletal abnormalities, 
Eye = Ectopia Lentis/ glaucoma/ severe myopia, 
CNS = psychomotor retardation/ mental retardation/ abnormal 
electroencephalogram/ seizures/ psychosis, 
VitB6resp = VitB6-responsivity where partial = partially responsive 
to VitB6, 
Treat = “Referred by the parents” whatever that means?...... 
And DNA mutations are given where provided by the authors, and 
amino acid substitutions provided in lieu where not. 
 
Note: It appears safe to assume that the tHcy was that at the time of 
diagnosis, ie pre-treatment (they may have been given VitB6 and 
complied with that, while all being noted for dietary non-compliance. 
 
Note: It is difficult to infer whether the clinical manifestations apply 
to the time of diagnosis, or to the present – information not provided.                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcy 
 
211uM 
 
209uM 
 
161uM 
 
126uM 
 
193uM 
 
150uM 
 
261uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treat 
 
yes 
 
yes 
 
no 
 
no 
 
yes 
 
yes 
 
yes 
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Moat SJ et 
al (2004); 
Hum Mutat; 
U Colorado, 
Colorado, 
USA,  
Royal 
Manchester 
Children’s 
Hospital, 
Manchester 
UK,  
& others 
 (abstract) “The molecular basis of CBS-- has been studied in 536 patient alleles with 130 
different mutations described. 
To date, no study has reported on the incidence of any of the reported mutations in patients from 
the UK and the US.  
We developed a new antisense oligonucleotide (ASO) PCR/hybridization method to screen for 
12 of the most frequent CBS mutations in 14 unrelated patients from the UK and 38 unrelated 
patients from the US, a total of 104 independent alleles.  
We determined 16/28 (57%) and 28/76 (37%) of the affected alleles in the UK and US patients, 
respectively.  
4 different mutations were identified in the UK patients (c.374G>A, R125Q; c.430G>A, E144K; 
c.833C>T, I278T; c.919G>A, G307S) and 
8 mutations identified in the patients from the US (c.341C>T, A114V; c.374G>A, R125Q; 
c.785C>T, T262M; c.797G>A, R266K; c.833C>T, I278T; c.919G>A, G307S;  
g13217A>C(del ex 12);  c.1330G>A, D444N). 
The I278T was the predominant mutation in both populations, present in 8 (29%) of independent 
alleles from the UK and in 14 (18%) of 76 independent alleles form the US.  
The incidence of the G307S mutation was 21% in the UK patients and 8% in the US patients. 
The spectrum of mutations observed in the patients from the UK and US is closer to that which is 
observed in Northern Europe and bears less resemblance to that observed in Ireland.” 
 
“The G307S mutation has been detected in patients from the US and Australia with “Celtic” 
origin including families with Scottish, English, French, and Portuguese ancestry. However, the 
G307S mutation has not been detected in tested alleles in Italy, the Netherlands, Germany, Spain 
and the Czech Republic. Interestingly this mutation was recently detected in Norway, indicating 
that this allele may have originated in Scandinavia and spread elsewhere [Kim et al., 1997].  
The I278T mutation is panethnic…..Three mutations G116R, I152M, and C165Y were not 
detected in the 104 alleles. Most surprising is the absence of the C165Y mutation found 
previously in 8 alleles in patients of Dutch, Czech and South African origin.” 
Linnebank 
M et al 
(2004); 
Hum Mutat; 
U Hospital 
Bonn, 
Bonn, 
Germany, 
U Hospital 
Muenster, 
Muenster, 
Germany, 
Inst of 
Inhertited 
Metabolic 
Disorders, 
Prague, 
Czech 
Republic,  
U Colorado, 
Colorado, 
USA. 
17 CBS-- 
patients of 
Caucasian 
origin 
carrying 
the 
mutation 
c.1224-
2A>C. 
“17 CBS-- patients of Caucasian origin carrying the mutation c.1224-2A>C were included in this 
study. They were known from the CBS database, from personal communication or from our own 
hospitals and laboratories. Except for 1 patient of Turkish origin, all these patients were of 
“Central” Europe ancestry: 4 Polish, 4 Slovak, 3 Czech, 2 German, 1 Austrian, 1 Croatian, 1 
Hungarian….In the present study, response to VitB6 supplementation – usually 500-1000mg/day 
– was defined as a decrease of fasting tHcy to <=50uM, partial response as a decrease to 50-
200uM…. 
The clinical spectrum varied from rather mild phenotypes with isolated thrombotic events or 
ocular lense dislocation to severe phenotypes with disabling mental retardation and generalised 
involvement of connective tissue. 
At the time of diagnosis, the 2 patients homozygous for c.1224-2A>C presented with severe 
phenotypes. They exhibited VitB6-nonresponsiveness, while VitB6-responsiveness of the other 
patients depended on the mutation of the second allele…. 
 
None of the patients with thrombotic events carried the FVLeiden or the prothrombin 
polymorphism confirming that these are not necessary for thrombotic events in CBS--…… 
 
In the 17 patients we analysed 10 polymorphisms in the CBS gene and constructed haplotypes by 
maximum likelihood approach. All 19 c.1224-2A>C chromosomes shared the same haplotype. 
These data indicate that c.1224-2A>C originated from a single mutational event, and a founder 
effect may be responsible for the origin of the mutation in Europe.”   
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                Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Refsum H 
et al (2004); 
J Pediatr; 
U Oxford, 
UK, 
U Bergen, 
Bergen, 
Norway, 
Rikhospit-
alet U 
Hospital, 
Oslo, 
Norway. 
 “From February to April 1999, ~5000 samples were randomly selected among ~12,000 capillary 
blood samples that weee sent to the RUH, Oslo, for routine newborn screening of 
phenylketonuria and congenital hypothyroidism……..Genotyping for CBS mutations was 
performed in 1133 random samples. 
We have previously identified 6 different mutations among Norwegian families CBS--: 785C>T, 
797G>A, 833T>C, 919G>A, 959T>C, and 1105C>T.  
Using a multiplex, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
method (cites Harksen A et al 1999). 
The prevalence of homocystinuria was calculated on the basis of the assumption that Hardy-
Weinberg equilibrium exists and that babies with 2 mutated alleles will have homocystinuria. 
When the frequencies are “w” for the wild-type allele and “m” for the mutant allele, the 
frequencies will be w2, 2wm, and m2 for the homozygous wild-type, the heterozygotes, and the 
homozygous mutant genotype, respectively. Since we know the prevalence of w2 (CBS++) and 
2wm (CBS-+), we can calculate the prevalence of m2 (CBS--). 
 
Mutation    VitB6-responsive     n                  %  
 
785C>T                no                   0                   .00  
 
919G>A                no                  2                  0.18 
 
959T>C                 no                  0                   .00 
 
 
797G>A               yes                  1                   .09  
 
833T>C                yes                  7                  0.62 
 
1105C>T               yes                18                 1.59 
 
 
Any Mut                                     28                 2.47 
 
….Overall CBS-+ was observed in 2.47% (95%CI, 1.57-3.37) of the samples, yielding an 
estimated birth prevalence of CBS-- of ~ 1:6400 (I agree DV)…. 
We limited our investigation to 6 CBS mutations previously found in Norwegians, but there are 
numerous other CBS mutations associated with homocystinuria. Thus our estimate is probably 
too low….. 
However, we do not know whether CBS mutations in the mother or fetus cause reduced 
reproductive fitness. This could lead to a lower prevalence of live-born babies with CBS--. Hence 
the the H-W equilibrium may not exist. 
Another factor is clinical penetrance, that is, whether homozygosity or compound heterozygosity 
for any pair of these mutations will lead to a clinically evident homocystinuria (means other 
CBS-- stigmata? DV).  
We found that 90% of the mutated alleles in newborn infants are associated with a  pyridoxine 
responsive phenotype.  
This proportion differs markedly from the widespread experience that only ~50% of patients 
respond to pyridoxine.  
Pyridoxine-responsiveness is usually associated with a less severe clinical disease.  
The discrepancy between the genetic findings in newborn blood samples and that observed in 
patients could suggest that many CBS-- have a pyridoxine-responsive variant with mild or no 
symptoms.  
Another possibility is that diagnosis is frequently missed because the medical community is not 
fully aware of this disorder and its clinical manifestations. 
Our findings indicate that novel high throughput techniques for mutation detection may be a 
useful procedure to identify babies with mutations causing both mild and severe variants of  
CBS--. However this approach will miss cases caused by unknown or rare CBS mutations and 
may include those with a genetic defect but normal biochemical and clinical phenotype. Thus, the 
optimal approach for detection of CBS-- remains to be determined.”  
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      Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease Hcy level Treatmnt 
and 
biochem 
etc 
contexts 
Mulvihill A 
et al (2004); 
J AAPOS; 
National 
Centre for 
Inherited 
Metabolic 
Disorders, 
The 
Children’s 
Hospital, 
Dublin, 
Ireland. 
27 CBS--, 
Irish, 70% 
VitB6-
non-resp 
G307S 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Group#,n 
 
I, n = 14 
 
 
 
II, n = 6 
 
 
 
III, n = 7 
“Subjects. 
All patients attending the Irish NCIMD were considered for inclusion 
in the study.  
The patients were either diagnosed through the national newborn 
screening program or clinically detected.  
The initial findings of hypermethionemia and hyperhomocyateinemia 
were further confirmed by either enzymology of CBS in fibroblast or 
CBS mutational analysis.  
Over 70% of the defective alleles in this study cohort were due to 
919G>A (G307S). 
 
Treatment and Metabolic Control. 
….a trial of pyridoxine is given.to ascertain in vivo response of the 
patient to pyridoxine while remaining on a normal diet.  
Half of the patients with Hcy-uria worldwide are pyridoxine 
responsive, which makes pyridoxine the mainstay of treatment in 
these patients. 
In pyridoxine nonresponsive patients, dietary treatment with 
methionine restriction and cystine supplementation is commenced.  
In addition, pyridoxine and folic acid with VitB12 are also prescribed 
(Should give some quantitative info on trends in prevalence on the 
use of the addition fo folate and VitB12, and to which patients it is 
applied (ie as function of compliance with dietary recommendations), 
and also, given their exact wording here, whether cystine 
supplementation is also included with any treatments using 
pyridoxine, folate and VitB12.  DV). 
For this study cohort of patients, treatment would have started within 
6weeks of birth for those detected through newborn screening and at 
the time of diagnosis for the late detected patients. 
Biochemical control was monitored using free Hcy(ine) (“fHcy(ine)” 
DV). Free Hcy is normally undetectable.  
Each patient studied would have had at least 8 measurements of fHcy 
per year.” 
 
 
OcularPathology              Age      AgeD(mean:individuals)  fHcy(ine) 
 
 None                                21.4y      :12*NBS, 2.5y, 15y           <11uM 
RefractiveError -0.25D 
AxialLength 23.4mm+/-0.9 
 
Phacodonesis/EctLentis   26.1y       :3*NBS, 1.5y, 2.4y, 27y   >11uM     
RefractiveError -10.7D 
AxialLength 23.8mm+/-1.8 
 
1or2 EctLent into vitrous  27.5 y      8.8y: 2.8, 3.0, 4.1, 5.3,       
RefractiveError +12.9D                             7.2, 11.5, 28y 
AxialLength 24.9mm+/-0.9** 
 
Where: ss for RefractiveError was not provided, and ss (**) for 
AxialLength was vs Group I, P = .0018, 
Age = mean age at time of study,    AgeD = age at time of diagnosis, 
NBS = newborn screening,         
EctLentis, EctLent = Ectopia Lentis, 
 
And, where tHcy was derived using the relationship of fHcy(ine) 
(data values provided by Mulvihill et al here) to tHcy reported by 
Bonham et al (1997), such that:  tHcy = 60 + 4.5(fHcy(ine)) for 
values of  fHcy(ine) < 20uM, and  
tHcy = 60 + 90 + (fHcy(ine) – 20) for values of tHcy(ine) >=21uM                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tHcy 
(derived 
fromn 
fHcy) 
 
<110uM 
 
 
 
>110uM 
 
 
 
>200uM 
roughly, 
assumed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment 
(see 
column 2 
to left just 
above 
here) 
Complian
-ce 
 
Good 
 
 
 
Poor 
(derived fr 
Hcy level) 
 
NotApplic 
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     Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal,  
Study 
Group 
Disease 
Gomber S 
et al (2004); 
Indian 
Pediatrics; 
Guru Teg 
Bahadur 
Hospital, 
Delhi, India 
1 CBS-- An 8y-old boy…..first presented with pallor..…..history of progressively increasing pallor for the past 2years and of 
receiving one blood transfusion at the age of 6years…. 
no: pedal edema, jaundice, petechia, ecchymosis, hepatosplenomegaly, lymphadenopathy, sternal tenderness, 
Hb 7.15g/dL, total leukocytes 5700/mm3, normal differential count, platelets 80,000/ mm3, reticulocytes 1.8%. 
Peripheral smear revealed normochromic RBCs with few macrocytes and reduced platelets. Mean corpuscular volume 
128fL, mean corpuscular Hb 37pg.  
Bone marrow megaloblastic changes.  
Patient started on treatment for megaloblastic anemia: folate 5mg/day + VitB12 100ug/day oral.  
After 1month of treatment the Hb improved to 10.4g/dL and mean corpuscular voume reduced to 98fL while the 
reticulocyte count increased to 4%.  
After initial improvement in anemia the patient was lost to follow-up.  
After 2years the patient again came with pallor, and redness and pain in the right eye.  
On examination the intraocular pressure of the right eye was increased and  
bilateral inferonasal subluxation of the lens was found.  
The right lens showed cataract and atrophic patches on the iris while the left lens was clear. The blood pressure was 
within normal limits.  
Hb 4.5g/dL, total leukocytes 7500/mm3, platelets 69,000/ mm3, Mean corpuscular volume 112fL, mean corpuscular 
Hb 37pg.  Peripheral smear showed anisopoikilocytosis with macrocytes, ovalocytes, tear drop cells, polychromatic 
cells with course basophilic stippling, cabot rings and few microcytic hypochromic cells.  
tHcy 72uM (normal 5-15uM),  
VitB12 364pg/ml (normal 200-800pg/ml).  
Stool examination for fat malabsorption and reducing substance was negative. Normal urinalysis. Normal Doppler 
studies. No evidence of osteoporosis in radiographs of long bones… 
Diagnosed CBS-- and started on VitB6 200mg/day + folic acid 5mg/day.  
“There was a disappearance of fasting plasma methionine and urinary homocysteine and methionine after 8weeks of 
treatment.”  
After 12wks treatment, Hb 13.3g/dL, mean corpuscular volume 85fL, mean corpusc’r Hb 28pg. 
 
Note: Do the relatively low untreated tHcy levels (reduction to this level by (various) treatments generally 
(universally?) prevents ectopia lentis) here with the finding of Ectopia Lentis in the apparent presence of folate 
deficiency indicate an interaction between CBS--‘s metabolic derangements and folate deficiency? That is, unrelated 
to low folate increasing Hcy levels?....  
Bar-Or D et 
al (2004); 
Biochem 
Biophysic 
Res Comm; 
Swedish 
Medical 
Center, 
Englewood 
DMI 
BioSciences 
Inc, 
Englewood, 
U Colorado, 
Denver,  
all of 
Colorado, 
USA, 
Bowman 
Research 
Ltd, 
Newport, 
Gwent, UK 
CBS--
mice,  
and 
CBS++ 
rats 
“In oxidising environments (they state that this is the predominant environment in blood. DV), cysteine (Cys) is 
oxidized into its cystine disulfide which interacts with protein-free sulfhydryl groups, such as albumin Cys34, to form 
cysteinylated species of the protein.  
Cys34 is the only free sulfhydryl group on albumin, which accounts for over 80% of the total free thiols in plasma 
(cite Carballal S 2003). 
In cases of ischemia, when hypoxemia and acidosis are present, the activity of CBS in the area of ischemia is 
decreased (cite Taoka S 1998) leading to the accumulation of Hcy.  
When equilibrated with the normal non-ischemic circulation during reperfusion, Hcy is metabolized by non-inhibited 
CBS from non-ischemic areas into Cys.  
Consequently, Cys id oxidized into cystine which reacts with free sulfhydryl groups on proteins. Albumin Cys 34 is a 
major reactant antioxidant “buffer” molecule which absorbs the oxidant cystine to form a cysteinylated albumin 
species (CysAlb) and a free Cys (cite Carballal S 2003).” 
 
“Abstract. 
 
….Rats….The 3 treatment groups were as follows: 
Midline abdominal incision (Group A, n = 10); 
Ditto and followed by ligation of the superior mesenteric artery for 2hours (Group B, n = 3); 
Ditto followed by reperfusion for 1hour (Group C, n = 10). 
 
Hcy levels were 2.5-fold higher in Group C than Group A (P<.05), 
Hcy levels were 1.9-fold higher in Group C than Group B (P<.05). 
 
In Group A    51% of albumin were modified into CysAlb; 
In Group B    73% of albumin were modified into CysAlb; 
In Group C   100% of albumin were modified into CysAlb. 
 
…Mice…. 
CBS-- mice:      tHcy 180uM;   %CysAlb   0%;    %HcyAlb 23%; 
Normal mice:    tHcy     6uM;   %CysAlb 24%;    %HcyAlb   0%“  
    
“More importantly, the modification of 100% of albumin into cysteinylated species (as seen in Group C) indicates the 
loss of the majority of oxidant buffering capacity in the extracellular environment (no citation given – in humans, 
could vary widely as a function of dietary or supplemental (or pre-op IV….) antioxidant intake. DV).” 
Note: In mice, the loss of albumin’s Cys-oxidant-buffering capacity is approx equal in CBS--/++. 
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          Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Robert K et 
al (2005a); 
The 
Anatomical 
Record Part 
A; 
U Paris, 
INSERM, 
& U Necker 
Enfants 
Malades, 
All of Paris, 
France. 
CBS--, 
CBS-+, 
CBS++ 
mice 
 
 
 
 
 
 
CBS-- 
 
CBS-+  
 
CBS++ 
 
 
 
 
CBS-- 
 
CBS-+  
 
CBS++ 
 
 
 
 
CBS-- 
 
CBS-+  
 
CBS++ 
“At weaning, CBS--, CBS-+, and wild-type CBS++ mice from the same litter were fed on a diet supplemented 
with 1.6g/kg choline chloride salt because CBS—mice died young when fed a standard laboratory diet. CBS-+ 
and CBS++ littermates were also fed the same supplemented chow to avoid differences due to diet…..CBS--/-
+/++ mice were identified by PCR… 
We measured plasma tHcy in 3-8month-old mice. tHcy was 50-fold higher in CBS-- mice than in CBS++ mice 
(205uM+/-86 vs 3.9uM+/-0.9; P <.0001; n = 4 each)…..CBS-+ mice...tHcy was 2-fold higher than in CBS++ 
mice (9.1uM+/-2.4 vs 3.9uM+/-0.9; P<.0001; n = 4 each)….. 
 
Body weight mean of 3, 5, 8months                     Kyphotic Angle    
 
21.2g+/-1.1     P<.007 vs CBS++                          105+/-7     P<.004 vs CBS++ 
 
25.0g+/-1.1     nss  vs CBS++                                120+/-10   P<.005 vs CBS++ 
 
27.2g+/-1.1                                                             141+/-4      
 
 
Lengths(mm) @1month:           Femur             Tibia                Humerus                  Ulna    
 
                                                   8.0+/-0.3a       10.0+/-0.1b        7.6+/-0.1c                 9.0+/-0.1d   
 
                                                 13.5+/-0.3         15.7+/-0.2       10.6+/-0.3                12.4+/-0.1 
 
                                                 14.4+/-0.2         16.0+/-0.5       10.8+/-0.4                12.1+/-0.1 
 
 
Lengths(mm) @3months:         Femur              Tibia                Humerus                 Ulna    
 
                                                   15.0+/-0.1e       17.2+/-0.1f      12.5+/-.07                13.6+/-0.1 
 
                                                   14.5+/-0.2e       16.9+/-0.2
g      11.5+/-0.2                13.3+/-0.1 
 
                                                   16.0+/-.04        17.9+/-0.2        12.1+/-0.2                13.7+/-0.1 
 
 
Where:                        a is P<.0005;   b is P<.008;    c is P<.002 +;    d is P<.0001;   all vs CBS++; 
 
                                    e is P<.0005;  f is P<.007;    g is P<.01 +;                               all vs CBS++; 
 
(But, note: The reduction of variances in the last group of data is the reason for the ss values being similar to 
those of the foregoing group of data – this may be coincidental….DV) 
 
…..Microscopic examination showed expansion of the cartilaginous growth plate with the disruption of the 
ordered arrangement of chondrocytes during differentiation in CBS-- mice, especially in the hypertrophic zone.  
Cartilage differentiation of CBS-- mice was delayed at 1month compared to age-matched CBS++ mice, and 
hence the growth of the long bones was disturbed…… 
Therefore, hyperhomocystenemia due to CBS-- in mice was associated with delayed ossification rather than 
with failed ossification….. 
Growth retardation is not a characteristic of human patients with CBS--. Nevertheless, it has also been observed 
in rats fed excessive methionine or homocystine (cites Cohen et al 1958)…. 
Some of the skeletal abnormalities, such as kyphosis and arachnodactyly observed in CBS-- mice, shared an 
outward resemblance to those observed in mice with a hypomorphic fibrillin-1 mutation, which leads to Marfan 
syndrome-like manifestations (cites Periera et al 1999)….. 
Morover, CBS is not ubiquitously expressed in in mouse tissues (cites Robert et al 2003). In the early stages of 
development, the gene is expressed only in liver and in the skeletal, cardiac, and nervous systems. In the 
skeletal system, expression can be detected at early stages in chondroblasts in areas at which bone ossification is 
believed to be initiated. In adult mice, the signal for enzyme synthesis persists in the perichondrium in cartilage 
and in the periosteum in bone.  
This indicates that dietary cysteine is insufficient in some organs and there is a requirement for the local 
production of cysteine or its metabolic byproducts by transsulfuration. 
It should be noted that MTHFR-- mice, which do not have an impaired transsulfuration pathway, are 
significantly lighter and develop more slowly than MTHFR++, but kyphosis is only observed occasionally 
(cites Chen et al 2001).  
Although CBS-- phenotype appears to be caused by dramatically elevated Hcy, it is possible that blocking 
cysteine biosynthesis could contribute to the skeletal defects observed in CBS-- mice, where the transsulfuration 
pathway is impaired.” 
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       Cystathionine Beta Synthase Severe Homozygous (or compound heterozygous) Mutations 
Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Robert K et 
al (2005b); 
The 
Anatomical 
Record Part 
A; 
U Paris, 
INSERM, 
& U Necker 
Enfants 
Malades, 
All of Paris, 
France. 
CBS--, 
CBS-+, 
CBS++ 
mice??? 
 
 
 
 
 
 
(Same group of mice as for their 2005a paper immediately above) 
“At weaning, CBS--, CBS-+, and wild-type CBS++ mice from the same litter were fed on a diet supplemented with 
1.6g/kg choline chloride salt because CBS—mice died young when fed a standard laboratory diet. CBS-+ and 
CBS++ littermates were also fed the same supplemented chow to avoid differences due to diet…..CBS--/-+/++ mice 
were identified by PCR… 
We measured plasma tHcy in 3-8month-old mice. tHcy was 50-fold higher in CBS-- mice than in CBS++ mice 
(205uM+/-86 vs 3.9uM+/-0.9; P <.0001; n = 4 each)…..CBS-+ mice...tHcy was 2-fold higher than in CBS++ mice 
(9.1uM+/-2.4 vs 3.9uM+/-0.9; P<.0001; n = 4 each)….. 
 
(Abstract) 
Background & Aims. 
CBS-- causes severe hyperhomocysteinemia, which confers diverse clinical manifestations, notably liver 
disease…… 
Methods. 
The degree of liver injury and inflammation was assessed by histologic examination, by measurements of products 
of lipid peroxidation, and by formation of carbonyl groups on protein as a measure for the occurrence of protein 
oxidation. Analysis of profibrogenic, proinflammatory factors and cell apoptosis was performed by Western blots, 
real-time quantitative PCR, caspase-3 activity, DNA laddering, and TUNEL assay. 
Results. 
Histologic evaluation of liver specimens of 8- to32-week-old CBS-- mice showed that CBS--mice develop 
inflammation, fibrosis, and hepatic steatosis, concomitant with an enhanced expression of tissue inhibitor of 
metalloproteinase-1, alpha-smooth muscle actin, pro(alpha)1 collagen type 1, transforming growth factor-beta1, and 
proinflammatory cytokines. Moreover, even if the proapoptotic protein Bax was dominantly expressed and Bcl-2 
was down-regulated, caspase-3 was not activated, DNA laddering was not detected, and number of positive TUNEL 
cells was not increased in liver of CBS-- mice compared with CBS++ mice. 
Conclusions. 
The results show that hyperhomocysteinemia in liver of CBS-- mice promotes oxidative stress, which may cause 
mitochondrial damage in association with activation of hepatic stellate cells, leading to liver injury. The absence of 
caspase-3 activation, DNA fragmentation, and TUNEL-positive cells shows that protective signals may counteract 
apoptotic signals in liver of CBS--mice….. 
 
…..Densitometric analysis of immunoblots demonstrated an approximate increase of 30% in oxidatively mocified 
proteins (P<.01; n = 4 in each group)….. 
The levels of MDA and 4-HNE in liver of 12week-old male CBS-- mice were ~30% higher than in CBS++ mice 
(29.7+/-3.2 vs 21.4+/-1.5 pmol/mg protein respectively) (P<.02; n = 5 / group). 
Taken together these results demonstrate an enhanced protein oxidation and lipid peroxidation in liver of CBS—
mice….. 
 
Table 2. Analysis of relative expression of TGF-beta1, alphaSMA, Pro-(alpha)collagen-1, TNF-alpha, IL-6, and 
CD14 Gene based on Q-PCR data obtained from CBS++ and CBS-- livers. 
 
 mRNA                              CBS++                        CBS--                     ss 
 
 
TGF-beta1                         1.01+/-0.1                   8.8+/-2                    P<.003 
 
alphaSMA                         1+/-.03                        7.7+/-0.3                 P<.0001 
 
Pro-(alpha)collagen-1       1.06+/-0.2                   9.19+/-.07               P<.0001 
 
 
TNF-alpha                         1.06+/-0.2                 99.2+/-7                   P<.0001 
 
IL-6                                    1+/-.04                       3.5+/-0.1                 P<.0001   
 
CD14 Gene                        1.06+/-0.2                  1.62+/-.04               P<.03 
 
 
Discussion. Lipid peroxidation is the most important mechanism in the pathogenesis of acute liver damage….An 
inhibition of methyltransferases is considered to be one of the causes of fatty liver because the liver is the organ in 
which 85% of all transmethylation reactions occur. Choumenkovitch et al (2002) have shown an increase in SAH 
levels, a powerful inhibitor of of SAM-dependent transmethylation reactions, associated with lower genomicDNA 
methylation status in liver of CBS-- mice…. CBS-+ mice fed a hyperhomocysteinemic diet have increased hepatic 
cholesterol and triglyceride levels through increased hepatic expression of genes involved in cholesterol and 
triglyceride synthesis, uptake, and storage, which results in hepatic steatosis (cites Werstuck et al 2001).” 
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Authors, 
Journal, 
Site 
Study 
Group 
Disease 
Riksen N et 
al (2005); 
Arterioscler 
Thromb 
Vasc Biol; 
U Medical 
Centre 
Nijmegen, 
Nijmegen, 
The 
Netherlands 
 “According to this hypothesis, a Hcy-induced fall in extracellular adenosine contributes to the 
cardiovascular sequelae of hyperhomocystenemia. Fundamental to this is the reversibility of the 
reaction in which SAH is hydrolysed to Hcy and Ado. Although the equilibrium constant of this 
reaction favors SAH synthesis, under physiological conditions SAH is hydrolysed to to Hcy and 
Ado, because both reaction products are rapidly metabolized. In hyperhomocysteinemia, the 
reaction shifts towards SAH synthesis at the expense of free intracellular adenosine. 
Subsequently, facilitated diffusion of extracellular adenosine into the cells through the 
dipyridamole-sensitive equilibrative nucleoside transporter is enhanced, limiting stimulation of 
membrane-bound adenosine receptors. By stimulation of these receptors, extracellular adenosine 
induces several effects, which could protect against the development of atherosclerosis and 
thrombosis and against ischemia-reperfusion injury (cites Riksen et al 2003, Rongen et al 1997). 
Particularly in situations of hypoxia or ischemia, when the concentration of adenosine increases 
rapidly, these effects (not noted DV) work in concert to protect the affected tissue….. 
 
Subjects. 
…adult patients with hyperHcy due to CBS-- from our outpatient clinic were asked to participate 
if their fasting tHcy was >20uM despite treatment.  
Exclusion criteria were mental retardation, previous vascular events, asthma, and oral 
anticoagulation. 12 patients were considered eligible and 9 participated. (tHcy = 93uM+/-25) 
 
Their Hcy-lowering therapy consisted of  
VitB6 250-750mg, n = 9, 
Folic acid 5mg, n = 9, 
VitB12 10ug/day orally or 1mg intramuscularly each 2months, n = 7, 
Betaine anhydricum 6g, n = 7, 
With further treatments being acetylsalicylic acid 80mg in 1 patient (stopped 1week before 
experiment), and alendronic acid 70mg/week in 2 patients. 
 
A control group of 8 healthy volunteers was composed with similar age and BMI as the patient 
group.                                                                                                               (tHcy = 9uM+/-1) 
 
(Abstract) 
Methods and Results. 
Infusion of adenosine (0.5, 1.5, 5.0, and 15.0ug/min/dL forearm) into the brachial artery 
increased forearm blood flow, as measured with venous occlusion plethysmography, to  
2.9+/-0.4, 4.3+/-0.5, 5.6+/-1.1, and 9.6ml/min/dL+/-2.1 in the patients 
and to  
2.8+/-0.6, 4.4+/-1.0, 9.0+/-1.7, and 17.06ml/min/dL+/-3.1 in the controls                 (P<.05) 
However, adenosine-induced vasodilation in the presence of dipyridamole (100ug/min/dL) was 
similar in both groups (P = 0.9). 
Additionally, in isolated erythrocytes, adenosine uptake (from 1uM solution) was accelerated by 
incubation with Hcy (100uM, pre-incubation for 10minutes pre-adenosine addition)  
(half-time 6.4+/-0.3 versus 8.1+/-0.5minutes, P<.0001),  
associated with increased intracellular formation of SAH (P<.0001). 
Conclusions. 
In hyperhomocysteinemia, adenosine-induced vasodilation is impaired but is restored by 
dipyridamole. Accelerated cellular adenosine uptake probably accounts for these observations. 
These impaired actions of adenosine could well contribute to the cardiovascular complications of 
hyperhomocysteinemia.” 
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Peer and Expert Review 
 
 
A fairly comprehensive effort was made to solicit comprehensive peer/ expert review of/for this book.  
 
All those contacted were approached via an email including the following: 
 “The book has significant differences from your own work and that of others' in the field, though is 
muchly informed by that - accordingly a condition I will strictly adhere to is that your commentary 
would be reproduced in the final published form, in a section on peer review commentary, in the book 
exactly as you provide it, verbatim and in full, no matter how negative your comments - however, prior 
to the publication I have the right of reply (within 1 week), and then you and the others have the right of 
reply (within 1 week) to my replies, and so on until we have nothing new to contribute to the discussion 
- at whatever point you finalise your commentary and subsequent replies absolutely everything you have 
contributed would be included in the published book exactly as you provide it.” 
 
The following workers in the field of CBS-deficiency Homocystinuria, contacted by email, represent the 
large majority of more prominent treatment centres worldwide: 
 
Professor Harvey S Mudd, Scientist Emeritus at the Laboratory of Molecular Biology, National Institute 
of Mental Health, Bethesda, the USA, and author of the relevant chapter in the most authoritative The 
Metabolic and Molecular Bases of Inherited Disease (Scrivner CR, Beaudet AL, Sly WA, et al, eds). 
Prof Mudd contributed the reviewing and suggestions reproduced verbatim below. 
 
Professor Sufin Yap, a clinician, researcher and teacher of many years, at various times being a 
Consultant Paediatrician in Metabolic Medicine at Sheffield Children's Hospital, and similarly involved 
at the National Center for Inherited Metabolic Disorders, and the Society for Inherited Metabolic 
Disorders, mostly in Dublin of Ireland, The UK.  
Prof. Yap was unable to review this book, but provided information as acknowledged in citation. 
  
Professor Bridgett Wilcken, a clinician, researcher and teacher of many years, in paediatric and 
metabolic diseases, of the Children's Hospital Westmead, The University of Sydney, Australia. 
Prof. Wilcken was initially approached around 2010 with a view to co-authorship of a paper I was 
attempting to get published in scientific journals, the paper being around the statistical and other re-
analyses of the data and analyses of the Yap (2001) paper (of which she was a co-author) much as 
appears here in chapter 3. At that time she responded with a disputing of my analyses, to which I 
responded, inviting her further response on more than one occasion, which she declined to make. On 
deciding to publish as a book instead of in journal articles, in 2013 I notified her that I would be 
including our earlier dialogue on the matter in this book, as that matter was included much in its entirety 
in this book, and offered her the opportunity to provide me with a replacement reviewing of the whole 
book in its present form. On receiving as yet no response I proceed to reproduce the dialogue of 2010 
verbatim below.  
 
Professor GH Boers, Professor FJ Trijbels, Professor HJ Blom, and Dr. LA Kluijtmans, all of The 
Netherlands, I tried (after much failure elsewhere) to acquire the email contacts for from Prof Kozich of 
Czechoslovakia, but he informed me that Profs. Boers and Trijbels had retired quite some time ago, and 
that Prof. Blom and Dr. Kluijtmans are biochemists/ molecular geneticists, not clinicians, so I ceased 
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attempts to contact them, though I would welcome any feedback they would care to make and include it 
in the book soon after receipt. 
 
Professor Viktor Kozich and colleagues, of Czechoslavakia were requested to review or comment, but 
other than a congratulation (probably merely routine politeness) from Prof. Kozich I have received 
nothing in response. 
In Sweden, Associate Professor Olov Ekwall, Specialist Physician Annika Reims, Dietician Karina 
Eftring, all of The Queen Silvia Children’s Hospital, Gothenburg; and Associate Professor Anna 
Nordenström, Specialist Physician Rolf Zetterström,  and Dietician Carina Heidenborg of Children’s 
Hospital, Karolinska University Hospital, Huddinge, Stockholm; and Associate Professor Ulrika von 
Döbeln, of the Centre for Inherited Metabolic Diseases (CMMS), Karolinska University Hospital, Solna, 
Stockholm, were all invited to contribute review or comments, but none have yet been recieved. 
 
 
Response from Professor Harvey Mudd: 
 
Thanks very much for your response Prof. Mudd. 
I agree with virtually every change you suggested, and will carry them out as detailed here below. 
I respond in detail to your comments one by one as you provided them, below. 
What appears below will be reproduced exactly verbatim in the last section/ chapter of the book, so there 
should be no chance of the level of your involvement being misrepresented. 
Any further commentary would be very welcome, and as I am self-publishing via Amazon's CreateSpace (Print on 
Demand), even if you comment after the initial publication, which is unlikely to be sooner than two weeks from 
now, I will be able to modify the book as printable in the future. Of course the earlier I can include the expert 
review / commentary in books printed or downloaded the better. 
Thanks again, 
David Vance 
 
From: muddh@mail.nih.gov 
To: davidjmvance@hotmail.com 
Subject: RE: Thanks; CBS-- Homocystinuria book 
Date: Sat, 16 Mar 2013 22:49:36 +0000 
HM: I am writing hurriedly. Chiefly to respond to your request that I acknowledge receipt of your book – which I 
did receive.  Clearly you have done a great deal of work and analysis – too much for me to go over in any detail 
in the few moments I have had available that were not distracted by other events.  I offer here a few relatively 
minor suggestions for changes that occurred to me as I no more than skimmed your draft: 
HM: p.8 , line 4:  Mention might be made of disorders of homocysteine remethylation in addition to MTHFR 
deficiency that are not covered: cblC disorder (probably currently the most frequently detected cause of 
elevated tHcy when screened for), cblD, cblE and cblG disorders. 
(DV: Yes, I will make this addition) 
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HM: p. 9, text line 2 (and elsewhere): Either replace “homocystinurics” with “CBS-deficient individuals” or 
explain that the word “homocystinuric” is used with a restricted meaning.  
(DV: OK, I will change "homocystinurics due to cystathionine beta synthase deficiency" to "cystathionine beta 
synthase deficient homocystinurics") 
  
HM: p. 19, first line of 3.3 and many other places:  In most instances what is being discussed when you say 
“homozygous CBS-deficiency” is in reality either homozygous or compound heterozygous-CBS 
deficiency.  Probably most of the headlines on p. 55-157 have similar mis-terminologies (although there may be 
a few papers where only homozygotes are discussed). 
(DV: Yes, I will change to "homozygous or compound heterozygous CBS deficiency") 
  
HM: p. 29, middle paragraph:  I may have missed, but it would be a convenience for the reader if, when you first 
discuss “homocysteine” levels, you specify the difference between homocysteine and total Hcy (tHcy) and, 
perhaps, present examples of how to covert relevant values to tHcy. 
(DV: Yes, I will put " 'total' homocysteine (tHcy) (homocysteine in Hcy-Hcy dimer + Hcy-Cysteine mixed disulfide 
+ Hcy bound to plasma proteins + free homocysteine)" 
At the bottom of Table 1 I have already detailed the algorithms I used to convert other Hcy values to tHcy) 
  
HM: p. 55-157: For the many instances when you talk about “homocytinuria”, explain what is actually found in 
urine in the way of homocysteine derivatives, and explain how you converted to tHcy (although that may or may 
not be appropriate in this situation, given that there is probably little or no free homocysteine in urine). 
(DV: Yes, on these pages I will change the line above the tables to "Cystathionine beta Synthase deficiency by 
severe homozygous or compound heterozygous mutations" 
Yes, I will reproduce the Bonham (1987) and Wiley (1989) algorithms on p27 at the bottom of Table 1, to also 
appear under the section heading on p 54) 
  
HM: More importantly, I do agree with the need to recalculate treatment outcomes in the studies such as those 
in the Yap et al paper.  However, I have not had time to go over the details you present on this matter.  Again, I 
may have missed it, but another concern I have is that the time-to-event curves for B6-responders presented by 
Mudd et al 1985 may have been severely affected by ascertainment bias (you must have seen the paper by 
Skovby et al (Mol. Genet. Metb 101, 172-177, 2010).  If the tentative conclusion in that paper holds up, the risk 
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for untreated B6-responders in Mudd et al 1985 probably was severely overestimated.   You may choose to at 
least mention this possibility. 
(DV: I agree, and I did address this on p 24-25 where I noted that the relative risk of .09 given by Yap et al. was 
actually closer to 0.2 when determined using only the actual portions of your (1985) survival curves that are 
applicable to the cases, this being a two-fold exaggeration of efficacy, and that consideration of the 
ascertainment bias you note would indicate probably nearly a three-fold exaggeration of the real efficacy in 
total.) 
  
HM: Hope this helps.  Use it as you wish, but please do not quote me in a way that suggests I have gone over 
your draft in detail.  I may or may not find time to read more carefully those portions on which I might have 
further comments (e.g. chapter3), but my schedule is too crowded to offer even a vague deadline to try to do so. 
(DV: Thank you very much Prof. Mudd, as noted from the outset there should be virtually no chance of such 
misrepresentation because all of your comments here, and my responses to them, will be reproduced verbatim 
in their entirety in the last section/ chapter of the published book. 
Any further commentary would be very welcome, and as I am self-publishing via Amazon's CreateSpace (Print on 
Demand), even if you comment after the initial publication, which is unlikely to be sooner than two weeks from 
now, I will be able to modify the book as printable in the future.) 
  
Harvey Mudd  
   
 
Response from Professor Bridget Wilcken: 
 
 
BW: Dear David, I have just been re-reading your paper.  
 
While I think there are excellent points, there are also aspects that you haven’t taken into account. Firstly, it is 
evident that the treatments, various, do result in benefit with regards to occurrence thrombo-embolism (and 
maybe that should in fact be vascular disease in general),  
 
(DV: Yes, but unfortunately, as I noted in my work under discussion here, and as you have not noted in your 
comments here, the thrombo-embolism is very likely to still be substantially above the level of the general 
population (except in the Dublin cases where there isn’t any at all…..), and therefore it is desirable to reduce 
it still further if possible, for example by some sensible, safe, cost-effective method(s), perhaps such as I have 
suggested…..)  
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BW: and that we do not really know what aspects of the treatments are the most important.  
 
(DV: Indeed “we do not know what aspects of the treatments are most important”– that is why I carried out 
my study under discussion here – to further elucidate what aspects of treatment may be not necessarily most 
important (which is not quite the point) but be important enough to be done (which is more the point).)  
 
BW: It is clear that the treatments used all resulted in lowering of homocysteine levels, but that the great 
majority of patients continued to have very significant elevations.  
 
(DV: And therefore will have very significant decreases in cysteine, unless receiving it in supplements, 
particularly if they are receiving folate and/or vitaminB12 and/or betaine (which they are….) as explained 
again here below in response to your response here.) 
 
BW: However, it is not at all reasonable to compare Dublin (and maybe Manchester also) with the other 
centres, as almost all the patients from Dublin and most from Manchester were diagnosed by screening 
(newborn or family studies) and started on treatment in the first few months. Thus the homocysteine levels 
that group obtained would have been extremely well-controlled in childhood.  
 
(DV: I‟ll begin here by agreeing with you that I haven‟t dealt sufficiently with the differences between Dublin 
(and less so Manchester) and the other centers regards the former centers’ patients being on treatment in 
early childhood whereas the latter centers’ patients were not. I fully acknowledge this oversight. And I have 
now included the following points in the discussion in my work under discussion here.  
However, comparing the centers with each other is quite reasonable if it is done reasonably, adjusting 
properly for relevant factors where known and possible, and properly noting the caveats including known 
factors not adjustable for or adjusted for, and mentioning as far as possible the possibility and probability of 
factors that might be unknown.  
Firstly, the homocysteine levels of the Dublin cases are nonetheless in the middle of the range of the five 
centers (tHcy approximately 110 micromoles per liter versus approximately 80-130), though it might well be 
the case that the B6-non-responsive cases in the other centers have higher tHcy, and the B6-responsive 
cases lower tHcy, than the combined averages given.  
Now, if early treatment confers some advantage other than later adherence to homocysteine- lowering 
treatment, it is very likely to be due to differences in the body‟s more permanent structures, rather than to 
differences in less permanent things like platelets and biochemicals in solution.  
For example the protein fiber scaffolding of tissues including the walls of arteries and veins, in particular the 
protein fibrillin with its unusually high cysteine content and cysteine-cysteine double bonds.  
Furthermore, the Irish (Dublin) cases are nearly all of the more severe vitamin B6-unresponsive type whereas 
all the other centers are much closer (roughly 1:1 to 1:2) to being evenly comprised of B6-unresponsive and 
B6-responsive (which fact I neglected to point out in discussion (although the facts are clear in the table), 
and thank you for inadvertently causing to me to have to look again to respond to your comments, and I 
have now added that point to the discussion).  
Such cases would nearly all be detected clinically within the first five years of life. It is possible that clinical 
detection would drive a higher compliance with treatment, due to non-trivial disease manifestations being 
already experienced by the patient or members of their family, whereas this is less so for those ascertained 
via family studies, and even less so for those ascertained by population screening.  
Compliance is of course a function of the experienced burden of the treatment, which might be reasonably 
said to be greater insofar as it included the unpalatable cysteine supplementation (though this should be 
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able to be given as a single amino acid in a capsule(s) rather than as a more voluminous mixture of amino 
acids, relying on food for the other amino acids).  
However compliance is also a function of patient-doctor contact type and frequency. It should be borne in 
mind that Dublin has absolutely no events of thrombosis, as yet.  
Note that there is no ascertainment bias unreasonably against the other four centers in comparison, because 
the Dublin cases are absolutely more severe – if anything the ascertainment bias would be unreasonably in 
favour of the other four centers in comparison, even if this is in the reverse direction to most ascertainment 
bias noted in the field of epidemiology.  
The point is that when, as my numerical data analysis does, the case severity is adjusted for, which is a 
substantial improvement over all prior such studies (which you do not acknowledge and seem not to 
understand), Dublin does better.  
I do not claim that this proves that Dublin‟s treatment practice is better, I claim only that it suggests it.  
And consideration also of other facts as provided in my work under discussion here provides a reasonable 
theoretical support for cysteine supplementation being important.) 
 
BW: From my long experience of treating large numbers of phenylketonuria subjects, who also need a low-
protein diet with a (different) amino acid supplement, I can say that it is usually not possible to get them to 
comply fully unless treatment is started in infancy. The taste of the supplement is simply not acceptable to 
many unless they have become accustomed in infancy.  
 
(DV: I am well aware of the taste factor, and thought that this was sufficiently well implied to the expected 
readership when I raised compliance with treatment as an issue, and explicitly suggested that compliance 
will be better when treatment is implemented early and doctor-patient contact type and schedule is 
optimized.  
However, again, it seems to me that cysteine supplementation should be able to be given as a single amino 
acid in a capsule(s) rather than as a more voluminous mixture of amino acids, relying on food for the other 
amino acids, sufficiently increased compliance being the justification.)  
 
BW: I don’t think therefore that it is valid to make a sudden, evidence-free leap, and say that cysteine 
supplementation is likely to be a major factor in better results. It could be so and it seems quite reasonable 
that more cysteine could be needed, but the better results obtained by Dublin are not sound evidence for 
this. They are much more likely to be due to earlier treatment  
 
(DV: My suggestion is not a “leap”, and it is most certainly not “evidence-free”.  
More the point, you are one of the experts that have unfortunately overlooked the significance of low 
cysteine as the other half (versus high homocysteine) of one of the main, if not the main problem(s).  
Note that the area of structural tissue involved in the ectopia lensis (eye lense displacement) of CBS-- 
homocystinuria has a very high (almost singularly so, compared to other body proteins) content of cysteine 
in its proteins, and cysteine-cysteine double bonds in its structure. To copy verbatim from my work being 
discussed here by way of citing references contributing evidence “In accord with the enzyme defect in CBS it 
has been shown that requirement for cysteine is increased in CBS--: Perry et al (1968), Komrower et al (1966), 
Perry et al (1966), Brenton et al (1966), Laster et al (1965). …… ……. ……… Majors and Pyeritz (2000) report 
their investigations following on speculation by themselves and others that in CBS-- the altered plasma 
concentrations of homocysteine and/or cysteine may hinder the synthesis, deposition, or both, of fibrillin-1. 
They report that when arterial smooth muscle cells were cultured under conditions of cysteine deficiency 
fibrillin-1 deposition into the extracellular matrix was greatly diminished (and restored with addition of 
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cysteine), but that excessive homocysteine in contrast had little if any effect on fibrillin-1 deposition.  
Furthermore, in the reference book Homocysteine in Health and Disease (Carmel and Jacobsen, editors 
(2001) p238) Kraus and Victor cite Mudd and Levy (1978) in the universally accepted as authoritative The 
Metabolic Basis of Inherited Disease to the effect that “Dietary manipulation of methionine and cysteine 
intake is an option for treating patients who are partially or fully nonresponsive to vitamin B6. ……. For 
patients with no residual CBS activity, cysteine must be provided……..”  
Now, if treatment of CBS homocystinuria (in particular, but not only, the partially vitaminB6-responsive cases 
with vitamin B12 and/or folate and/or betaine causes a further reduction of flow of homocysteine through 
the transulfuration pathway and therefore further reduction of cysteine production, because the 
homocysteine escapes through the remethylation pathway instead, considered with all the evidence 
available, including but not limited to my data analysis (which you have not well if at all understood) in the 
work under discussion here, it is hardly a “leap” to suggest that failure to provide or take supplemental 
cysteine is likely to cause problems in later life.  
I acknowledge that you have other types of cases than CBS homocystinuria to deal with, whereas I have 
made the time to specialize in studying homocysteine for a few years, but I suggest that you, and more the 
point your patients, would benefit from yourself studying the situation further, regards aspects that I have 
raised, and changing your practice accordingly, unpalatable as that may be coming from someone outside 
your network. Furthermore, your statement “They are much more likely to be due to earlier treatment” is 
much more of an “evidence-free leap” than my suggestions, offering as it does no supporting evidence, and 
certainly my extensive reviewing of the literature (see also the 100-page tabulation of extracted data and 
word descriptions in the file on the Multifactor Health website {here above, now}) has not revealed any 
evidence in support of that statement. More likely you resent an outsider correcting a deficiency in your 
practice, and respond in a way very devoid of the objectivity and logic that are at least the cornerstones, if 
not much more as well, of scientific rigour.) 
 
BW: Now that we are screening for homocystinuria, there is accumulating evidence about the value of early 
instigation of treatment – not that this was not extremely likely, but now there is some slowly gathering data. 
There is some other evidence for the value of vitamin C (Bonham et al – cant look it up at present, I fear)  
 
(DV: Other than in Pullin, Bonham and McDowell (2002) as already cited in my work being discussed here, it 
must be very recent, and I would be pleased to add it to the literature review if available)  
 
BW: , and most of our older patients are on this  
 
(DV: Why only the older patients?).  
 
BW: I am writing this without the benefit of referring to our combined paper, as, unkindly, I am not able to 
access the internet due to some server glitch. This will have changed perforce, if I can send this to you, so I 
may add something at the end. But I thought that the method of computing the expected number of 
thrombo-embolic events was a simple method of summing the numerical risk for each patient derived from 
the Mudd graph. Then it is not necessary to know the average age at treatment. Eg, from Mudd’s graph one 
can see that the risk for patient “A” aged 20 years and B6 non-responsive, if untreated would be about 0.26 (I 
cant see the graph very clearly), for patient “B” B6 responsive and aged 32 would be about 0.51, for patient 
“C” B-6 non-responsive and aged 6y would be c. 0.04, and so forth.  
 
(DV: No, one may not reasonably claim a treatment success for time periods that one has not been applying 
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the treatment – this had the effect in the Yap et al (2001) paper of inflating the actual treatment success 
from a risk rate of approximately 0.2 (by my calculations using only the (average) periods the patient groups 
were actually treated for) to one of .09, which I noted in my work (also noting that I would not belabor the 
point, as I was then inclined to be a little less combative than I presently am inclined) which is not a trivial 
difference (It is a claim to have been approximately twice as successful as one could reasonably claim, and 
probably closer to three times as successful as one could reasonably claim, for four non-Dublin groups, 
considering the ascertainment bias towards more severe cases of the vitaminB6-responsive cases in the 
Mudd (1985) study used for comparison to derive the risk ratio in Yap et al (2001) ).  
Indeed, had I had the individual data, I would have used them instead of the averages, but the small gain in 
precision thereby achieved would not much change the outcome of my numerical analysis, and it certainly 
would not negate the fact of my analysis being far more reasonable than that of Yap et al (2001) due to my 
use of the appropriate time period (the period during which treatment actually occurred).  
Furthermore, Yap et al (2001) did not at all sufficiently detail their numerical analysis methods, leaving it to 
readers to have to trial various possible methods in order to determine what they had in fact done – 
doubtless very few readers if any other than myself actually did so, although some may well have realized 
what shortcomings the lack of given detail could imply.)  
 
BW: Unfortunately I found your statistical analysis difficult to follow, but I am not expert in that area. 
However, I’m not sure it was necessary in the first place.  
 
(DV: The statistical analysis is indeed more difficult to follow than much of what appears in the literature. I 
also would not call myself an expert statistician, or even rank myself with the very competent. I am, however, 
better qualified and more competent as an epidemiologist than the average medical doctor, and also than 
the average journal article author with a medical degree, judging from the shortcomings and mistakes that I 
repeatedly or very often find in the hundreds of journal articles that I review. I hope you will understand, with 
further consideration, the appropriateness of my statistical analysis here. If not, there are various courses that 
you can take to improve competence in that field, should your time commitments permit and you incline to.)  
 
BW: From a publication point of view your paper would need very substantial revision. It is much too long for 
most journals, and I would advise aiming for a text of c. 3,000 words, certainly less than 4,000  
 
(DV: To revise it back to this length would remove so much material as to reduce the quality of the work 
unacceptably, which should be somewhat obvious – if it is too long for a standard journal article, then so be 
it, for the moment.) .  
 
BW: It is also not very focused  
 
(DV: It is quite appropriately focused, on optimizing the treatment of cystathionine beta synthase deficiency 
homocystinuria) .  
 
BW: I think the discussion section (which is not a discussion at all of what you have analysed)  
 
(DV: It is a discussion, including of what I have analysed, of what is potentially relevant to optimizing the 
treatment of cystathionine beta synthase deficiency homocystinuria.)  
 
BW: is interesting, and it might be that your work could become publishable if it was mainly focused on this 
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– a review of possible treatment modalities. Homocystinuria is relatively rare and the clinical outcomes are 
very long-term  
 
(DV: Ultimately all clinical outcomes should include old age, and this is hardly unique to homocystinuria, in 
which outcomes addressed in formal analysis to date have only included life periods up to and including 
middle age, not old age, which is an explicitly stated reason for seeking to further optimize treatment.) 
 
BW:  , which is why we have so little reliable information about ideal treatment aims. (One thing of note, not 
obviously related to thrombo-embolism, is the much better intellectual outcome with early treatment. Quite 
a proportion of B6 non-responsive patients clinically diagnosed have intellectual handical to some degree, 
whereas it seems likely from screening data that this does not occur at all with early treatment.)  
 
(DV: This has been quite well noted for many years now.)  
 
BW: I’m sorry to sound negative overall. I am not sure I can be of much more help with this, and certainly 
ought not to be an author.  
 
Kind regards,  
 
Bridget  
 
Professor Bridget Wilcken AM, MD, FRACP, FRCPA(hon)  
NSW Biochemical Genetics and Newborn Screening Service  
The Children's Hospital at Westmead, Sydney, Australia  
(Contact details removed by Vance as a courtesy, they will be readily available elsewhere) 
